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Analysis of the CFTR 1811H1.6kbA)G mutation by lightcycler system.
detection of a new polymorphism
M.D. Ramos, F. Rico, J. Gimenez, T. Casals(Presenting)´
Medical and Molecular Genetics Department, Institut Recerca Oncologica, Bar-`
celona, Spain
The 1811q1.6kbA)G mutation accounts 2% of CF chromosomes in the Spanish
population. The LightCycler (LC) system (Roche Applied Science) is a real-time
PCR with fluorescent hybridization probes that allows the target amplification and
product analysis to be done consecutively without sample handling. The LC system
uses air to transfer efficiently heat to the PCR samples in glass capillaries, allowing
30–40 amplification cycles in 20–30 min. The LC provides a platform for moni-
toring fluorescence during temperature transitions. At the end of the PCR run,
samples can be quantitated, thereby avoiding the need to run and stain a gel, show-
ing image and estimating quantity. The use of hybridization probes allows the anal-
ysis of point mutations, including multiplex analysis or mutations of unknown
mismatches. Our laboratory have applied the LC technology for the analysis of the
CFTR 1811q1.6KbA)G mutation. The oligonucleotides and hybridization probes
used in this study were: CF1811F: 5-ACTTTTAAAgTTTTgCCATTggT CF1811R:
5-CAgTTCCCATATTAATAgAAATg CF1811 Anchor: 5-LCRed 640-CATAgg-
ATTCTCTgTTTATACATgTAATTg p Sensor(G): 5-TTgATAg-
TAACCTTACTTACATCTCAAg X The electropherograms obtained showed a
good discrimination of the two alleles, normal and mutant, however we detected
an abnormal pattern in some samples. The direct sequencing of these samples (nor-
mal controls and heterozygous for the mutation) led to the identification of a new
polymorphism (T)A) 16bp downstream the mutation. In our opinion, the LC sys-
tem is a rapid and efficient method that allows to analyze known mutations and
also to find unknown DNA variants in the region studied by the sensor probe.
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The impact of quantitative genetics on CF: CFTR transcript levels
modulate the CF phenotype
J. Sanz (Presenting), B. Steiner , A. Schaller , C. Casaulta , M. Schoni , R.1* 1 1 2 2¨
Kraemer , S. Gallati2 1
Department of Clinical Research, Division of Human Genetics, Bern, Switzerland,1
Department of Pediatrics, Children’s Hospital, Bern, Switzerland2
The genotype-phenotype relation in Cystic Fibrosis (CF) is known to be very com-
plex. In some cases, typical classic CF patients bearing two CFTR mutations can
have normal or borderline functional laboratory findings (sweat electrolyte test,
nasal potential difference measurements etc.). On the other hand, CF patients can
also show mild phenotypes and in these cases only one or even no mutation is
detected. Strikingly, this variability can even be observed among patients carrying
the same genotype. Consequently, CF remains a clinical CF diagnosis. Our assump-
tion is that differences in the amounts of functional cystic fibrosis transmembrane
conductance (CFTR) transcripts, caused by different allelic expression and mRNA
processing, may directly correlate with the variable clinical disease phenotype
observed. Using real-time RT-PCR in the LightCycler and an allele-specific assay,
we quantified the splice variants and the unmutated full-length CFTR transcripts in
two unrelated families. In both families only one patient presented classical CF
symptoms, although two siblings in one family and one in the other carried the
same genotype. Both affected CF patients showed high levels of exon 9 skipping
and highly decreased amounts of unmutated full-length transcripts. In the three other
siblings, however, exon 9 skipping and the reduced amounts of unmutated full-
length transcripts were less pronounced, so that the mild clinical symptoms escaped
the medical attention. Our results indicate that the levels of functional CFTR tran-
scripts correlate with the clinical phenotype of these patients. Thus, quantitative
genetic analysis could be a valuable genotypic approach for the assistance to the
clinician’s decision of CF diagnosis
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Extensive CFTR mutational analysis: a 96-well cycle sequencing
protocol
M. Lucarelli (Presenting), R. Piergentili , F. Grandoni , V. Borrelli , L. Narzi , E.1 2 3 4 2
Mangia , S. Quattrucci , R. Strom4 2 4
Universita di Roma ‘La Sapienza’, Roma, Italy, Centro Fibrosi Cistica Regione1 2`
Lazio, Universita di Roma, Roma, Italy, Centro FC and Ist. Sper. Zootecnia Mon-3`
terotondo, Universita di Roma ‘La Sapienza’, Roma, Italy, Dip. Biotecnologie Cel-4`
lulari ed Ematologia, Universita di Roma ‘La Sapienza’, Roma, Italy`
CFTR mutational analysis is complicated by the large number of mutations actually
identified and from their variable geographical distribution. This work was aimed
at optimizing, within a 96-well format, a multistep procedure of CFTR complete
sequencing, from PCR amplification to final capillary electrophoresis. As a first
step, we performed the analysis of CFTR exons 4, 5, 7, 11, 14a, 17b, 19, 20,
including their intronyexon adjacent sequences. These exons has been chosen to
maximize the sensitivity of the test span 395 known mutations that represents
approximately 40% of all known CFTR mutations. The sequencing step was per-
formed, on ABI PRISM 310 by the ddNTPs based cycle sequencing method
(Applied Biosystems), using internal primers in order to overcome the possible
presence of aspecific amplicons. A first group of 33 subjects, representative of 3
categories of patients, were analyzed: (1) 11 subjects affected by CF, whose CFTR
mutations had both escaped identification at a first 31 PCRyOLAySCS (Celera
Diagnostics) mutation panel; (2) 11 subjects affected by CF with only one mutation
found in the 31 panel; (3) 11 subjects with atypical or incomplete form of CF, or
simply suspected to be affected by CF. The first 8 exons indicated above were
amplified and sequenced by this procedure (a total of 264 amplicons and
sequencesq24 negative control). The analysis of about one half of these sequences
evidenced 6 mutations that had not been evidenced previously. This allowed the
complete genetic characterization of 3 CF subjects and the demonstration of at least
one mutation in one CBAVD patient as well as in one subject with uncertain diag-
nosis. This procedure appears therefore as a powerful method for mutations search
without the need of a preliminary screening approach, reducing the frequency of
false negative results and also saving time and effort. P.R. and G.F. were supported
by a grant of Associazione Laziale Fibrosi Cistica.
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Use of Pyrosequencing technology for detection of common cystic
fibrosis mutations
M.P. Audrezet (Presenting), J. Dunker , I. Quere , C. Ferec , A. Schiller1 2 1 1 2
Laboratoire de Genetique Moleculaire, CHU Morvan, BREST, France, Pyrose-1 2´ ´ ´
quencing AB, UPPSALA, Sweden
Fourteen years after the discovery of the cystic fibrosis transmembrane conductance
regulator (CFTR) gene and the characterization of over 1000 mutations, CF is now
to become the first disease targeted for population-wide genetic screening. Pyro-
sequencing technology for DNA analysis is based on real-time detection of pyro-
phosphate released upon nucleotide incorporation by DNA polymerase. The
genotype as well as the sequence context for each mutation is obtained, ensuring
that the risk for false positive and negatives is minimized. Twenty-seven Pyrose-
quencing assays were designed and developed for the analysis of 30 CFTR muta-
tions with a frequency of s0.1% in the French population, including point
mutations as well as insertions and deletions. These were evaluated on previously
genotyped samples carrying the mutations. Neighboring mutations were easily gen-
otyped in a single reaction, rendering additional reflex tests for distinguishing
benign variants redundant. This technique distinguishes between homozygotes and
heterozygotes for all the mutations tested. In all cases the results were in agreement
with data obtained using DGGE or DHPLC technology. These Pyrosequencing
assays can easily be modified to allow simultaneous analysis of less common muta-
tions in the same region. Pyrosequencing AB (Sweden) offers analytical systems
well suited to meet the demand for research and routine testing of mutations in the
CFTR gene, providing simple, rapid, cost efficient and extremely accurate detection
of all relevant mutations, including internal controls for each analyzed position.
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Cystic fibrosis transmembrane conductance regulator (CFTR) gene.
mutation detection made easy by the linear array technology
A. Myers (Presenting), L. Wang , L. Boppuri , J. Nolley , M. Macek Jr.1 1 1 1 2
Roche Molecular Systems, Alameda, USA, School of Medicine, Charles University,1 2
Prague, Czech Republic
Purpose: To evaluate reliability and robustness of genotyping with a low-density
oligonucleotide probe array in comparison to other DNA-based typing methods for
determination mutations in the CFTR gene. Method: Genetic analysis by PCR
amplification and hybridization with immobilized sequence-specific capture oligon-
ucleotides of 400 clinical specimens that were previously genotyped by other meth-
ods. This study used a striped array of 79 immobilized, capture oligonucleotides
for genotyping. This Linear Array was validated using DNA extracted from whole
blood, although other methods for DNA extraction are suitable for the test (buccal
swab or dried blood spots). Genomic DNA is amplified in a single PCR followed
by detection of 38 mutations and 4 polymorphisms. Probes are designed to be
complementary to either the wild type or the mutant allele. The denatured biotin
labeled PCR product binds to the complementary capture oligonucleotide followed
by colorimetric determination of the duplex formation, using Streptavidin –HRP.
Results: Because, the geographical distribution of mutations and their relative fre-
quencies vary considerably, testing for these 38 mutations will lead to a detection
rate of 80–95% in the Scandinavian and Western European countries and significant
detection levels in remaining European countries. This may be sufficiently sensitive
for the majority of diagnostic requests, for routine carrier screening and in con-
junction with conventional tests for newborn screening. Conclusion: To provide a
cost-effective CF test and optimize the CF detection rate, the selection of a subset
of mutations to be analyzed must be carefully considered and appropriate to the
target population. Expanding the panel of screened mutations only marginally
increases the sensitivity of the assay. This molecular diagnostic assay is simple and
accurate. The assay identifies most of the carriers and affected persons (high sen-
sitivity) with few false positives (high specificity).
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Extended mutational analysis in heterozygous newborns selected by
neonatal screening for cystic fibrosis
L. Narzi (Presenting), G. Ferraguti , A. Stamato , F. Narzi , O. De Luca , M.1 2 3 3 3
Lucarelli , R. Strom , S. Quattrucci2 2 3
Universita di Roma ‘La Sapienza’, Roma, Italy, Dip. Biotecnologie Cellulari ed1 2`
Ematologia, Universita di Roma ‘La Sapienza’, Roma, Italy, Centro Fibrosi Cistica3`
Regione Lazio, Universita di Roma ‘La Sapienza’, Roma, Italy`
The IRTyDNAyIRT neonatal screening protocol for Cystic Fibrosis (CF), allows
the selection not only of affected subjects but also of CF heterozygotes. Infants
with hypertrypsinemia at birth and one CF mutation (found by the 31 PCRyOLAy
SCS protocol, Celera Diagnostics), but negative sweat test and pancreatic suffi-
ciency, are usually considered as carriers. Nevertheless at least some of these
hypertrypsinemic heterozygous newborns might have another undetected mild
mutation. In order to contribute to the understanding of the correlation between
hypertrypsinemia and heterozygous condition, an extended Cystic Fibrosis trans-
membrane conductance regulator (CFTR) mutation search was performed by cycle
sequencing (Applied Biosystem). Among newborns screened, 47 were selected for
the presence of one CFTR mutation with a negative sweat test (Cl -60 mmolyl)y
and pancreatic sufficiency. Among these 47 heterozygous subjects, 14 (30%)
showed a persistent hypertrypsinemia and 12 (26%) showed a sweat chloride con-
centration)30 mmolyl. We have at present analyzed 25 of the 47 selected subjects,
searching variant (TG)m and Tn tracts in the intron 8-exon 9 region, as well as
mutations in exons 4, 7 and 17b of the CFTR gene, detecting 2 T5 and 4 TG12
alleles, comprising 2 TG12T5 aplotypes. These aplotypes were indeed found in 2
newborns that had also been found positive for a first common mutation, suggesting
the presence of an oligosymptomatic form of CF. Moreover, the ‘non-carrier’ parents
of 2 heterozygous newborns were indeed found to be carrier respectively of a CFTR
mutation (different from that found in the corresponding child) and of a TG12T5
allele; the possible transmission of these mutationsyvariant tracts to the infants is
yet to be assessed. In conclusion, hypertrypsinemia, possibly associated with sweat
test values at the upper limit of normal range, can indicate the presence of some
mild or atypical manifestation of CF.
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How should we screen newborns for cystic fibrosis?
P. Farrell(Presenting)
Pediatrics, University of Wisconsin Medical School, Madison, USA
After the benefits of cystic fibrosis (CF) neonatal screening were demonstrated, the
Wisconsin group recommended ‘‘10 steps to success’’ for implementation (Advanc-
es in Pediatrics 47:79–115, 2000) as follows: (1) An effective working relationship
must first be established between a region’s CF center and their screening labora-
tory. (2) The region’s screening laboratory should establish a combination of tryp-
sinogen and DNA testing with quality control mechanisms that will ensure a
successful laboratory component. (3) Trypsinogen cutoff values must be set care-
fully with a full knowledge of issues involved. (4) The incidence of CF and the
frequency of the DF508 mutation among existing patients must be known. (5) The
other CFTR mutations in the region should also be known. (6) Reliable financial
support must be secured to implement and sustain a new CF neonatal screening
program. (7) Follow-up plans for diagnosis and treatment by CF centers must be
established. (8) A care delivery system designed with an appropriate health care
provider mix specifically for infants and young children with CF must be organized
in each CF center participating in the newborn screening program. (9) A compre-
hensive education program must be available to the community providers and the
lay population. (10) Monitoring outcomes of the regional CF neonatal screening
program must be part of the implementation plan. Finally, it must be kept in mind
that early diagnosis of CF through neonatal screening only provides the opportunity
for better outcomes, and that ensuring more good than harm requires optimum care
and communication.
8
Neonatal screening program for cystic fibrosis in Catalonia (Spain)
T. Casals (Presenting), A. Maya , O. Asensio , N. Cobos , S. Gartner , J.L.1 2 3 4 4
Seculi , M.T. Marco , X. Estivill , M. Puliol , R. Prats5 3 6 2 7´
Medical and Molecular Genetics Department, IRO, Barcelona, Spain, Institut Bio-1 2
quimica Clinica, Hospital Clinic, Barcelona, Spain, Cystic Fibrosis Unit, Corpor-3
acio Parc Taulı, Sabadell, Spain, Cystic Fibrosis Unit, Hospital Vall d’Hebron,4´ ´ ´
Barcelona, Spain, Cystic Fibrosis Unit, Hospital S. Joan de Deu, Barcelona, Spain,5
Genes and Disease Progam, CRG, Barcelona, Spain, Medecina Preventiva, Direc-6 7
cio General de Salut Publica, Barcelona, Spain´ ´
Neonatal screening allows earlier CF diagnosis and more accurate treatment. The
effect of the prevention on the disease evolution is under study. Additionally, we
have assessed the CF incidence in our population. We have studied 194,394 new-
borns in Catalonia from September 1999 to August 2002. The neonatal blood spot
protocol includes two determinations of inmunoreactive trypsinogen (IRT) (Immu-
nochem. Blood Spot Trypsin-MW Elisa. ICN) at 3–5 days and before 40 days of
life. The samples with both IRT higher than the cut-off (120 and 60 ngyml) was
submitted to CFTR gene analysis (31 common mutations) and the families remitted
to a CF Unit. Newborns presenting one CF mutation and positive sweat test were
analyzed for the complete CFTR gene (DGGE, SSCP and sequencing of abnormal
patterns). The IRT-1 was positive in 2,346 (1.2%) and the IRT-2 in 593 (0.3%).
Another 118 cases out of protocol were included by other reasons for CFTR anal-
ysis. Analysis of 31 CF mutations identified 80 positive samples (21 with CFyCF
genotype). When all CFTR genes was analyzed the second mutation was identified
in 15 samples. Clinical symptoms confirmed the diagnosis in another 2 cases. In
total, we found 38 affected newborns, 29 carriers (without symptoms and normal
sweat test) and 13 with a CFyvariant genotype. Newborns with variants (5T, R75Q,
L997F, Y1014C, R1162L) presented normal phenotype and normal sweat test. The
most frequent variant was the 5T allele (8 cases). The program sensibility was
95.2%. The estimated CF incidence was 1y5,115 live births being lower than the
expected average (1y2,500).
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Qualitative and quantitative analysis of mRNA associated with three
splicing mutations in the CFTR gene and clinical phenotypes of
patients
M. Tzetis (Presenting), A. Tsiamouri , A. Efthymiadou , J. Traeger-Synodinos , S.1* 1 1 1
Doudounakis , E. Kanavakis2 1
Medical Genetics, University of Athens, Athens, Greece, Cystic Fibrosis Clinic,1 2
St Sophia’s Children’s Hospital, Athens, Greece
Three splicing mutations were studied with mRNA extracted from nasal epithelial
cells. Seventeen patients carried 2789q5G)A (8 with F508del, 3 with 574delA,
2 with unknown, 1 with G551D, 1 with 574insTA, 1 with G542X, and 1 homo-
zygous for 2789q5G)A), seven the 711q3A)G (2 with F508del, 2 with
1677delTA, 1 with R1070QqS466X, 1 with 3120q1G)A and 1 with G1069R),
another 2 the 1525-1G)A (1 with 3120q1G)A and 1 with 4382delA). Samples
for the 2789q5G)A were reverse-transcribed into cDNA with primers (one flu-
orescent): BM1D (nucleotide 2528) and BM2R (3056). For 711q3A)G with
primers: F12 (399) and 10K (809). For 1525-1G)A with primers: F23 (1051)
and RTCF1798 (1798). Relative amounts of mutant and normal cDNA products
were sized and quantitated after electrophoresis on 6% acrylamide denaturing gel.
Aberrant splicing products were cut from agarose gels, extracted and sequenced.
2798q5G)A resulted in skipping of exon 14b (18.6"6.4% of total cDNA), plus
a minor product (3.4"2%) from skipping of exon 14a, also observed in the con-
trols. Four of the 17 were PI (with F508del or 574delA in trans) and low FEV1
and FVC values. The rest presented with mild clinical phenotype. 711q3A)G
resulted in skipping of exon 5 (36.6"7.8%of total cDNA). One patient(R1070Qq
S466X in trans) was PI, the rest being PS. Two cases have unusually mild phe-
notypes, one presenting with CBAVD and chronic cough (F508del in trans) and
the other (mother of a CF patient), with no clinical symptoms (G1069R in trans).
Mutation 1525-1G)A resulted in four aberrantly spliced products: skipping of exon
10 (24.9"4.5%), skipping of exon 9 (15.4"4.5%) also present in the controls,
combined skipping of exons 9 and 10 (14.5"3.5%) and a product containing an
extra 119bp (22.5"4.2%), probably resulting from activation of an alternative
splice site within intron 10 and not observed in the controls. One patient is PI
(3120q1G)A in trans) and the other PS.
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Identification of a new deletion in two French CF patients
O. Raguenes (Presenting), M. Guillot , M.P. Audrezet , C. Le Marechal , I.1 2 1 1´ ` ´ ´
Quere , S. Ravilly , C. Ferec1 3 1´ ´ ´
Equipe mixte INSERMyUBOyEFS 0115, Brest, France, CRCM, CHG Robert Bis-1 2
son, Lisieux, France, Association ‘Vaincre La Mucoviscidose’, Paris, France3
With more than one thousand of mutated alleles so far reported to the CF Genetic
Analysis Consortium Mutation Database, the gene responsible for CF is probably
one of the most frequently mutated among those involved in human disorders
(www.genet.sickkids.on.ca). To identify both the common mutations and the myriad
of private alleles disseminated throughout the 27 exons, we have recently developed
and proposed a full scanning technique of the coding sequence using a D-HPLCy
sequencing procedure. This approach enables us to identify nearly 100% of the
point mutations over a few days and it represents today the gold standard for ana-
lysing the CFTR gene (Le Marechal et al., Hum Genet, 2001). However, the pro-´
cedure missed the large deletions that could not be so rare in the CFTR gene, this
is especially true in some populations of eastern European origin. To complete our
gene strategy analysis, we have set up a quantitative PCR analysis. This approach
has allowed us to find a new deletion encompassing exon 22 and 23. We determined
the precise size of the deletion (4095q2912 del 1532) and its segregation in this
particular family; the mother displays a mild CF phenotype (sweat test: 78 mmoly
l, genotype: del508yunidentified), her three children harboring three different gen-
otypes (4095q2912 del 1532ydel508 - sweat test: 70 mmolyl; del508yunidentified
- sweat test: 68 mmolyl; 4095q2912 del 1532yunidentified - sweat test: 85 mmoly
l). Hypothesis about this particular segregation will be discussed. A complete scan-
ning for point mutations in the CFTR gene should be completed by a search for
deletion if one wants to improve our knowledge on the molecular basis of Cystic
Fibrosis. We thank the French Association ‘Vaincre La Mucoviscidose’ for support.
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The D1152H mutation of the CFTR gene: a relatively common allele
associated to neonatal hypertrypsinaemia
R. Padoan (Presenting), C. Colombo , C. Corbetta , D. Coviello , L. Porcaro , M.1* 2 3 4 4
Seia4
Cystic Fibrosis Centre, AO Istituti Clinici di Perfezionamento, Milano, Italy, Cys-1 2
tic Fibrosis Centre, University of Milan, Milano, Italy, Neonatal Screening Centre,3
AO Istituti Clinici di Perfezionamento, Milano, Italy, Clinical Research molecular4
Genetic Laboratory, AO Istituti Clinici di Perfezionamento, Milano, Italy
D1152H is a missense mutation on exon 18 of the CFTR gene, associated with
mild phenotypic expression (CBAVD, mild late onset of lung disease, pancreatitis)
and borderline or normal sweat test. The frequency of this mutation in Italy is
reported to be 0.11% (data from the Italian Registry). Aim of our study was to
establish the frequency of this allele in our CF population (Lombardia, North-
western Italy) and clarify clinical features of patients bearing at least one D1152H
allelle. Among 600 CF patients, we identified 21 patients bearing the D1152H allele
(two siblings), giving a frequency of 1.7% (20y1176 unrelated chromosomes) high-
er than previously reported for European populations. This allele is presently one
of the ten most frequent mutations in our whole population. CF patients bearing
D1152H were found to pertain to two distinct subgroups: (a) 8 infants (38%)
presenting with persistent neonatal hypertrypsinaemia and borderline sweat test
(mean sweat chloride 38,64 mEqyL; range 28–57); (b) 7 adults diagnosed after
the age of 16 yr (range of age 16–48 yr), because of chronic pulmonary disease
(mean FEV at diagnosis 71%; range 37–101%). Of the remaining six patients, 41
were diagnosed between 2 and 15 yr, because of recurrent pulmonary symptoms,
one girl (8 yr) for idiopatic pancreatitis and an adult, because of CBAVD. Our data
suggest that the D1152H allele may be more frequent than previously reported and
is not consistently associated with mild lung disease. The search of the D1152H
allele seems to be indicated in adolescents and adults with chronic pulmonary dis-
ease and borderline or normal sweat test, as well as in infants with persistent neo-
natal hypertrypsinaemia and sweat test in the borderline range, to timely diagnose
and treat CF in patients with chronic respiratory disease and to prevent the disease
progression.
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Identification of a new large deletion in the CFTR gene in a patient from
Saudi Arabia
M. Audrezet (Presenting), S. El Mouatassim , O. Raguenes , I. Quere , C. Le1 2 3 1
Marechal , M. Becker , F. Forestier , C. Ferec1 2 2 1
Equipe mixte InsermyUBOyEFS O115, CHU Morvan, Brest, BREST, France,1
Laboratoire Marcel Merieux, Service de genetique humaine, LYON, France, Equi-2 3´ ´ ´
pe mixte InsermyUBOyEFS O115, CGU Morvan, BREST, France
More than 1000 mutations have now been described throughout the CFTR gene,
the majority of them being point mutations. Several commercial kits are available
to screen for the most common mutations in the CFTR gene and they are useful to
rapidly identify the genotype of CF patients. A child and his parents (1st cousin
parents) from Saudi Arabia were referred to our laboratories for CFTR mutations
screening, because of recurrent chest infection. Using with the Innolipa CF(12q
17) assay for 29 common mutations, we obtained a normal pattern in the parental
samples, as in the controls. In contrast, only specific bands corresponding to muta-
tions located in exons 9 and 19 were present in the child’s sample, whereas the 10
bands harbored mutations in exons 10, 11, 13 and 14b were not detected. In order
to characterize more precisely this large deletion, specific primers for exons 9 to
18 were used to amplify the patient’s DNA. PCR products were obtained for exons
9, 10, 17a, 17b and 18, thus suggesting that the breakpoints were located in exon
10 and between exons 16 and 17a. Several long ranges PCR experiments were
performed using forward primers located in exon 10 and reverse primers located in
intron 16. A 1.2 kb fragment was obtained with the child’s DNA. Direct sequencing
identified the deletion breakpoints. It started at nucleotide 1716q9 in intron 10 and
spanned 47492 pb. Large deletions in the CFTR gene are not routinely screened by
the conventional techniques and their frequency is probably underestimated. As an
example, 2 frequent large deletions have been reported in Israeli-Arab and Slavic
patients. This illustrates the need to develop specific techniques to search for these
deletions in order to increase the mutation detection rate in cystic fibrosis.
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Recurrent mutations: are they the same second time around?
M. Raynor (Presenting), M.J. Schwarz1 1
Molecular Genetics Laboratory, Royal Manchester Children’s Hospital, Manches-1
ter, United Kingdom
A number of cystic fibrosis mutations have been shown to be recurrent, rather than
identical by descent. When mutations do recur, they may be associated with dif-
ferent chromosomal haplotypes, although these do not necessarily confer different
phenotypes. We describe two mutations that are widely screened for and which are
present on at least two chromosomal backgrounds; one (E60X) appears to be uni-
formly severe, while the other (I148T) ranges from a typical cystic fibrosis mutation
to what is possibly a benign variant, depending on the associated marker haplotype.
Chromosomal background was determined by testing the intragenic markers
IVS17bTA, IVS17bCA, IVS8CA, IVS6bTTGA, M470V, the intron 8 polythymidine
repeat (Tn), 2694TyG and the intron 1 CA repeat and, in the case of I148T, a 6-
base deletion in exon 17a. We suggest that the 6-base deletion confers mutation
status on the I148T mutation and that all other forms are of less clinical significance.
Our findings highlight the dangers of accepting missense mutations of the CFTR
gene at face value, when they may only be acting as a benign marker for a more
serious mutation.
14
Genotypeyphenotype analysis of Y122X, a mutation particularly
frequent in the Reunion Island (France)
I. Dugueperoux (Presenting), G. Bellis , J.F. Lesure , M. Renouil , M. De1 2 3 3´ ´
Braekeleer1
Laboratoire de Cytogenetique, Universite de Bretagne Occidentale and CHU Mor-1 ´ ´ ´
van, Brest, France, INED, Paris, France, Service de Pediatrie, Hopital d’Enfants,2 3 ´ ˆ
Saint Denis de La Reunion, France´
Cystic fibrosis (CF) accounts for 1y1000 live births in the population of French
ancestry of the Reunion Island. Eighty-one CF patients born in the island are reg-
istered in the French CF Registry. Fourteen mutations are identified, 3 accounting
for 73.6% of the chromosomes identified (DeltaF508, Y122X, 3120q1G-)A).
The DeltaF508yDeltaF508, DeltaF508yY122X and Y122XyY122X genotypes rep-
resent 58.3% of the patients. We compared the phenotype (signs at diagnosis,
anthropometry, lung function, morbidity, etc.) for the patients registered in 2000.
The mean age was 12.4 yr in all three groups. The Y122X homozygotes (ns11)
were diagnosed at a mean age of 18.1 months, compared to 23.8 and 27.7 in the
DeltaF508yY122X (ns17) and DeltaF508yDeltaF508 (ns28) groups respectively
(Ps0.84). All of the patients were pancreatic insufficient. Those carrying at least
one Y122X mutation had lower height (Ps0.014), weight (Ps0.13) and body
mass index (Ps0.36) that the DeltaF508 homozygotes. Mean FCV and FEV val-1
ues were similar in all three groups. No differences were noted in the presence of
germs at the sputum culture, but a higher rate of Haemophilus influenzae among
DeltaF508yDeltaF508 and of Aspergillus among the patients carrying at least one
Y122X mutation. The rates of liver cirrhosis and mellitus diabetes were similar in
all three groups. The small size of the populations under study may explain why
some differences, although large, as in the anthropometric values, did not reach
significance. In conclusion, the Y122X mutation has to be considered as a severe
allele. Supported by ‘Vaincre la Mucoviscidose’.
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CFTR gene mutations, polythimidine tract(T-tract)of intron 8 and
polimorphic site M470V (exon 10):GenotypeyPhenotype correlation
Caterina, Di Girgenti (Presenting), Antonina, Cannuscio , Lisa, Termini , Rosalia,1 1 2
Messineo , Luciana, Iapichino1 2
Molecolar Biology laboratory, Ospedale dei Bambini, Palermo, Italy, CF center,1 2
Ospedale dei Bambini, Palermo, Italy
It is well known that the lenght of the T-tract of intron 8 influences the splicing
efficiency of exon 9, and that the homozygous presence of the 470V allele of the
polymorphic site M470V increases the penetrance of the 5T allele. In this study,
we try to explain the phenotypic differences of the members of 2 families on this
base. FAMILY 1: Propositus Z.A 34 yr diagnosed for infertility and mild respiratory
symptoms, sweat Chloride 98, genotype: N1303K_N,TG10-9T_TG12-5T_470M_
470V. Brother Z.Ax 39 yr, no CF symptoms, unmarried, no children, sweat chloride
79, genotype N1303K_N,TG11-7T_TG10-9T,470M_470V. Brother Z.S.36 yr, no
symptoms, married, 2 children, sweat chloride 82.Sister Z.R.M. 43 yr, no symptoms,
sweat chloride 44, genotype N1303K_N,TG10-9T_TG11-7T,470M_470V. Sister
Z.R., 41 yr, no symptoms, sweat chloride 52, genotype N_N,TG12-5T_TG11-
7T,470 V_470V. FAMILY 2:Propositus C.C 8 yr, mild respiratory symptoms, sweat
chloride 37–77, genotype G542X_N,TG10-9T_TG12-5T,470M_470V. Father
C.G.no symptoms, sweat chloride 66, genotype N_N,TG11-5T_TG12-5T,470M_
470V. Mother M.V.no symptoms, sweat chloride 36, genotype G542X_N,TG10-
7T_TG10-9T,470M_470M. We suppose that in the propositi the co-presence of one
mutation, the TG12-5T allele and 470 V allele is responsible of the CF symptoms.
This genetic condition is present in nobody else in the families, but the co-presence
of TG12-5T and 470V alleles is responsible of the high sweat chloride values.
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The deltaI507 mutation: a rare allele associated with a severe
phenotype
I. Dugueperoux (Presenting), G. Bellis , M. De Braekeleer1 2 2´ ´
Laboratoire de Cytogenetique, Universite de Bretagne Occidentale and CHU Mor-1 ´ ´ ´
van, Brest, France, INED, Paris, France2
DeltaI507 is a mutation due to the deletion of 3 nucleotides between position 1648
and 1653 in exon 10 of the CFTR gene, leading to the deletion of an isoleucine at
position 507 (or 506) of the protein. Its prevalence appears to be low (0.2%).
Forty-seven patients (23 males, 24 females) compound heterozygous for the
deltaI507 are registered in the French CF registry. Of them, 30 (63.8%) are
deltaF508ydeltaI507. Sixteen of the 40 patients (40%) for whom the information
was available were born in Brittany and Normandy (Western France). Data on 21
deltaF508ydeltaI507 patients and matched homozygotes for the deltaF508 mutation
seen at least once in 2000 was extracted from the registry. All 42 patients were
pancreatic insufficient and five in both groups had meconial ileus. Thirteen patients
(6 and 7) were identified following neonatal screening. The mean age at diagnosis,
excluding the screened patients, was 24.4 and 11.3 months in the deltaF508y
deltaI507 and deltaF508ydeltaF508 groups, respectively (Ps0.14). The frequency
of the clinical signs at diagnosis was similar (Ps0.85). Small differences in the
anthropometry, lung function and bacteriology were noted between both groups, but
none reached statistical significance (P)0.05). Clinical events, such as liver cir-
rhosis and mellitus diabetes, were similar in both groups. Although the size of the
deltaI507ydeltaF508 group is small, the deltaI507 mutation is a rare allele leading
to a severe phenotype. The authors thank the participating centers to the French CF
Registry. Supported by ‘Vaincre la Mucoviscidose’.
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First L997F homozygous patient: diagnosis cystic fibrosis without any
symptoms, normal sweat and intestinal chloride secretion?
N. Derichs (Presenting), I. Grund , A. Schuster , C. Stolpe , A. Ernsting , S. Kort-1 2 3 1 2 ¨
ge-Jung , P. Kozlowski , M. Ballmann2 2 1
Department of Pediatrics, Medical School Hannover, Hannover, Germany, Pre-1 2
natal Diagnostics and Genetics, Dusseldorf, Germany, Childrens University Hos-3¨
pital, Dusseldorf, Germany¨
The current CF consensus diagnostic criteria (Rosenstein 1998) include a combi-
nation of (1) any CF symptom or a CF sibling or a positive newborn screening;
and (2) any demonstration of CFTR abnormality. In the last years also intestinal
current measurement (ICM) has been shown to be a useful diagnostic method to
investigate CFTR function (Veeze, 1994; Derichs, 2000). We report the case of a
15 months old Turkish girl. Genetic CFTR analysis in the consanguineous parents
revealed heterozygosity for L997F in both parents. Prenatal analysis in the girl, who
has no CF sibling, showed homozygosity for L997F. After premature birth she
developed normally and showed no CF symptoms up to now. We performed addi-
tional CF-relevant diagnostic tests: sweat tests were normal on several occasions,
also ICM exhibited no abnormality in CFTR chloride secretion. The girl has pan-
creatic sufficiency, negative Pseudomonas aeruginosa serum antibodies and a nor-
mal chest X-ray, microbiological cultures identified only E.coli so far. The patient
requires no treatment at the moment. This is the first L997F homozygous case in
the literature. The mutation had initially been described as a DNA variant (Fanen
1992), and later classified as CF-mutation upon analysis of a compound hetero-
zygous 5-year-old boy from northern India. Our patient does currently not fulfil the
CF consensus diagnostic criteria despite CFTR mutation analysis. L997F may be a
CFTR gene mutation without associated CFTR-related disease, or a polymorphism.
The diagnosis CF should not be based on the genetic analysis alone, but remain a
clinical decision.
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Identification of four novel mutations in black CF patients
M.N.F. Feuillet-Fieux (Presenting), M.F. Ferrec , N.G. Gigarel , D.B. Boree , I.S.1 1 2 1
Sermet , G.L. Lenoir , L.T. Thuillier , J.P.B. Bonnefont3 3 1 2
Biochimie Genetique B, Hopital Necker-Enfants Malades, Paris, France, Depar-1 2´ ´ ˆ ´
tement de Genetique Medicale, Hopital Necker-Enfants Malades, Paris, France,´ ´ ´ ˆ
Service de Pediatrie Generale, Hopital Necker-Enfants Malades, Paris, France3 ´ ´ ´ ˆ
While native Africans have been reported with a classical form of CF, few data are,
however, available with respect to the ‘African’ pannel of CF mutations. Some CF
mutations identified in African–American have not been found in Caucasian
patients. One of them, 3120q1A)G accounts for approximately 50 and 12% of
CF alleles in the South African and African–American patients, respectively.
3120q1A)G is one of the few mutations detected in Central African patients so
far. We report herein four novel mutations in three Central African patients native
of Cameroon wY109Xx and Senegal wIVS2q28A)G, EX17a-EX18delx, and in one
Guianese patientwIVS22q1G)Ax. CFTR gene analysis by DGGEysequencing
identified three homozygous CFTR mutations: (1) Y109X (exon 4), predicted to
truncate the C terminal end of CFTR from the first transmembrane domain, resulted
in a severe typical CF phenotype; (2) A large deletion spanning exons 16 to 18 of
CFTR yielded to a very serious form of CF. This deletion was different from the
founder EX17a-EX18 deletion reported in Palestinian Arabs; (3) IVS22q1G)A,
affecting the splice donor site of the intron 22, resulted in a typical form of CF
with exocrine pancreatic sufficiency. Heterozygous IVS2q28A)G substitution
(intron 2) likely to affect the CFTR mRNA splicing, was the only mutation iden-
tified in the last patient despite extensive scanning of the CFTR gene, suggestive
of a second mutation located in the CFTR promoter or intronic regions. The rela-
tively mild phenotype observed that the patient (absence of pulmonary symptoms
and borderline sweat test) might be ascribed to factors other than CFTR mutations,
as recently suggested in some patients with nonclassic CF phenotypes. Detection
of novel CF-causing mutations provides a better knowledge of the spectrum of black
CFTR mutations, especially in native Central African patients where very few
molecular data are available. This study was supported by Association Mucovis-
cidose ‘ABCF proteins’.
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Severe mannose-binding lectin-deficiency leads to impaired lung
function and raised systemic inflammatory markers in adults with CF
J.C. Davies (Presenting), N. Shen , C. Booth , K. Fidler , D.M. Geddes , E.W.F.W.1* 2 2 2 2
Alton , M.W. Turner , N. Klein2 2 2
Imperial College, Royal Brompton Hospital and Institute of Child Health, London,1
United Kingdom, London, United Kingdom2
Much interest is focusing on modifier genes, such as the innate defence protein,
MBL, to explain the variable severity of the CF phenotype. We have studied the
clinical impact of low MBL in 273 adult CF patients. Genomic DNA was analysed
for structural mutations (wild-type A, mutations O) and the XyY promoter poly-
morphism. Haplotype frequencies reflecting those of healthy populations (AyA
59.7%, AyO 36.3%, OyO 4.0%) and similar mean ages between groups, make a
significant survival disadvantage of one haplotype group unlikely. Over a 13-year
period mean wSEMx FEV was significantly lower in 11 OyO patients (47.6(4.8)%1
predicted) than in 163 AyA subjects (65(1.9)%) (P-0.05). Levels in AyO subjects
(60.8(2.2)%; ns99) were not significantly different from the AyA group. FVC
was significantly lower in the OyO group (64.8(4.7)%) than in either of the other
two groups (AyA 83.4(1.6)%, P-0.01; 82.0(2.0)%, Ps0.02). Low MBL was not
related to infection with either P. aeruginosa or B. cepacia The low-expressing X
promoter was not associated with poor lung function. White blood count (WBC)
was significantly (Ps0.03) higher in the OyO group (13.4(2.1)=106yl) than in
the rest of the cohort (10.7(0.2)=106yl) with a trend towards an increased CRP
(OyO 22.6(7.4) mgyml; AyAqAyO 12.8(1.0); Ps0.06). CF adults with two
structural MBL-2 mutations have significantly impaired lung function, whereas het-
erozygotes do not. MBL deficiency did not increase the risk of infection, but the
raised WBC and CRP suggest that the protein is playing an important role in the
inflammatory response to chronic infection. We have not observed the same pattern
in a paediatric CF population, which confirms our impression that the effects of
modifier genes may be specific to either certain age groups or disease stages.
Severely MBL-deficient CF patients may be candidates either for more aggressive
conventional treatments, or for novel approaches such as MBL replacement therapy.
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Polymerase chain reaction and automated fluorescent DNA sequencing
to identify functionally important mutations in the mannose-binding
lectin gene
A.T. Cunnane (Presenting), K.W. Southern , R.C. Mountford1 1 2
Paediatrics, University of Liverpool, Liverpool, United Kingdom, Molecular1 2
Genetics, Liverpool Women’s Hospital, Liverpool, United Kingdom
Introduction: The mannose binding lectin (MBL) protein is an important component
of the intrinsic immune system. Three missense mutations in exon 1 of the MBL
gene have been associated with reduced serum MBL concentration and poorer res-
piratory condition in CF patients (P. Garred et al., JCI 104 (1999) 431–437). We
have utilised the close genomic proximity of these three mutations (codons 52, 54
and 57 of exon 1) to develop a simple molecular assay for identification of the
respective base changes (154 CT; 161 GA; 170 GA). Methods: Patients with avail-
able stored DNA were approached for consent. DNA was amplified using novel
primers (MBL-1F, ACTGTGACCTGTGAGGATGC; MBL-2R, GGGCTGGCAA-
GACAACTATTA). The amplified DNA was then sequenced using an automated
fluorescent method and incorporating one of the primers (MBL-1F) to initiate the
sequence. Heterozygote or homozygote mutations were identified by analysis of the
respective peak heights by eye. Results: DNA was stored and consent obtained from
47 patients. MBL genotype and frequency are shown in the table.
Genotype n %
Wild type 27 57.4
Heterozygous 52 4 8.5
Heterozygous 54 13 27.7
Heterozygous 57 1 2.1
Homozygous 52 0 0
Homozygous 54 1 2.1
Homozygous 57 0 0
Compound heterozygote 54 and 57 1 2.1
Conclusions: MBL mutations occur at a high frequency in this population,
consistent with data published from other European populations. This method
provides a reliable and valid tool for identifying these three commonly reported
mutations.
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Metabolic gene polymorphisms (CYP1A1, EPHX1, GSTM1 and GSTP1)
associations with the severity of cystic fibrosis airway disease
G. Korytina (Presenting), Dily Yanbaeva , Tatyana1 2 2
Institute of Biochemistry and Genetics, Ufa Scientific Center, Russian Academy of1
Sciences, Ufa, Russia, Ufa, Russia, Victorova, Ufa, Russia2 3
Some of clinical variations in cystic fibrosis patients may be explained by the type
of mutations in the CFTR gene, but the severity of clinical disease in CF modified
by secondary genetic and environmental factors. Blood samples were taken from
60 patients with CF (32 middle CF, 28 severe CF) and 164 control subjects. The
frequency of ValyVal genotype of CYP1A1 gene was significantly higher in patients
with severe CF (0.07) compared to control (0.00) and middle CF (0.00) patients
(P-0.01). The frequency of IleyVal genotype was higher in middle CF patients
(0.160 versus 0.06 in control) (ORs2.82) and in severe CF patients (0.11). These
appears to be high in association between severity of CF phenotype and the muta-
tion of CYP1A1 gene, which increase enzyme activity (ORs27.64). The EPHX1
is an enzyme, which plays an important role in metabolizing highly reactive epoxide
intermediates in the lung. Earlier was showed that the Tyr113His and His139Arg
polymorphisms correlate with the level of EPHX1 enzymatic activity. We observed
association of severe CF airway disease with the very slow metabolizing form of
EPHX1 (ORs19.32) (0.11 vs. 0.006 in control and 0.00 in middle CF; P-0.01).
The combination of high enzyme activity CYP1A1 and very slow metabolizing
form of EPHX1 has been associated with increased risk of severe lung disease at
CF patients (ORs12.3; P-0.05). The frequency of GSTM1* 0y0 genotype in CF
patients was 0.28 vs. 0.42 in control (P-0.05). The frequency of GSTP1* IyV
genotype was higher in patients with severe CF airway disease (0.63 vs. 0.33 in
control, P-0.01). We observed association of severe CF airway disease association
with GSTM1 * (qyq and 0yq) and GSTP1* IyV combinations (0.51 vs. 0.19
in control; ORs4.49 P-0.002). It is therefore possible that GSTP1 may play an
important role in local detoxification of xenobiotics such as EPHX1 in the lung.
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CFTR mutation 394delTT correlates with severe clinical phenotype in
Estonian CF patients
T. Kahre (Presenting), M. Teder , M. Panov , M. Parlist , A. Metspalu1 2 3 4 2¨
Molecular Diagnostics Centre, Tartu University Clinics, Tartu, Estonia, Estonia1 2
Biocentre, Tartu, Estonia, Tartu Children’s Clinic, Tartu University Clinics, Tartu,3
Estonia, Tallinn Children’s Hospital, Tallinn, Estonia4
Objectives: The incidence of cystic fibrosis (CF) in Estonia is 1:8000. The most
common mutation in CFTR gene, F508del, is represented in 52% of Estonian CF
chromosomes. 394delTT mutation accounts for approximately 13% of Estonian CF
alleles and ranks as the second most common CF alteration in Estonia as well as
in Northern European countries. The aim of the study was to evaluate retrospec-
tively the clinical and laboratory findings of Estonian CF patients carrying the
394delTT mutation. The study group consisted of 9 patients aged 1–22 yr. One
patient carried 394delTT in both alleles and 8 were compound heterozygotes for
394delTTyF508del. Obtained data were compared with clinical findings from 11
F508del homozygous patients aged 1 month to 20 yr. Results: All studied patients
had elevated sweat chloride levels (90–142 mmolyl for 394delTT, 75–168 mmoly
l for F508del patients) and pancreatic insufficiency. In both groups 3 patients devel-
oped liver disease. The severity of pulmonary disease was the most variable finding.
Although 8y9 patients, carrying 394delTT mutation, and 10y11, homozygotes for
the F508del, developed chronic lung disease. Statistical comparison of the groups
(The SAS system) revealed that there was no statistically significant difference (p-
value 0.05) in the mean current age or age at the diagnosis, sweat chloride levels,
or predicted values of pulmonary functional tests as well as in development of
chronic pulmonary disease, chronic sinusitis or liver disease between both groups.
Conclusions: This group of patients indicates that in most cases 394delTT leads to
development of severe CF. There was no statistically significant difference in disease
severity between 394delTT and F508del patients groups.
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Genotypic, phenotypic matching and sweat chloride levels of new
CFTR mutations in the cohort of Jordanian CF patients
M. Rawashdeh (Presenting), I. Aznarez , D. Markiewicz , J. Tzountzouris , M. Al-1 1 1 1
Khateeb , L.C. Tsui , J. Zielenski1 2 2
Jordan CF Association, Jordan, Canada1 2
Contrary to earlier beliefs, cystic fibrosis(CF) is relatively common in Arab pop-
ulations with an estimated incidence of approximately 1y2560 live births in Jordan.
In this report, total of 306 (175 males and 131 females) cases of Arab CF patients
were followed up over a period of 12 yr from diagnosis. In order to characterize
the spectrum of the CFTR mutations in this population, DNA samples from 77
patients and 65 parents coming from 78 families were obtained and subjected to
complete CFTR gene screening, which was completed for 71 subjects. We used a
multiplex heteroduplex (mHET) shift analysis followed by direct sequencing. The
screening region included promoter, all exons with flanking intron sequence as well
as the (including T-tract in intron 8). Genetic screening resulted in identification of
25 different mutations accounting for 50% of tested CF chromosomes. The DF508
mutation was found to account only for 7.4%. Eight new mutationsyvariants were
found in the Jordanian CF cohort (CFTRdele2ins186, 296q9A-T, 297-10T-
G,T388M, T760M, 3670delA and 4006delA and G1244D). Genotypic and phe-
notypic matching of 8 new CFTR mutations are shown in the table below.
Mutation Nucleotide
change
Exony
Intron
Consequence Second mutation Age at DX
(mo)
Lung
disease
PIy
PS
CFTRdele2
(ins186)
Complex 2 Larde del. Unknown 28 Moderate PI
296q9A-
)T
IVS 2 Splicing 296-10T-)
G
72 severe PI
296-10T-)
G
IVS 2 Splicing 296q9A-)
T
same same same
T388M T to ?y at 1295 8 Missense W1282X 11 moderate PI
T760M C to T at 2411 13 Missense DF508y
1677delTA
60 moderate PI
3670delA 19 Frameshift 3670delA 4 severe PI
4006delA 21 Frameshift DF508 14 mild PI
G1244D ? ? DF508 4 mild PI
The large number of mutations reflects ethnic diversity of the Jordanian population
and the complex history of the country. Despite the large diversity in the CFTR
mutations occurring in Jordanian CF patients, these results can help to improve
genetic counselling, prenatal diagnosis as well as our understanding of the molecular
basis of the pathophysiology of cystic fibrosis.
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CFTR gene mutation screening in the Northern Ireland regional
genetics centre
D. Beattie (Presenting), C.A. Graham , S. Elborn , A. Reid1 1 1 2
Regional Genetics Centre, Belfast City Hospital Trust, Belfast, United Kingdom,1
Royal Group of Hospitals Trust, Belfast, United Kingdom2
The Regional Genetics Centre currently offers routine screening of 29 mutations
and the intron 8 polyT variant on a variety of referrals. Since 1996, samples have
been received on nearly 1000 patients suspected of having some form of Cystic
Fibrosis. Screening has detected a range of mutations in certain patient groups.
% mutations detected within each group
Patient types %
Total
patients
Two
mutations
One
mutation
One mutationy5T
or 7T variant
5T
varaint
only
Bronchiectasis 24.0 1.7 6.0
Other possible affecteds 64.6 11.5 7.6
Infertility investigation (no
clinical details)
7.7 3.9 21.0 10.5
Azoospermia specified 3.7 5.5 2.8 44.0 2.8
A rare mutation screening program using temporal temperature gradient gel
electrophoresis (TTGE) and direct sequencing is in development for patients who
are mutation negative, but clinically affected or have one detectable mutation. TTGE
conditions have been optimised for 22 fragments from 16 exons using primers from
the CF Consortium and the system has detected all available previously known
mutaions in the population. Optimisation allows that the fast throughput of patients
on 96 well plates and multiple fragments can be separated under similar TTGE
conditions. 13 patients, heterozygous for DF508, have been screened for 7
fragments by TTGE. 2 exon 10 mutations and an exon 3 variant have been detected.
Unique mobility patterns for the exon 10 mutations were observed allowing them
to be distinguished from the DF508 pattern. Initial screening detected a slight
increase in CFTR mutation frequency in bronchiectasis patients. However, among
infertility investigation and azoospermia patients there was a significant increase in
mutation incidence. Atypical Cystic Fibrosis is therefore a common cause of male
infertility and mutation screening should be considered a priority. Rare mutation
screening should clarify the contribution that CFTR mutations make to the
bronchiectasis phenotype and allow better targeting of resources in the future.
s10 Journal of Cystic Fibrosis 2 (2003) S3–S12
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Comparison of the CFTR mutation spectrum in three cohorts of
patients of Celtic origin from Brittany (France) and Ireland
V. Scotet (Presenting), D.E. Barton , J.B.C. Watson , M.P. Audrezet , T.1 2 3 4´
McDevitt , S. McQuaid , C. Shortt , M. De Braekeleer , C. Ferec , C. Le2 2 3 5 1´
Marechal1´
Equipe mixte INSERMyUBOyEFS (EMI 01-15), Brest, France, National Centre1 2
for Medical Genetics, University College Dublin, Our Lady’s Hospital for Sick
Children, Dublin, Ireland, Cork Regional Hospital, Southern Health Board, Cork,3
Ireland, Equipe mixte INSERMyUBOyEFS, CHU Morvan, Brest, France, Labor-4 5
atoire de cytogenetique, Equipe mixte INSERMyUBOyEFS, Brest, France´ ´
This aim of this study is to compare the spectrum of the mutations identified in the
gene responsible for cystic fibrosis (CF) in three cohorts of patients of Celtic origin
from Brittany and Ireland. This study included 389 patients from Brittany, 631 from
Dublin and 139 from Cork, i.e. a total of more than 2000 CF alleles. The CFTR
gene analysis relied on the detection of the most common mutations followed by
a complete gene scanning using DGGE or D-HPLC. High mutation detection rates
were obtained in each cohort: 99.6, 96.8 and 96.0%, respectively. A high frequency
of the F508del mutation (74.8 to 81.3%) and of the ‘Celtic’ mutation (G551D: 3.7
to 9.7%) was observed in each population. Apart from this, the mutation spectrum
observed in each region differed. In Brittany, the most common abnormalities were:
1078delT (3.6%), N1303K (1.4%), W846X2 (1.0%) and 1717-1G)A (1.0%),
whereas in the cohort of Dublin, the most frequent mutations were: R117H (3.0%),
R560T (2.4%) and 621q1G)T (1.7%). Finally, in the Cork area, only the R117H
mutation reached a frequency of 1%. This collaborative study highlights the simi-
larities of the CFTR alleles in the Breton and Irish populations, but also the dis-
parities that exist between these populations, despite their common origin. Each
population has its own history, with its mixture of founder effects and genetic drifts,
which are at the origin of the current mutation distribution. The molecular study of
the CFTR gene provides new tools for retracing European populations’ histories.
This improved knowledge of CF epidemiology allows the improvement of diag-
nostic strategies and the refinement of genetic counselling.
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Impact of public health strategies on the birth incidence of cystic
fibrosis in Brittany, France
V. Scotet (Presenting), M.P. Audrezet , M. Roussey , G. Rault , M. Blayau , M.1 2 3 4 5´
De Braekeleer , C. Ferec6 1´
Equipe Mixte INSERMyUBOyEFS (EMI 01-15), Brest, France, Equipe mixte1 2
INSERMyUBOyEFS, CHU Morvan, Brest, France, Service de pediatrie, CHRU3 ´
Ponchaillou, Rennes, France, Centre de Perharidy, Roscoff, France, Laboratoire4 5
de Genetique Moleculaire, CHRU Ponchaillou, Rennes, France, Laboratoire de6´ ´ ´
cytogenetique, Equipe mixte INSERMyUBOyEFS, Brest, France´ ´
The cloning of the CFTR gene and the identification of its numerous mutations
have enabled to implement efficient strategies of public health. Taking into account
the situation of Brittany, a region of western France where cystic fibrosis (CF) is
common and where a neonatal screening program was set up 14 years ago, the aim
of this study was to assess the changing birth incidence of CF and to determine
how it was influenced by different programs, such as neonatal screening and pre-
natal diagnosis. From 1992 to 2001, 123 CF children were screened in Brittany,
leading to an incidence of 1y2838. Over the same period, we collected the prenatal
diagnoses realised in families related to a CF child, as well as those made following
the detection of an echogenic bowel during pregnancy. By considering the 54 CF-
affected pregnancies terminated during this period, the corrected CF incidence was
1y1972. Prenatal diagnosis was therefore responsible for a global decrease of 30.5%
in birth incidence of CF. Two-thirds of these abortions were chosen by couples
related to a CF child (ns36); this led to a change of 22.6% in birth incidence.
The 18 other abortions were made following the in utero detection of an echogenic
bowel; this ultrasound examination of pregnancies was responsible for a decrease
of 12.8% in CF birth incidence. Moreover, neonatal screening, through early diag-
nosis, enables couples to benefit from prenatal diagnosis, sometimes before the first
symptoms appeared on their previously screened child. This was the case for 13
couples in our study, which allowed to modify the incidence of 6.1%. Finally,
cascade screening, through the detection of 17 new 1-in-4-risk couples in the kin
of a CF child, led to a decrease of 3.9% in birth incidence. This work constitutes
the first study able to determine the evolution of CF incidence through both neonatal
screening, prenatal diagnosis, ultrasonographic exams and cascade screening.
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CFTR mutation analysis in infertile couples
K. Huber(Presenting), B. Worofka, E. Kittl, J. Hofmann, M. Hejtman, K. Bauer
Zentrallabor, Donauspital, Wien, Austria
Clinically affected male CF patients present a spectrum of genital phenotypes. Thus,
for assisted reproduction, screening of CFTR mutations in infertile couples has
become an essential diagnostic procedure. Methods: Twenty-one men and 13 of
their female partners were analyzed for CFTR mutations in the last two years.
Twelve of the men were diagnosed with CBAVD, four had epididymis aplasy, for
five, no specific information could be attained. Results: Of the persons with
CBAVD, 7 were heterozygous for a CFTR mutation (six dF508, one 542X), four
had a 5T allele in intron 8, additionally. No mutation was found in 5 men with
CBAVD with our tests. Of the men with epididymis aplasy, two were heterozygous
for dF508; one of these had a 5T allele in intron 8. Two showed none of the 29
mutations analyzed and 7Ty7T alleles in intron 8. Finally, the five men with unspe-
cified referral included two men with a heterozygous deletion at locus 508 (dF508y
WT) plus the 5T allele in intron 8; the three others had normal alleles at the loci
analyzed. The women in this group (all without clinical symptoms and normal
genotype) supposedly have the normal population risk of being a CF carrier. Con-
clusion: For more than half of the men referred from IVF clinics, a conclusive
analysis could be offered by our tests. Still, mutations other than the 29 most
common ones analyzed by our tests must be involved in the pathogenesis of
CBAVD (42% of men with CBAVD had normal genotypes with our tests). Whether
or not these will turn out to be CFTR mutations remains to be resolved.
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Identification of a T3 allele in a CBAVD (congenital bilateral absence of
vas deferens) patient : in vitro studies demonstrate tissue specificity of
aberrant exon 9 splicing
A. Disset (Presenting), C. Michot , C. Guittard , M. DesGeorges , A. Harris , M.-1 1 1 1 2
C. Romey , M. Claustres , S. Tuffery-Giraud1 1 1
Laboratoire de Genetique Moleculaire, IURC and CHU, Montpellier, France,1
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, Unit-2
ed Kingdom
We report for the first time a CBAVD patient carrying a T3 allele at the IVS8 T(n)
locus, wTG12T3 (F508C)yTG11T7x genotype. This very rare allele has previously
been reported only once in a CF patient with pancreatic sufficiency carrying a
wTG10T9(DeltaF508)yTG13T3(wt)x genotype. Elucidation of the alternative splic-
ing mechanisms that are induced by the poly(T) alleles are important in understand-
ing pathogenicity of CFTR variants as well as differences observed between
different tissues. Aim: To study the cell type specificity of the alternative splicing
of the CFTR exon 9 in the presence of T3, T5, or T7 allele at the IVS8 (Tn) locus
by transfecting a variety of cell types derived from different tissues. Methods: Four
minigenes carrying human CFTR exons 8, 9 and 10 with flanking intronic sequenc-
es and the following TGm and Tn alleles at the 3’ end of intron 8 (TG12T3,
TG12T5, TG12T7, TG11T7), were transfected in human cell lines. Exon 9q and
Exon 9y mRNA species were quantified by RT-PCR and analyzed on an ABI 377
system. Results: As previously described, we observed that the degree of CFTR
exon 9 skipping was inversely correlated with the length of the Tn (T3)T5)T7).
We showed that the TG12T3 allele leads to a low amount of normally spliced
transcripts in all tested lines (12 to 37 %). Transfection experiments in different
cell lines demonstrated that exon 9 alternative splicing is differentially regulated in
tissues. The proportion of transcripts lacking exon 9 was significantly increased in
an epididymis cell line compared with pulmonary cell lines, independent of the Tn
genotype. Conclusion: Exon 9q transcript quantification in different cell lines con-
firms that the T3 allele should be regarded as a severe CF mutation. Moreover, the
transfections experiments suggest that each cell type carries a specific combination
of transacting factors that determine the degree of inclusion or exclusion of the
alternatively spliced CFTR exon 9.
s11Journal of Cystic Fibrosis 2 (2003) S3–S12
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Genetic analysis of CFTR in subjects with congenital bilateral absence
of vas deferens: an update
F. Grandoni (Presenting), A. Ferraro , L. Narzi , M. Seia , S. Cingolani , M.1 2 3 4 3
Lucarelli , R. Strom , S. Quattrucci2 2 3
Universita ‘La Sapienza’ and Min. Pol. Forestali a Ambientali, Roma, Italy, Dip.1 2`
Biotecnologie Cellulari ed Ematologia, Universita di Roma ‘La Sapienza’, Roma,`
Italy, Centro Fibrosi Cistica Regione Lazio, Universita di Roma ‘La Sapienza’,3 `
Roma, Italy, Istituti Clinici di Perfezionamento, Universita di Milano, Milano, Italy4 `
For a more complete characterization of genotypeyphenotype correlation in con-
genital bilateral absence of vas deferens (CBAVD), and for a definition of the most
suitable approach in the genetic analysis of this disease, we performed a mutational
analysis of Cystic Fibrosis transmembrane conductance regulator (CFTR) gene in
a group of CBAVD patients. In 61 of these patients we analyzed a preliminary
mutation panel, searching 31 most common mutations of CFTR by the PCRyOLAy
SCS procedure (Celera Diagnostics). For 42 of these patients a clinical character-
ization was performed, as well as a specific evaluation of (TG)m and Tn
polymorphic tracts obtained by cycle sequencing (Applied Biosystems). As a third
step of genetic characterization we planned to perform the sequencing of all CFTR
exons and adiacent intronic regions; sofar exon 4 was sequenced in all subjects and
exons 7, 10 and 19 in some of them. In the 61 subjects studied by the 31 mutation
panel, 2 mutations were detected in 1 subject, only one mutation was detected in
28 subjects. In 16 subjects (out of 42) variant (TG)12T5 or (TG)11T5 tracts were
evidenced. Sequencing step evidenced 4 additional mutations. The application of
this protocol, though still incomplete, allowed full characterization of 15 subjects
with 2 mutations andyor variant tracts, while 10 subjects appeared to have only
one mutation or variant tract. The sensitivity of this approach had therefore a value
of 36% for subjects with 2 mutations and of 60% for subjects with at least one
mutation. The sensitivity values are essentially reached by the combined application
of the 31 PCRyOLAySCS panel plus the (TG)m Tn tracts analysis. The overall
multistep approach greatly improves the clarification of genotypeyphenotype cor-
relation in CBAVD, a consistent fraction of the subjects with 2 mutations or variant
tracts showing, in addition to CBAVD, also other ‘mild’ clinical manifestations of
Cystic Fibrosis.
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Clinical features and CFTR mutations in patients with CBAVD
G. Pizzamiglio , D. Costantini (Presenting), M.A. Monti , M. Seia , C. Colombo1 2 1 3 2
CF Adult Center, Internal Medicine Department of I.C.P., Milano, Italy, CF Cen-1 2
ter, Pediatric Department, University of Milan, Milano, Italy, Molecular Genetic3
Laboratory, I.C.P., Milano, Italy
Role of CFTR is well recognized in the pathogenesis of congenital bilateral absence
of vas deferens (CBAVD). It has been suggested that Cystic Fibrosis (CF) may
present as isolated CBAVD in the absence of other clinical symptoms. 7 patients
(pts) with CBAVD and oneytwo CFTR mutations or polymorphism were referred
to our CF center to assess the diagnosis of CF. Mean age was 30.7, range 26–39.
Clinical history was not relevant in all patients; but one patient who presented three
bronchopneumonias occurred in infancy and adolescence. 5y7 pts had been smokers
in their life. Genetic assessment showed the combination of a severe with mild CF
mutation in 5 cases, the association between a severe mutation and poli-T 5y7
polymorphism in one case, and poli-T 5y9 polymorphism in one case. Sweat test
was positive in 4 cases, borderline in 3 cases (mean values59.74, range 46–71).
Chest X-ray demonstrated minimal changes in 5 pts was normal in 2 pts. Sputum
culture was positive for P. aeruginosa in 2 cases, St. maltophilia in 1 case was
negative in 4 cases. Mean FEV was 101%, range 84–116. No sign of malabsorp-1
tion was detected in these patients. BMI resulted normal (mean values22.3, range
20–26) in all patients. Sinusopathy was detected in 1 case, no other CF-related
disease was demonstrated in these patients at the diagnosis. In conclusion diagnosis
of CF was made in 5y7 cases. In these patients the association between a severe
and mild CF mutation isn’t related to a positive sweat test. Bronchopulmonary
involvement was absent or mild. Follow up is now short to be conclusive and
clinical observation of these patients for several years is necessary.
Pts Age of diagnosis Sweat test FEV %1 Sputum Mutation 1 Mutation 2 CF confirmed
1 26 46.2 116 neg DeltaF V1153E yes
2 27 66.5 95 neg DeltaF A238V-PoliT yes
3 26 52.0 84 P. aeruginosa G542X D1152H yes
4 32 55.0 97 neg DeltaF PoliT 5-7 no
5 31 71.5 91 P. aeruginosa DeltaF D1152H yes
6 39 64.0 115 neg Poli 5-9 -no
7 34 63.0 111 S. maltophilia 1717GA R3344L yes
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How often is the high viscosity of seminal fluid a minimal clinical
expression of cystic fibrosis?
T. Rossi , F. Grandoni , F. Mazzilli , L. Narzi , A. Ferraro , S. Quattrucci , R.1 2 1 3 4 3
Strom , M. Lucarelli (Presenting)4 4
Dip. Fiopatologia Medica, Universita di Roma ‘La Sapienza’, Roma, Italy, Centro1 2`
FC and Ist Sper Zootecnia Monterotondo, Universita ‘La Sapienza’ and Min Pol`
Agricole e Forestali, Roma, Italy, Centro Fibrosi Cistica Regione Lazio, Universita3 `
di Roma ‘La Sapienza’, Roma, Italy, Dip. Biotecnologie Cellulari ed Ematologia,4
Universita di Roma ‘La Sapienza’, Roma, Italy`
The aim of this work was to study the possibility of a genetic involvement in the
pathogenesis of decreased semen fluidity. The possible correlation between abnor-
mal semen consistency and mutations in the Cystic Fibrosis Transmembrane Con-
ductance Regulator (CFTR) gene was studied. 46 infertile male, selected on the
basis of sine causa high semen viscosity with negative spermculture were examined
together with 72 normospermic subjects studied as controls. A panel of 31 mutations
(by the PCRyOLAySCS assay, Celera Diagnostics) was analyzed, together with the
(TG)m Tn polymorphic tracts at the splice acceptor site of exon 9 by cycle sequenc-
ing (Applied Biosystems) (Lucarelli et al., BioTechniques 32 (2002) 540–547).
The frequency of most common mutations found in subjects with abnormal semen
consistency did not differ significantly from the frequency in the control group as
well as from that in the normal population. On the other hand, the frequencies of
the (TG)12 (17.4%) and T5 (7.6%) variant alleles were significantly higher in
subjects with high semen viscosity than in the control group (6.9 and 1.4%, respec-
tively). Moreover, the 39.1% of subjects with high semen viscosity carrying at least
one variant tract as compared with a value of 16.7% of control subject with normal
consistency of seminal fluid. Finally, four (TG)12T5 alleles were found exclusively
in subjects with high semen viscosity (none in the control group), one of these
subjects being a homozygous T5. A significantly higher frequencies of variant
(TG)m Tn tracts suggests that in some selected situations, abnormal semen consis-
tency can be a ‘minimal clinical expression’ of CF and that CFTR sequence vari-
ations can constitute the genetic basis of semen hyperviscosity, as is the case for
congenital absence of vas deferens. These findings can be of interest for appropriate
genetic counseling to patients with abnormal semen consistency, which are accepted
for in vitro fertilization programs.
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Interleukin-1 receptor antagonist gene polymorphism and
Pseudomonas aeruginosa chronic infection in children with cystic
fibrosis
H. Corvol (Presenting), K. Chadelat , H. Corvol , C. Flamant , M. Roussey , F.1* 1 1 1 2
Bremont , A. Flahault , J.M. Cavaillon , M.C. Miesch , A. Clement , A. Henrion-3 4 5 1 1
Caude1
INSERM E213, Laboratoire de biologie moleculaire, Hopital Armand Trousseau,1
Paris, France, Department of Paediatrics, Hopital Sud, Rennes, France, Depart-2 3ˆ
ment of Paediatrics, Hopital Purpan , Toulouse, France, Unite de Biostatistiques,4ˆ
INSERM U444, Hopital Tenon, Paris, France, eUP Cytokines and Inflammation,5ˆ
Institut Pasteur, Paris, France
Cystic fibrosis (CF) is the most common severe autosomal recessive disease among
Caucasian. The decline of pulmonary function in CF is due to a vicious cycle of
airway infection and inflammation. Pseudomonas aeruginosa (P. aeruginosa)
colonisation and subsequent chronic infection of respiratory tract are associated with
reduced survival. Interleukin-1 receptor antagonist (IL-1ra) is a key mediator of
inflammation that inhibits the IL-1-induced pro-inflammatory activity. The IL-1ra
gene presents an penta-allelic tandem repeats polymorphism, of which allele 2 (IL-
1RN*2) is associated with several chronic inflammatory disease. We therefore,
examined whether the presence of IL-1RN*2 was associated with the status of
infection by P. aeruginosa in a cohort of 182 CF children. Age, gender, CFTR
mutations, colonisation and chronic infection by P. aeruginosa were retrieved from
hospital records. P. aeruginosa colonisation was noted in 73% (133y182) of the
studied population, out of which 30% (40y133) children were chronically infected.
The frequency of IL-1RN*2 was significantly higher in patients who were chron-
ically infected as compared to the other (Ps0.012). Our data lend support to the
hypothesis that IL-1RN*2 could impact on the control resistance to P. aeruginosa.
Although the molecular mechanism remains to be investigated, our data provide a
rationale for evaluating novel therapeutics such as IL-1ra to counteract the chronic
infection by P. aeruginosa in CF.
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CFTR mutation screening in patients with alcohol induced pancreatitis
J. Zielenski (Presenting), S. Martin , J. Kawasoe, P. Kortan , S. Freedman , J.1* 1 2 3
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Purpose: The presence of CFTR mutations has been well documented in patients
with idiopathic acute and chronic pancreatitis. However, previous studies have
shown either no association or a weak association between the most common CFTR
mutations and alcohol-induced chronic pancreatitis (AICP). In this study, we
assessed for an association between CFTR and AIP by performing extensive gen-
otype analysis. Methods: 23 patients with a confirmed diagnosis of AICP were
recruited. Complete CFTR genotyping of patient genomic DNA was performed by
PCR-based heteroduplex analysis, followed by DNA sequencing. We compared the
results with DNA obtained from 50 random blood donors analyzed by the same
CFTR screening protocol. Results: The mean age of the patients was 52.6"10.8 yr
and mean age at onset of pancreatitis were 42.5"12.0 yr. 21 of the patients was
males. Twenty one were of European origin, one was East Indian and one was of
mixed origin. Complete CFTR screening of patients with AICP revealed 11 CFTR
mutationsyvariants (DF508, V754M, 1716G-)A, 5T (4x), R75Q (2x), S1234R, -
799delT) with an allelic frequency of 0.24. Overall, 39% of the patients carried at
least one CFTR variant (two patients carried 2 variants) as compared with 22%
(0.11 allelic frequency) in the control cohort (P-0.026). No one in the control
group carried two CFTR variants. Conlusions: These data show that there is a
significant increase in CFTR alterations in patients with AIP as compared with the
control group. The frequency of CFTR abnormalities in this cohort is similar to
that reported in patients with idiopathic pancreatitis. However, CFTR changes in
the AIP patients are considerably milder than those observed in idiopathic patients.
In conclusion, single CFTR abnormalities ranging from CF-causing mutations to
very mild variants may predispose to pancreatitis in the presence of a toxic insult.
Supported by NIH and CCFF.
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Mutational spectrum of CFTR gene in patients with chronic pancreatitis
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CFTR gene mutations have been postulated as a predisposing risk factor to chronic
pancreatitis (CP). The aim of this study was to determine the frequency and spec-
trum of CFTR mutations in our population. Patients: Following the criteria con-
sensus, 68 CP patients were enrolled for CFTR gene analysis, 37 presented CP
alcohol related (ACP) and 31 idiopathic aetiology (ICP). Clinical features of CP
(injury, calcifications, pseudocysts, diabetes, «) and cystic fibrosis (CF) (pulmo-
nary function, lung infections, esteatorrhea, infertility, sweat test) were collected in
available patients. Methods: The 27 exons and flanking regions of CFTR gene were
analyzed using the DGGE (denaturing gradient gel electrophoresis) and SSCP (sin-
gle strand conformation polymorphism) techniques. Mutations were characterized
by direct sequencing of each abnormal pattern. Additionally, we analyzed the 5T
variant (DGGE) and the polymorphisms (TG)m (sequencing) and M470V (enzy-
matic digestion) involved in the 5T penetrance. Results: Sixteen CFTR mutationsy
variants were identified in 27 (40%) of CP patients. The most common mutation,
F508del, was found in 8% of ACP patients. The 5T variant was found in 8% of
ACP and 6% of ICP being the hypofunctional haplotype 5T-12TG-V470 identified
in 1 ACP patient. The 1716GyA variant showed the higher frequency with different
distribution, 22% in the ICP group and 5% in the ACP group. Twenty-four patients
(35%) presented only one CFTR mutant gene. No significant differences were
found in the clinical characteristics of CF between patients with and without muta-
tions. Conclusion: Our study supports the involvement of the CFTR mutations in
the aetiology of CP showing a high carrier frequency (35%) among CP patients.
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Acidic intracellular pH stimulates the activity of the CFTR Cl channelI
J.H. Chen*(Presenting), Z. Cai, D.N. Sheppard
Physiology, University of Bristol, Bristol, United Kingdom
Three cytoplasmic domains control Cl flow through the cystic fibrosis transmem-y
brane conductance regulator (CFTR). The location of these domains suggests that
intracellular pH might regulate CFTR function. To test this idea, we studied CFTR
Cl channels in excised inside-out membrane patches from C127 cells expressingy
wild-type human CFTR. The pipette (external) solution contained 10 mM Cl aty
pH 7.3 and the bath (internal) solution contained 147 mM Cl at pH 6.3, 7.3 ory
8.3, PKA (75 nM) and ATP (0.3 mM) at 37 8C; voltage was y50 mV. At pH 8.3,
current magnitude was decreased (pH 7.3, 100%; pH 8.3, 74"5%; means"SEM;
ns6, P-0.01; Student’s paired t-test). In contrast, at pH 6.3 current magnitude
was increased (pH 7.3, 100%; pH 6.3, 143"6%; ns6; P-0.01). To learn how
acidic pH stimulates CFTR activity, we studied single CFTR Cl channels. At pHy
6.3, there was a large increase in open probability (Po; pH 7.3, Pos0.44"0.02;
pH 6.3, Pos0.60"0.02; ns9; P-0.001), but no change in current amplitude (ns
9; Ps0.75). To learn how Po was increased, we studied gating kinetics. At pH 6.3,
mean burst duration (MBD) was increased (pH 7.3, MBDs147"7 ms; pH 6.3,
MBDs214"27 ms; ns4; Ps0.09), whereas interburst interval (IBI) was
decreased (pH 7.3, IBIs166"10 ms; pH 6.3, IBIs107"12 ms; ns4; P-0.001).
These results indicate that intracellular pH stimulates CFTR activity by altering
channel gating. They also suggest that several protein regions of CFTR might con-
tain pH-sensitive amino acid residues. These residues might represent important
targets for drug therapy for cystic fibrosis. Supported by the CF Trust and the
University of Bristol.
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Molecular identification of an anion binding site in the outer mouth of
the CFTR channel pore that coordinates multi-ion pore behaviour
P. Linsdell*(Presenting), X. Gong
Dalhousie University, Halifax, Canada
Chloride permeation through the CFTR channel pore is blocked by highly lyotropic
permeant anions that bind tightly within the pore. We have used a combination of
site-directed mutagenesis and patch clamp recording to investigate the interaction
between lyotropic Au(CN) ions and the CFTR pore. Several different substitutions2
of a positively charged amino acid residue, arginine 334, in the putative outer mouth
of the CFTR pore, greatly reduce the affinity with which Au(CN) ions block Cl2
permeation when applied to the intracellular face of excised membrane patches.
Fixed positive charge at this site plays a role in Au(CN) binding within the pore,2
as judged by the effects of different substitutions and also by the pH-dependence
of block conferred by the R334H mutant. However, non-charge-dependent effects
also appear to contribute to Au(CN) binding. Mutation of R334 also disrupts the2
apparent electrostatic interaction between intracellular Au(CN) ions and extracel-2
lular permeant anions. In wild type CFTR, this repulsive interaction destabilizes
Au(CN) binding inside the pore and serves to relieve Au(CN) block. In all six2 2
R334 mutants studied, but not in channels bearing mutations at other putative anion
binding sites in the pore, this repulsive interaction between intracellular Au(CN)2
and extracellular anions was greatly reduced. Since we assume this interaction
results from mutual electrostatic destabilization between anions bound simultane-
ously within the pore, we propose that the native arginine at position 334 possess
a unique ability to coordinate ion-ion interactions inside the pore. Our results sug-
gest that lyotropic anions bind tightly to a site in the outer mouth of the CFTR
pore that involves interaction with a fixed positive charge. Binding to this site is
also involved in coordination of multiple permeant anions within the pore, which
may be an important factor maximizing the rate of Cl throughout.
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The gating behaviour of murine CFTR differs dramatically from that of human
CFTR (Lansdell et al., J Physiol. 508, (1998) 379–392). To identify the protein
regions responsible for this difference, we constructed a series of human-murine
CFTR chimeras by replacing NBD1, NBD2 and the R domain of human CFTR
with the equivalent regions of murine CFTR (hmNBD1, hmNBD2 and hmRD,
respectively). To investigate the biophysical properties of CFTR chimeras, we stud-
ied CFTR Cl channels in inside-out membrane patches excised from CHO cellsy
transiently expressing hmNBD2 CFTR. The pipette (external) solution contained
10 mM Cl and the bath (internal) solution contained 147 mM Cl , 0.3 mM ATPy y
and 75 nM PKA at 37 8C; voltage was y50 mV. Upon stimulation with ATP (1
mM) and PKA (75 nM), the activation of hmNBD2 CFTR was slow (ns6),
whereas that of wild-type human CFTR was rapid (ns4). In the presence of ATP
(0.3 mM) and PKA (75 nM) at y50 mV, the single-channel current amplitude (i,
y0.78"0.06 pA; mean"SEM; ns3) and open-probability (Po, 0.44"0.03; ns
3) of hmNDB2 CFTR were comparable to those of human CFTR (i,y0.77"0.01
pA; Po, 0.42"0.01; ns4). In one hmNBD2 CFTR single-channel patch, the dura-
tion of bursts (232 ms) was longer than that of human CFTR (136 ms"7 ms; ns
4). This increase in burst duration of hmNBD2 CFTR was caused by increased
flickery closures interrupting bursts (Po burst; hmNBD2 CFTR, 0.89; human CFTR,
0.96"0.01; ns4). However, the interburst interval of hmNBD2 CFTR (211 ms)
did not differ from that of human CFTR (199"22 ms; ns4). Our results suggest
that the single-channel properties of hmNBD2 and wild-type human CFTR, while
broadly similar, display some interesting differences. Supported by the Cystic Fibro-
sis Trust.
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Decreased chloride secretion by nasal epithelium of P2Y4-null mice
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Aerosolised uridine 59-triphosphate (UTP) has been proposed for therapeutic use in
individuals with cystic fibrosis, based on its ability to increase calcium dependent
chloride conductances. The purpose of this study was to investigate the possible
role of P2Y4 receptor in the regulation of sodium and chloride transepithelial move-
ment in nasal epithelium. Mice knockout for the P2Y4 receptor (P2Y4-null) and
their littermate controls (P2Y4q) were bred at the Universite Libre de Bruxelles.´
Adult male mice were anaesthetised and a double lumen catheter was inserted into
one nostril. The nasal cavity was perfused with buffered solutions at a rate of 21
mlymin. The potential difference (PD) across the nasal mucosa was measured with
the subcutaneous space as a reference. PD values were negative at the luminal side.
Amiloride (10-4 M) decreased PD in both P2Y4q (n:8) and P2Y4-null (n:8)mice;
the effect was lower in P2Y4-null mice (y30%, P-0.03 on Mann-Whitney ANO-
VA test). The effect on chloride secretion was assessed by perfusing the nasal
mucosa, in the presence of amiloride, with a chloride-free solution followed by
addition of UTP (10-5 M); PD dropped to y32.8"1.66 mV (mean"sem) in
P2Y4q and to y21"1.78 mV in P2Y4-null mice (P-0.0002 on Welch ANOVA
test), but UTP had no acute effect. These data suggest that ATP andyor UTP are
released from the nasal mucosa either chronically or acutely when nasal catheter is
introduced and that P2Y4 receptor occupancy plays a role in the regulation of the
chloride secretory pathway in murine nasal epithelium.
s15Journal of Cystic Fibrosis 2 (2003) S13–S18
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A new pathway for the regulation of the cystic fibrosis transmembrane
conductance regulator: mitogen-activated protein kinase
A. Robay , G. Toumaniantz , V. Leblais , C. Gauthier1 1 2 1
Nantes, France, Bordeaux, France1 2
In A549 cells, we have demonstrated that beta3-adrenoceptor (beta3-AR) stimu-
lation regulates the activity of CFTR chloride channel. This regulation is independ-
ent of cAMPyprotein kinase A, but involved a Giyo protein. We investigated the
signalling pathway between beta3-AR and CFTR protein. The plasmids encoding
CFTR and beta3-AR were intranuclearly injected in A549 cells. CFTR activity was
functionally assayed using SPQ fluorescent probe. The beta3-AR stimulation per-
formed by the application of 1 mM CGP 12177 (CGP) increased the permeability
to halides (p) from 0.15"0.01 to 0.5"0.01 min (ns22, P-0.001). The over-y1
expression of beta-ARK, an inhibitor of beta-gamma subunits, blunted this increase,
suggesting the involvement of the beta-gamma subunits of Giyo protein in the
regulation of CFTR by beta3-AR stimulation. As NO is involved in the signalling
pathway of beta3-AR in the heart and vessels, we have pre-treated A549 cells with
NO synthase inhibitors, L-NAME or L-NMMA. In such conditions, the CFTR
activity was significantly reduced by 27% after 5 min application of CGP. This
effect is transient, because this inhibition was reversed after a prolonged incubation
of CGP (15 min). The NO pathway could partially regulate CFTR activity. Beta3-
AR stimulation could activate the MAPkinase and PI3K. To test this hypothesis,
A549 cells were pre-treated either with selective inhibitors of PI3K (wortmannin
and LY 294002), or MAPKinases (PD 98059 or U0126). In both conditions, the
effect of CGP on the CFTR activity was fully abolished. To confirm this obser-
vation, immunocolocalization studies demonstrated that only the beta3-AR positive
cells present an activation of MAPKinases by the application of beta3-AR agonist.
We demonstrated, for the first time, that beta3-AR stimulation regulates CFTR by
a GiyoyPI3KyMAPK signalling, which represents a new CFTR pathway.
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Phloxine B stimulation of CFTR is independent of cAMP-dependent
phosphorylation
Z. Cai(Presenting), D.N. Sheppard
Physiology, University of Bristol, Bristol, United Kingdom
The fluorescein derivative phloxine B is a potent activator of CFTR. Previously,
we suggested that phloxine B interacts directly with CFTR to augment channel
activity (Cai & Sheppard, J. Biol. Chem. 277 (2002) 19546–19553). However,
phloxine B might act indirectly, regulating the protein kinases and phosphatases that
control CFTR activity. Recently, Aleksandrov et al. (FEBS Lett. 518 (2002) 183–
188) demonstrated that 29-deoxy-ATP (29-d-ATP) stimulates CFTR independent of
R domain phosphorylation. Based on this result, we speculated that phloxine B
might stimulate CFTR activated by only 29-d-ATP. To test this idea, we used excised
membrane patches from C127 cells expressing wild-type human CFTR. The pipette
(external) solution contained 10 mM Cl , whereas the bath (internal) solutiony
contained 147 mM Cl at 37 8C; voltage was y50 mV. Following the activationy
of CFTR by 29-d-ATP (1 mM) in the absence of PKA, phloxine B (1 mM) aug-
mented CFTR activity by increasing open-probability (Po; 29-d-ATP, Pos
0.14"0.05; phloxine B, Pos0.31"0.07; mean"SEM; ns5; P-0.05; Student’s
t-test). Like its effects in the presence of ATP and PKA, phloxine B (1 mM)
increased Po by prolonging greatly mean burst duration (MBD; 29-d-ATP, MBDs
132"18 ms; phloxine B, MBDs652"93 ms; ns5; P-0.005) without altering
interburst interval (IBI; 29-d-ATP, IBIs828"195 ms; phloxine B, IBIs1160"219
ms; ns5; P)0.05). Consistent with these data, CFTR stimulation by phloxine B
(1 mM) and bromotetramisole (3 mM; an inhibitor of protein phosphatases) was
additive. These data suggest that phloxine B does not alter the activity of protein
kinases and phosphatases, but rather interacts directly with CFTR to augment chan-
nel activity. Supported by the CF Trust.
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Correlation of CFTR function between the cystic fibrosis children and
their parents
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France, INSERM U 467, Faculte Necker, Paris, France3 ´
Introduction: Our preliminary report suggests that a CFTR-related functional defect
of transepithelial ion transport in nasal epithelium exists in CFTR mutation heter-
ozygotes. The aim of the present study was to investigate, if this abnormality was
related between the parents and their CF children. Material: We explored the nasal
potential difference and the anion conductive pathway in nasal ciliated epithelial
cells (NCC) of 31 CF children and at least one of their parents and 20 control
subjects. The transmembrane Cl CFTR dependant conductive pathway in NCCy
was measured by a halide sensitive fluorescent dye assay after addition of the cAMP
agonists according to the method described by Verkman et al. Results: Application
of 100 mM amiloride induced a depolarisation of basal transepithelial potential
(mean Ds5.2(1.4) mV, 21.4(2.2) mv and 6.4(1.3) mV for CF parents, CF children
and control subjects, respectively. Addition of 10 mM isoproterenol induced a hyper-
polarisation (mean Dsy1.7(1) mV, y0.1(0.4) mV, y4.7(0.7) mV for parents,
CF children and the control subjects, respectively. The results from SPQ assay
analysed as percentage of cells displaying a cAMP-induced fluorescence change
per studied subject NCC (DFcAMP) provided the following results: 85% (10) for
control subjects, 30% (9) for the CF children and 65% (12) for their parents. There
was a significant correlation between the children and their parents for D VTE
amiloride (rs0.64; P-0.01), D VTE isoproterenol (rs0.47; Ps0.05) for the
NPD measurements and the percentage of NCC per subject displaying a cAMP-
stimulated anion conductive pathway (rs0.52; P-0.05). Conclusion: Our results
suggest a relationship between the CF children and their parents for the transepi-
thelial ion transport defect.
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Our laboratory developed a pharmacological strategy to repair CFTR dysfunctions
in cystic fibrosis. Many compounds were synthesized and their effects were eval-
uated on trafficking and CFTR chloride channel activity. For example, we developed
a xanthine family that presented many activators (Bulteau et al., Am. J. Physiol.
279, (2000) C1925) and now synthesized two new xanthine derivatives called X-
34 and X-42. These compounds differed only in an aliphatic chain by a single (X-
42) or double bond (X-34). Effects of X-34 and X-42 were evaluated on CFTR
activity with a robot-based iodide efflux assay. Surprisingly, we discovered that X-
34 was a potent inhibitor (IC50s12 mM) while X-42 was an activator (EC50s8
mM) of wt-CFTR and G551D-CFTR chloride channels. These opposite properties
were confirmed on CFTR currents at molecular, cellular and tissue levels with patch
clamp, whole cell recording and Ussing chamber. Single channel studies further
demonstrated that close molecular structure and opposite effects of these two xan-
thine derivatives were associated with activation vs. inhibition competition phenom-
enon on the phosphorylated CFTR channel. These results showed that a simple
chemical modification of the xanthine skeleton resulted in either an activator or an
inhibitor that might compete on the same binding site. Supported by VLM, CF-
PRONET and CNRS.
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Post-transcriptional regulation of CFTR gene expression
M. Baudouin-Legros (Presenting), A. Hinzpeter , N. Davezac , N. Ben-Salem , A.1* 1 1 1
Edelman1
U467, INSERM, Paris, France1
The present study was designed to investigate the functional importance and the
origin of altered stability of the CFTR transcripts in induced modulations of CFTR
gene expression. The work was performed in HT-29 and Calu-3 cells incubated
with IL-1b, TNFa, extracellular hyperosmolarity, or ouabain. It was based on: (1)
measurements of the variations of the cell contents in CFTR transcripts; (2) analysis
of the in vitro degradation of CFTR mRNAs (obtained from untreated Calu-3 cells)
incubated with cytosolic proteins extracted from either type of cells in basal state
or under stimulation and (3) the in vitro experiments with ‘short’ or ‘long’ CFTR
mRNAs extracted from HeLa cells transfected with CFTR cDNAs without (‘short’)
or with (‘long’) the 39 untranslated part of the CF gene (39UTR). All stimuli affect
the stability of the CFTR transcripts in cell-dependent manner. The sensitivity of
the CFTR transcripts to the cytosolic extracts from Calu-3yHT-29 cells is related
to the 39 UTR sequence since the results on the stability of the CFTR mRNAs were
reproduced only on the ‘long’ CFTR mRNAs derived from HeLa cells. Pre-incu-
bating the cytosolic extracts with polyuridylic acid able to compeat with AUUUA
sequences (sequences known to control mRNAs stability, which are present in the
CFTR 39 UTR) prevents the effects of stimuli on the stability of the ‘long’ CFTR
transcripts. This suggests that the regulation of the stability of the CFTR mRNAs
may be related to these AUUUA sequences also known to control the expression
of genes involved in inflammation.
51*
Molecular interactions involved in the processing of CFTR protein:
identification of new partners
A. Hasnain (Presenting), N. Arous , P. Pagesy , J. Clain , M. Goossens , P.1* 1 1 2 1
Fanen1
INSERM U.468, Creteil, France, Faculte de Pharmacie, Paris 5, France1 2
Cystic fibrosis (CF) is a channelopathy, which is characterised in more than 90%
of patients by an absence or a dramatic decrease of CFTR protein at the apical
membrane of epithelia. The third cytoplasmic loop (CL3) is a large loop in which
many disease-causing mutations affect CFTR processing of the whole protein high-
lighting the importance of its correct secondary structure. We used the 53 residues
of CL3 as a bait to screen the pre-transformed Human Testis MATCHMAKER
cDNA library (Clontech) by the yeast two-hybrid system. This screening allowed
us to identify 25 independent clones, out of which 15 were cytoplasmic proteins,
5 are unknown, 5 were irrelevant (i.e. nuclear). The positive interactions were later
tested with the class II mutants S945L, H949Y, D979A. We are currently analysing
two proteins from the proteasome subunits by expressing them in HeLa cells. We
cloned the full-length cDNAs in pcDNA3.1yV5-His-TOPO vector (Invitrogen)
and we analyzed: (i) protein interaction by co-immunoprecipitation; (ii) pulse-chase
experiments and (iii) immunocytochemistry using anti-V5 antibody and anti-CFTR
antibody. Analysis of other cytoplasmic proteins is currently under process. This
identification of unknown interacting proteins should allow us to decipher the
molecular mechanisms of CFTR processing and define new therapeutic targets to
direct the CFTR mutant proteins to the plasma membrane. This work was supported
by grants from INSERM and the French association, Vaincre la Mucoviscidose.
52*
CFTR trafficking in the endocytic pathway
M. Gentzsch*(Presenting), X.-B. Chang, Y. Wu, J.-H. Chen, J.R. Riordan
Mayo Clinic and Mayo Foundation, Scottsdale, USA
CFTR is synthesized on ER-associated ribosomes, core-glycosylated co-translation-
ally and transported to the Golgi. Secretory vesicles then deliver CFTR to the
plasma membrane. Mature CFTR is known to be endocytosed, but details of its
routing through the endocytic and secretory pathways are not well understood. Ear-
lier findings localized a CFTR subpopulation with trans-Golgi network (TGN)
markers, but not in the Golgi stack (Gentzsch et al., J. Biol. Chem. 278 (2003)
6440–6449; Yoo et al., J. Biol. Chem. 277 (2002) 11401–11409). This suggested
that CFTR may take an unconventional route from ER to reach the Golgi through
the TGN rather than the more conventional cis-Golgi route (Yoo et al., J. Biol.
Chem. 277 (2002) 11401–11409). To trace CFTR movement inwardly from the
cell surface, we have followed an extracytoplasmically-expose epitope after initial
binding of an antibody from the outside. Endocytosis was observed directly by
confocal immunofluorescence at various times after binding. Initially, CFTR
appeared in vesicles beneath the plasma membrane and at later times in close prox-
imity to the TGN. Several markers of the endosomalylysosomalyTGN system as
well as specific dominant negative mutant Rab GTPases were employed to identify
subcompartments through which CFTR moves after internalization. (Supported by
NIH grant DK 51870.)
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Actions of a range of PDE inhibitors on CFTR-mediated mucin
secretion and Cl transportI
M. Pereira (Presenting), R.L. Dormer , F. Becq , K.J. Murray , M.A.1* 1 2 3
McPherson1
Medical Biochemistry, University of Wales College of Medicine, Cardiff, United1
Kingdom, Laboratory of Physiology, UMR6558 CNRS, University of Poitiers, Poi-2
tiers, France, GlaxoSmithKline, Stevenage, United Kingdom3
Our results have shown that CFTR is a key regulator of secretion of mucins and
serous proteins . We have shown that PDE (cyclic nucleotide phosphodiesterase)1
inhibitors correct defective mucin secretion in CFTR antibody-containing acinar
cells . The aim is to investigate the actions of a range of PDE inhibitors on CFTR-1,2
mediated mucin secretion in rat submandibular acini, in conjunction with their abil-
ity to activate CFTR Cl secretion. Mucin secretion was measured by pulse–chasey
labelling of rat submandibular acini with 3H-glucosamine and measurement of
effects of PDE inhibitors on release of 3H-labelled mucins in the absence of other
agonists. The assay for Cl secretion was carried out by measuring iodide effluxy
in transfected CHO cells, in the presence of a submaximal dose (1 mm) of forskolin.
The results show that nine structurally related PDE inhibitors, differing in potency
and specificity, all significantly stimulated mucin secretion to a similar degree (163–
238% basal (ranges)), but were weaker agonists than the ß-adrenergic agonist iso-
proterenol (297% basal). Although all compounds stimulated CFTR-mediated
mucin secretion, only five increased CFTR-mediated Cl transport (1.7 to 3.3-foldy
increased rate of iodide efflux compared to forskolin alone) and were weaker ago-
nists than IBMX (5.8-fold increased rate of iodide efflux); four compounds were
inactive. In conjunction with our data showing that CFTR-mediated mucin secretion
was not inhibited by glybenclamide (isoproterenol alone: 230"13% basal, ns5;
isoproterenolqglybenclamide (100 mM) 278"21% basal, ns5), the results indi-
cate that stimulation of CFTR-mediated mucin secretion is not obligatorily linked
to stimulation of CFTR Cl channel activation.y
C. Lloyd Mills, et al., Biochem. Biophys. Res. Commun. 188 (1992) 1146–1152.1
M.A. McPherson et al., FEBS Lett. 464 (1999) 48–52.2
Supported by the CF Trust, U.K and VLM, France.
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PAR-2 receptor activation increases mucin release from ovine airway
epithelium via a tachykinin independent mechanism
A. Baldwin (Presenting), K. Affleck , K. Bunce , M. Lethem1* 2 2 1
School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton,1
United Kingdom, Glaxo SmithKline Pharmaceuticals, Stevenage, United Kingdom2
Airway mucus hypersecretion is characteristic of several airway diseases including
cystic fibrosis. The mechanisms responsible for hypersecretion are unclear, but may
involve increased protease activity. This study investigates whether activation of
PAR-2 receptors by proteases such as tryptase can cause mucin secretion from
airway goblet cells. Sheep tracheal epithelial explants were assessed for secretory
activity by bathing in medium with and without PAR-2 activating agents and assay-
ing the samples for mucin content by lectin-based assay. The PAR-2 activating
peptide (PAR2-AP), SLIGRL-NH2 (3=10 M), transiently increased muciny4
secretion by 269"44% (P-0.05) whilst tryptase (17 mUyml) caused a sustained
doubling of mucin secretion. A control peptide, LRSLIG-NH2 (3=10 M), whichy4
is ineffective at PAR-2 receptors, had no affect on mucin secretion. Since PAR-2
activation is thought to cause gastric mucin secretion via release of tachykinins e.g.
substance P (SP) from sensory nerves, we investigated the role of tachykinins in
the PAR-2 response in the airways. SP (10 M) induced a transient increase in-8
mucin secretion (275"55%, P-0.05). Secretion was also stimulated by neuroki-
nins A and B (NKA, NKB) with an order of potency, SP)NKA)NKB. Responses
to SP (10 M) and NKA (10 M) were abolished by the NK1 receptor antagonists,-8 -6
L732,138 and GR205171, but not the NK2 receptor antagonist GR159897 (all
10 M). Treatment of explants with capsaicin (10 M) to release endogenous-6 -6
tachykinins had no effect on mucin secretion. Further, the response to PAR2-AP
was unaffected by GR205171 (10 M). In conclusion, activation of PAR-2 and-6
NK1 receptors induces mucin secretion from ovine airway explants. The fact that
the PAR2-AP induced secretion was unaffected by an NK1-R antagonist and that
capsaicin did not alter mucin secretion suggests that the PAR-2 induced mucin
secretion was independent of tachykinin release and that tachykinin containing
nerves are absent in this system.
55*
Cell cycle regulation in response to oxidative stress in human airway
cells expressing wild-type and mutant cystic fibrosis transmembrane
conductance regulator
E. Boncoeur*(Presenting), A. Clement, J. Jacquot, A. Henrion-Caude
Department of Molecular Biology, INSERM E213, Paris, France
Hyperoxia increases free radical production, leading to DNA damage. Recent stud-
ies indicate that oxygen increases apoptosis in airway epithelium, causes the expres-
sion of the tumor suppressor p53 and its downstream target, the cyclin-dependent
kinase inhibitor p21CIP1, which is involved in G1yS arrest in cell cycle. Our study
was conducted to characterize cell cycle regulation in response to oxygen deriva-
tives, which are important mediators of tissue damage in CF airways. Three cell
lines: a CF bronchial cell line with DF508yW1282X mutation, IB3-1, the same line
corrected for wild-type CFTR, C38, and a normal human bronchial cell line, Beas-
2B, were placed in room air or 95% O for 3 days to evaluate the cell proliferation2
and expression of cell-cycle regulatory gene products. In response to hyperoxia for
24 to 48 h, IB3-1 cells were more sensitive to oxidative stress, as assessed by the
decreased cell number as early as the 24 h-exposure. To determine whether growth
arrest was mediated through activation of the p21-dependent G1 checkpoint,
p21CIP1 protein levels and the associated inhibition of cyclin-cdk kinase activity
were assessed. In each cell line, the patterns of p21CIP1 expression in the cytoplasm
and the nucleus were similar. Oxygen dramatically increased expression of p21CIP1
in the wild-type CFTR background, whereas its expression was significantly
decreased in IB3-1 cells at 24 and 48 h of exposure, which highlights a different
regulation of p21CIP1 in CF cells. Our results suggest that repair process in
response to oxidative stress might be compromised in CF airway epithelium.
56*
Composition of airway-surface liquid determined by X-ray
microanalysis
G. Roomans*(Presenting), I. Kozlova, B. Almgren, M. Hogman¨
Medical Cell Biology, Uppsala University, Uppsala, Sweden
The composition of the airway-surface liquid (ASL) has been a matter of dispute,
and wildly varying data for the concentrations of Na, Cl and K have been reported.
It has been difficult to sample the fluid by a method that does not disturb its
composition. We have attempted to determine the elemental composition of the
ASL in the pig trachea and principal bronchi by X-ray microanalysis, using two
different sampling methods. One method was to shock-freeze pieces of the airway
in liquid propane, transfer the sample to the scanning electron microscope and
analyze the ASL in situ in the frozen state aty150 8C, with the beam perpendicular
to the surface of the ASL-covered epithelium. Results from this study indicated a
near-isotonic composition of the ASL in trachea and principal bronchi, but values
for potassium (K) and phosphorus (P) were unexpectedly high, possibly due to
excitation of cellular structures such as cilia together with the ASL. The second
method was to let Sephadex G-25 ion-exchange beads equilibrate with the ASL
during 30 min in a moisture chamber at 100% humidity. The beads were then rinsed
in silicon oil to remove excess ASL and dried. Results from this study indicated
again that the concentrations of sodium (Na) and chloride (Cl) in ASL are some-
what lower compared to serum, but that the K concentration in the ASL is nearly
5 times that in serum. The calcium (Ca) concentration in the ASL is more than 10
times that in serum. Combined results indicate that ASL is close to isotonic fluid
with somewhat lower Na and Cl, but higher K and Ca than in serum. The Ca may
be bound to macromolecules since also the concentrations of P and sulfur (S) in
ASL are higher than in serum.
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Methods for determining of the composition of nasal fluid by X-ray
microanalysis
G. Roomans(Presenting), V. Vanthanouvong
Medical Cell Biology, Uppsala University, Uppsala, Sweden
The nasal fluid is an easily accessible form of airway-surface liquid. The object of
this study was to find a technically easy and reproducible method for sampling and
analysis of this fluid. In a pilot study, several methods to carry out X-ray microa-
nalysis of sub-microliter droplets were compared. Acceptable results were obtained
with several of these methods (pipeting on filter paper or analysis of frozen-hydrat-
ed droplets at low temperature) provided that formation of salt crystals was avoided.
Nasal fluid was collected from the inferior turbinate with a micropipette after occlu-
sion of a nostril for 5–10 min. Ion concentrations in nasal fluid from 6 control
subjects were (in mM, mean"standard error): sodium (Na): 127"6, chloride (Cl)
140"7, potassium (K) 27"3, and calcium (Ca) 5"1. Subjects suffering from cold
or rhinitis had significantly higher values for Na and Cl. This sampling method
proved difficult to apply to cystic fibrosis (CF) patients, because of the viscous
quality of their nasal secretion. Therefore, an alternative method was devised.
Sephadex G-25 ion exchange beads were mounted on double-sided tape, which was
stuck on a filter paper as support. The filter paper was applied for 10 min. to the
occluded nostril of a subject. During the exposure period, the nasal fluid equilibrates
with the beads. After removal of the filter paper with the beads from the nostril,
the beads were rinsed with silicon oil to remove excess nasal fluid, dried and
analyzed. This method of collection is not cumbersome for the subject and gives
results similar to those obtained by the direct collection method used previously.
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MPB compounds increaseDF508-CFTR trafficking inDF508 mouse
colonic epithelial cells
C.M. Harris , Z. Clark (Presenting), F. Becq , M.A. McPherson , R.L. Dormer1 1* 2 1 1
Medical Biochemistry and Immunology, University of Wales College of Medicine,1
Cardiff, United Kingdom, Laboratory of Physiologie, University of Poitiers, Poi-2
tiers, France
We have shown in native airway epithelial cells from CF individuals that DF508-
CFTR is mislocalised and present predominantly within the cell. Our studies also
demonstrated that MPB compounds caused dramatic movements of DF508-CFTR
to the apical membrane. The aim is to investigate whether MPB compounds are1
active in moving DF508-CFTR to the apical membrane in the gastrointestinal tract
by using tissues from DF508 mice. Tissues were harvested from wild type and
DF508 mice and incubated at 37 8C in the presence or absence of drugs, fixed and
sectioned. Immunolocalisation of CFTR was carried out using our well-character-
ised C-terminal antibody, MPCT-1. Wild type CFTR had an apical location in colon1
crypts, whereas DF508-CFTR was located predominantly within the cell. Following
incubation with MPB-07 (250 mM, 2 h at 37 8C) a marked change in location of
DF508-CFTR, but not wild type CFTR, was observed. Thus, DF508-CFTR was
moved to the apical membrane following MPB-07 treatment such that, in tissues
from 4 DF508 mice,)50% of crypts contained apically located DF508-CFTR. The
most marked change was from approximately 10% of crypts (untreated) with some
apical DF508-CFTR to 90% (MPB-07 treated) with apical DF508-CFTR. The
methods established will allow investigation of drug treatments of other affected
epithelial tissues. The results indicate that MPB-07, which increases DF508-CFTR
trafficking in CF human airway epithelial cells, is also effective in the gastrointes-
tinal tract and potentially useful in all cells affected in CF.
Dormer, R.L. et al., J. Cell Sci. 114 (2001) 4073–4081.1
We thank Dr. WH College, University of Cambridge for supplying the dF508 mice
and VLM, WORD and the CF Trust for financial support.
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A coordinated genomic analysis of bacterial and epithelial cell
response to iron-regulated Pseudomonas aeruginosa virulence
M. Saavedra (Presenting), J. Nick , J. West , U. Ochsner , B. Potter , S.1* 1 1 2 1
Randell , D. Rodman , M. Vasil3 1 2
Pulmonary, University of Colorado, Denver, USA, Microbiology, University of1 2
Colorado, Denver, USA, CF Research Center, UNC Chapel Hill, Chapel Hill, USA3
Background: In the CF airway, P. aeruginosa has evolved well-characterized viru-
lence factors to sequester iron from host cells. Hypothesis: P. aeruginosa grown in
iron-depleted conditions manifests bacterial and epithelial transcriptional changes
that characterize the maladaptive effects of specific low iron virulence factors on
the host inflammatory response. Methods: Iron replete and depleted cultures of P.
aeruginosa strain PAO1 were grown to stationary phase overnight. Primary culture
human bronchial epithelial cells (3 donors) were infected with low and high iron
PAO1, RNA harvested and labeled cRNA hybridized to Affymetrix U133A&B
Genechips. Controls were treated with iron enriched, sterile, low endotoxin tissue
culture media. Software analysis was done with Affymetrix Microarray Suite and
Genespring. PAO1 itself, grown in low and high iron conditions, as well as the
sigma factor PvdS mutant of PAO1 had RNA extracted and hybridized to PAO1
Affymetrix GeneChips . The PvdS sigma factor is critical in production of low
iron associated virulence factors. Results: In iron-starved PAO1, expression of 118
genes was increased)5-fold. Analysis confirmed novel PvdS regulated genes relat-
ed to pyoverdin synthesis. Genespring analysis confirmed clusters of genes reg-
ulated by epithelial cells in response to iron-replete vs. iron-starved PAO1 exposure.
Functional studies of cell viability (LDH release), TUNEL assay, TNFa release
and luciferase reporter assays confirm a less inflammatory paradigm in these iron-
replete PAO1 exposed epithelial cells. Conclusions: Gene array analysis of two
important mediators of inflammation in the CF airway, the epithelial cell and P.
aeruginosa, reveals novel iron-regulated PAO1 virulence genes. Activation of spe-
cific pathways occurs within the host inflammatory response in concert with these
virulence factors.
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Analysis of differentially displayed proteins in HeLa cells expressing
CFTR and DeltaF508 CFTR
N. Davezac (Presenting), D. Tondelier , J. Debski , A. Schrattenholtz , M. Cahill ,1 1 2 3 3
M. Dadlez , F. Demaugre , A. Edelman2 4 1
U467, INSERM, Paris, France, IBB , Polish Academy of Science, Warsaw, Poland,1 2
Proteosys, Mainz, Germany, U370, INSERM, Paris, France3 4
Cystic fibrosis (CF) is the most common genetic disorder in Caucasians caused by
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
which encodes a cAMP-regulated Cl channel expressed in several epithelial cells.y
The most common mutation of CFTR is a three base pair deletion that results in
the absence of a phenylalanine residue at amino acid position 508 (DF508).
Although CF is a monogenic disease, it is clear that epigenetic factors play an
important role in the phenotype of CF patients. Several arguments also point to the
role of modulator genes and interacting proteins in the pathogenesis of CF. The aim
of the present study was to identify the differentially expressed proteins derived
from HeLa cells over-expressing WT-CFTR and DF508-CFTR using two-dimen-
sional gel electrophoresis (isoelectrofocalisation and SDS-PAGE) and mass spec-
trometry. The total proteins from three cell lines (WT-CFTR, DF508-CFTR and
pTracer (empty vector) HeLa were investigated. A new protocol for extraction of
total proteins was developed. Proteins were detected using silver staining. Isoelec-
trofocusing was performed on acrylamid strips with pH range from 4 to 7 and SDS-
PAGE on 10% polyacrylamide gels. Three spots were found differentially expressed
between WT-CFTR and DF508-CFTR (overexpressed in DF508-CFTR and down-
regulated in WT-CFTR). The different spots are currently being analysed by mass
spectrometry MALDI-TOF and nanoelectrospray ESI-MS. Acknowledgments: This
work is supported by CEE grant QLG2-CT-2001-01335, a grant from Vaincre la
Mucoviscidose. The two-dimensional gels were performed in the Plateau Proteome´
of IRNEM, Paris, France.
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Transcriptional response of airway epithelial cells to Staphylococcus
aureus by microarray analysis
C. Moreilhon (Presenting), C. Hologne , M. Merten , O. Bajolet , K. Taouil , P.1 2 3 2 2
Barbry , E. Puchelle1 2
CNRS UMR 6097, Sophia Antipolis, France, INSERM UMR-S 514, Reims,1 2
France, EMI 10014 INSERM, Vandoeuvre-Les-Nancy, France3
Staphylococcus aureus appears during the initial colonization of the CF airway
epithelium and may alter the expression of pro-inflammatory cytokines and pro-
apoptotic factors by airway epithelial cells. To identify critical traits of the host
response after a S. aureus infection (8325-4 strain), and roles of its virulence factors,
the well-polarized human airway epithelial cells MM-39 were analyzed with a DNA
microarray probing 4200 distinct genes. RNA was extracted from epithelial cell
pellet after interaction with S. aureus (10 cfuyml) either during exponential or8
stationary phase of bacterial growth. While genes encoding subunits of the AP1
complex, such as Fos and Jun or EGR1, an immediate-early gene implicated in the
CD 40 L pathway, were up regulated in both experimental conditions, other genes
were differentially expressed in the two experimental conditions. The pro-inflam-
matory cytokines IL-8 and TNF-a were only overexpressed in the presence of S.
aureus at stationary phase. The increased expression and release of IL-8 was con-
firmed by RTyPCR and ELISA techniques. The genes encoding thromboxane A
synthase 1 (TBXAS1), Caspase 10, CFTR, KCNJ2 and KCNJ3 were upregulated
in the presence of S. aureus in log phase, but not in stationary phase where virulence
factors are numerous. Claudin 1, a tight junction epithelial marker, was down reg-
ulated only in the presence of S. aureus at stationary phase. These differential
regulations highlight the existence of distinct concomitant responses to infection
linked either to a direct contact between airway epithelial cells and bacteria, or to
the effect of S. aureus virulence factors on airway epithelial cells. This work was
supported by INSERM, CNRS, GSK, GIP Aventis and Association Francaise Vain-¸
cre la Mucoviscidose.
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Development of gutless canine adenovirus–2 (CAV-2) vectors for CF
gene therapy
A. Keriel (Presenting), M.C. Romey , C. Galer , J. Zabner , M. Claustres , E.J.1* 2 3 3 2
Kremer1
IGMM, CNRS UMR5535, Montpellier, France, Laboratoire de Genetique Mole-1 2 ´ ´ ´
culaire, IGH, CNRS UPR1142, Montpellier, France, Department of Internal Med-3
icine, University of Iowa, Iowa City, USA
The first clinical trials of CF gene therapy established the potential of this approach,
but also identified the drawbacks of using human adenovirus (Ad) vectors: a low
efficiency of gene transfer and a short duration of the transgene expression, due to
the immunity that neutralizes either the vector (pre-existing) or the transduced cells
(induced). Another disadvantage is the risk of recombination andyor co-replication
with wild-type Ad.Canine adenovirus-2 (CAV-2) vectors possesses several advan-
tages: (1) no pre-existing immunity in human; (2) efficient transduction of human
cells; (3) no replication in human cells (thus a low risk of propagation in the
organism) and (4) no detectable recombination or co-replication with human Ad.
Moreover, the ‘gutless’ vectors (depleted of all viral genes) allow long-term expres-
sion of the transgene in vivo. Thus, the absence of pre-existing immunity and
production of viral proteins makes gutless CAV-2 vectors potential tools for CF
gene therapy. We established the feasibility of this approach. CAV-2 vectors can
efficiently transduce two human pulmonary cell lines and primary cultures of well
differentiated human bronchial cells. These vectors also transduce epithelial cells
in vivo, from the upper airways to the alveoli, after nasal instillation in mice. We
have to optimize the level of transduction and the duration of the transgene expres-
sion in mice lung by: (1) stimulating expression of the Ad receptor (CAR) in
epithelial cells; (2) partially disrupting the airways epithelium; (3) limiting the
clearance of the vector by mucus andyor (4) inhibiting the inflammation induced
by the administration of Ad. Furthermore, we are developing gutless CAV-2 vectors
allowing expression of human CFTR cDNA, under the control of either its endog-
enous minimal promoter or the mouse PGK promoter. We will then evaluate the
efficiency of these vectors in primary cultures of epithelial cells from CF patients
or in animal models.
67*
Pseudomonas aeruginosa infection of airway epithelium in a human
fetal respiratory xenograft model in view of lentiviral gene therapy of CF
lung disease
E. Copreni (Presenting), A. Bagnacani , A. Colombo , M. Conese1* 1 2 1
Institute for Experimental Treatment of CF – Associazione Lombarda Fibrosi Cis-1
ticayH.S. Raffaele, Milano, Italy, Istituti Clinici di Perfezionamento – Clinica2
Regina Elena, Milano, Italy
Previous studies have shown that lentivirus-mediated CFTR gene transfer partially
recovered the electrophysiological function in the nasal epithelium of CF mice.
However, the efficacy of lentiviral vectors in recovering bacterial clearance in the
CF lungs is not known yet. Our preliminary data have shown that lentiviral vectors
can transduce human lung and tracheal xenografts in a SCID-hu model (Biffi et
al., Ped. Pulmunol. Suppl. 20 (2000) 238). To assess the efficacy of lentivirus, we
have established an infection model of fetal airway tissue xenografts. Human lung
and tracheal rudiments, obtained from therapeutic abortions (20"2 weeks of ges-
tation), were subcutaneously implanted in the flanks of SCID mice and infected
after 18 weeks of engraftment. At this period, tracheae and lungs were morpholog-
ically identical to the adult human tissues, as evaluated by standard histology. Lungs
were surgically exposed and P. aeruginosa PAO-1 (10e4–10e6 cfu) was injected
in the pulmonary parenchyma. Opercula closing the tracheal openings were excised,
mucus removed and bacterial inoculum (7=10e6 cfu) was injected into the lumen.
Animals were sacrificed after 24 h and xenografts were removed and homogenised.
Serial dilutions of homogenates were plated onto TSA (tryptic soy agar) plates and
bacterial cfu were counted. Both the lung and tracheal xenografts cleared the inject-
ed bacteria for each inoculum (Table), indicating that the anti-bacterial properties
of matured respiratory xenografts are similar to those of adult tissues. Future studies
will include the evaluation of bacterial clearance in CF xenografts and, if found
defective as compared to that of non-CF, of its recovery by lentivirus-mediated
CFTR gene transfer.
INJECTED CFU 10e4 10e5 10e6 7=10e6
Lungs, recovered cfu (ns2–4) 1100"82 6138"3759 232,927"96,305 –
Tracheae, recovered cfu (ns3) – – – 34,668"6283
Supported by the Italian Fondazione per la Ricerca sulla Fibrosi Cistica
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Polyethylenimine as a promising agent for gene therapy of CF lung
disease
S. Carrabino*(Presenting), E. Copreni, A. Bragonzi, S. Di Gioia, M. Conese
Institute for Experimental Treatment of CF - Associazione Lombarda Fibrosi Cis-
ticayH. S. Raffaele, Milano, Italy
Non-viral vectors, such as cationic lipids, have been used in CF patients to transfer
the CFTR gene into the airways. Transfection efficiency was low and probably
insufficient to be of therapeutic benefit. We sought to evaluate the efficiency and
efficacy for CF of polyethylenimine (PEI), a cationic polymer, which is able to
transfer reporter genes into the murine airways with higher efficiency than cationic
lipids and does not interact with surfactant protein A (Bragonzi and Conese, Curr.
Gene Ther. 2 (2002) 295–305). PEI efficiency should be tested in the presence of
CF mucus that is rich in negative charged proteins, such as albumin. To avoid the
interaction of polyplexes with mucus proteins, PEI was complexed to 1 mg DNA
in the presence of bovine serum albumin (BSA, 0.2–64 mg) and used to transfect
A549 type II pneumocytes and 9HTEo- tracheal epithelial cells. The ternary com-
plexes increased luciferase expression in confluent monolayers by 100 times as
compared to PEIyDNA. The number of GFP-expressing cells, as evaluated by epi-
fluorescence was also augmented three-fold. These data show that PEI efficiency
could be increased by adding a protein component and prompt to test PEIyBSAy
DNA complexes in the presence of CF mucus. To evaluate PEI efficacy in a CF
context, we have established in vitro methods to analyse P. aeruginosa uptake and
killing by respiratory epithelial cells. dF508 and CFTR-null cells showed a defect
of both uptake and intracellular killing of internalised bacteria. Transfer of CFTR
cDNA through PEI recovered the uptake and bacterial killing activity of CF cells,
whereas an irrelevant gene (firefly luciferase) did not. Overall, these results indicate
that PEI might be used in a higher efficient formulation to recover bacterial uptake
and killing by airway epithelial cells in CF murine models of experimental respi-
ratory infection. Supported by Italian Telethon A.164 grant and Lega Italiana Fibrosi
Cistica ONLUS.
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A series of aminoglycoside-derived cationic lipids for gene transfection
in vitro and into the mouse airways in vivo
N. Oudrhiri , M. Hauchecorne , M. Sainlos , A. Aissaoui , P. Belmont , S. Zertal-1 1 2 1 2
Zidani , J. Navarro (Presenting), J.P. Vigneron , J.M. Lehn , P. Lehn1 1* 2 2 1
INSERM U458, Hospital Robert Debre, Paris, France, Laboratoire de Chimie,1 2´
College-de-France, Paris, France`
Over the last several years we have directed our research effort towards the dis-
covery and development of novel cationic lipids for gene transfection. Indeed, non-
viral vectors have emerged as attractive alternatives to recombinant viruses for gene
therapy applications. However, there is clearly a requirement for newer generation
cationic liposomes with improved efficiency. Thus, as it is recognized that the nature
of the positive headgroup plays a key role in the transfection activity of cationic
lipids, we have undertaken to explore the transfection potential of lipophilic deriv-
atives of aminoglycosides. Aminosugars are indeed RNA-binding molecules with
structural features particularly well suited for the synthesis of a variety of deriva-
tives. We have recently reported that a cationic cholesterol derivative characterized
by a kanamycin headgroup (KanaChol) can mediate gene transfer in vitro and that
pegylated KanaCholyDOPE lipoplexes were efficient for gene transfection into the
mouse airways via intranasal instillation (Belmont et al., J. Gene Med. 4, (2002)
517–526). More recently, we have synthesized several novel lipidic derivatives of
kanamycin (characterized by longer linkers and other hydrophobic moieties than in
KanaChol) and also lipids derived from neomycin (NeoChol) and paramomycin
(ParamoChol). The data obtained thus far show that some new kanamycin deriv-
atives may have an enhanced in vitro transfection activity and that cationic lipo-
somes containing the neomycin-based cholesterol derivative NeoChol are efficient
in vitro as well as in vivo (mouse airways). In ongoing experiments, we attempt
at present to complete the evaluation of the in vivo transfection efficiency of these
various novel aminoglycoside-based formulations, to identify the airway cells actu-
ally transfected in vivo and to assess the toxicity of these novel non-viral gene
therapy vectors. (Supported by Vaincre La Mucoviscidose and Gencell).
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Gene transfer with human papillomavirus: development of vectors that
do not induce neutralizing antibodies
G. Carpentier(Presenting), J.R. Sadeyen, M. Shkreli, S. Tourne, P. Coursaget
Laboratoire de Virologie Moleculaire, Faculte de Pharmacie, Tours, France´ ´
Human papillomavirus (HPV) pseudovirions are an attractive vehicle for gene ther-
apy. However, they induce a strong immune response and thus gene transfer is
significantly reduced following a third administration of the vector. The HPV pseu-
dovirions used are composed of the major protein (L1) of HPV type 16 (HPV-16)
self assembled into virus-like particles (VLPs) associated in vitro with a plasmid
coding for a reporter gene. Definition of neutralizing epitopes should facilitate the
design of mutated VLPs to overcome the immunological barriers to gene therapy.
The aim of this study was to generate chimeric VLPs in order to identify immu-
nogenic domains and conformational neutralizing epitopes by insertion of a foreign
sequence on capsid surface loops of human papillomavirus type 16 VLPs. We
hypothesized that these regions could be on L1 protein loops since they are exposed
on the surface of VLPs. Six amino acids encoding for the epitope 78–83 of the
hepatitis B core antigen were introduced within the different loops of the L1 protein.
All these chimeric L1 proteins were capable of self-assembly into VLPs. The anti-
genicity and immunogenicity of some of these VLPs were reduced compared to the
levels observed with wild-type VLPs. All were nevertheless able to induce neu-
tralizing antibodies. VLPs with insertion at position 266y267 induced lower levels
of neutralizing antibodies, suggesting the involvement of residues situated on the
FG loop in L1 neutralizing epitopes. In order to define more precisely the confor-
mational neutralizing epitope and to obtain less immunogenic vectors, we designed
four additional mutants with 6 to 29 amino acid substitutions within the FG loop.
Production of such chimeric VLPs and analysis of their antigenicity and immuno-
genicity in mice are currently being investigated. Taken together, our findings sug-
gest the possibility of designing HPV-derived vectors that are less immunogenic.
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Assembly of a human minichromosome with a GFP-tagged CFTR gene
F. Ascenzioni(Presenting), Cristina Auriche, Elisabetta Testa
Biologia Cellulare e dello Sviluppo, University La Sapienza, Rome, Italy
Some of the problems raised by the current protocols for gene therapy protocols
for cystic fibrosis (CF) could overcome by the use of large fragments of DNA
containing the transgene and its regulators, and by the use of a MAC (mammalian
artificial chromosome), as vector for the transgene. We have demonstrated that a
human minichromosome derived from chromosome 1 and made to contain the intact
human CFTR locus can support functional CFTR production in CHO cells. Utili-
zation of this vector to study transchromosomic CFTR expression and function will
be facilitated by the insertion of a specific tag. This modification will allow detec-
tion of the transchromosomic CFTR in CF models expressing the endogenous gene.
It was shown that GFP fused to the N terminus of CFTR did not affect protein
localization and function, thus we designed a construct to introduce the GFP tag to
the 39 end of the CFTR gene contained in the YAC 37AB12. Since YAC vectors
can be easy modified using the pop-in-pop-out procedure, we prepared a gene tar-
geting GFP construct, which was linearized in the segment of homology and trans-
fected into yeast cells containing the YAC (pop in). Subsequently, duplicated CFTR
sequences and the yeast marker were eliminated by FOA selection (pop out). The
resulting construct contains a GFP-fused to the first CFTR codon. This molecule
(GFP-CFTR-YAC) will be used to assemble minichromosomes based on MC1,
which was demonstrated previously to be a good vector for CFTR expression.
Moreover, it could also be useful for studying expression and traffcking of CFTR
from its own promoter and regulators. In fact, most of the expression and CFTR
localization analysis done to date made use of engineered vectors containing CFTR
cDNA and exogenous promoters, which may not recapitulate the physiological
expression and processing of CFTR. This work was supported by Telethon-Onlus,
grant N A.164 and Italian cystic fibrosis research foundation.
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Mucosal and therapeutic vaccination against Pseudomonas aeruginosa
(PA)
A. Zuercher (Presenting), V. Pavelic , M.P. Horn , M. Tarkoy , C.J. Bundgaard ,1 1 1 1 2¨
H.K. Johansen , N. Høiby , A.B. Lang2 2 1
Research Immunology, Berna Biotech Ltd., Bern, Switzerland, Inst Clin Microbiol,1 2
Rigshospitalet, Copenhagen, Denmark
In a 10-year open-label phase II longitudinal study in CF patients we found a
significantly lower rate of chronic lung infection with PA and increased time to
initial infection in patients vaccinated with an octovalent O-polysaccharide toxin
A-conjugate vaccine compared to a matched control group. As acquisition of PA
occurs via the upper respiratory tract, we have analyzed in mice mucosal immunity
after intra-muscular (i.m.) or intra-nasal (i.n.) immunization. Local immune
responses were assessed using the organ fragment culture technique and ELISA.
We found induction of specific serum IgG antibodies by both routes of immuni-
zation. In contrast, specific IgA antibodies in the upper respiratory tract were elicited
via the i.n. route only. These results indicate that i.n. administration of anti-PA
conjugate vaccine might represent an alternative route of immunization with induc-
tion of mucosal in addition to systemic immunity. Since the current vaccine induces
antibodies to surface O-polysaccharides it will not target mucoid forms of PA.
Therefore, to complement our current approach, we are evaluating the feasibility of
therapeutic vaccination against chronically established PA infection. To this end, a
new alginate-toxin A-conjugate vaccine is used to immunize cftr-y- mice, chroni-
cally infected with an alginate hyperproducing strain of PA. We hypothesize that
induction of high-affinity anti-alginate antibodies might enable targeting of mucoid
forms of PA.
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Kinetics of specific serum IgG antibodies after longterm immunization
with an Anti-Pseudomonas aeruginosa (PA) conjugate vaccine
Alois B. Lang (Presenting), A. Rudeberg , M.H. Schoeni , J. Que , A.W.1 2 2 1¨
Zuercher , U.B. Schaad1 3
Research Immunology, Berna Biotech Limited, Bern, Switzerland, Department of1 2
Pediatrics, University Hosital, Bern, Switzerland, Department of Pediatrics, Uni-3
versity of Basel, Basel, Switzerland
A prophylactic anti-PA conjugate vaccine, composed of the O-polysaccharides of
the 8 most frequent PA serotypes covalently coupled to toxin A of PA was evaluated
in previously non-colonized CF patients. Analysis of a 10-year open-label phase II
longitudinal study proved the efficacy of this vaccine in preventing chronic lung
colonization with PA. Notably, the rate of infection was significantly lower (P-
0.001) and the time to colonization increased in vaccines compared to a matched
control group. Furthermore, significantly better (P-0.05) lung function was
observed in the Y18 year group of vaccinated patients as assessed by determination´
of FEV . Preservation of lung function was accompanied by improvement in body1
weight. Here we present the analysis of the kinetics of specific serum anti-polysac-
charide and toxin A IgG antibodies over the study period, assessed by ELISA. We
observed induction of specific serum IgG against all serotypes of PA after vacci-
nation. The serum levels of anti-polysaccharide antibodies waned after immuniza-
tion and could be re-induced by regular booster immunizations. Using this
immunization schedule a baseline level of high-affinity antibody necessary for pro-
tection was maintained. Nevertheless, the specific serum IgG levels induced by
vaccination were clearly lower than levels induced by chronic PA infection, inde-
pendent of previous vaccination. These data underline that protection against PA
infection is not correlated to specific serum IgG levels, but rather to functional
characteristics of the induced antibodies. The dramatic elevation of polysaccharide-
specific IgG antibodies after infection was paralleled by the increase of PA-specific
precipitins. In line with the lower infection frequency and longer time to infection
the mean number of precipitins in vaccinated patients was lower than in non-vac-
cinated control patients.
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Reduction in pulmonary hospitalizations during a randomized,
controlled, open-label study of tobramycin solution for inhalation in
young CF patients with mild lung disease
A.A. Colin (Presenting), R.D. Anbar , X. Yu1 2 3
Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, Depart-1 2
ment of Pediatrics, Upstate Medical University, Syracuse, NY, USA, Chiron Cor-3
poration, Seattle, WA, USA
An open label, randomized, multicenter controlled trial of month-on-month-off bid
300 mgy5 ml nebulized tobramycin solution for inhalation (TOBI ) revealed a
significantly higher incidence of respiratory hospitalizations in control relative to
treated subjects during a routine sponsor-conducted interim safety analysis. The
protocol had called for 400 chronically Pseudomonas-infected CF subjects from the
US and Canada, ages 6–10 yr (FEV from 70 to 110% predicted) and 11–15 yr1
(FEV from 70 to 90% predicted) to be randomized to routine care (control) or1
routine care plus TOBI (treatment) for 14 months. Primary endpoints included
effect on rate of spirometric decline, hospitalization and concomitant antibiotic use.
Enrollment was difficult due to narrow inclusion criteria and was closed at 184
subjects. Inability to obtain timely modified informed consent following the interim
analysis, forced the sponsor to halt the trial after 96 subjects had ended the protocol;
63 by completion and the rest by withdrawal. 10y91 (11%) of treated subjects
experienced pulmonary hospitalization, vs. 23y88 (26%) of control (P-0.01).
FEV decline rates were not significantly different (y2.0 vs. y1.6% predictedyyr,1
control vs. treated, respectively, Ps0.9). Difference in change of FEF25–75% pre-
dicted was significant at 8 months (P-0.04), but not thereafter. Oral antibiotic use
was significantly reduced (P-0.01) in the treatment arm. Generally mild treatment-
related adverse events (e.g. 13.2% hoarseness, 3.3% sore throat, 2.2% tinnitus)
ultimately resolved, consistent with previous studies. Lack of significant difference
of FEF25–75% beyond 8 months may have resulted from insufficient statistical
power due to the study’s early termination. Thus, use of TOBI in young CF patients
with mild lung disease and infected with Pseudomonas appears to decrease the rate
of hospitalization and concomitant antibiotic use, and may slow the rate of spiro-
metric decline. Sponsored by Chiron Corporation.
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Cross-over study of TOBI vs. intravenous tobramycin in combination
treatment of pulmonary exacerbations in cystic fibrosis patients
A. Geborek , L. Hjelte , A. Lindblad , L. Mared , L. Eriksson , M. Johannesson ,1 1 2 3 3 4
B. Strandvik2
Department of Pediatrics , Karolinska Intitutet, Stockholm, Sweden (Presenting),1
Department of Pediatrics, Goteborg University, Goteborg, Sweden, Department2 3¨ ¨
of Respiratory Medicine, Lund University, Lund, Sweden, Department of Pediat-4
rics, Uppsala University, Uppsala, Sweden
The aim of the study was to investigate the efficacy and tolerance of inhaled
(TOBI ) vs. intravenous(iv) tobramycin combined with a b-lactam in pulmonary
exacerbations of CF patients chronically colonised with Pseudomonas aerugino-
sa.Design and methods: The study was performed as a randomised open, crossover,
multicenter study with CF patients participating from the four Swedish CF-centres.
No patient was previously treated with long-term inhalation of antibiotics. The
patients were randomised at pulmonary exacerbations for a 10 days treatment with
either TOBI or iv tobramycin combined with an iv b-lactam. At the following
exacerbation there was a cross over maintaining the same b-lactam. Serum con-
centrations of tobramycin were measured before and 1 h after the administration.
At the start and end of each treatment routine blood and sputum samples were
analysed and a dynamic spirometry was performed. The median age of the 27
patients that completed the study was 30 yr (13–43). Results
TOBI TOBI Iv tobramycin Iv tobramycin
Lungfunction FEV start1.0 FEV end1.0 FEV start1.0 FEV end1.0
Median (range) 60% (21–19%) 67% (29–3%) 61% (23–1%) 73%(28–33%)
Concentrations
(mgyml)
0 h 1 h 0 h 1 h
Median (range) 0.5 (0–2.6) 2.0 (0–4.8) 1.2 (0.3–1.4) 8.1 (6.1–12)
Lung function as measured with FEV increased significantly with both treatments,1.0
Ps0.005 and Ps0.002, respectively, and there was no difference between the
treatments. The average time to the next exacerbation was for TOBI 89(36–179)
and for iv admin 80(12–194) days (ns). The inflammatory parameters showed no
difference between the groups. No adverse effects were registered. Conclusion
TOBI was as effective and safe as iv tobramycin when combined with a b-lactam
for short-term treatments of exacerbations in CF patients chronically colonised with
P. aeruginosa. The use of inhaled tobramycin giving lower systemic concentrations
might in the long run reduce the risk for permanent damage to kidneys and hearing.
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A multi-route approach to the production of recombinant b-defensins
R. Langley (Presenting), D. Clarke , J. Dorin , D. Campopiano , J.R.W. Govan1 2 3 2 1
Medical Microbiology, University of Edinburgh, Edinburgh, United Kingdom,1
School of Chemistry, University of Edinburgh, Edinburgh, United Kingdom,2
Human Genetics Unit, MRC, Edinburgh, United Kingdom3
Burkholderia cepacia complex infections in cystic fibrosis (CF) are both life-threat-
ening and resistant to most antimicrobial therapies. Thus, there is an urgent need
for new therapies. b-Defensins are cationic peptides characterised by having 6-
cysteine residues, which form 3 disulphide bonds. Recent studies have shown that
defensins containing 5-cysteines expressed in airway epithelial cells have antimi-
crobial activity against Pseudomonas aeruginosa and B. cenocepacia (formally gen-
omovar III) strain J2315. J2315, which represents the ET-12 lineage, is highly
resistant to all known classes of antibiotics, is capable of epidemic spread and is
associated with the majority of cases of ‘cepacia syndrome’. To avoid the heavy
costs of synthetic peptides, production of large amounts of recombinant 5-cysteine
containing b-defensins, suitable for structural and functional studies has been
achieved via a number of different E. coli expression systems. The antimicrobial
activity of these novel defensins against a panel of B. cepacia complex strains will
be presented.
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Influence of azythromycin on ion transport of respiratory epithelia
D. Schuler(Presenting), J. Wagner, K. Weber, G. Huls, H. Lindemann¨ ¨
Pediatric Pneumonology of Medical Center of Pediatrics and Youth Medicine, Gies-
sen, Germany
Azithromyzin (AZM) have become of interest in cystic fibrosis (CF) for more than
their well established antibacterial properties. A study from Verona showed in four
from seven CF-patients, treated with 500 mg AZM once daily, after four weeks a
shift towards hyperpolarisation of stimulation of chloride transport by chloride-free
solution.1 The purpose of this study was to verify if AZM could improve the ion
transport, especially CFTR-dependent chloride transport, typically defective in CF.
Nasal potential difference (NPD) is measured between a fluid-filled exploring
bridge on the airway surface below concha nasalis inferior and a fluid-filled ref-
erence bridge in the subcutaneous space.2 In 18 CF-patients (16 to 39 yr) NPD-
measurements were performed before and after a nasal application of AZM for two
weeks daily. The protocol includes sodium channel blocking and stimulation of
CFTR-dependent chloride channels. After treatment, sodium conductance remained
abnormal in the 18 CF-patients. Neither the stimulation of alternative chloride chan-
nels nor the effect on CFTR-dependent chloride transport was significantly different
to the NPD before treatment (Table 1).
Table 1. Results of NPD measurements before and after azithromycin (nasal appli-
cation for 2 weeks daily in 18 CF-patients, Mean"S.D. mV)
NPD b dNPD a dNPD 0c dNPD s
before azm y38.3"10.2 25.1"11.1 2.4"7.4 0.9"6.5
after azm y35.3"8.1 22.1"9.3 2.2"4.1 1.6"4.8
NPDsNasal potential difference, azmsazithromycin, bsbasal, asamiloride, 0cs
chloride-free sssalbutamol, dsdeviation
Nasal application of azithromycin for two weeks daily could not demonstrate a
significantly different effect on respiratory ion transport, neither on sodium channels
nor on apical chloride transport.
1 Pradal U, Delmarco A, Morganti M, Cipolli M, Mini E, Cazzola G (2002)
(Monduzzi Editore, 25th ECFConference, Genoa 2002, Poster WS8.3)
2 Schuler D. Moerkerk W. Alter H. Geidel C. Huls G. Lindemann H (2000)¨ ¨
Pneumologie 54:S46.
s23Journal of Cystic Fibrosis 2 (2003) S19–S23
81
The rational to use anti-pseudomonas IgY for prophylaxis and
treatment of CF patients
H. Kollberg (Presenting), David Carlander , Bengt Wretlind , Per-Erik Wejaker ,1 2 3 2˚
Anders Larsson2
Department of Pediatrics, Uppsala, Sweden, Department of Medical Science, Uni-1 2
versity Hospital, Uppsala, Sweden, Department of microbiology, Huddinge Uni-3
versity Hospital, Stockholm, Sweden
Background: Treatment with specific anti-PA IgY (anti Pseudomonas chicken
immunoglobuline) reduces the amount of PA positive cultures and the need of
antibiotics for CF patients. The Swedish Medical Agency has now granted 12 CF
patients a licence to be treated with anti-PA IgY. CF and PA infections: Respiratory
infections are the major cause of morbidity and mortality in CF. It is impossible to
eradicate PA from a patient with chronic colonisation. Specific IgY has attracted
considerable attention as an alternative to treat infectious diseases. Its biochemical
properties make it attractive for oral immunotherapy. IgY -preparation: A single
hen produces ;40 g IgY per year in their egg yolk. Hens vaccinated with whole
bacteria or other antigens produce specific IgY against these antigens. In vitro
studies: IgY preparations are stable for years. Specific IgY antibodies may decrease
bacterial adhesion to epithelial cells and neutralize toxins. Our anti-PA IgY showed
inhibition of adhesion to epithelial cells, mainly serotype-specific. Animal studies:
Oral administration of IgY has proved successful for treatment of a variety of GI
infections. Human studies: After gargling with our anti-PA IgY solution in the
evening, antibody activity against PA could be detected in the saliva of all controls
the next morning. Toxicology: Orally administered IgY neither activates the human
complement system or reacts with any cell activators or mediators of inflammation.
IgY is ‘generally recognised as safe’ (GRAS) for use as a food for humans (United
States Code of Federal Regulations). Allergy: Those few individuals, who have a
known allergy against orally taken eggs, have to be excluded from this treatment.
Resistance: Humans do not produce anti-IgY antibodies against oral IgY. Thus,
there is no risk that pathogens will develop resistance against IgY. Conclusion: IgY
offers great opportunities to design strategies against infectious diseases in humans
and animals.
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Activation of CFTR-dependent chloride channels by tiotropium bromide
K. Weber , D. Schuler (Presenting), C. Barth , G. Huls , P. Bittner-Dersch , J.1 1 1 1 1¨ ¨
Pabst , H. Lindemann2 1
CF-Center of JL-University, Pediatric Pulmonology of Medical Center of Pediat-1
rics and Youth Medicine, Giessen, Germany, PulmoTec GmbH, Hochstadt,2 ¨ ¨
Germany
Tiotropium bromide, a long-acting inhaled anticholinergic drug, is now commer-
cially available for inhalation to treat chronic pulmonary obstructive disease. The
question was, if tiotropium—like ipratropium bromide —is able to activate chloride1
channels in the apical membrane of respiratory epithelia. In 13 healthy subjects
(19–30 yr) the basal nasal transepithelial potential difference (NPD) was deter-
mined below concha nasalis inferior. After that, to block apical sodium channels,
5 puffs of amiloride powder in form of a compacted solid ring tablet was admin-
istered at the nose by a jet nebulizer (formerly MAGhaler). After reaching a stable2
depolarisate standard of NPD (10 min) nasal mucosa was treated with tiotropium
powder or with placebo (lactose powder) both via Aerolizer connected to a nose
olive. The effect was evaluated by increase of NPD (10 min) after application of
tiotropium. The mean basal NPD was y25.3 mV. Amiloride decreased the NPD
typically and the NPD was not effected by placebo. On the contrary, tiotropium
increased the NPD more than 50 % (mean 82.2"30.6%) (Table 1).
Table 1. Results of NPD measurements before and after amiloride and after tiotro-
pium or placebo, respectively
ns13 NPD b (mV) NPD a (mV) NPD p (mV) NPD t (mV) dNPD t (mV) dNPD t (%)
Mean y25.3 y10.0 y0.3 y22.2 12.9 82.2
S.D. "8.3 "4.8 "1.6 "10.6 "7.3 "30.6
NPDsNasal potential difference, bsbasal, asamiloride, tstiotropium, ps
placebo, dsdeviation
The effect of tiotropium on nasal transepithelial potential difference during blockage
of apical sodium channels suggests an additional specific effect on CFTR-chloride
transport in healthy subjects. In cystic fibrosis patients with CFTR-restfunction
tiotropium may be a therapeutic approach.
D. Schuler, J. Wagner, G. Huls, H. Lindemann, Monduzzi Editore, 25th European1 ¨ ¨
Cystic Fibrosis Conference, Genoa, 2002.
A. Krahl, C. Geidel, H. Alter, T. Hoffmann, G. Huls, J. Pabst, H. Lindemann,2 ¨
Pediatr Pulmonol Suppl. 17 (1998) S280
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Phase IIa clinical study of a new human neutrophil elastase inhibitor
(hNE), EPI-hNE4 (DX-890), with repeated administration by inhalation
in adult cystic fibrosis patients
F. Saudubray (Presenting), A. Labbe , I. Durieu , B. Wallaert , H. Sayah , B.1* 2 3 4 5
Assael , G. Cazzola , C. Dubray , A. Poncin , C. Lafuma , T. Williams , A.6 6 7 8 9 10
Bokman , H. Clavien1 1
DEBIOPHARM SA, Lausanne, Switzerland, Departement de Pediatrie, CHU,1 2 ´ ´
Clermont-Ferrand, France, Service de medecine interne, CHU Lyon-Sud, Pierre-3 ´
Benite, France, Clinique des Maladies Respiratoires, Hopital A. Calmette, Lille,4´ ˆ
France, Centre d’Investigation Clinique, Hopital de Cardiologie, Lille, France,5 ˆ
Cystic Fibrosis Center, Ospedale Civile Maggiore, Verona, Italy, Centre de Phar-6 7
macologie Clinique, CHU Clermont, Clermont-Ferrand, France, EUROGENTEC,8
Seraing, Belgium, INSERM U492, Creteil, France, DYAX, Cambridge, USA9 10´
Introduction: EPI-hNE4, a highly potent hNE inhibitor, exhibited already an increase
of anti-elastase capacity and good tolerability in healthy volunteers phase I studies;1
the purpose of this phase IIa study was to assess pharmacodynamic effects and safety
in CF adult patients. Methods: It was an open, non-randomised, dose-escalating mul-
ticenter study, in 24 adult CF patients receiving EPI-hNE4 by nebulisation during 15
min daily for 14 days, of a solution at 1 of the 2 concentrations: 2.5 mgyml (ns6)
or 10 mgyml (ns18). Results: 17 patients completed the study showing a good tol-
erability with no significant changes in PFT values. The relatively high number of drop
outs was mostly not related to the drug, but due to the severity of lung disease; 2 drop
outs after withdrawal of consent were replaced. Elastase activity assayed in sputum
showed a significant decrease after daily nebulisation in 5 out of 7 patients in the low
dose group, and 15 out of 19 patients in the high dose group, with a complete inhibition
of this activity in respectively, 3 and 10 patients in these two groups. Moreover, one
week after the end of treatment, elastase remained significantly lower than baseline
values observed before treatment. A relative decrease of IL8 levels was observed in
the 2 dose groups after treatment. Conclusion: This study showed that EPI-hNE4 inhib-
ited elastase activity and decrease IL8 level in sputum and was well tolerated in CF
adult patients. A second phase IIa study is presently running in CF children and
adolescents.
Reference
2001 International Conference American Thoracic Society. Poster presentation: Phase1
I studies with a new human neutrophil elastase inhibitor, EPI-hNE4, administered by
inhalation in healthy volunteers.
C. Dubray, F. Saudubray, H. Clavien, A. Bokman, C. Lafuma, A. Poncin, S. Hirani,
A. Labbe Am. J. Respir. Crit. Care Med. Sup. 163(5) (April 2001) A564.´
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Outcomes of the use of intravenous pamidronate in an adult cystic
fibrosis centre
A. Verma*(Presenting), J. Biesty, J. Redfern, M. Dodd, A. Jones, K. Webb
Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester, Unit-
ed Kingdom
Introduction: Intravenous pamidronate (pam) can improve bone mineral density
(BMD) as measured by dual energy ray absorptiometry (DEXA) in patients with
CF related bone disease. It has been our policy to treat patients who are osteoporotic
or osteopaenic on long-term prednisolone with pam 30 mg every three months and
prescribe calcichew D3 forte. The response is monitored by annual DEXA scanning.
This report evaluates the response to pam and the practicalities of adhering to our
protocol. Methods: Casenotes were examined for patients prescribed pam. Demo-
graphics, infective status (i.e. microbiology, use of regular nebulised and intrave-
nous antibiotics), pancreatic status, DEXA and blood results were recorded. Patients
who received 3 or more doses per year of 30 mg of pamidronate and prescribed
calcichew D3 forte were classed as fulfilling the protocol. Reasons for non-adher-
ence to the protocol were noted. DEXA scans were classed as either no change
improved or deteriorated in three sites (spine, hip and femur). Results: Thirty two
patients (19 male, mean age 27.8 yr) received pam during the study period and
20y32 patients received their pam as per protocol and 27y32 calcichew D3 forte.
There were 13 responders, 10 non-responders and 9 who did not have follow up
DEXAs. There was no significant difference between the responders and non-
responders for any measured parameter including those who did not have their pam
as per protocol. However, 6y10 of the non-responders had a trend towards having
lower VitD levels compared to 4y13 in the responder group (Ps0.30). Reasons
for non-adherence included problems having DEXAs and pam being time consum-
ing for both staff and patients. Conclusions: This small numbered study has shown
that there were responders and non-responders to regular 3 month intravenous pam.
There are practical difficulties in following the protocol in large numbers of patients
in a busy centre.
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Leukocyte serine-proteinases elastase and cathepsin G cooperate in
the proteolytic regulation of membrane and soluble CD87yuPAR
N. Beaufort(Presenting), D. Leduc, M. Chignard, D. Pidard
Institut Pasteur, Paris, France
One major characteristics of cystic fibrosis is the accumulation of neutrophils in
the airways and the spreading of their granule proteinases, participating to chronic
airway inflammation. CD87yuPAR, the GPI-anchored, three-domain urokinase
receptor: (i) is expressed by both the respiratory epithelium and the leucocytes; (ii)
participates to the inflammation process through matrix proteolysis and recruitment
of inflammatory cells and (iii) is susceptible to proteolytic regulation. Our aim was
thus to determine whether leucocyte serine-proteinases can affect CD87 structure
and functions. Using a quantitative immunoblotting approach, our results estab-
lished first that both purified neutrophil elastase (EL) and cathepsin G (CG) pro-
teolyse a recombinant soluble CD87 at the aminoterminal part, between its D1 and
D2 domains, whereas CG can also alter the carboxyterminal part of the molecule
within domain D3. Then, using both immunoblotting and flow cytometry approach-
es on the monocytic, CD87-expressing cell line U937, we observed that EL was
efficient in releasing the aminoterminal D1 domain from cells, while CG was mostly
active on a CD87 juxtamembrane sequence, thus resulting in the release of full-
length, three-domain soluble receptor. When testing the natural combination of EL
and CG as it results from their release from activated neutrophils, we found that
the two proteinases cooperated to produce a unique D2D3 truncated soluble form
of the receptor from the U937 cell membrane. This was accompanied by a drastic
reduction of the cell capacity to bind urokinase. Our findings thus provide a molec-
ular basis for the process leading to the generation of soluble D2D3 fragments of
CD87, which have been previously observed in various extracellular fluids during
inflammatory diseases, and which are endowed with a potent chemotactic activity
towards leucocytes (F. Blasi et al., Nature Rev. Molec. Cell Biol. 3 (2002) 932).
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Proteolytic regulation of the leukocyte and respiratory epithelial cell
urokinase receptor (CD87yuPAR) by elastase from Pseudomonas
aeruginosa
D. Leduc, M. Chignard, D. Pidard*(Presenting)
Molecular Medicine, Institut Pasteur, Paris, France
The GPI-anchored, 3-domain urokinase receptor CD87 (i) is expressed by both the
respiratory epithelium and leukocytes; (ii) participates to inflammation through
matrix degradation and migration of inflammatory and epithelial cells and (iii) is
susceptible to regulation through endoproteolysis. Among virulence factors contrib-
uting to the lung pathogenicity of P. aeruginosa in patients with cystic fibrosis are
proteases, including an elastolytic metalloproteinase (EPa). In this study, we con-
sidered the potential for EPa to modulate CD87 structure and function. An immu-
noblotting approach using domain-specific anti-CD87 antibodies showed that EPa
over 30 nM cleaves rapidly a recombinant CD87 to generate a D1 domain, which
is further degraded, and a larger, stable fragment made of the D2 and D3 domains
(D2D3) showing further cleavage at the carboxyterminus of domain D3. Based on
both flow cytometry and immunoblotting analysis, it was found that exposure of
the CD87-expressing monocytic cells U937 to EPa results in the rapid conversion
of the membrane, full-length CD87 into a D2D3 fragment. In parallel, analysis of
the extracellular milieus showed that part of this truncated receptor is released as a
soluble form (sD2D3). Similar results were obtained when monolayers of two res-
piratory cell lines of bronchial (16HBE) and alveolar (A549) origin, which con-
stitutively express CD87, were exposed to EPa. Finally, proteolytic removal of the
D1 domain to generate membrane D2D3 was accompanied by a drastic reduction
in the capacity of cells to bind urokinase. Our results thus extend the capacity to
proteolytically modulate the structure and functionality of the urokinase receptor to
a bacterial product of major importance in cystic fibrosis. Formationyrelease of a
D2D3 fragment of CD87, which is endowed with a potential chemotactic activity,
may be an important step in the evolution of the disease to chronic inflammation.
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Kinetic investigation of the inhibition of neutrophil elastase and
proteinase 3 by elafin and its precursor, trappin-2
S. Nobar (Presenting), M.-L. Zani , C. Boudier , J.G. Bieth , T. Moreau1 2 1 1 2
Laboratoire d’Enzymologie, Inserm 392, Universite Louis Pasteur de Strasbourg,1 ´
Inserm 392, Illkirch-graffenstaden, France, Laboratoire d’Enzymologie et chimie2
des Proteines, Inserm EMI-U 0010, Faculte de Medecine, Tours, France´ ´ ´
Excessive accumulation and cell death of neutrophils in the lung of cystic fibrosis
patients causes an important release of matrix-degrading serine proteinases, such as
elastase (NE), proteinase 3 (Pr3) and cathepsine G, which overcome the local
antiproteinase screen. The present work is the fist step towards the design of aerosol-
delivered inhibitors for the treatment of cystic fibrosis. We have expressed recom-
binant elafin, a human lung inhibitor and its precursor, trappin-2 in the yeast Pichia
pastoris. The two proteins were purified and the kinetics of their interaction with
NE and Pr3 were measured by fast kinetics using a stopped-flow device. They are
reversible inhibitors characterized by an association rate constant k , a dissociationass
rate constant k and an equilibrium constant Ksk y . Elafin inhibits NE anddiss i diss kass
Pr3 with Ks0.8e–10 M and 1.2e–10 M, respectively. Trappin inhibits NE and Pr3i
with Ks0.3e–10 M and 1.8e–10 M. These preliminary data show that both pro-i
teins are potent enough to be potential therapeutic agents for cystic fibrosis. It
remains to be experienced to which extent their activity is impaired by oxidants
present in cystic fibrosis lung secretions (preliminary experiments point to a dele-
terious effect of oxidants), and if they were stable to aerolization. Since trappin has
a transglutaminization domain, it will also be worth investigating whether the
matrix-bound protein is still an antiproteinase.
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Quantification of human neutrophil elastase, proteinase 3 and
cathepsin G in sputum of CF patients, using specific fluorogenic
substrates
S. Attucci(Presenting), Brice Korkmaz, Eric Hazouard, Francis Gauthier
Laboratory of Enzymology and Protein Chemistry, INSERM EMI-10 Proteases and
Vectorisation, Tours cedex, France
Targetting human neutrophil proteases by inhibitors has been reported as a thera-
peutic mean for cystic fibrosis. Up to now, interest has focused mainly on neutrophil
elastase (HNE), though other related proteases such as proteinase 3 (Pr3) and
cathepsin G (cat G) are involved in the proteolytic degradation of extracellular
matrix components and participate in the chronicity of inflammation observed in
CF. These three structurally and functionally related proteases are stored in similar
amounts in primary granules of human neutrophils and released at the same time
from activated cells. Therefore, the fate of each one upon neutrophil degranulation
is difficult to follow mainly, because there was no substrate until recently that could
allow to discriminate between their activities, especially that of HNE and Pr3. We
designed new specific substrates with intramolecularly quenched fluorescence that
allows specific measurement of HNE, Pr3 and cat G in supernatants and cell pellets
of CF sputum. Preliminary results show that all three proteases are present at similar
concentration in supernatants of CF sputum. However, a large part of proteolytic
activity remained entrapped in the pellet fractions from which it could be released
by repeated PBS washing, the last one being supplemented with 1.5 M NaCl to
solubilize membrane-bound proteolytic activity. This latter activity was mainly due
to cathepsin G. We conclude that simultaneous inhibition of soluble and membrane-
bound forms of these three proteases should be considered for designing a protease
inhibitor of therapeutic interest in CF.
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Correlation of cathepsin B-like activity with neutrophil elastase and
other markers of inflammation in CF sputum
K. Moffitt (Presenting), S.L. Martin , A. McDowell , B. Walker , J.S. Elborn , R.1 1 1 1 2
Bright-Thomas , A.M. Jones , A.K. Webb3 3 3
School of Pharmacy, Queen’s University, Belfast, Belfast, United Kingdom,1
Department of Respiratory Medicine, Queen’s University, Belfast, Belfast, United2
Kingdom, Bradbury Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Man-3
chester, United Kingdom
Many of the lysosomal cysteine proteases are potent elastinolytic and collagenolytic
enzymes, which are released in active form by stimulated macrophages during the
inflammatory process. In this study levels of cathepsin B-like activity (catB) were
measured in sputum obtained from 36 cystic fibrosis patients, and the relationship
to neutrophil elastase (NE) activity and other reputed markers of inflammation
assessed. Sputum was diluted weight for weight with 0.9% (wyv) saline in a 1:5
ratio, centrifuged at 1000 g for 30 min and the supernatant stored in aliquots aty
70 8C, pending the measurement of inflammatory mediators. CatB, cathepsin S
(catS) and NE activities were detected by spectrophotometric and fluorogenic assay,
utilising the substrates Z-Arg-Arg-aminomethylcoumarin, Z-Val-Val-Arg-amino-
methylcoumarin and N-Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide, respec-
tively, whereas all other parameters were measured by ELISA. Highly significant
correlations were observed between catB levels and catS (rs0.80; P-0.0001), NE
(rs0.60; P-0.0001), IL-8 (rs0.64; P-0.0001) and TNFa (rs0.61; P-
0.0001), all measured from sputum supernatant. To a lesser extent a significant
correlation was found between sputum catB and plasma IL-6 levels (rs0.29; Ps
0.04). Interestingly, no correlation was observed between plasma IL-6 and NE and
catS activities. No correlations were shown between sputum catB and plasma NEy
a -antitrypsin complexes and urine TNFr1. This was also the case with sputum NE1
and catS. These observations indicate that cathepsin B-like activity is elevated in
CF sputum and as such may play an important role in elastin degradation. Its
relationship to other markers of inflammation indicates that catB analysis may be
a useful activity end-point in clinical studies. This enzyme may also be a putative
target for anti-protease therapy in CF.
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Role of matrix metalloproteinases and cytokines during airway
epithelial regeneration in a humanized xenograft model
C. Catusse, C. Coraux(Presenting), S. Escotte, J. Hinnrasky, B. Nawrocki-Raby, E.
Puchelle
INSERM UMRS 514, IFR 53, Reims, France
In numerous airway inflammation and infectious diseases such as CF, severe epi-
thelial lesions are observed. An ‘air-opened’ in vivo xenograft model of human
airway epithelial regeneration has been developed in our laboratory in order to study
the molecular events involved during this process. After dedifferentiation, the
human epithelial cells adhere on the denuded basal lamina of the host trachea where
they spread, migrate, proliferate, stratify and then redifferentiate. After 35 days, a
normal human pseudostratified differentiated epithelium is restored. The different
steps of epithelium regeneration involve extensive extracellular matrix remodeling
where matrix metalloproteinases (MMPs) play a key role. We have analysed the
implication of MMPs, their inhibitors (TIMPs), cytokines and growth factors during
epithelial regeneration. MMPs and TIMPs revealed, by immunohistochemistry, an
apical distribution in the regenerating airway epithelial cells. By ELISA assays on
the liquids collected in the grafts, we observed a progressive significant decrease
of IL-8 all along epithelial regeneration associated to an increase of IL-10 level.
HGF and IL-6 increased during the epithelial cell proliferation and stratification of
the epithelium. During the same periods, we observed by RT-PCR with specific
human probes or mouseyhuman probes, an overexpression of mRNA levels of
MMP-2, its activator (MT1-MMP) and inhibitor (TIMP-2), as well as an increase
of MMP-2 and MMP-9 protein by zymography. These findings suggest a key role
of MMPs and TIMPs during the proliferation and stratification of epithelial cells
and put forward an important regulatory role of IL-10 during the inflammatory
process associated with human airway epithelial regeneration. This work was sup-
ported by INSERM, Association Francaise Vaincre la Mucoviscidose and INSERM¸
ATC 2002 : ‘Cellules souches a finalite therapeutique’.` ´ ´
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Elastase of Pseudomonas aeruginosa disarms proteinase-activated
receptor 2
S. Dulon (Presenting), D. Leduc , G. Cottrell , N.W. Bunnett , D. Pidard , M.1 1 2 2 1
Chignard1
Molecular Medicine, Institut Pasteur, Paris, France, Surgery and Physiology, Uni-1 2
versity of California, San Francisco, USA
P. aeruginosa is an ubiquitous pathogen capable of infecting all tissues. A large
variety of virulence factors contribute to its pathogenicity in lungs of patients with
cystic fibrosis, including proteases such as elastase (EPa). In this study, our interest
was focused on the effects of EPa on the proteinase-activated receptor 2 (PAR2).
PAR2 has been reported to be involved in inflammation within the lungs (T.M.
Cocks, J.D. Moffatt, Pulm. Pharmacol. Ther. 14, (2001) 183–191). This receptor
is cleaved within its aminoterminal extracellular domain by serine-proteinases such
as trypsin, unmasking a new aminoterminus starting with the sequence SLIGKV,
which binds intramolecularly and activates the receptor. We show that in human
alveolar (A549) and bronchial (16HBE) epithelial cell lines, PAR2-associated epi-
topes disappear at the surface of cells exposed to EPa, using flow cytometry analysis
with various PAR2 antibodies. Confocal microscopy analysis of a PAR2-transfected
cell line (KNRK-PAR2) exposed to EPa shows that this disappearance is not due
to endocytosis, and thus is rather the result of a proteolytic event within the receptor
extracellular domain. PAR2 activation by trypsin and by the activating peptide
SLIGKV-NH leads to intracellular calcium mobilization. We demonstrate that EPa2
does not activate PAR2, but rather prevents receptor activation by trypsin, but not
by SLIGKV-NH in the three cell lines. We hypothesize that EPa disarms PAR2 by2
proteolysis of the extracellular domain downstream from the trypsin cleavageyacti-
vation site, while leaving unmodified the SLIGKV-NH binding site. These findings2
suggest that EPa may inhibit PAR2 activity during lung inflammation.
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Airway acidification and exhaled nitric oxide in cystic fibrosis
S.A. Mulrennan(Presenting), J.C. Ojoo, J.A. Kastelik, A.H. Morice, A.E. Redington
Division of Academic Medicine, Postgraduate Medical Institute, Castle Hill Hos-
pital, Cottingham, United Kingdom
Background: Exhaled breath condensate (EBC) has recently attracted interest as a
noninvasive technique to sample the lower airways in respiratory disease, but there
is little information about its use in cystic fibrosis. Aims: To compare EBC pH in
patients with CF and healthy controls, to study its relationship to fractional exhaled
nitric oxide concentration (FENO), and to examine the effect of acute exacerbations
of CF on these parameters. Methods: We studied 18 (7 female) adult patients with
stable CF aged 24"2 yr with FEV 67.0"5.8% predicted. The control group con-1
sisted of 15 (9 female) healthy non-atopic non-smoking volunteers aged 39"3 yr
with no history of lung disease and normal pulmonary function (FEV 1.03"3.8%1
predicted). 7 of the CF patients were also studied at the start of an acute exacer-
bation. FENO was measured with a chemiluminescence analyzer (Logan LR2500
series) with a 250 mlys restrictor. EBC was collected and the pH measured imme-
diately. Results: During stable disease, the EBC pH of CF patients was significantly
lower than that of control subjects (5.71"0.11 vs. 6.05"0.07, Ps0.0034). The
FENO was also reduced in stable CF patients compared with healthy subjects (4"1
vs. 9.1"1 ppb, Ps0.0002). FENO in stable CF was correlated with FEV (rs1
0.63, Ps0.02), but not with EBC pH. During exacerbations of CF, EBC pH values
were significantly reduced compared with stable disease (5.40"0.13, Ps0.028),
whereas FENO measurements (3"1 ppb, Ps0.89) were very similar. Conclusions:
In stable CF, there is acidification of EBC, but this is not associated with an ele-
vation in FENO. An exacerbations of CF results in further reduction in EBC pH,
but no change in FENO.
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Nitration of tyrosine residues in inflamed lungs of CF patients is
restricted to eosinophil granule proteins
M. Ulrich (Presenting), F. Promm , P. Schmid , M. Schirle , M. Priemer , F.1 1 2 3 3¨
Ratjen , D. Worlitzsch , J.J. Lee , J. Checkel , G. Doring4 1 5 6 1¨
Institute of General and Environmental Hygiene, Eberhard-Karls University, Tub-1 ¨
ingen, Germany, Swiss Institute of Allergy and Asthma Research, Davos, Switzer-2
land, Institute for Cell Biology, University of Tubingen, Tubingen, Germany,3 ¨ ¨
Department of Pediatrics, University of Essen, Essen, Germany, Scottsdale, USA,4 5
Rochester, USA6
Bacterial infections provoke chronic inflammation in airways of CF patients. Reac-
tive oxygen radicals in conjunction with nitric oxide are thought to produce nitration
of tyrosine residues (NT) in many proteins during inflammation. Therefore, we
assessed NT in CF lung tissues using indirect immunofluorescence. NT residues
were detected in human eosinophils only, whereas NT staining in other immuno-
competent cells such as human neutrophils, mast cells, monocytesymacrophages
and T lymphocytes and in the CF lung epithelium was negative. Separation of
eosinophil proteins by gel electrophoresis, Western blotting and the application of
MALDITOF led to the identification of four nitrated proteins: eosinophil peroxidase
(EPO), eosinophil cationic protein, eosinophil derived neuro-toxin and major basic
protein. Western blotting of proteins in bronchoalveolar lavage samples from CF
patients using NT antibodies revealed that only EPO was NT positive. The mech-
anism of NT seems to be dependent on the presence of EPO and hydrogen peroxide,
since eosinophils of a EPO knock-out mouse strain were completely NT negative
and eosinophils of a patient with chronic granulomatous disease (lacking NADPH
oxidase) were 73.6% NT negative. We conclude that NT residues in inflamed CF
airways are not produced by reactive oxygen radicals in conjunction with nitric
oxide, but by an enzymatic mechanism involving EPO within eosinophils. These
results are in accordance with previous findings, which show that hydrogen peroxide
and nitric oxide levels are not increased in airways of CF patients.
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Neutrophil cell death, activation and bacterial infection in cystic
fibrosis
A.P. Watt (Presenting), J. Courtney , J. Moore , J.S. Elborn , M. Ennis1* 1 2 1 1
Respiratory Research Group, The Queens University of Belfast, Belfast, United1
Kingdom, Department of Bacteriology, Belfast City Hospital, Belfast, United2
Kingdom
Cystic fibrosis is characterised by bacterial infection and neutrophil dominated air-
way inflammation. Neutrophil priming by cytokines increases cell response to acti-
vating agents and delay apoptosis. Apoptosis is essential for resolution of
inflammation. This study assessed the relationship between neutrophil cell death,
activation and sputum microbiology in matched clinically stable CF patients. We
recruited 34 patients—9 (5M) with no Gram negative infection, 10 (4M) colonised
with P. aeruginosa (PA), 10(4M) with B. cepacia (BC) and 5 (3M) with other
Gram negative infections. Sputum was induced as previously described (Kelly et
al., Chest, 122, (2002) 955–959). Cell death and activation were assessed by flow
cytometric methods. Interleukin 8 (IL8) was measured in sputum sol by ELISA.
The percentage necrotic granulocytes were significantly higher in the PA
(17.1"2.5%, Ps0.01) and BC groups (13.9"1.2%, Ps0.02) compared to those
with no Gram negative infection (8.3"1.7%). Patients with no Gram negative
infection had a significantly higher percentage viable cells (77.3"4.2%) than the
BC and PA groups (60.2"4.3%, Ps0.01, 62"5.6%, Ps0.03, respectively) and
significantly lower percentage of activated cells (76.4"4.4%) than the BC
(85.3"6.1%, Ps0.04) and PA groups (91.2"2.0%, Ps0.003). BC and PA
patients also had significantly higher levels of IL8 (188.6"34.6 ngyml, Ps0.01
and 200.5"44.4 ngyml, Ps0.01) than those with no Gram negative infection
(62.3"26.3 ngyml). These results indicate there are greater numbers of granulo-
cytes in necrotic and activation pathways from patients infected with PA and BC,
suggesting this may be a mechanism of greater inflammation and subsequent lung
injury, which is amplified by higher levels of IL8.
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Differential cytokine profile in patients with cystic fibrosis
J. Brazova , A. Sediva , D. Pospisilova , V. Vavrova , P. Pohunek , M. Macek1 1 1 2 2
Jr. , J. Bartunkova , H. Lauschman3 1 4
Institute of Immunology, Charles University Prague – University Hospital Motol,1
Prague, Czech Republic, Pediatric Clinic, Charles University Prague – University2
Hospital Motol, Prague, Czech Republic, Institute of Biology and Medical Genet-3
ics, Charles University Prague – University Hospital Motol, Prague, Czech Repub-
lic, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical4
University, Prague, Czech Republic
Introduction: The previously observed occurrence of antineutrophil cytoplasmic
autoantibodies (ANCA) in patients cystic fibrosis (CF), together with the reported
decrease of IgG as the only Th1-controlled isotype, led us to the analysis of poten-2
tial Th1yTh2 imbalance in CF with suggested Th2 predominance. Methods: In 48
CF patients and 16 controls levels of cytokines IFNg, IL-4 and IL-10 have been
measured in supernatants of whole blood cell culture stimulated by lipopolysac-
charide (LPS) and phytohemaglutinine (PHA). Results: Based on the results the
patients were divided into 2 delineated groups: ‘low responders’ – with a negligible
secretion of cytokines (IFNg: 10.0–200.0 pgyml, IL-4: in a range 0.0–0.3 pgyml)
and ‘high responders’, who produced high levels of both IFNg (500.0–2000.0 pgy
ml) and IL-4 (1.0–200.0 pgyml). We observed more commonly (10 positive out
of 16) chronic lung infection by P. aeruginosa in the ‘low responder’ group while
such colonization was less prevalent in the ‘high responders’ (13 positive out of
32 cases). Shift towards Th2 response was observed in the group of ‘high respond-
ers’ when patients chronically infected with P. aeruginosa had a tendency to higher
IL-4 (1.0–200.0 pgyml) production than non-infected patients within the same
cohort. Autoantibodies ANCA that were simultaneously examined were positive
only in the ‘high responders’ group. Conclusion: Contrary to our initial expectations
we observed a trend towards Th2 predominance in CF patients only in a subset of
investigated cases that have been associated with chronic P. aeruginosa infection.
Supported by IGA MZ CR: 5865-3, 6464-3, 6462-3, 00000064203; MSMT-
111300001, 111300003, LN00A079.
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Bronchoalveolar S100A8y9 levels in children with CF
R. Morris (Presenting), I.J.M. Doull1* 2
University of Wales College of Medicine, Cardiff, United Kingdom, CFyRespi-1 2
ratory Unit, University Hospital of Wales, Cardiff, United Kingdom
Background: S100A8y9 (previously known as the CF antigen) is the most abundant
cytosolic protein in neutrophils, accounting for 40% of the cytosolic protein. Its
release has been demonstrated during phagocytosis by neutrophils ex vivo, and its
presence may therefore act as a marker for neutrophil phagocytic activity within
the inflamed lung. We hypothesised that S100A8y0 levels might be deranged in
the lungs of patients with CF. Methods: Broncho-alveolar lavage (BAL) samples
were obtained from 21 patients with CF (mean age 7.5 yr) and 17 non-CF subjects
(mean age 5.4 yr) undergoing investigation for recurrent respiratory infections.
S100A8y9 was measured by Western blotting and chemiluminescence detection,
and were expressed as relative units both total levels and corrected for whole total
protein and. Results: BAL lavage S100A8y9 concentrations were significantly lower
in the CF group compared to non-CF controls (77.7 vs. 112.6 U; diff 35.9, 95%CI
15.56; P-0.001), while there were no significant difference in levels corrected for
total BAL protein (25.7 vs. 26.5). Conclusions: BAL S100A8y9 levels are signif-
icantly decreased in CF. This is consistent with our previous findings suggesting
decreased phagocytic activity by neutrophils in the CF lung.
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Relationship between the expression of secreted phospholipase A2
and CFTR deficiency in pulmonary cells and tissues
S. Medjane(Presenting), Y. Wu, L. Touqui
Unite Defense innee et inflammation, Institut Pasteur, Paris, France´ ´ ´
The aim of this study was to determine the role of CFTR in the control of secreted
phospholipase A2 (sPLA2) expression in pulmonary cells and tissues. Increased
levels of arachidonic acid (AA) metabolites have been observed in the sputum from
CF patient. PGE2, an AA-derived metabolite, has been shown to modulate the
sPLA2 expression in various cell types. Previous studies show an increased AA
release from epithelial cell and skin fibroblasts from CF patients, as well as CF
epithelial cell line (CFT-2: ?F508 homozygote). This led us to study different types
of sPLA2 expression in CFT-2 (NT-1 cell line as control) and in CFTR KO mice
and its potential relation with CFTR deficiency. In the first part, RT-PCR showed
that CFT-2 cells constitutively expressed higher level of sPLA-IIA compared to NT-
1 cells. CFT-2 cells constitutively expressed lowest transcription level of sPLA2-X
compared to NT-1 cells. LPS increased this expression in both cell lines. However,
PGE2 stimulation increased the transcription level of sPLA2-X in NT-1 cells, but
decreased it in CFT-2 cells in the presence or in the absence of LPS. Moreover, we
showed that CFT-2 cells released higher PGE2 level than NT-1 cells. In the second
part, we showed that sPLA2-IIE and sPLA2-X mRNAs levels were higher in KO
mice lung compared to wild type mice. We also showed that LPS instillation
increased sPLA2-IIE mRNA level in CF mice, but had no effect in wild type mice.
However, sPLA2-X mRNA level was decreased by LPS in both mouse strain and
CF mice release more PGE2 in BALF with or without LPS compared to wild type
mice. These results suggest a possible relationship between deficiency of CFTR
and sPLA2 expression in pulmonary cells. Because, sPLA2s are known to play a
role in inflammation and to exhibit antibacterial activities, the regulation of their
expression might have an important physiopathological relevance in the context of
CF.
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T cell chimiotactism during stimulation of airway epithelial cell by
Staphylococcus.aureus
S. Escotte (Presenting), S.C. Gangloff , M. Merten , E. Puchelle , M.1 1 2 3
Guenounou1
Laboratoire d’Immunologie et de Biotechnologies, EA2070, IFR53, Reims, France,1
Laboratoire de pathologie Cellulaire et Moleculair, EMI INSERM 0014, Vandoeu-2 ´
vre-Les-Nancy, France, INSERM UMRS 514, IFR53, Reims, France3
The airway epithelium provides a physical and immunological barrier against micro-
organisms and toxic substances. In response to injuries like bacterial infection, the
airway epithelium is able to release pro-inflammatory cytokines. This study inves-
tigated the migration of lymphocytes across resting and S. aureus stimulated glan-
dular human epithelial cell cultures (MM-39). To look at these events, we have
used a double chamber of polarized airway epithelial cultures. We have shown that
T cells preferentially transmigrate in a physiologically appropriate direction, basal
to apical epithelial cell surface and that the relative number of transmigrated T cells
increased when airway epithelial cells were in contact with S. aureus at the apical
side. We also studied the chemotactic effect of resting and stimulated airway epi-
thelial cells supernatants. Our results show that apical supernatants induce a greater
migration of T cells as compared to the migration induced by basolateral super-
natants. The chemotactic capacity of apical supernatants increased when airway
epithelial cells were stimulated by S. aureus. In addition, we found that airway
epithelial cells preferentially secrete IL-8 through the apical cell surface thereby
establishing a chemical gradient for chemotaxis across the epithelium and that IL-
8 secretion increased during S. aureus stimulation. Taken together, these results
define how specific apical production of chemotactic molecule(s), like IL-8, may
serve to mediate the intensity and direction of T cell trafficking through airway
epithelium during inflammation or early infection. This work was supported by
Association Francaise Vaincre la Mucoviscidose.¸
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Cytokine messenger RNA (mRNA expression) in airway epithelial and
inflammatory cells in young patients with cystic fibrosis
M. Muhlebach-Sponer*(Presenting), W. Reed, T.L. Noah
Paediatric Pulmonlogy, University of North Carolina at Chapel Hill, Chapel Hill,
USA
Inflammation is early and sustained in CF lung disease. Pro-inflammatorymediators
in bronchoalveolar lavage fluid (BALF) e.g. interleukin-8 (IL-8) appear to be
increased relative to bacterial burden, but the anti-inflammatory IL-10 may be
decreased. Few studies have tried to quantify cytokine expression by airway cells
in vivo in young CF patients. These study compares IL-8 and IL-10 mRNA expres-
sion in bronchial epithelial cells (BEC) and BALF cells (BALFC) of CF vs. non-
CF disease control patients (N). mRNA was isolated from cells obtained by
bronchial brush biopsy and BALFC from children less than 4 yr undergoing clin-
ically indicated BALF. mRNA abundance of IL-8 and IL-10 was estimated by real-
time PCR and normalized to GAPDH mRNA. 21 CF and 29 N patients participated,
but some BALFC or BEC samples did not fulfill inclusion criteria. Mean age was
23.2"3.5 for CF and 15.3"2.3 months for N patients (Ps0.08). CF patients had
higher total cell counts and a higher percentage of PMN and lower percent mac-
rophages in BALF. IL-8yGAPDH tended to be higher in BALFC from CF compared
to N (1.5"0.4 vs. 0.8"0.3; Ps0.12), which reached significance when comparing
uninfected CF vs. N samples (Ps0.05). IL-10 was detectable in 50% of CF and
in 37% of N BALFC samples. In BEC cell yield and differentials were similar in
CF and N. IL-8yGAPDH mRNA was significantly higher in CF vs. N patients
(1.2"0.4 vs.0.4"0.1; Ps0.01). Comparing samples according to infection, the
difference was not significant. IL-10 mRNA was detectable in 73% of CF and in
52% of N samples. The fold increase in IL-8 protein in CF airways was significantly
higher than that observed for IL-8 mRNA in BEC and BALFC, suggesting that
both the increase in total BALF cells and a subtle increase in IL-8 mRNA expression
contribute to enhanced IL-8 protein in CF BALF. IL-10 mRNA expression was not
substantially different in CF vs. N regardless of infection.
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Mucosal immunity of the respiratory tract in infants with cystic fibrosis
(CF)
Z. Vancikova(Presenting), V. Skalicka
Paediatric Department, Charles University and Medical Faculty, University Hos-
pital Motol, Prague, Czech Republic
Introduction: cystic fibrosis is one of the most frequent inherited diseases in the
white population. Despite of our increasing knowledge about the pathogenesis of
cystic fibrosis organ damage, the effective therapy of CF lung disease is untill not
known. Local non-specific as well as specific immunological mechanism plays the
most important role. The information about local immunity in the CF respiratory
tract is very sporadic. The aim of this study was to investigate mucosal immunity
in the respiratory tract of CF infants. Methods: levels of secretory IgA (SIgA),
ANCA and anti-Haemophilus B antibodies in induced sputum of 15 CF infants
were measured by radial immunodiffusion and ELISA, respectively. The same par-
ameters were measured in the patients’ sera. A random population of 30 infants
with urinary tract infections was used as a control group. Results: Out of 15 inves-
tigated infants, only 2 had lower sputum SIgA and 5 had lower serum IgA when
compared to controls. 2 infants had protective sputum anti-Haemophilus B anti-
bodies, 5 infants had protective serum anti-Haemophilus B antibodies. In one
patient, local anti-Haemophilus B IgG production was detected. Serum ANCA was
positive in 5 infants, sputum ANCA was negative in all patients. Conclusion: Non-
specific mucosal immunity is not significantly depressed and local specific immune
response can be stimulated in young CF infants. Despite of serum ANCA positivity,
local ANCA production was not detected in CF infants’ sputum. The role of these
autoantibodies in the pathogenesis of CF lung injury is still controversial.
s30 Journal of Cystic Fibrosis 2 (2003) S25–S30
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Characterisation of the intracellular Ca mobilisation response in2H
cystic fibrosis white blood cells
G.T. Rijkers, J.F. Gaiser, C.K. van der Ent
Pediatric Immunology, University Medical Centre, Utrecht, Netherlands
Introduction: In cystic fibrosis CFTR mutation leads to altered intracellular chloride
homeostasis. This in turn might secondarily lead to dysregulation of other intra-
cellular ion concentrations like intracellular ionised calcium (wCa xi).To address2q
this issue we studied wCa xi in lymphocytes and PMNs of CF patients and of2q
healthy controls. Methods: Blood was withdrawn from 10 healthy adults (5 male,
age range 21–40 yr) and from 5 CF patients (3 male, age range 2–18 yr) in
clinically stable condition. Lymphocytes and PMNs were separated from blood by
centrifugation over Ficoll. Changes in wCa xi were measured using either fura red2q
and fluo-3-AM, measured on a FACS Calibur (Becton Dickinson) or with indo-1,
measured on a FACS Star Plus (Becton Dickinson). Stimulation of PMNs was
performed by adding fMLP and stimulation of lymphocytes by adding anti-CD3.
Results: Resting wCa xi was comparable between CF patients and controls. The2q
magnitude of the wCa xi response was higher for lymphocytes and PMNs of CF2q
patients. For PMN the wCa xi response was also faster in CF patients compared2q
to controls (8.6"1.5 vs. 17.6"7.7 s). These differences in wCa xi response were2q
found both in fura red and fluo-3 as well as in indo-1 labelled cells. Conclusions:
There is a difference in wCa xi measurements in both lymphocytes and PMNs of2q
clinically stable CF patients compared to controls. Since wCa xi plays a role as a2q
key mediator in different inflammatory processes in various cell types, this may
contribute to the increased and ongoing inflammatory reaction seen in clinically
stable CF patients.
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Humoral immune response of children with cystic fibrosis
R. Ujhelyi (Presenting), M. Szolnoky , A. Madarasi , K. Holics , A. Kalmar1 2 2 1 2
Heim Pal Hospital for Children, Budapest, Hungary, Buda Children’s Hospital,1 2
Budapest, Hungary
Aims: Although it is widely accepted that the immune functions of patients with
cystic fibrosis (CF) are intact1, studies on the specific immune response to any
bacteria other than P. aeruginosa are missing. The levels of the specific antibodies
to the capsular polysaccharide antigen of Streptococcus pneumoniae (anti-PCP-AB)
as a good indicator of this immune function were lower in these patients 2. Mate-
rials and methods: Specific antibody production to two bacteria, S. pneumoniae and
Haemophilus influenzae type b were measured by enzyme linked immunosorbent
assay (ELISA) in 51 children with CF. Antibody titres of the patients were com-
pared to the levels of an age-matched control group (n: 80). Results: Anti-pneu-
mococcal antibody titres were found to be significantly lower in the patients with
cystic fibrosis, compared to the controls (33.81"24.27 mgyl vs. 78.32"77.98 mgy
l, respectively, P: 0.006), and did not increase by the age. Antigen challenge with
Pneumovax 23 vaccine were performed in 19 patients, out of them 16 produced
more than threefold quantities of specific anti-pneumococcal polysaccharide anti-
body 1 month after the immunisation. Antibodies against the H. influenzae type b
capsular polysaccharide have been shown to reach protective level in 85% of the
patients and did not differ significantly from the control population (4.01"3 38
mgyl vs. 4.64"3.37 mgyl, respectively, P: 0.22). Conclusion: The specific antibody
production of the children suffering from cystic fibrosis may be impaired, but can
be corrected by active immunisation, which in turn can reduce the frequency and
severity of infections in these risk patient population.
Journal of Cystic Fibrosis 2 (2003) S31–S48
Microbiology and Antibiotics
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Survival of cystic fibrosis patients infected with Burkholderia cepacia
complex genomovar III, Burkholderia multivorans and Pseudomonas
aeruginosa
A.M. Jones (Presenting), M.E. Dodd , J.R.W. Govan , C.J. Doherty , V. Barcus ,1 1 2 2 2
A.K. Webb1
Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals1
NHS Trust, Manchester, United Kingdom, Medical Microbiology, University of2
Edinburgh, Edinburgh, United Kingdom
Introduction: Burkholderia cepacia comprises a number of distinct genomic species,
known as genomovars. The majority of cystic fibrosis (CF) clinical isolates belong
to genomovars II (B. multivorans) and III. The different severity of infection attrib-
utable to separate genomovars is unknown. We investigated whether survival differs
between patients infected with B. multivorans, B. cepacia genomovar III and Pseu-
domonas aeruginosa. Methods: Patients at the Manchester Adult CF Centre who
developed chronic infection (1982–2001) with B. multivorans and genomovar III
were included; each was matched with another CF patient with chronic P. aerugi-
nosa infection using the percentage predicted FEV when the Burkholderia species1
was first isolated. The two Burkholderia species groups were each compared to
their respective control groups for median survival time using the log rank test.
Cepacia syndrome deaths and numbers progressing from initial to chronic infection
were assessed for patients infected with Burkholderia species. Results: Forty-eight
patients had an initial infection with B. multivorans (ns15) or genomovar III (ns
33); 8y15 and 31y33, respectively, developed chronic infection (P-0.001). For
the B. multivorans group and their matched controls there were 4y8 (1=‘cepacia
syndrome’) and 3y8 deaths with a median survival of 112 and 114 months, respec-
tively, (Ps0.63). For the genomovar III group and their controls there were 21y
31 (2=‘cepacia syndrome’) and 12y31 deaths with a median survival time of 94
and 130 months, respectively, (Ps0.05). Conclusions: CF patients with B. cepacia
genomovar III infection have a shortened survival in comparison with those with
P. aeruginosa infection; however there is no difference in survival between patients
infected with B. multivorans and P. aeruginosa.
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The French ‘Observatoire Burkholderia cepacia’; an identification and
genotyping surveillance network: design, methods and statement of
results for 2001
C. Segonds (Presenting), E. Bingen , P. Plesiat , S. Ravilly , G. Chabanon1 2 3 4 5
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The ‘Observatoire B. cepacia’ was established in 1993 with the support of the CF
association ‘Vaincre la mucoviscidose’ to assess the epidemiology of B. cepacia in
France and to contribute to the management of colonised patients. To date, the
surveillance network involves 110 CF Centres (near 3400 patients). Both clinical
epidemiological data and bacterial isolates are collected. Isolates are identified by
means of ARDRA, and typed both by PCR-ribotyping and EcoRI-ribotyping, and
whenever necessary by PFGE. Five transmissible clones have been identified, Xy
RyAB and FyAyS (B. multivorans); AyDyA, DyByC and LyQyM (B. cepacia
genomovar (gv) I or III). In 2001, 113 cases were recorded in 47y110 CF Centres;
19 were primary colonisations (prevalence: 3.3%; incidence: 0.5%). The mean age
was 18 (1–33), with a male predominance (1.4M:1F). The mean age of B. cepacia
acquisition was 14 (-1–32). For 104y113 patients, at least one isolate was ana-
lysed: 48 patients (46%) harboured B. multivorans, 44 (42%) B. cepacia gv I or
III and 2, both species; 4 B. vietnamiensis, 2 B. stabilis or pyrrocinia, 2 B. gladioli,
2 Ralstonia mannitolilytica. Epidemic clones accounted for 28y50 (56%) B. mul-
tivorans colonisations, and 32y46 (70%) B. cepacia gv I or III colonisations. Blood-
stream infection occurred in 3 patients: in 2 patients harbouring the AyDyA clone
(B. cepacia gv I or III), sepsis followed lung transplantation and led to death; the
last patient, harbouring the XyRyAB clone (B. multivorans), was successfully treat-
ed. Thus, the 2001 prevalence and incidence of B. cepacia complex and related
species in French CF patients were 3.3% and 0.5%, respectively, and mostly
involved B. multivorans and B. cepacia gv I or III. Bloodstream infection occurred
in 3y113 patients (2.6%), and was fatal in 2 cases following transplantation.
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Early identification of Burkholderia cepacia infection and its prognostic
role: experience of the Prague CF centre
J. Bartosova (Presenting), D. Zemkova , P. Drevinek , O. Nyc , V. Skalicka , O.1 2 2 3 2
Cinek , M. Macek Jr. , V. Vavrova2 4 2
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Czech Republic, Institute of Microbiology, Charles University Prague – University3
Hospital Motol, Prague, Czech Republic, Institute of Biology and Medical Genet-4
ics, Charles University Prague – University Hospital Motol, Prague, Czech
Republic
Introduction: Infection with B. cepacia (BC) is associated with higher morbidityy
mortality and BC is patient-to-patient transmissible. Unfortunately, our CF centre
has a higher BC colonization rate (61y216; 28.2%). Thus, our aim was to assess
the microbiological andyor PCR-based diagnostics of BC and its influence on the
clinical progression of CF. Methods: Since 1994 BC testing has been performed by
culture, followed from 2001 by BC complex PCR-based detection, together with
identification of its genomovars (recA gene). Patients: Group 1: 92 cases (age 8.0–
21.0 yr) BC negative, their semi-longitudinal clinical monitoring generated age-
specific standards for FEV . Group 2: 25 cases (age 8.0–22.0 yr) colonized by1
BC)3 yr; Group 3: 10 cases (mean age 13.9"3.5) with BC detected during the
last 2 yr and Group 4: 19 cases (mean age 7.9"4.6) that have been culture negative,
but PCR positive. Results: Group 2 had significantly (P-0.0001) decreased
FEV compared to Group 1 (y0.9"0.9 S.D. vs. 0.0). However, FEV values did1 1
not correlate with the duration of infection. Patients from Group 3 had non-signif-
icantly worse PFTs 1 yr prior to the detection of BC (y0.6"0.8 S.D. vs. 0.0) and
afterwards their PFTs remained stable, with the exception of 2 cases. Furthermore,
BC colonization has not been associated with the deterioration of patients’ nutri-
tional status. Cases from Group 4 were younger than those from Group 3, but no
other differences have been observed. Conclusion: Despite strict epidemiological
measures the incidence of BC infection has not decreased, so far. Intriguingly, BC
colonization does not have a negative impact in the short-term horizon. Further
studies are necessary to evaluate the prognostic value early BC infection detection,
its progression into a chronic status and the role of its early treatment. Supported
by IGA MZCR: 6464-3, 6568-3, 00000064203 and MSMT: LN00A079,
111300003.
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Molecular typing of Burkholderia cepacia genomovar III-A isolates
recovered from Czech CF patients
P. Drevinek (Presenting), O. Cinek , F. Prusik , H. Reitzova , J. Bartosova , V.1 2 3 2 2
Vavrova , P. Pohunek2 2
Medical School of Charles University, Prague, Czech Republic, Department of1 2
Paediatrics, Medical School of Charles University, Prague, Czech Republic,
Department of Clinical Microbiology, University Hospital Motol, Prague, Czech3
Republic
In sputum of Czech CF patients, genomovar III-A is by far the most frequently
recovered pathogen within Burkholderia cepacia complex (Bcc). In total, this gen-
omovar accounts for more than 90% of infection with Bcc. We sought to apply
molecular typing methods to further analyse this genomovar-homogeneous group
of Bcc, which may suggest an occurrence of patient-to-patient transmissible
strain(s). Since May 2001 we have cultured 95 Bcc from 55 CF patients. Using
PCR with primers targeted the recA gene polymorphisms, we identified the geno-
movar status of Bcc. Eighty-six isolates from 50 patients belonged to genomovar
III, recA group III-A. At least one III-A isolate from every patient has been analysed
by PCR-based RAPD assay (E. Mahenthiralingam et al. JCM 34(12) 1996). The
method was modified by use of fluorescent-tagged RAPD primer and by analysis
on an AlfExpress II sequencer machine (Pharmacia). The obtained electrophoretic
patterns contained approximately 30 bands in every isolate. The pattern of examined
isolate has been completely reproducible between PCR runs. Comparing III-A iso-
lates from 50 CF patients, we found identical RAPD patterns in 30 patients. Isolates
of 18 patients yielded minor changes in range of 1–2 bands, and only two isolates
remarkably differed in their genomic profiles from the predominant one. RAPD
results indicate the occurrence of an epidemic strain within genomovar III-A, which
may have caused the spread of infection among our CF patients. To confirm this
hypothesis, we performed PFGE typing method, often considered gold standard, in
five RAPD indistinguishable isolates. Contrary to RAPD, we gained seven and more
fragment differences among these isolates what suggests genomovar III-A strain
diversity. These preliminary results indicate inevitability of PFGE analysis and the
lack of discriminatory power of RAPD if used in large-scale study of Bcc infection
in the CF community. Support: MZCR 6568-3, MSMT 111300003.
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Genomovar status and DNA fingerprinting of Burkholderia cepacia
complex isolates from Italian cystic fibrosis patients
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B. cepacia complex (BCC) has emerged as a major pathogen in CF patients. These
organisms are resistant to many antibiotics and exist as 9 distinct genomovars (gv) which
vary in their transmissibility and virulence. Aims: To investigate the national prevalence
and genomovar status of BCC in patients from 16 (61.1%) Italian CF centers. Hundred
and Seventy-eight isolates presumed to be BCC were obtained from 178 subjects. The
gv status of these isolates was determined by a polyphasic approach including whole cell
protein analysis, DNA–DNA hybridisation experiments, and recA sequence and RFLP
analysis. PFGE using the restriction enzymes XbaI and SpeI was performed to analyse
the clonality of the isolates. 167 out of 178 strains belonged to the BCC, 1 was Pseu-
domonas spp, 7 B. gladioli, 1 Inquilinus limosus, 1 A. xylosoxidans, and 1 P. huttiensis.
Genomovar analysis showed that B. cenocepacia (gv III) was the most prevalent BCC
species (70.6%), followed by B. cepacia (gv I – 9.0%), B. stabilis (gv IV – 7.2%), B.
multivorans (gv II – 5.4%) and B. pyrrocinia (gv IX – 4.8%). B. vietnamiensis (gv V
– 0.6%), gv VI (0%), B. ambifaria (gv VII – 0%) and B. anthina (gv VIII – 0%) were
not or only rarely found. Genomic fingerprinting has been performed on 135 BCC isolates
cultured from patients attending 11 Italian CF clinics. PFGE revealed 57 unique strains.
The remaining isolates were divided into 19 clusters. The number of isolates within these
clusters ranged from 2 to 8. Clusters of 8 patients sharing the same B. cenocepacia clone
were identified in 2 separate CF centres. Two clusters (one with 5 patients from a center
and one with 3 patients from another) were identified as B. pyrrocinia.Discussion:
– 167 (94%) isolates were correctly identified as BCC.
– The genomovar distribution is characterized by a predominance of gv III and relatively
few gv II isolates.
– Most patients were colonised by gv III clones representing different RecA RFLP types.
– This is the first report of transmission of B. pyrrocinia among CF patients.
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Survival benefit of lung transplantation in cystic fibrosis patients with
Burkholderia cepacia genomar III
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Although cystic fibrosis (CF) is the principal indication for bilateral lung trans-
plantation, the prognosis for CF patients infected with B. cepacia (Bc) has been
much worse than for those with Pseudomonas aeruginosa (Pa) only. Methods: We
used survival regression models to analyze the effect of lung transplantation on the
risk of dying in a cohort of 271 Toronto CF patients with positive sputum cultures
for Bc from January 1, 1987 to December 31, 2001. Virtually all were genomovar
III, which has been associated with the poorest post-transplant outcome. Cox pro-
portional hazard models were computed with sex and age on entry as fixed cov-
ariates, and time-dependent covariates for FEV and lung transplantation. A second1
set of models was computed for a contemporaneous cohort of 399 patients whose
lungs were colonized with Pa only. Results: There were 42 transplants and 133
deaths in the Bc cohort, 28 transplants and 35 deaths in the Pa cohort. When the
effects of sex and FEV were accounted for in a multivariable model the hazard1
ratio for lung transplant was 0.62 (Ps0.059) indicating a marginally significant
benefit. An interaction effect added to the model (Ps0.035) showed the transplant
benefit was greater at lower levels of FEV , with a hazard ratio of 1 at FEV s1 1
27% predicted, 0.5 and 0.3 at FEV s20% and 15%, respectively. Overall the hazard1
ratio for lung transplant was 0.57 (Ps0.026) in the Bc cohort and 0.18 (Ps0.029)
in the Pa cohort. Conclusions: Lung transplantation provides significant survival
benefit to CF patients with Bc genomovar III, reducing mortality risk by an average
57%, compared to a reduction of 18% for patients with Pa only. These findings are
consistent with previous reports, but also show that lung transplantation is a positive
option for CF patients with Bc, even though those with genomovar III, motivating
continued efforts to improve outcome.
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A laboratory-based risk assessment model to assess Burkholderia
cepacia status in patients with cystic fibrosis within an adult CF centre
J. Moore (Presenting), J.S. Elborn1 2
Northern Ireland Public Health Laboratory, BELFAST, United Kingdom, Regional1 2
Adult CF Centre, Belfast City Hospital, Belfast, United Kingdom
Burkholderia cepacia complex (BCC) organisms, particularly B. cepacia geno-
movar III and B. multivorans, are important causes of morbidity and mortality. BCC
organisms have been shown to be transmissible from patient-to-patient, with impor-
tant consequences for the control of infection at CF centres. Recently, several molec-
ular assays have been developed independently to help determine its presence in
sputum, genomovar type, virulence and transmissible nature of organism, although
there has been no combined attempt made to date to bring together such assays to
direct optimum patient management. It was therefore, the aim of this study to
develop a laboratory-based risk assessment model to direct the optimum and eco-
nomic integration of such assays into routine laboratory practice to help guide
effective infection control policy within the CF unit, as well as provide quality
laboratory data for optimum antibiotic and clinical management of CF patients with
BCC infection. The working model proposes to assign an individual BCC category
status from five category types (A–E) ranging from chronic infection for greater
than 1 yr (A) to no history of colonisation with minimal risk factors of acquisition
(E). In addition, patients are assigned to an extra clinical category i.e. stable or
non-stable (1 or 2). Presently, seven laboratory assays are offered to help define
BCC status of the patient and information relating to the isolate, consisting of two
phenotypic (platingqselective enrichment) and six molecular assays. Employment
of assay type and frequency of performance is correlated with BCC category and
clinical status. Where more monitoring controls are needed or where there is a
change in the dynamics of infection, i.e. from colonisation to non-colonisation,
increased monitoring is introduced. Overall, this model is useful in helping to direct
the appropriate employment of laboratory assays to address difficult infection con-
trol issues surrounding CF.
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The genomovar distribution of Burkholderia cepacia complex isolates
collected from Australian cystic fibrosis units
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Respiratory infection with Burkholderia cepacia complex organisms has been asso-
ciated with poor outcomes for patients with cystic fibrosis. This complex of organ-
isms is subdivided into nine genetically distinct genomovars. Prognosis may vary
according to genomovar type. To date, most genomovar prevalence studies have
been largely based on isolates collected from patients located in the Northern Hem-
isphere. We report the genomovar distribution of B. cepacia complex isolates col-
lected from patients with cystic fibrosis throughout Australia and New Zealand. In
this study, a combination of recA-based PCR and 16s ribosomal DNA restriction
fragment length polymorphism (RFLP) analysis was used to determine the identity
and genomovar diversity of 100 individual isolates collected from a total of 97
patients with cystic fibrosis. The isolates were collected from 13 Australian labo-
ratories and one from New Zealand. 16s rDNA sequence analysis was employed
to provide additional identifications for two further recA B. cepacia complex spe-
cific PCR negative isolates. A diversity of genomovars was detected amongst the
total collection of isolates tested (ns100): B. cepacia genomovar I (14%), B.
multivorans (27%), B. cepacia genomovar III (47%; clade As16%, clade Bs
31%), B. vietnamiensis (5%), B. cepacia genomovar VI (1%) and B. ambifaria
(6%). A further two recA B. cepacia complex specific PCR negative isolates, were
classified as B. cepacia-like bacteria following 16s rDNA sequence analysis. The
genomovar diversity of Australian B. cepacia complex isolates is similar to that of
the USA CF population and are more diverse when compared to countries such as
Canada, Ireland and the United Kingdom. Strain typing is now required to assess
the relatedness within each genomovar.
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Burkholderia cepacia infection and clinical course in cystic fibrosis
patients
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In order to determine if any correlation exists between B. cepacia genomovar and the
progression of respiratory symptoms in CF we reviewed the clinical course of 50
patients (31 M, 19 F) chronically colonized by B. cepacia attending our centre since
1992. B. cepacia complex strains were identified by API20NE (Biomerieux). Molec-
ular identification of genomovars was performed by PCR amplification of 16S rDNA
and recAgenes followed by analysis of RFLPs generated by DdeIand Hae IIIenzyme
digestion. The mean colonisation period was 6.8 yr (range 0.6–10). The genomovar
prevalence was the following: genomovar I 8.0; genomovar II 4.0; genomovar III-A
32.0; genomovar III-B 54.0 and genomovar V 2.0. The clinical course was categorized
as Group A – rapid functional deterioration andyor cepacia syndrome; B – slowly
progressive disease; C – lack of change in functional trend. Results: All types of clinical
course were seen with Gen I,II,III-A or B (Table 1). One patient with Gen V had no
progression of his disease. Four patients with Gen III were lung transplanted, three had
no serious complication in the 1–3 yr period following surgery, one died 2 months
after transplantation. Based on our experience we conclude that: (1) although B. cepa-
cia colonisation is associated with a poor outcome in CF, specific genomovars are not
predictive of rapid deterioration; (2) Chronic infection with B. cepacia genomovar III
should not preclude transplantation.
Functional
deterioration
Functional
deterioration
Functional
deterioration
Genomovar Total no.
patients
A B C
GEN I 4 1 1 2
GEN II 2 1 1 –
GEN IIIA 16 4 6 6
GEN IIIB 27 3 10 14
GEN V 1 – – 1
Mean follow up (yr)
range
50 3.7 (0.6y5) 7.6 (2y10) 7.3 (2y10)
Acknowledgments: This work was partially supported by a grant from Italian Cystic
Fibrosis Research Foundation.
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Epidemiology and clinical outcome in relation to Burkholderia cepacia
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a Portuguese cystic fibrosis center
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This work reports results from a systematic molecular analysis involving 113 Burk-
holderia cepacia complex isolates obtained from 23 cystic fibrosis (CF) patients
under surveillance over a 7 year-period at the major Portuguese CF center, the Santa
Maria Hospital in Lisbon. The majority of the isolates were serial isolates from
persistently infected patients (more than one half of the population examined). In
agreement with previous studies, B. cenocepacia (formerly genomovar III) was the
most prevalent species, being isolated from 52% of the B. cepacia complex infected
patients. However, in contrast with previous reports, a very significant percentage
of the Portuguese CF sub-population examined was infected with B. cepacia gen-
omovar I (36%) and B. stabilis (18%). B. multivorans was recovered from 2 of
the infected patients.As the result of the unusual predominance of genomovar I and
B. stabilis isolates in this Portuguese CF population, this study supports the concept
that strains of these genomovars are also capable of causing devastating infections,
including the ‘cepacia syndrome’, and of giving rise to chronic and transient infec-
tions, the clinical outcome depending on the patient and on other still unidentified
factors. No clear relation was found between the presence of the BCESM or the
cblA markers and severity of infection or transmissibility. Altogether, our results
concerning a specific and clinically characterized CF population, receiving care for
an extended period of time, indicate that the use of these putative transmissibility
markers or the genomovar status in identifying patients at higher risk is uncertain.
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Cepacia syndrome secondary to Burkholderia multivorans occurring
nine years after initial colonisation
L. Blackburn (Presenting), K. Brownlee, S. Conway, M. Denton
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Burkholderia cepacia complex (Bcc) is an important pathogen in cystic fibrosis.
Colonisation can result in an accelerated decline in respiratory function and can
reduce life expectancy. Around 20% of colonised patients develop cepacia
syndrome . Cepacia syndrome is usually associated with genomovar (gv) III strains.1
A case is described of a 16-year old boy with cystic fibrosis who developed cepacia
syndrome secondary to Burkholderia multivorans (gv II). This occurred after the
boy had been colonised for nine years. The boy became unwell while receiving a
course of intravenous antibiotics for a respiratory exacerbation. He deteriorated
quite suddenly with marked pyrexia, rigors, nausea and vomiting. He was treated
with intravenous tobramycin, tazocin, teicoplanin and fluconazole. His clinical state
deteriorated and despite full intensive care he developed multiorgan failure. Care
was withdrawn 14 days later. Burkholderia multivorans was grown in blood culture
and sputum specimens. Gv II strains account for 17.3% of all Bcc infections in the
CF population . There have been reports of patient-to-patient spread of gv II2
strains . Thus the ability of gv II strains to cause cepacia syndrome has important2
clinical significance. The case also highlights that cepacia syndrome can occur after
many years of colonisation.
C. Dobbin, R. Soni, T. Jelihovsky et al., Cepacia syndrome occurring following1
prolonged colonisation with Burkholderia cepacia. Aust. NZ. J. Med. 30(2) (2000)
288–289.
E. Mahenthiralingham, A. Baldwin, P. Vandamme, Burkholderia cepacia complex2
infection in patients with cystic fibrosis. J. Med. Microbiol. 51 (2002) 533–538.
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Risk of septicaemia and level of host inflammatory response with acute
B. cepacia is dependent on strain and genomovar: a murine
comparative study
J.C. Davies* (Presenting), R. Shaw, A. Titley, T. Lloyd, D.M. Geddes, E.W.F.W.
Alton
Imperial College, London, United Kingdom
Certain genomovars of B. cepacia appear more detrimental than others, possibly
related to invasive properties or pro-inflammatory activity. To explore the mecha-
nisms behind these observations, we tested a variety of B. cepacia strains in a
murine model of acute pulmonary infection. C57Bly6 mice were instilled intran-
asally with either PBS or 10 CF organisms: 18822 & 13010 (GII), 16656 (ET12)9
& 18830 & 16654 (GIII), and 18870 & 14294 (GIV) (BCCMyLMG, Belgium).
Forty-eight hours later blood was obtained by abdominal venesection, the spleen
was removed and a BAL performed. Homogenised spleens were cultured in a semi-
quantitative fashion on cepacia-specific medium. Growth was scored as 0 (nega-
tive), 1 (scanty colonies), 2 (multiple colonies) or 3 (confluent growth).
Consistently high levels of systemic invasion were seen in animals infected with
ET12 and both GII strains (scores of 3 in every animal). In contrast, the other GIII
and the GIV strains produced less frequent and lower levels of invasion. The sys-
temic inflammatory response (IL-6, IL-1b, TNFa) was most pronounced in the
GIII genomovar strains: ET12 induced high levels of IL-6 and the other 2 strains
higher levels of IL-1b. In contrast, a significant local inflammatory response was
seen consistently only with ET12. This model confirms a differential host response
to various B. cepacia organisms. Strains from GII and GIII, those associated with
cepacia syndrome in patients, were highly invasive; despite this, GII organisms did
not elicit a detectable systemic inflammatory response. A greater response was seen
with ET12 and the other GIII strains, 18830 and 16654, despite lower levels of
invasion with these two strains. This may suggest a mechanism for the reported
poor outcome following immuno-suppression post-lung transplantation in patients
with GIII organisms.
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Invasion of epithelial cells by Burkholderia cepacia complex strains
and J2315 quorum sensing mutants
K. Markey (Presenting), M. Callaghan , P. Murphy , J. Collins1 1 2 2
Biology Research, Institute of Technology Tallaght, Dublin, Ireland, Adelaide and1 2
Meath Hospitals Incorporating the National Children’s Hospital, Dublin, Ireland
The Burkholderia cepacia complex is a family of at least nine different genomovars
that can cause severe pulmonary deterioration in patients with cystic fibrosis (cepa-
cia syndrome). The virulence factors of this opportunistic pathogen are poorly
understood and the distribution of putative pathogenic determinants is relatively
unknown. It has been found that B. cepacia. genomovar III is responsible for the
most virulent and epidemic outbreaks and is more closely associated with cepacia
syndrome. Strains belonging to B. multivorans (genomovar II) have also been
shown to cause lung damage and therefore these two genomovars are considered
the most clinically important. An antibiotic protection assay demonstrated that iso-
lates belonging to B. cepacia genomovar III invaded a pulmonary epithelial cell
line (A459) in significantly higher numbers than the other members of the complex.
Strains belonging to all genomovars were also found to survive and multiply intra-
cellularly. The ability of B. cepacia to invade and survive intracellularly results in
evasion of the host immune system and antibiotics. The fact that strains belonging
to the most clinically important genomovar invaded pulmonary epithelial cells at
increased rates indicates that this characteristic may play a role in its pathogenesis.
Quorum-sensing refers to the ability of bacteria to communicate to each other
through the use of small molecules called autoinducers and is believed to play a
large role in the pathogenesis of a number of virulent bacteria. Mutant strains of
genomovar III, J2315, were constructed that lacked functioning cepI and cepR genes
and therefore lost the ability to produce its autoinducer and transcriptional activator.
It was found that mutants deficient in quorum-sensing molecules retained the ability
to invade and survive in epithelial cells at rates similar to the J2315 wildtype.
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Characterisation of Burkholderia cepacia mutants sensitive to
antimicrobial peptides
Z. Yousuf (Presenting), M. Morgan , W.A. Bonass , A. Ashcroft , J. Keen , K.1* 1 1 2 2
Kerr , P.D. Marsh , R. Percival , M. Phillips-Jones , D.A. Devine3 4 1 5 1
Oral Biology, Leeds University, Leeds, United Kingdom, Biochemistry, Leeds Uni-1 2
versity, Leeds, United Kingdom, Microbiology, Harrogate General Hospital, Har-3
rogate, United Kingdom, Microbial Pathogenicity, CAMR, Salisbury, United4
Kingdom, Medical Microbiology, Leeds University, Leeds, United Kingdom5
A major problem in combating B. cepacia infection in cystic fibrosis (CF) patients
is the organism’s resistance to a wide range of antibiotics including antimicrobial
peptides (AMPs). Bacterial resistance and the relative inactivity of AMPs in high
concentrations of NaCl may be important in the pathogenesis of CF lung infections.
Environmental ion composition may also regulate outer membrane structure in
Gram-negative bacteria; this has been linked in some organisms to altered sensitivity
to AMPs. Our aim was to examine the sensitivity of B. cepacia to AMPs, and to
produce and characterise mutants with altered sensitivities. Double layer agarose
diffusion assays and MIC determinations of 18 strains representing 6 B. cepacia
complex genomovars confirmed high levels of resistance to AMPs of human, mam-
malian and insect origin and de novo design. Only SMAP-29 and D2A-22 had anti-
B. cepacia activity. Strain LMG 16659 (genomovar III), resistant to all AMPs, was
selected for mutagenesis using Tn5-OT182, with E. coli S17-1 as donor. Three
thousand mutants, showing resistance to tetracycline, were screened and 14 clones
sensitive to polymyxin B (PMB) isolated by replica plating. PCR amplification,
with primers specific for Tn5, was performed on 50 randomly selected mutants;
confirming that )90% harboured the transposon. We are currently examining if
there is a correlation between sensitivity to PMB and increased sensitivity to LL-
37, SMAP-29 or D2A-22. Genomovar II PMB sensitive mutants showed no cor-
relation, however electrospray MS-MS of lipid A profiles revealed differences in
profiles compared with the wild-type. These changes may correlate with changes
in acylation of lipid A. Similar correlations are being investigated in our genomovar
III PMB sensitive mutants. In order to understand more about the mechanisms
involved in the altered sensitivities to AMPs the site of Tn5 insertion within selected
mutants will be determined by sequencing the DNA flanking the insertion site.
129
Comparison of invasion of Burkholderia cepacia in different lung
epithelial cell lines
C. Duff (Presenting), M. Callaghan , P.G. Murphy , S. McClean1 1 2 1
Applied Science, Institute of Technology Tallaght, Dublin, Ireland, Adelaide,1 2
Meath and National Children’s Hospital, Dublin, Ireland
Burkholderia cepacia is an opportunistic pathogen, which can cause serious respi-
ratory infections in cystic fibrosis patients. There are currently nine genomovars of
this pathogen, with varying clinical outcomes. The mechanisms of adhesion, inva-
sion and translocation of this pathogen are not yet fully understood. Invasion of up
to 30 B. cepacia strains has previously been quantitated in vitro using A549 lung
epithelial cells. However, in order to examine the mechanisms by which B. cepacia
enter and penetrate through lung epithelia, a polarised cell model of lung epithelia
can be more predictive. Since A549 cells do not readily form tight junctions, they
can be somewhat limited for mechanistic studies. The objective of this research is
to examine alternative epithelial cell models for the investigation of B. cepacia
invasion. We have evaluated different lung epithelial cell lines, including Calu-3,
as models for studying invasion by a series of B. cepacia strains. Using an antibiotic
protection assay, we have not found significant differences between B. cepacia
invading Calu-3 cells compared with A549 cells when grown on 24-well plates.
These cells were then grown on Transwell filters and formation of tight junctions
confirmed using transepithelial resistance measurements. Invasion by a series of B.
cepacia strains on these epithelial monolayers was quantitated. In addition, the
interaction of B. cepacia genomovars with the polarised lung epithelial cells was
examined using microscopy. Study of tight lung epithelia cell models are very useful
in examining mechanisms of invasion by lung pathogens. In addition, epithelial
monolayers also provide a suitable model for evaluation of proinflammatory cyto-
kine stimulation by various strains of B. cepacia complex.
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A rabbit antibody specific for exopolysaccharides of 10 different
Burkholderia cepacia genomovars detects B. cepacia macrocolony
formation in sputum of CF patients
D. Worlitzsch (Presenting), S. Nonnenmacher , M. Ulrich , S. Sousa , J. Leitao ,1* 1 1 2 2
I. Sa-Correia , T. Coenye , P. Vandamme , G. Doring2 3 3 1¨
Institute of General and Environmental Hygiene, University of Tuebingen, Tuebin-1
gen, Germany, Chemical Engineering Department, Instituto Superior Tecnico, Lis-2
bon, Portugal, Laboratory of Microbiology, University of Ghent, Ghent, Belgium3
Infection of airways in CF patients with the Burkholderia cepacia complex may
lead to cepacia syndrome, characterized by high fever, bacteraemia, rapid pulmonary
deterioration and death. Despite the development of several selective media and
molecular techniques for the identification of B. cepacia complex strains in sputum
specimens of CF patients, false-positive and false-negative results have been report-
ed in this context. Based on the observation that B. cepacia complex strains produce
exopolysaccharide (EPS) in vitro (J. Richau et al., Molecular typing and exopo-
lysaccharide biosynthesis of Burkholderia cepacia isolates from a Portuguese cystic
fibrosis center. J. Clin. Microbiol. 38 (2000) 1651–1655), we developed a poly-
clonal rabbit antibody against B. cepacia EPS. In vitro the antibody reacted with
102 genotypically different B. cepacia complex strains of 10 known genomovars,
whereas no binding to 13 Pseudomonas aeruginosa, 15 Staphylococcus aureus and
2 Streptococcus pneumoniae strains was observed using indirect immunofluoresc-
ence. Additionally, purified alginate and albumin did not react with the antibody.
In a sputum sample of a CF patient chronically infected with B. cepacia complex,
many cells forming macrocoloniesybiofilms were detectable by indirect immuno-
fluorescence. We conclude that this immunological method is suitable for rapid
screening and detection of the B. cepacia complex in vitro and in vivo. Supported
by Deutscher Akademischer Austauschdienst (DAAD) and Instituto de Cooperacao
Cientifica e Tecnologica International (ICCTI).
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Is there a difference in inflammatory marker levels between CF patients
who harbour sporadic and transmissible strains of Pseudomonas
aeruginosa?
A.M. Jones (Presenting), R.J. Bright-Thomas , L, Martin , A. McDowell , K.1 1 2 2
Moffitt , M.E. Dodd , J.S. Elborn , A.K. Webb2 1 3 1
Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals1
NHS Trust, Manchester, United Kingdom, School of Pharmacy, Queen’s University,2
Belfast, United Kingdom, Northern Ireland Adult Cystic Fibrosis Unit, Belfast City3
Hospital, Belfast, United Kingdom
Introduction: Pseudomonas aeruginosa cross-infection is a concern for CF centres.
The clinical effects of infection by a transmissible P. aeruginosa in comparison with
sporadic strains are unclear. We measured inflammatory markers in adult CF
patients infected with transmissible and sporadic P. aeruginosa. Methods: Patients
infected with transmissible P. aeruginosa were matched using %predicted FEV1
with patients harbouring sporadic P. aeruginosa. All patients were clinically stable
and had received intravenous antibiotics 4–6 weeks earlier. Sputum, urine, plasma
and serum samples were stored at y80 8C and analysed as a single batch by a
blinded investigator. Sputum neutrophil elastase (NE), interleukin (IL)-8, Cathepsin
S and tumour necrosis factor (TNF)a; plasma IL-6 and NEya -antitrypsin com-1
plexes; serum C-reactive protein (CRP); and urine TNFr1 were measured. The two
groups were compared using the Mann Whitney U tests results are median (range),
ns20 both groups, except sputum samples sporadic group ns18, urine samples
transmissible group ns18.
Sporadic P. aeruginosa Transmissible
P. aeruginosa
P
IL-6 (pgyml) 6 (1, 26) 6 (1, 39) 0.91
NEya1AT (ngyml) 246 (109, 2114) 229 (118, 533) 0.57
CRP (mgyl) 8 (1, 29) 8 (1, 71) 0.61
IL-8 (ngyml) 13 (6, 57) 10 (4, 156) 0.24
Cathepsin S (ngyml) 301 (97, 612) 366 (29, 703) 0.75
TNFa ( pgyml) 11 (0, 169) 9 (0, 278) 0.78
NE (mgyml) 22 (11, 39) 17 (7, 174) 0.67
TNFr1 (pgyml) 1167 (286, 3531) 988 (286, 5082) 0.55
Conclusions: There are no differences in inflammatory marker levels between
clinically stable adult CF patients infected with transmissible and sporadic P.
aeruginosa.
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Early eradication of Pseudomonas aeruginosa in cystic fibrosis
patients
G. Thalhammer (Presenting), B. Pratl, E. Eber, M. Zach,
Paediatric Department, Respiratory and Allergic Disease Division, Graz, Austria
Background: Chronic airway infection with Pseudomonas aeruginosa (PA) con-
tributes to lung disease in cystic fibrosis (CF). Early aggressive antibiotic therapy
may delay chronic infection, and thus improve lung function and survival. Conse-
quently, an early eradication regimen was introduced into the clinical routine of our
centre in 1999. We performed a retrospective analysis (1999–2002) of the outcome.
Patients and methods: Sputum or throat swab samples were obtained from all CF
patients at least for every 3 months. At first PA positivity, an eradication regimen
consists of an IV. anti-PA therapy for 3 weeks, followed by oral ciprofloxacin for
6 weeks and twice daily inhaled anti-PA therapy (colistin or gentamicin) for at least
2 yr, was started. Evaluation of this regimen was done by microbiological studies
from bronchial lavage (BL) fluid 2 weeks after stopping oral ciprofloxacin. There
was a time interval of at least 18 h between flexible bronchoscopy with BL and
the last inhalation of antibiotics. Results: We performed 25 PA eradications in 20
CF patients (8m, 12f; age range 0.3–31.3 yr). Twenty-two PA eradications (88%)
were initially successful, as demonstrated by a negative microbiological BL fluid
result, in 3 patients (12%), we obtained PA positive BL fluid cultures. In one of
the latter patients a subsequent second PA eradication was successful, in 2 it again
failed. At present, 18 patients are PA-free for a period of 389"258 days (range
44–912). Conclusion: These preliminary results of our ongoing study are encour-
aging; such positive clinical experience, however, should be confirmed by prospec-
tive studies.
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A comparison of the organisms isolated from an adult cystic fibrosis
population
T.E. McManus (Presenting), A. McDowell , J.E. Moore , C.C. Patterson , J.S.1 2 2 3
Elborn1
Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, United King-1
dom, Department of Microbiology, Belfast City Hospital, Belfast, United Kingdom,2
Department of Epidemiology, Queen’s University Belfast, Belfast, United Kingdom3
Introduction: Patients with Cystic Fibrosis (CF) have frequent pulmonary exacer-
bations associated with the isolation of bacterial organisms from sputum samples.
It is not clear however, if there are differences in the types of additional organisms
isolated from patients who are infected with Burkholderia cepacia complex infec-
tion (BC) or Pseudomonas aeruginosa (PA) in comparison to those who are not
infected with either of these organisms (NI). Methods: Adult patients attending the
regional CF unit at the Belfast City Hospital were followed over a two year period.
Patients were assigned to three groups depending on whether they were known to
be chronically infected with BC, PA or NI. We compared the numbers and types
of organisms, which were isolated in each of these groups. Changes in patients’
weight and FEV were also measured. Results: Information was available on a total1
of 79 patients. Numbers in each group were as follows: BC 23, PA 30 and NI 26.
Prophylactic antibiotic use was similar throughout all groups. The change in weight
between the start and end of the study period was significant for the BC group
compared to the PA and NI (P-0.05). The changes in FEV were not significant1
between the groups. Total numbers of organisms isolated (Ps0.045) and numbers
of co-infecting organisms (Ps0.003) are significantly higher in the BC group com-
pared to PA and in the PA group (P-0.001, Ps0.007) compared to NI. IV anti-
biotic use was similar in the BC and PA patients, but significantly more compared
to NI (P-0.001). The pattern of co-infecting organisms was similar in all three
groups. Conclusion: Patients with BC and PA infection have a similar use of anti-
biotics. Co-infection with P. aeruginosa and other common CF pathogens is similar
in patients chronically infected with B. cepacia. The types of organisms most fre-
quently co-isolated are similar for all groups of patients.
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Changes in the prevalence of Pseudomonas isolation in Cardiff 1998–
2002
K. Pardy (Presenting), H.C. Ryley , I.J.M. Doull1 2 2
Department of Child Health, Cardiff, United Kingdom, Department of Medical1 2
Microbiology, University of Wales College of Medicine, Cardiff, United Kingdom
There is an increasing concern over the possible transmission of Pseudomonas
aeruginosa between patients attending large CF clinics. We retrospectively reviewed
P. aeruginosa isolation in sputum and cough swabs of all patients attending the
Paediatric CF clinic at UHW over a five-year period from 1998–2002. In 2002, all
P. aeruginosa isolates were individually characterised through RFPL analysis with
separate digestion of the PCR product. Prevalence (at least one isolation in the 12
month period) declined progressively from 46.7% in 1998 to 29.1% in 2001, but
rose again to 45.5% in 2002. These variations in prevalence were not explained by
changes in incidence of Pseudomonas infection, which remained stable over the
five-year period, nor could it be explained by a cohort effect. Potential cross infec-
tion was found in only two patients when strains were analysed by RFLP. Changes
in prevalence were seen predominantly among the 5–9 yr and over 15 yr age
groups. There were no alterations in microbiological detection methods, clinic pro-
tocols or treatment policies towards P. aeruginosa during the five-year period to
explain the changes in prevalence seen. We have observed marked unexplained
changes in the prevalence Pseudomonas colonisation within our clinic. We speculate
that temporal environmental factors independent of CF may affect the rate of Pseu-
domonas isolation.
s37Journal of Cystic Fibrosis 2 (2003) S31–S48
135
The effect of colonisation by multiple drug resistant Pseudomonas
aeruginosa on the outcome of lung transplantation in cystic fibrosis
patients
D. Melley (Presenting), M. Hodson, K. Gyi
Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
Lung transplantation is the only therapeutic intervention that prolongs lifespan in
end-stage cystic fibrosis. Studies have indicated a favourable outcome despite the
presence of panresistant pseudomonas . However, this continues to be cited as a1
relative contraindication to the procedure . A retrospective analysis was undertaken2
of the sputum cultures of 97 patients with Pseudomonas aeruginosa taken imme-
diately prior to heart-lung transplant or double lung transplant for end-stage cystic
fibrosis between 1987 and 1999. The in vitro antibiotic susceptibility pattern was
noted and the patients were divided into groups according to resistance to two or
more b-lactams, three aminoglycosides, quinolones or all antibiotics tested. Kaplan-
Meier analysis of the groups was undertaken. Three patients had organism sensitive
to all antibiotics tested (1 yr survival 66%). No differences in outcome at one year
were noted between patients colonised with pseudomonas resistant to one, two or
three groups of antibiotics (respectively, 54% ns13, 69% ns61, 60% ns9). In
addition, 11 patients were found to be colonised with pseudomonas resistant to all
antibiotics tested. There was no difference in one-year survival, which was 64%.
The results provide further evidence that the presence of drug resistant pseudomonas
is not a factor, which influence outcome following lung transplantation. Therefore,
it should not be used as a criterion to exclude patients from selection for
transplantation.
The effects of panresistant bacteria in cystic fibrosis patients on lung transplant1
outcome.R.M. Aris et al., Am. J. Respir. Crit. Care Med. 155(5) (May 1997) 1699–
1704
Lung Transplantation.M. Selim, M.D. Arcasoy, M. Robert, M.D. Kotloff, N. Engl.2
J. Med. 340 (1999) 1081–1091
136*
Prospective surveillance for Pseudomonas aeruginosa cross-infection
at an adult cystic fibrosis centre
A.M. Jones (Presenting), M.E. Dodd , C.J. Doherty , J.R.W. Govan , A.K.1* 1 2 2
Webb1
Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals1
NHS Trust, Manchester, United Kingdom, Medical Microbiology, University of2
Edinburgh, Edinburgh, United Kingdom
Introduction: There is concern surrounding the emergence and spread of transmis-
sible multi-resistant strains of Pseudomonas aeruginosa at CF centres. An initial
study at our adult centre established convincing evidence for P. aeruginosa cross-
infection . No environmental reservoir has been found at the CF centre . We have1 2
continued microbiological surveillance for P. aeruginosa cross-infection and now
report the incidence and prevalence of transmissible P. aeruginosa at our centre for
the years 1999–2002. Methods: P. aeruginosa isolates were cultured from sputa of
patients attending the Manchester Adult CF Centre. Different morphotypes on the
same culture plate were investigated individually. Samples were initially investi-
gated by pyocin typing, then further evaluated by pulse-field gel electrophoresis
using restriction enzymes Xba1 and SpeI. Results: All patients who acquired infec-
tion with the transmissible strain have been in-patients.
Year 1999 2000 2001 2002
Total CF patients 216 221 228 250
New cases – 6 5 6
Deaths – 4 0 2
Incidence (%) – 3.1% 2.5% 2.8%
Prevalance (%) 12.9% 13.5% 15.3% 15.9%
Conclusions: The annual incidence rate of new infections with transmissible P.
aeruginosa is between 2 and 3% at this adult CF centre. The contact density of
patients may be a factor in risk of spread of infection, as patients who have recently
been inpatients have acquired all new infections. Future work: New infection control
policies have been implemented at the CF centre. Continuing microbiological
surveillance is required to establish the effectiveness of these interventions.
References:
Jones et al., Lancet (2001) 557–558.1
Jones et al., Thorax (2001) iii38.2
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Shared pathogens in Birmingham
D. Chambers (Presenting), F. Scott , R. Bangur , R. Davies , A. Lim , S.1 2 1 1 1
Walters , G. Smith , D. Honeybourne , T. Pitt , D. Stableforth3 4 1 2 1
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Public Health Department, University of Birmingham, Birmingham, United King-3
dom, Microbiology, Heartlands Hospital, Birmingham, United Kingdom4
P. aeruginosa (PA) is the most common colonising organism in patients with cystic
fibrosis (CF), however, most PA typing studies suggest that cross-infection is rare
except among siblings. Recent evidence of epidemic spread of PA in the UK
prompted the genotyping of PA isolates in our adult clinic and an attempt to identify
predictors for colonisation by epidemic strains. Sputum was cultured from 205y227
patients. PA isolates were genotyped using Spe1 endonuclease and pulsed-field gel
electrophoresis. Demographics, CF genotype, body mass index, spirometry, pancre-
atic sufficiency, presence of diabetes, liver disease, allergic bronchopulmonary
aspergillosis or transplant, shared care, source of referral and density of out- and
inpatient exposure to epidemic strain colonised patients were recorded. PA was
isolated in 169y205 patients. 113y169 patients were genotyped. Four new UK clus-
tered strains were identified: B (ns33), C (ns3), F (ns4) and J (ns7). Fourteen
patients clustered with previously identified UK strains (Liverpool, ns13; Man-
chester, ns1). Other than those tabulated, no patient factors were associated
(P vs. unique) B (ns33) Any cluster (ns61) Unique (ns
52)
Age (SEM) 23.2 (0.75, P-
0.01)
24.2 (0.77, Ps
0.03)
27.2 (1.02)
% from regional paediatric CF
centre
72.7%, Ps0.02 73.3%, P-0.01 48.1%
with clustered strain colonisation. There is concerning evidence of cross-infection
amongst these patients. The above results are also suggestive of a possible cohort
effect whereby exposure(s) in the relatively distant past may influence the current
colonising PA genotype.
138
Cross colonization of Pseudomonas aeruginosa between closely
related cystic fibrosis patients
G. Agarwal (Presenting), S.K. Kabra, B. Das
Microbiology, All India Institute of Medical Sciences, New Delhi, India
P. aeruginosa is the predominant bacterium associated with pulmonary infection
and mortality among cystic fibrosis (CF) patients. Previous studies have reported
cross-colonization among CF patients to be rare unless the contact between patients
was close and prolonged. P. aeruginosa had been acquired at CF recreation camps,
clinics, wards, home and rehabilitation centers. We have prospectively followed 59
CF patients attending the Pediatric Chest Clinic at All India Institute of Medical
Sciences, New Delhi, INDIA past 2 yr during August 1998–August 2001 where
maleyfemale ratio was 2y1 and mean age at enrollment was 5.2"(4.5 S.D.). The
respiratory samples were collected, processed by standard bacteriological methods
and P. aeruginosa was identified. These isolates were characterized by phenotypic
and genotypic methods. The phenotypic methods included antibiogram and auxo-
trophy while the genotypic methods included enterobacterial repetitive intergenic
consensus sequence (ERIC) polymerase chain reaction and PCR-Ribotyping. Out
of 59 CF patients, 23 were colonized with P. aeruginosa and a total of 346 isolates
were collected and studied. By phenotypic methods, 8 antibiograms (designated
A1–A8) and 2 auxotypes (designated A1 and A2) were found while by genotypic
methods, 20 ERIC-PCR patterns (designated E1–E20) and 5 PCR-Ribotyping pat-
terns (designated P1–P5) patterns were constructed. P. aeruginosa isolates from 2
out of 23 patients colonized with P. aeruginosa shared similar antibiogram (A1),
auxotype (A1), ERIC-PCR pattern (E1) and PCR-Ribotyping pattern (P1). After
examination of detailed history, these 2 patients were found to be first cousins,
residing in the same place and had frequent contacts. The study documents the
possibility of cross-colonization among CF patients with close contacts.
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Presence of epidemic strains of Pseudomonas aeruginosa shared
between paediatric and adult cystic fibrosis clinics
M.P. O’Carroll , M. Syrmis , C. Coulter , C.E. Wainwright , M. Nissen , T.1 2 3 4 2
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Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Aus-1
tralia, Clinical Virology Research Unit, SASVRC, Royal Children’s Hospital, Bris-2
bane, Australia, Queensland Health Pathology Service, The Prince Charles3
Hospital, Brisbane, Australia, Department of Respiratory Medicine, Royal Chil-4
dren’s Hospital, Brisbane, Australia
Background: There have been recent reports of epidemic strains of P. aeruginosa
in cystic fibrosis (CF) units, including two within Australia. Epidemic strains do
not seem to occur in all CF care settings despite the use of similar molecular
methods. The need for routine microbiological surveillance within CF units there-
fore remains contentious. Methods: Sputum was collected prospectively from all
productive patients attending the CF clinics at TPCH and RCH. All P. aeruginosa
isolates were typed using pulse field gel electrophoresis (PFGE) after digestion
with SpeI, and Tenover criteria applied to describe relatedness. Lung function,
anthropometrics, hospitalisations, demographics and antibiotic sensitivity data were
recorded. Results: The first 100 patients (50 from each clinic) harboured 167 iso-
lates. Thirty-nine patients (62 isolates) shared an epidemic strain (pulsotype A),
20 patients shared a strain with at least one other patient and 41 patients harboured
unique strains (67 isolates). Eight patients shared a pulsotype identical to the epi-
demic strain previously reported in Australia. Antibiograms showed pulsotype A to
be no more resistant than unique strains (multi-resistance 27.4% vs.16.4%, chi-
squares0.97, P)0.2). Compared to those with unique strains, the pulsotype A
group were younger (mean age (S.D.) 16.7 (7.3) vs. 24.0 (12.3), Ps0.002) and
had similar lung function and hospitalisations. Conclusions: Epidemic strains of P.
aeruginosa are shared by a large proportion of patients across two CF clinics in
Brisbane. Our dominant pulsotype was neither multi-resistant nor associated with
clinical parameters of more severe disease. These findings support the need for
routine microbiological surveillance within CF clinics. Supported by the RCH
Foundation.
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Rapid genotyping of Pseudomonas aeruginosa isolates using
repetitive element based PCR assays
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Background: Transmissible strains of P. aeruginosa have recently been reported in
several adult and paediatric cystic fibrosis (CF) clinics. Pulse field gel electropho-
resis (PFGE) is currently recognised as the gold standard of molecular typing tech-
niques for P. aeruginosa, however, it is labour intensive and limited by high cost
and extended turnaround times. Transmissible strains represent an expanding prob-
lem and routine microbiological surveillance may be necessary in the near future.
A screening method that is rapid, relatively inexpensive and highly specific is
required. We compared two repetitive element based PCR genotyping assays with
PFGE. Methods: Sputum was collected prospectively from all productive patients
attending the CF clinics at the RCH and TPCH and in Brisbane from December
2001. Genomic DNA was extracted from P. aeruginosa isolates using an AquaPure
Genomic DNA kit (BioRAD). Two Rep PCR assays (Enterobacterial Repetitive
Intergenic Consensus (ERIC) PCR and BOX PCR) were modifications of previ-
ously published methods. PFGE was performed following digestion with SpeI,
results compared with Gelcompar and Tenover criteria were applied to determine
relatedness. Results: One hundred and sixty three isolates from the first 100 patients
(50 from each clinic) were tested using both techniques. Each of the isolates that
had two or more band differences by either the BOX or ERIC PCR assay was
unrelated by the PFGE method. These results were concordant without exception.
Conclusions: We have developed a rapid PCR based genotyping method with high
specificity. This could serve as a screening tool for microbiological surveillance in
CF clinics. Whilst this method does not eliminate the need for PFGE, it will sig-
nificantly reduce the number of isolates that need testing by this method, thereby
reducing costs and improving efficiency. Supported by The Royal Children’s Hos-
pital Foundation.
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PCR detection of a CF epidemic strain of Pseudomonas aeruginosa
(Pa)
S. Panagea (Presenting), M.J. Ledson , M.J. Walshaw , C. Winstanley , C.A.1 2 2 1
Hart1
Department of Medical Microbiology, University of Liverpool, Liverpool, United1
Kingdom, Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom2
The Liverpool epidemic strain (LES) colonises many patients in Liverpool and also
other UK clinics. Previously, this could only be reliably detected by pulsed-field
gel electrophoresis (PFGE), which is difficult to perform. We have developed a
diagnostic PCR amplification assay with a set of primers based on a unique DNA
sequence (PS21) of LES. To test its utility in identifying and detecting LES from
colonies and directly from sputum, 65 samples from 43 adult CF patients were
cultured for P. aeruginosa colony isolation. Antibiotic sensitivity was performed by
disk diffusion. All colonies were tested by PCR and typed by macrorestriction
analysis of SpeI-digested DNA by PFGE. Subsequently, DNA was extracted from
62 samples using a QIAamp DNA Mini Kit (Qiagen). PCR with PS21 primer set
was performed to detect LES and PCR amplification of the exotoxin A gene and
16S rDNA conserved sequences carried out as controls for the presence of the Pa
and bacterial DNA, respectively. The results of the PCR assay with the PS21 primers
set were compared with culture and PFGE typing of the isolates. Forty patients
were colonised with Pa, 29 by LES (72.5%). Of 122 morphotypes, 87 were LES
and 35 other genotypes. Antibiograms were unreliable for the identification of LES.
There was 100% concordance between the PCR assay and PFGE typing on colonies.
Sensitivity of the PCR assay on DNA isolated from sputum was 95.2% (40 of 42
positive samples for LES) and specificity was 90% (18 of 20 negative samples)
compared to culture. Two false positive PCR samples belonged to patients positive
for LES previously and this might indicate that PCR is more sensitive than culture.
This study shows that the PCR amplification assay with PS21 primers set can be
used for effective and unequivocal identification of LES. Furthermore, the test used
directly on sputum is an accurate method for LES detection and can provide the
means for simple and rapid screening of CF patients.
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Environmental contamination with an epidemic strain of Pseudomonas
aeruginosa (Pa) in a Liverpool CF centre
S. Panagea (Presenting), M.J. Ledson , M.J. Walshaw , C. Winstanley , C.A.1* 2 2 1
Hart1
Department of Medical Microbiology, University of Liverpool, Liverpool, United1
Kingdom, Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom2
The Liverpool epidemic strain (LES) of Pa that colonises many CF patients in
Liverpool is believed to be transmitted by direct patient to patient spread since it
has not previously been found in the environment. Using a new PCR amplification
assay specific for LES, we have looked for possible reservoirs and routes of cross
infection in the Liverpool Adult CF Centre environment.Over a four-week period,
137 samples were collected from staff, patients, and the ward environment (drains,
bathtubs, showers, dry surfaces, respiratory equipment and air). Also, 16 samples
were collected from staff hands, air and dry surfaces in the CF outpatient clinic. In
the ward, no Pa was isolated from staff hands or uniforms or any communal areas.
Of 18 moist sites tested, 11 (61%) harboured Pa but only one sink in a patients
room was LES positive (6%). LES was detected on patients’ hands (25% of sam-
ples), clothes (12.5%), bed linen (25%) and from external surfaces of their respi-
ratory equipment (20%). The sink drain tested negative at one week, and the
positive dry surfaces were negative after room cleaning. LES was detected in 80%
of air samples from inside patients’ rooms and 60% of those from the ward corridor.
No other Pa strain was detected in the air. In the out patient clinic, all staff hands
were negative, but 62.5% of samples were positive for LES including those taken
in the consultation rooms, spirometry room and patient waiting area. LES were
detected on the surfaces of the spirometry machine tubing and chair after use by
colonised patients. We have shown ward and outpatient environmental contamina-
tion with LES in this study. It appears to occur only in close proximity to colonised
patients and to be short-lived. No persistent environmental reservoirs were detected.
The presence of LES in the majority of the air samples in both the inpatient and
outpatient areas is worrying, since air contamination in communal areas may con-
tribute to cross infection.
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Emergence and elimination of colistin resistant Pseudomonas
aeruginosa (PA) in chronically infected Danish cystic fibrosis patients
H.K. Johansen (Presenting), O. Ciofu , C. Koch , N. Høiby1 2 3 1
Department of Clinical Microbiology, Rigshospitalet, Copenhagen Ø, Denmark,1
Institute of Medical Microbiology and Immunology, Panum Institute, Copenhagen2
N, Denmark, Danish Cystic Fibrosis Centre, H:S Rigshospitalet, Copenhagen Ø,3
Denmark
Since 1984, colistin inhalation has been used in all chronically infected CF patients
between the regular IV courses. All patients have inhaled 2 mega-units of colistin
twice daily except when admitted to hospital for IV antibiotic treatment. The first
colistin resistant isolates appeared in 1995 (9 of 167 isolates), and reappeared in
1997 (16 of 173 isolates) and 1999 (12 of 184 isolates). We found 27 CF patients
with non-mucoid PA isolates, with MIC values )50 mgyml. The median age of
the patients was 23 yr and 9 months, and they have been treated with colistin for
a median of 10 yr. The median number of days patients harboured a colistin resistant
isolate in their sputum was 75. No significant changes were observed in FEV %,1
FVC or anti-PA precipitins after infection with a colistin resistant PA isolate. When
resistant PA isolates were identified in-patients they were isolated from other
patients with colistin sensitive PA. Furthermore, colistin was replaced by tobramycin
inhalation for 6 months and colistin inhalation was abandoned in the wards where
chronically infected patients were admitted for IV antibiotic treatment. We found
that inhalation with colistin is safe and the few resistance problems can be managed
by isolation of the patients and elimination of the selective pressure in the centre.
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Pseudomonas aeruginosa-DNA fingerprinting of colonized CF-patients
in a rehabilitation centre: a two years survey
S. Van daele (Presenting), P. Schelstraete , F. Haerynck , H. Francxk , G.1 1 1 2
Claeys , M. Vaneechoutte , F. De Baets3 3 1
Pediatric Pulmonology, University Hospital, Ghent, Belgium, Zeepreventoruim,1 2
De Haan, Belgium, Microbiology, University Hospital, Ghent, Belgium3
Introduction: P. aeruginosa is the leading pathogen in CF lungs. After initial infec-
tion, colonization leads to destruction of lung tissue and loss of FEV . The means1
by which P. aeruginosa is acquired are not yet understood. A reasonable fear exists,
however for patient-to-patient transmission. Aim: In order to study possible cross-
infection, P. aeruginosa isolates of the residents of Zeepreventorium, De Haan,
Belgium, were genotyped and compared. Patients and methods: The sputum of 85
colonized patients (27 male, aged 5 months–38 yr, mean age: 20 1y2 yr) was
cultured and P. aeruginosa strains were genotyped, at arrival and departure, during
the study period of 1y1y2001–30y4y2001 and 1y9y2001–31y10y2002. All mor-
phologically different colonies were picked, cultured and genotyped by RAPD. The
P. aeruginosa-strains that grew out of 13 environmental samples (sinks, swimming
pool etc.) were also genotyped and compared to the patient’s genotype. Results: Of
85 patients, a total of 855 isolates were typed. Out of these 855 isolates only 93
different genotypes were found. Forty-fiveyEighty-five had only one strain, 30 had
2 genotypes, 7 had 3, 1 had 4 and 2 had 5 genotypes. Of 85 patients, 36 had a
separate genotype, whereas 49 had one or more shared genotypes (scluster type).
Forty-twoyForty-nine cluster patients already showed their cluster type at arrival.
FourteenyEighty-five patients got cross-infected by a cluster type (2 persistent, 8
transient, 4 uncertain). Eight genotypes were isolated out of 13 environmental sam-
ples, with one match with a patient’s type, however with an interval of 6 months.
Conclusions: Most patients had only one or two genotypes. The risk of persistent
cross-infection was relatively low during the study period. Most cluster patients had
already their cluster genotype at arrival, so cross-infection seems to have happened
in the past. P. aeruginosa types, originated from the environment, could not be
linked to patient’s genotype, except once.
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Effect of epidemic Pseudomonas aeruginosa in CF: five year review
M. Al-Aloul* (Presenting), M.J. Ledson, M.J. Walshaw
Department of Respiratory Medicine, The Cardiothoracic Centre, Liverpool, United
Kingdom
Although Pseudomonas aeruginosa is a poor prognostic indicator in CF patients,
whether colonisation by epidemic strains carries a worse prognosis in unknown. To
investigate this further, we followed the clinical course over 5 yr (1998–2002) of
9 adult CF patients colonised by the Liverpool epidemic strain and compared it
with 9 patients colonised by unique strains. Patients were matched for age (epidemic
group: mean 21 yr (range 18–25) vs. unique group: 22.5 (17–30)), spirometry
(FEV % predicted: mean 82.3 (59–110) vs. 81.3 (60–109)) and nutritional state1
(BMI: mean 20.6 (16.9–27.1) vs. 21.0 (16.2–28)) at the study start. Those patients
colonised by the epidemic strain had a greater loss of lung function than the remain-
der (change in FEV % predicted: mean – 5% per year (range –14.2 to q2.2) vs.1
y0.7% (y4.6 to q5.0), P-0.05) such that by 2002 they had worse FEV %1
predicted (60.6 (16–82) vs. 77.6 (53–120), P-0.03). Furthermore, they lost
weight over the study period (rate of change of BMI per year: y0.21 (y1.01 to
q0.60) vs. q0.31 (y0.51 to q1.42), P-0.05) such that by 2002 they were
significantly malnourished compared to the remainder (BMI: 19.6 (16–23.9) vs.
22.4 (17.8–31.9), P-0.04). There was no difference in the incidence of diabetes
or liver disease between the two groups, or the number of admissions, outpatient
attendances, respiratory exacerbations requiring oral or IV antibiotics, or total IV
antibiotic days given. Thus, we have shown that colonisation with the Liverpool
epidemic strain confers a worse prognosis than colonisation with unique P. aeru-
ginosa strains alone. This confirms the need for segregation of epidemic strain
colonised individuals from all CF patients, and not just from those who have any
evidence of P. aeruginosa colonisation. Such strain segregation can only be carried
out using genomic typing methods.
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Identification and characterisation of transmissible Pseudomonas
aeruginosa strains in UK cystic fibrosis centres
F. Scott* (Presenting), T.L. Pitt
LHCAI, Central Public Health Laboratory, London, United Kingdom
Early molecular typing studies reported that the initial Pseudomonas aeruginosa
strain acquired by cystic fibrosis (CF) patients pre-dominates in the lung and is
retained for long periods. Cross infection with identical or closely related strains
occurs between siblings and transmission of strains between unrelated individuals
was reported to be rare. However, in 1996, an epidemic multi-drug resistant P.
aeruginosa strain was found in a paediatric CF Centre in Liverpool (Cheng et al.,
Lancet 348 (1996) 639–642). Since then, other epidemic strains have been found
in adult CF Centres including Manchester (Jones et al., Lancet 358 (2001) 557–
558) and Liverpool (McCallum et al., Thorax 57(6) (2002) 559–560). A study
funded by the CF Trust is currently underway to identify epidemic strains circulating
in CF centres in Great Britain. P. aeruginosa isolates are characterised using pulsed-
field gel electrophoresis (PFGE) and resulting banding patterns are compared in
BioNumerics. Approximately 1000 isolates have been received and results suggest
that cross-infection has occurred in a number of CF centres. The Liverpool epidemic
genotype was found in 13 centres, the Manchester epidemic genotype in two centres
and a new genotype pre-dominantly associated with one centre in the Midlands was
found in a further five centres. Further confirmation of identity using Fluorescent
Amplified Fragment Length Polymorphism (FAFLP) antibiogram typing and PS21
PCR (Parsons et al., J. Clin. Microbiol. 40(12) (2002) 4607–4611) has been per-
formed. Our conclusions are: (i) most patients examined harboured unique strains
of P. aeruginosa, (ii) there were small clusters of patients with the same local strain,
(iii) there was extensive spread of the Liverpool genotype and (iv) the second
strain most associated with inter-patient spread was pre-dominantly confined to a
single geographical area.
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Dissemination of extended-spectrum b-lactamases and
carbapenemases in Pseudomonas aeruginosa at a UK CF centre-
another infection control hazard
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Brownlee , D. Peckham , S. Conway3 4 4
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St. James’s University Hospital, Leeds, United Kingdom, Regional Adult CF Unit,4
Seacroft Hospital, Leeds, United Kingdom
Segregation is a controversial issue in cystic fibrosis (CF) units. Recent outbreaks
of multi-resistant Pseudomonas aeruginosa in some CF units have resulted in seg-
regation policies targeted at those colonised with ‘transmissible’ strains. We present
a small survey of P. aeruginosa isolates, which suggests that this approach may be
flawed. Between January and October 2002 we performed susceptibility tests on
5,116 isolates of P. aeruginosa obtained from 290 CF patients. Twenty-three isolates
were selected for further analysis. All were screened for the presence of extended-
spectrum b-lactamases (ESBLs) using MIC determination, double disk test, E-test
and for class B carbapenemases using the MBL test. Positive isolates were further
screened using PCR for genes conferring TEM, SHV, VEB and OXA ESBLs or
IMP and VIM carbapenemases. The clonality of isolates was assessed using PFGE.
Six of the 23 isolates were positive by double disk andyor E-test for ESBLs. Three
were positive on PCR for genes conferring ESBLs (two VEB, one OXA). Sixteen
of the 23 isolates were meropenem-resistant. Five of these were positive for class
B carbapenemases using the MBL test. PCR screening revealed the presence of the
gene conferring VIM in three of these isolates. Further PCR suggests that the VIM
gene is integron-borne. PFGE confirmed the presence of transmissible strains of P.
aeruginosa in both the adult and pediatric CF units in Leeds. However, the ESBLs
and carbapenemases were disseminated among related and unrelated strains. The
existence of mobile resistance elements in CF strains of P. aeruginosa suggests that
segregation policies only targeting transmissible strains may not prevent the spread
of multi-resistant P. aeruginosa in CF units.
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Global differential gene expression of Pseudomonas aeruginosa during
aerobic and anaerobic growth
D. Worlitzsch (Presenting), M. Hentzer , M. Ulrich , G. Doring1* 2 1 1¨
Institute of General and Environmental Hygiene, University of Tuebingen, Tuebin-1
gen, Germany, Molecular Microbial Ecology Group, Technical University of Den-2
mark, Lyngby, Denmark
We have recently shown (Worlitzsch et al., J. Clin. Invest. 109 (2002) 317) that
Pseudomonas aeruginosa adapts from an aerobic to the anaerobic environment in
the mucus layer overlaying the airway epithelium in CF patients by a switch from
a non-mucoid to a mucoid, alginate positive phenotype. Here we assessed the global
differential gene regulation of P. aeruginosa strain PAO1 under aerobic and anaer-
obic growth conditions using DNA microarray technique. P. aeruginosa strain PAO1
was grown aerobically overnight in Trypticase Soy Broth (TSB), pH 7.2, to mid-
log phase. Aliquots were transferred to anaerobic jars and grown for 24–96 h.
Bacteria were harvested at 4 h aerobically and at day 1, 2, 3 and 4 anaerobically.
RNA was isolated and transformed to cDNA, which was labeled and fragmented.
Differential gene expression was investigated using the Affymetrix Genechip tech-
nique. At day 1, 404 P. aeruginosa genes (7.2%) were up-regulated and 482 genes
(8.6%) were down-regulated by more than 5-fold. Specifically, the ATP synthesis
gene cluster (PA5553-PA5561) was down-regulated, whereas the nitrate and argi-
nine deiminase clusters (napEFDABC, nirSMCFDLGHJEN, arcDABC), involved
in anaerobic metabolism were up-regulated. Expression of the alternative sigma
factor algU and that of several algU dependent genes were up-regulated including
algD. The study gives new insight into the genotype of P. aeruginosa in CF airways,
revealing that the phenotypic adaptation of P. aeruginosa to CF airways is accom-
panied by a large number of gene regulatory events. Some of these genes may serve
as candidates for new antibacterial therapy strategies. Supported by Cystic Fibrosis
Foundation, USA, and Mukoviszidose e.V. Germany.
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Analysis of metabolic activity levels exhibited by bacteria colonising
the cystic fibrosis lung, using Reverse Transcription Terminal
Restriction Fragment Length Polymorphism analysis (RT-T-RFLP)
G. Rogers (Presenting), K. Bruce , D. Serisier , M. Carroll1 1 2 2
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Southampton University Hospital, Southampton, United Kingdom
A wide range of bacterial species has been shown to colonise the lungs of cystic
fibrosis patients. However, the impact of the presence of these species is a function
not only of their prevalence, but also of their rate of growth. Although levels of
metabolic activity may have important clinical implications, the relative degrees to
which these species are active, and the ways in which growth rates change in
relation to factors, such as the initiation of infectious exacerbation, remain unde-
termined. In this study, molecular-based methodologies were used to analyse the
metabolically and phylogenetically informative ribosomal operon. RNA and DNA
extracted directly from sputum were used to provide measures of relative species
activity and species prevalence, respectively. Levels of metabolic activity were
determined through the use of Reverse Transcription (RT), combined with the Ter-
minal Restriction Fragment Length Polymorphism analysis (T-RFLP), used in the
profiling of relative bacterial species prevalence. Twenty-four sputum samples taken
from 17 adult CF patients were analysed, with the relative levels of metabolic
activity determined for all the 1070 detected bacterial populations. Levels of met-
abolic activity were found to vary widely between different species and between
different populations of the same species. In addition, levels of activity of certain
species increased or decreased in response to changes in disease status, or treatment
regime. This methodology could provide a valuable means of assessing a number
of aspects of treatment efficacy, including the time scale over which drugs work,
the species against which they are effective, and whether sensitive species are erad-
icated or merely rendered senescent. In addition, it could further understanding of
the way in which species interact in the CF lung, and ultimately provide a tool for
the prediction of changes in infection status, such as the onset of infectious
exacerbation.
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High frequency of mutators in the Pseudomonas aeruginosa
population from sputum samples of patients with cystic fibrosis
O. Ciofu (Presenting), T. Pressler , U. Johansen , N. Høiby1 2 3 3
Institute for Medical Microbiology, University of Copenhagen, Copenhagen, Den-1
mark, Cystic Fibrosis Clinic, University Hospital, Rigshospitalet, Copenhagen,2
Denmark, Department of Clinical Microbiology, University Hospital, Rigshospi-3
talet, Copenhagen, Denmark
A high frequency of hypermutable Pseudomonas aeruginosa (PA) isolates (muta-
tors) was found in CF lung infection compared to PA isolated from acute infections
of non-CF patients (Oliver et al., 2000). This analysis was though biased by the
random selection of the PA isolates from sputum samples. Therefore, we decided
to investigate the frequency of mutators in the PA population from sputum of CF
patients. Sputum from 68 CF patients (mean age 30.5 yr with a mean duration of
the chronic lung infection of 21.4 yr) were investigated for the presence of hyper-
mutable PA by plating the sputum samples on plates with Rifampicin (300 mgy
ml), Streptomycin (500 mgyml) and on substrate without antibiotics. We found that
38 of the 68 CF (56%) patients had mutators in the sputum and this percentage is
much higher than the previously reported frequency of 36% of the patients. We
found a frequency of mutators (mean"S.D.) of 1"6=10 for Rifampicin andy3
4"11=10 for Streptomycin (mean"S.D.) and this is much higher than they3
previously reported frequency of 3.2"2.5=10 . The high number of CF patients6
bearing mutator PA strains in the lung and the high frequency of mutators in the
PA population from CF sputum found in our study, shows that the CF lung is an
ideal environment for the occurrence and maintenance of mutators, probably due
to the chronic inflammation and the continuous antibiotic pressure.
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Ginseng inhibits quorum sensing in Pseudomonas aeruginosa
Z. Song (Presenting), Hong Wu , Kok-Fai Kong , Niels Høiby , Oana Ciofu ,1 1 2 1 1
Kalai Mathee2
Department of Clinical Microbiology, University Hospital of Copenhagen, Rig-1
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International University, Miami, USA,
Our previous study showed that ginseng treatment enhanced the lung bacterial clear-
ance and reduced the severity of lung pathology in animals with chronic P. aeru-
ginosa lung infection. This was attributed to the immunomodulatory properties of
ginseng resulting in a shift of immune response from a Th2-like to a Th1-like
response. We hypothesized that the enhanced bacterial clearance in the lungs may
be due to a direct effect of ginseng on bacterial survival. In the present study, we
analyzed the effects of various concentrations of aqueous extract of Chinese ginseng
on bacterial growth and expression of known extra-cellular virulence factors in the
prototypic non-mucoid P. aeruginosa PAO1. Media containing 2.5% or 5% of gin-
seng had no effect on PAO1 growth. However, both Las A protease and elastase
production from PAO1 were inhibited by 5% of ginseng, whereas 2.5% of ginseng
stimulated the production of elastase compared to the control. The expression of
many of the virulence factors including the protease is co-ordinately regulated by
quorum sensing systems via bacterial signal molecules called N-acyl homoserine
lactones. As predicted, the production of bacterial signal molecules, BHL and
OdDHL from PAO1 was inhibited by ginseng in a dosage-dependent manner. These
results indicate that ginseng does affect the expression of the factors necessary for
a successful colonization of P. aeruginosa. The inhibitory effects on bacterial quo-
rum sensing system could partially explain the favorable therapeutic effects of gin-
seng found in our animal study.
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Cox 2 inhibitors interfere with quorum sensing in Pseudomonas
aeruginosa strain PAO1
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Background: During P. aeruginosa growth, quorum sensing signaling is modulated
via autoinducer homoserine lactones (AHL’s). Recently, quorum sensing has been
inhibited by synthetic furanone compounds, which possess AHL-antagonistic activ-
ity and AHL structural similarity. Hypothesis: COX2 inhibitors, a class of drugs
possessing a furanone structure, block quorum sensing in P. aeruginosa, independ-
ent of effects on bacterial density. Methods: Primary human airway epithelial cells
were infected with 10 cfuyml of P. aeruginosa strain PAO1 in the presence and8
absence of rofecoxib. Cells were analyzed for release of lactate dehydrogenase
(LDH), TNF-a and IL-8. RNA was hybridized to Affymetrix human U133A and
U133B gene chips. Naproxen sodium, a non-selective COX inhibitor, served as a
positive control for rofecoxib. Positive controls for rofecoxib-treated PAO1 included
LasIrhlI, LasRrhlR and pilAB mutants. Bacterial studies included digital video
microscopy to assess movement, as well as swim, twitch and swarm plates, and
bio-film formation assays. Results: Rofecoxib, but not naproxen sodium reduces
PAO1-induced necrosis of epithelial cells, from 75 to 30% (P-0.05) via LDH
release assays. This survival effect was duplicated when the LasIRhlI PAO1 mutant
was used in comparison to rofecoxib treated wild type PAO1. Rofecoxib treated
PAO1 manifested impaired swarming and twitching. Epithelial cell gene expression
in response to rofecoxib treated PAO1 clustered most closely to that seen in response
to the pilAB mutant by Genespring analysis. Conclusion: Rofecoxib reduces
PAO1 induced epithelial cell cytotoxicity in a dose-dependent fashion without
affecting bacterial density. Rofecoxib treated cells demonstrated impaired swarming,
twitching and biofilm formation. Use of this drug does not induce airway epithelium
cytotoxicity in vitro and may prove useful in the attenuation of bacterial virulence.
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Gene regulation and adaptive mutation of Pseudomonas aeruginosa in
a mouse model for cystic fibrosis
Alessandra Bragonzi* (Presenting), Gerd Doering
Institute of General Hygiene, University of Tuebingen, Tuebingen, Germany
Optimal survival of microorganisms under changing environmental conditions
demands adaption resulting in the emergence of the new phenotype. During long-
term adaption to the anaerobic niche in the airways of Cystic Fibrosis (CF) patients,
P. aeruginosa increases its fitnessysurvival by getting mucoid. Both gene regulation
or adaptive mutation could induce alginate expression but how these two events
relate to each other is not understood. Here, we use the agar bead mouse model for
airway colonization to follow alginate gene regulation and adaptive mutation from
the acute to the chronic infection state. We demonstrate that P. aeruginosa PAO1
rapidly switches to a mucoid phenotype within one day after challenge due to the
anaerobicymicroaerobic environmental conditions provided by the agar beads. Gene
regulation leads to alginate expression during the first week of infection while in
the subsequent course of the disease; adaptive mutation leads to a stable phenotype.
Sequence analysis of the alginate repressor mucB reveals seven different stop muta-
tions in colonies isolated from long-term infected mice. The mucB mutation is also
a trait characteristic of P. aeruginosa strains isolated from chronically infected CF
patients. In summary, the agar beads model allows to study the relation between
gene regulation and adaptive mutation of the P. aeruginosa infection in CF patients.
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Tracking observation of effects of quorum sensing on serum IgG and
IgG subclasses in chronic Pseudomonas aeruginosa lung infection in
rats
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Chronic P. aeruginosa lung infection in cystic fibrosis (CF) patients is characterized
by a pre-dominant and persistent elevation of serum antibody and the infiltration
of numerous neutrophils in the lung foci resembling a Th2-like immune response.
It has been demonstrated that the elevated serum antibody response is correlated
with poor prognosis in CF patients. Few studies reported that signal molecule from
quorum sensing (QS) of P. aeruginosa involved in stimulating a Th2-like immune
response in P. aeruginosa lung infection. In the present study, chronic lung infection
in rats created by P. aeruginosa PAO1 and its QS mutant lasI-rhlI was tracked at
different time points for 3.5 months, in order to compare the humoral immune
response against the bacterial infection. On day 106, 27% of the rats infected with
PAO1 still carried the bacteria in the lungs whereas in the rats infected with lasI-
rhlI mutant, the bacteria were cleared completely (P-0.05). In the PAO1 infected
rats, serum specific IgG level increased from day 21 and reached the peak on day
63. In the lasI-rhlI group, serum IgG decreased from day 21 on and kept signifi-
cantly lower from day 35 to day 77 compared to the PAO1 group. In IgG1
responses, PAO1 infection induced persistently higher IgG1 production, whereas
lasI-rhlI infection resulted in a continuous reduction of IgG1 response. The differ-
ences of IgG1 between the two groups were significant from day 49 to day 98. No
obvious difference was found in IgG2a response. However, the ratios of IgG1y
IgG2a were significantly lower in the lasI-rhlI group from day 49 to day 98 when
compared with the PAO1 group. Higher anti-alginate IgG was found in the PAO1
group, especially on day 63 (P-0.04). These results indicate that QS plays an
important role in the induction of a Th2-like immune response and in the coloni-
zation of the pathogen in the lungs during a chronic lung infection course.
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Diversity of Stenotrophomonas maltophilia isolates recovered from CF
patients
T. Coenye , E. Vanlaere , J. LiPuma , P. Vandamme (Presenting)1 1 2 1*
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Stenotrophomonas maltophilia is increasingly being recognized as an important
cause of nosocomial infections in debilitated and immunosuppressed individuals
and the organism is resistant to many currently available antimicrobial agents. S.
maltophilia was first identified in CF specimens in the 1970’s and its prevalence
has been rising since. There are large regional differences in prevalence, which is
usually lower in the USA (1.8–10.3%) than in Europe (up to 25%). Previous
studies have shown that there is a remarkable diversity among S. maltophilia isolates
recovered from human clinical samples and the environment. In this study, we
investigated the genomic diversity of S. maltophilia using restriction fragment
length polymorphism analysis of the gyrase B gene (gyrB RFLP). We included a
large number of reference strains of S. maltophilia and other Stenotrophomonas
species and S. maltophilia isolates recovered from CF patients receiving care in the
USA and Europe. Our data and data from previously published DNA-DNA hybri-
disation experiments indicate that there are at least seven genomic groups within
the species S. maltophilia. The majority of CF isolates can be found in two of these
seven genomic groups. It remains to be determined what the clinical implications
of this finding are.
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Isolation of Inquilinus limosus from sputum of a UK cystic fibrosis
patient
R.P.D. Cooke (Presenting), W.A. O’Neill , J. Xu , J.E. Moore , G.1 1 2 2
Gopalakishnan3
Medical Microbiology, East Sussex Hospitals NHS Trust, Eastbourne, United King-1
dom, Bacteriology, Northern Ireland Public Health Laboratory, Belfast, Ireland,2
Paediatrics, East Sussex Hospitals NHS Trust, Eastbourne, United Kingdom3
Introduction: Inquilinus limosus is a very recently described genus and species,
previously only isolated from 8 cystic fibrosis (CF) patients in the USA. I. limosus1
has not been reported to date from CF patients in UK or Ireland. Materials and
results: I. limosus was cultured from the sputum of a 9-year old CF patient treated
with 3-monthly maintenance courses of intravenous anti-pseudomonal antibiotics
and bi-monthly courses of nebulised tobramycin. The isolate had been cultured on
12 occasions over a 2-year period during which time the patient was clinically well.
On Burkholderia cepacia medium (Mast, UK), the organism produced a mucoid,
red colony and was identified as an oxidase-positive, Gram-negative rod which grew
at 42 8C but gave an unrecognisable biochemical profile using the API20NE system
(bioMerieux, France). Fatty acid analysis showed a very low similarity to Ochro-´
bactrum anthropi. However, using DNA sequencing of a partial region of the 16S
rRNA gene locus, the isolate had a 99.7% homology with I. limosus. The strain
was colistin resistant but otherwise initially sensitive to all anti-pseudomonal anti-
biotics tested. Subsequently, tobramycin resistance has emerged. Conclusions: Unu-
sual Gram-negative organisms are being increasingly isolated from CF sputa. To
avoid confusion with B. cepacia complex and ensure accurate identification, close
collaboration between district and reference laboratories is essential. Though there
are no previous clinical reports of this organism in the literature, I. limosus did not
appear to act as a pathogen in this case.
Coeyne T., Goris J., Spilker T. et al., J. Clin. Microbiol. 40 (2002) 2062–2069.1
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Chronic colonization with a mucoıd strain of Klebsiella pneumoniae¨
subsp.ozaenae in a patient with cystic fibrosis
M. Murris (Presenting), C. Segonds , J.L. Rittie , A. Didier , G. Chabanon , P.1 2 1 1 2
Leophonte1
CRCM adulte – Service de Pneumologie, Hopital de Rangueil – Larrey, TOU-1 ˆ
LOUSE, France, Laboratoire de Bacteriologie – Hygiene, Hopital de Rangueil –2 ˆ
Larrey, TOULOUSE, France
Klebsiella ozaenae (KO), a biochemical inactive subspecies of K. pneumoniae, is
an unusual clinical isolat, mainly associated with atrophic rhinitis and occasionally
recovered from miscellaneous infections such as bacteremia, urinary tract and soft
tissue infections. We report the case of a patient with cystic fibrosis (CF) who
became chronically infected with a mucoıd strain of K. ozaenae. A male patient¨
born in 1973, with CF diagnosed at the age of five, chronically colonized with a
penicillinase producing methicillin susceptible Staphylococcus aureus (SA) since
1979, with no history of Pseudomonas aeruginosa colonization. Since May 1998,
a mucoıd Gram negative bacillus was regularly recovered from sputum cultures,¨
and was identified as K. pneumoniae subsp.ozaenae. The isolate was resistant to
amino- and carboxypenicillins and susceptible to other b-lactamins, aminoglyco-
sides and quinolones. In 1998, his pulmonary function tests showed a FVC of 3.6
l and FEV of 2.3 l. After the patient was colonized with KO, his condition was1
slowly deteriorating clinically. Pulmonary function test performed in December
2001 showed a FVC of 2.4 l and a FEV of 1.52 l, he received IV antibiotic therapy1
(ceftriaxone and levofloxacine). Seven months after treatment, KO and SA have
disappeared from sputum culture with no identification of P. aeruginosa, the patient
has a good and stable respiratory status. The recovery of K. ozaenae in sputum has
already been described as evocative of bronchiectasis and one case of chronic col-
onization in a patient with CF has been reported, but it is the first time, to our
knowledge, that a respiratory deterioration is mentioned.
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The use of 16s rDNA restriction fragment length polymorphism
analysis for the identification of non-fermenting gram negative bacilli in
a cystic fibrosis microbiology referral service
T.J. Kidd (Presenting), R. Lumb , S.C. Bell , C. Coulter1 2 3 1
Department of Microbiology, The Prince Charles Hospital, Brisbane, Australia,1
Institute of Medical and Veterinary Science, Adelaide, Australia, Adult Cystic2 3
Fibrosis Unit, Department of Medicine, The Prince Charles Hospital, University of
Queensland, Brisbane, Australia
The utility of 16s rDNA restriction fragment length polymorphism (RFLP) analysis
for the partial genomovar differentiation of Burkholderia cepacia complex bacte-
rium is well documented. We compared the 16s rDNA RFLP signatures for a num-
ber of non-fermenting gram negative bacilli (NF GNB) LMG control strains and
clinical isolates pertaining to the genera Burkholderia, Pseudomonas, Achromobac-
ter (Alcaligenes), Ralstonia, Stenotrophomonas and Pandoraea. A collection of 24
control strain (LMG) and 25 clinical isolates were included in the study. Using
conventional PCR, a 1.2 kbp 16s rDNA fragment was generated for each organism.
Following restriction digestion and electrophoresis, each clinical isolate RFLP sig-
nature was compared to those of the control strain panel. Nineteen different RFLP
signatures were detected from the 28 control strains included in the study. Twenty-
oneyTwenty-five of the clinical isolates could be classified by RFLP analysis into
a single genus and species when compared to the patterns produced by the control
strain panel. Four clinical B. pseudomallei isolates produced RFLP signatures which
were indistinguishable from B. cepacia genomovars I, III and VIII. The identity of
these four isolates were confirmed using B. pseudomallei specific PCR. 16s rDNA
RFLP analysis can be a useful identification strategy when applied to NF GNB,
particularly for those which exhibit colistin sulfate resistance. The use of this molec-
ular based methodology has proved very useful in the setting of a CF referral
laboratory particularly when utilised in conjunction with B. cepacia complex and
genomovar specific PCR techniques. Species specific PCR or sequence analysis
should be considered for selected isolates; especially where discrepancies between
epidemiology, phenotypic and genotypic characteristics occur.
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A cluster of Haemophilus parainfluenzae respiratory infections
E. Simmonds (Presenting), K. Struthers1
Medical Microbiology, University Hospitals Coventry and Warwickshire NHS Trust,
Coventry, United Kingdom
We report an unusual clustering of respiratory infections with Haemophilus parain-
fluenzae in our clinic population. The CF clinic in Coventry manages the care of
45 children. During the summer (JuneyJuly) of 2002 respiratory cultures from 9
young children (aged 16 months–10 yr) attending the outpatient clinic isolated H.
parainfluenzae. It is our practice to segregate clinics on the basis of Pseudomonas
colonisation. Eight were attending the clinic for non-colonised patients. All H. par-
ainfluenzae strains were amoxycillin resistant with variable resistance reported to
co-amoxiclav and trimethoprim. Although 4 children who attended the clinic on the
same day had positive cultures, the remaining positive cultures were obtained on
different days. There was no obvious point source or recent contact between the
patients, which suggests the infections were community acquired. Of the 9 patients
4 were asymptomatic at the time of their clinic visit and managed by repeating their
respiratory culture andyor a course of oral antibiotics. Five were symptomatic or
became so shortly after. Despite oral antibiotics, prescribed on the basis of reported
sensitivities, they remained symptomatic and required intravenous antibiotics before
their symptoms settled. This cluster of cases was unusual. It occurred during the
summer months affecting children who previously were normally well. The organ-
isms isolated were resistant to commonly used oral antibiotics. Several patients
required intravenous antibiotics. Our observations reiterate that Haemophilus infec-
tions are an important cause of morbidity in CF patients.
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Non-tuberculous mycobacteria in cystic fibrosis patients
I. Adams (Presenting), G. Jilg , B. Konig , R. Schuster-Wonka , V. Sollich1 1 2 1 1¨
Department of General Paediatrics and Neonatology, Otto-von-Guericke Univer-1
sity, Magdeburg, Germany, Department of Microbiology, Otto-von-Guericke Uni-2
versity, Magdeburg, Germany
Non-tuberculous mycobacteria (NTM) are ubiquitous in the environment, mainly
they are isolated from water and soil. They can cause lymphadenitis in children,
pulmonal infections mainly in-patients with underlying chronic lung disease and
disseminated disease in immunosuppressed patients. The prevalence of NTM in the
sputum of cystic fibrosis patients varies from 4 to 22% in different countries. The
most common species include M. avium intracellular, M. kansasii, M. chelonae and
M. abscessus. In our center, we found positive cultures for NTM in the sputum
andyor bronchoalveolar lavage fluid in five patients with an age between 14 and
19 yr. In three of these patients we could observe clinical deterioration of the
pulmonal situation and new infiltrates in the chest X-ray, which persisted after IV-
antibiosis. In these patients, we successfully followed an anti-mycobacterial treat-
ment regimen against M. avium intracellulare (1x) and M. abscessus (2x). Two
patients had only colonization with M. abscessus. Positive cultures for NTM are
common in CF-patients and it is difficult to differentiate between colonization and
clinical relevant infection in these patients with underlying chronic lung disease.
Additionally, it is often problematic to eradicate these frequent multi-resistant organ-
isms. If there is no other reason for clinical deterioration in CF-patients, it is impor-
tant to consider the possibility of non-tuberculous mycobacterial disease and to start
appropriate diagnostic measures and therapy.
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Long-term persistence and resistance pattern of isogenic Candida
strains in the sputum of CF patients
F. Mueller (Presenting), M. Muthig , A. Hebestreit , M. Frosch1 1 1 2
Department of Pediatrics, University Heidelberg, Heidelberg, Germany, Micro-1 2
biology Department, University Wuerzburg, Wuerzburg, Germany
Introduction: Cystic fibrosis patients are frequently colonized in their sputum with
yeast isolates. Candida albicans is the leading pathogen, but recently the percentage
of non-albicans Candida spp. has increased. Little is known about the persistence
of isogenic Candida strains in the bronchial system of CF patients. Methods: During
the study period of 30 months 420 Candida sputum isolates from 56 CF children
and young adults were differentiated by the API-system and for different growth
on CHROMagar and on Staib-Agar. For in vitro susceptibility testing of the anti-
fungal fluconazole, itraconazole, voriconazole, amphotericin B and micafungin a
microdilution method following NCCLS guidelines using HR medium was per-
formed. For persistence of isogenic strains all isolates were molecular biotyped by
RAPD using primer RPO (GCGATCCCCA) and southern hybridization with the2
C. albicans specific CARE-2 probe. Results: Three hundred and thirty-two isolates
(79%) were identified as C. albicans and 89 as non-albicans Candida spp. (21%):
C. glabrata (31), C. dubliniensis (22), C. parapsilosis (20), C. tropicalis (6), C.
kefyr (4), C. lusitaniae, C. krusei (2), C. rugosa, C. pelliculosa (1). MICs for all
C. albicans isolates were obtained in the range of (mgyml): fluconazole (0.12–)
128), itraconazole (0.03–)4), voriconazole (0.03–)16), amphotericin B (0.12–
1), and micafungin (0.12–2) Molecular biotyping revealed persistence of isogenic
strains between 8 and 18 months: C. albicans (16.7 mo.), C. glabrata (14.2 mo.),
C. dubliniensis (12 mo.), C. parapsilosis (13 mo.), C. tropicalis (18 mo.), C. kefyr
(8.5 mo.), C. krusei (8 mo.). Conclusion: Further studies need to be elaborate
whether long-term persistence of isogenic Candida and development of antifungal
drug resistance has implications on chronic lung inflammation in CF.
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Macrocolony formation of Staphylococcus aureus contributes to its
persistence in cystic fibrosis airways
M. Ulrich (Presenting), K. Ziegler , S. Cramton , G. Doring1 1 2 1¨
Institute of General and Environmental Hygiene, University of Tubingen, Tubin-1 ¨ ¨
gen, Germany, Department of Microbial Genetics, University of Tubingen, Tub-2 ¨ ¨
ingen, Germany
Staphylococcus aureus adapts to the anaerobicymicroaerobic growth conditions in
the mucus layer overlaying the airway epithelium in CF patients by gene regulation
involving the ica gene locus encoding the Polysaccharide Intercellular Adhesin
(PIA). This leads to the formation of S. aureus macrocolonies, which may impair
the phagocyticykilling functions of polymorphonuclear leukocytes (PMN) and con-
tribute to bacterial persistence. Additionally, PMN are compromised in bacterial
killing under anaerobic conditions due to the lack of reactive oxygen species (ROS).
Here we investigated the impact of PIA production of S. aureus on bacterial killing
under aerobic and anaerobic conditions. S. aureus strain ATCC 35556 and its PIA
negative mutant 35556Dica::tet were incubated with human PMN for 1.5 h at 37
8C under anaerobic and aerobic conditions. Bacterial killing was assessed by routine
methods and PIA production using a specific polyclonal PIA antibody and immu-
nofluorescence. PMN killed both strains equally well under aerobic conditions (sur-
vival percentage: ATCC 35556: 1.7"0.7; 35556Dica::tet: 5.3"2.1). Similarly,
under anaerobic conditions the mutant was killed to a high extent. However, sig-
nificantly higher numbers of the wild type strain survived (survival percentage:
ATCC 35556: 38.2"7.3; 35556Dica::tet: 4.7"0.56). PIA production was detect-
able during the experiments by S. aureus ATCC 35556 only under anaerobic con-
ditions. We conclude that PIA protects S. aureus against killing by human PMN
only under anaerobic environmental conditions, which explains why S. aureus is a
persistent pathogen in CF patients.
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Staphylococcus aureus from CF patient airway secretions may induce
an upregulation of Fas and apoptosis of airway epithelial cells
L.A. Vidipo , M.C.A. Silva , M.C. Assis , O. Bajolet , E. Puchelle , M.C.1 1 1 2 2´
Plotkowski (Presenting)1
Rio de Janeiro, Brazil, Reims, France1 2
Although S. aureus is classically an early pulmonary pathogen in CF patients, the
effects of infections on airway cells have been poorly investigated. In this report,
16 HBE cells were exposed to S. aureus strains isolated from CF airway secretions
of recently (group 1; ns3) or chronically infected CF patients (group 2; ns7).
By light microscopy and gentamicin exclusion assay, all strains were seen to be
similarly internalized by host cells. Intracellular (IC) infection by strains 658 and
661 from group 2 induced a significant increase in IL-8 release by host cells, as
determined by ELISA assays. FACS analysis showed that cells harboring IC 658
strain exhibited a significant increase of annexin V staining. No staining was
observed when cells were exposed to propidium iodide, suggesting the induction
of apoptosis. IC infection by the strain 658 led to a mild but significant increase
in cell surface expression of Fas (from 2.5%"0.3 in non-infected cells to
6.9%"2.2 in infected cells; P-0.05), as determined by FACS analysis. To inves-
tigate a relationship between the production of oxidant radicals by infected cells
and up-regulation of surface Fas, cells harboring IC bacteria were exposed to C-11
fluor, a lipophilic fluorescein derivative whose fluorescence decreases gradually
with the peroxidation of membrane lipids. Cell labeling was analysed by FACS. No
difference in C-11 labeling was detected between non-infected and 658-infected
cells, suggesting that oxidant radicals produced in response to bacterial infection
did not promote Fas up-regulation. In vivo, the increased expression of Fas may
favor the apoptosis of S. aureus-infected cells by soluble FasL or by FasL-express-
ing inflammatory cells detected in CF patient airways. This suggests that S. aureus
CF clinical strains may induce epithelial damage, contributing to the airway colo-
nization by secondary opportunistic pathogens. Supported by AVLM (France) and
CAPES (Brazil).
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Prevalence of agr-specificity groups and agr-activity in persistent
Staphylococcus aureus airway infection of CF patients
B. Kahl (Presenting), G. Belling, K. Becker, S. Deiwick, B. Schuhen, G. Peters
University of Muenster Hospital and Clinics, Muenster, Germany
The airways of cystic fibrosis (CF) patients are often persistently colonizedyinfected
by Staphylococcus aureus (B. Kahl et al., J. Infect. Dis. 177 (1998) 1023–1029).
Virulence of S. aureus is controlled by the agr-locus, which is auto-induced by a
short secreted peptide (auto-inducing peptide; AIP) (G. Ji et al., Science 276 (1997)
2027–2030). Four different agr-groups have been described according to the vari-
ability of the AIP, which account for bacterial interference between members of
different agr-groups by cross-activation of the agr-locus within and inhibition
between the different groups (S. Jarraud et al., Bacteriol. 182 (2000) 6517–6522).
To assess, if S. aureus strains isolated from the airways of CF patients are associated
with a specific agr-group and to analyze if bacterial interference might occur, we
determined the agr-groups of S. aureus strains collected over a 72 month period
from 52 CF patients. Prior to multiplex-PCR for agr-group determination, clonal
relationship of strains was analyzed by pulsed-field gel electrophoresis (PFGE).
Activity of the agr-regulon was assessed by transcription analysis. Thirty-five strains
were assigned to agr-group I, 23 strains to agr-group II, 16 strains to agr-group III
and 4 strains to agr-group IV. If patients were infected by several strains, these
isolates mostly belonged to different agr-groups (14y17; 82%). 34.6% of 101 tested
isolates displayed an inactive agr-locus. Conclusions: (i) Strains of agr-groups I and
II were most prevalent in CF patients. (ii) Most patients were infected by single
strains suggesting that agr-related bacterial interference may prevent co-infection by
other strains. (iii) Strains of different agr-types were favored in individual patients
with multiple strains probably due to the inhibiting effect upon the agr-regulon. (iv)
The inactive agr-locus in app. 35% of the strains indicates that agr-activated genes
may not be essential for persistent airway infection of CF patients.
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Successful treatment of methicillin-resistant Staphylococcal aureus
infection in cystic fibrosis patients with rifampicin and fusidic acid
R. Donnelly (Presenting), J. Bradley , C. Goldsmith , K. O’Gorman , J. Moore ,1 2 3 3 3
S. Elborn2
Belfast City Hospital, Belfast, United Kingdom, Cystic Fibrosis Unit, Belfast City1 2
Hospital, Belfast, United Kingdom, Belfast Link Labs, Belfast City Hospital, Bel-3
fast, United Kingdom
Methicillin-resistent Staphylococcus aureus (MRSA) is an important nosocomial
pathogen in cystic fibrosis (CF). CF patients are at increased risk of infection with
MRSA but its pathological significance is controversial. There is a paucity of evi-
dence with regard to effective treatment regimes. There are previous reports of
successful treatment of MRSA with IV vancomycin, and one case report of suc-
cessful treatment with linezoid. Ten patients attending the Adult CF unit at the
Belfast City Hospital between the periods of March 1998–2002 had positive sputum
cultures growing MRSA. The patient’s age range was 20–41 with mean (S.D.) 27.4
(6.66). Four patients were homozygous and five patients were heterozygous for the
deltaF508 mutation. Seven had associated chronic Pseudomonas aeruginosa infec-
tion. The mean forced expiratory volume in 1 s (FEV ) was 69.9 (20.7)% predicted1
and mean body mass index 21.63 (2.46) kgym . There was no significant change2
in FEV before and after treatment. Patients received treatment with oral fusidic1
acid 500 mg twice daily and rifampicin 300 mg three times daily for six weeks,
bactroban nasal ointment for five days and aquasept washes 1 week. A strict infec-
tion control policy was implemented. Follow up involved six sputum cultures over
a six-month period. One patient re-cultured MRSA in sputum four months later. He
was retreated and subsequently has remained clear of MRSA. The other nine
patients had no recurrence of MRSA. In this study MRSA infection was successfully
treated with six weeks of oral rifampicin and fusidic acid and skin decontamination.
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Respiratory viral infections in childhood exacerbations of cystic
fibrosis
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Department of Respiratory Medicine, Royal Group of Hospitals Trust, Belfast,1
United Kingdom, Department of Child Health, Queen’s University Belfast, Belfast,2
United Kingdom, Royal Belfast Hospital for Sick Children, Royal Group of Hos-3
pitals Trust, Belfast, United Kingdom, Physiotherapy Department, Royal Group of4
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Introduction: Children with a history of Cystic Fibrosis (CF) are known to more
frequently suffer exacerbations in association with respiratory viruses when com-
pared to those who are not affected. These viral exacerbations have also been linked
with hospitalization, early acquisition of Pseudomonas aeruginosa and disease pro-
gression. We wished to examine the viruses, which precipitate acute exacerbations,
and the associated chemokine response. Methods: Children (less than 18 yr) who
presented to the regional paediatric CF unit with acute respiratory symptoms were
recruited. Height, weight, pulmonary function (if available) and date of onset of
symptoms were recorded. Nasal and pharyngeal swab samples were taken. Patients
were recruited over a 4-week period, January 2003–February 2003. Samples were
analysed using nested and real time PCR techniques for respiratory viruses and
chemokine responses. Results: Sixteen children were recruited into the study. Fifty-
six percentages were male with a mean age of 12.1 ("4.5) yr. Sixty-nine percentage
of patients cultured an infecting bacterium from their sputum. Organisms isolated
included: P. aeruginosa (6), Staphylococcal aureus (2), Haemophilus influenza (1),
Haemophilus parainfluenza (1) and Coliforms (1). Twelve respiratory viruses were
identified in 8 patients (50%). The viruses identified were as follows: Rhinovirus
(5), Adenovirus (3), RSV B (2), RSV A (1) and Influenza B (1). Herpes simplex
Virus 1 was identified in 3 cases (19%). In 4 cases (25%) there was dual infection
with both a bacterium and a respiratory virus. Conclusions: Endemic respiratory
viruses are an important cause of acute exacerbations in children with CF. The
profile of viruses identified from CF children differ from those seen in the normal
population.
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Prevalence of MRSA and Stenotrophomonas in Cardiff 1998–2002
K. Pardy (Presenting), H.C. Ryley , I.J.M. Doull1 2 3
Department of Child Health, Cardiff, United Kingdom, Department of Medical1 2
Microbiology, University of Wales College of Medicine, Cardiff, United Kingdom,
CFyRespiratory Unit, University Hospital of Wales, Cardiff, United Kingdom3
The clinical significance of isolation of methicillin resistant Staphylococcus aureus
(MRSA) or Stenotrophomonas maltophilia from airway cultures in patients with
CF is unclear. As a result the decision whether to treat these organisms or not is
difficult. We retrospectively reviewed all potential respiratory pathogens isolated
from sputum and cough swabs from all patients attending the pediatric CF unit in
Cardiff between 1998 and 2002. Virtually all our patients receive regular oral flu-
cloxacillin. The prevalence of MRSA isolation ranged from 1.3 to 5.3%. Over the
five years 10 patients isolated MRSA, of whom only one isolated MRSA for more
than one successive year. That patient presented at 10 yr of age, and MRSA was
identified at diagnosis. In all the other cases MRSA isolation resolved without
specific treatment except discontinuing flucloxacillin. The prevalence of S. malto-
philia isolation ranged from 3.9 to 11.6%. Peak prevalence was seen in 1999 and
in all years those affected were predominantly over five years of age. In total 19
patients isolated Stenotrophomonas and all were treated with oral cotrimoxazole.
Five patients isolated Stenotrophomonas for more than one successive year, but
only 2 patients isolated the organism for more than 2 years. Isolation of Stenotro-
phomonas appeared to have no deleterious effect in either patient. In our experience,
new isolation of MRSA resolves without treatment in the majority of cases. Simi-
larly new isolation of Stenotrophomonas resolves in the majority of cases with oral
cotrimoxazole. Significant chronic infection with either organism appears to be
unusual.
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Early bacterial colonization of the respiratory tract
L. Valdesorio (Presenting), Montserrat Bosque , Dolors Mariscal , Christian1 1 2
Domingo , Teresa Marco , Oscar Asensio , Helena Larramona1 1 1 1
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Introduction: The neonatal screening allows an early microbiological diagnosis of
the respiratory colonization in patients still asymptomatic and thereby being able
to determine the age of the first isolation, potential pathogen microorganisms of the
respiratory system, the initial age of the colonization and to find out which micro-
organisms are responsible for the bacterial infections of these patients. Method and
material: Observational prospective study. Patients: infants with newly-diagnosed
disease which were identified by neonatal screening, between October 1999 to
December 2001, from within the urban area. A collection of specimen is taken
applying the oropharinx aspirate (OAF) technique. These specimens are taken
monthly and should the infant develop respiratory infection symptoms, addition to
the specimen taken. Results: Ten patients were recruited, seven of them with genetic
diagnoses, with two mutations and the other three with only one recognised muta-
tion. All patients were followed up for one year and three of them for two years.
One hundred and thirty-eight AOF specimens were taken, 64 of that were positive
and 89 microorganisms were isolated. Every patient had positive cultures prior to
one year old. The more frequent isolated microorganisms were Staphylococcus
aureus (18), Pseudomonas aeruginosa (14), Escherichia coli (12). Other BGN less
frequent (45) from the Enterobacteriaceae and Pseudomonaceae families which rep-
resented 50% of the isolated cases. Conclusions: (1) The bacterial colonization in
the CF patients is very early. (2) The practice of taking routine monthly specimen
for culture from these patients, even asymptomatic, by AOF technique, allows the
aetiological treatment of acute respiratory infections. (3) This practice will allow
determining the implication of asymptomatic colonization in these patients with CF.
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Adrenal suppression in three cystic fibrosis (CF) patients with allergic
bronchopulmonary aspergillosis (ABPA)
R. Kanaan (Presenting), H. Mosnier-Pudar , N. Desmazes-Dufeu , D. Manach , D.1 2 1 1
Dusser , D. Hubert1 1
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The association of itraconazole and inhaled corticosteroids is widely used as a
treatment of ABPA in CF patients, increasing the risks of adverse effects in com-
bination with some of the numerous drugs prescribed to these patients. We diag-
nosed adrenal suppression in 3 ABPA-treated CF patients. All were treated with
high dose of budesonide or fluticasone, combined to itraconazole (400 mgyd) for
24, 11 and 2 months. All were suffering from fatigue during 1–6 months before
pituitary-adrenal-axis exploration revealed low cortisol level (-0.5, 3.3 and -10
ngyml) and negative synacthen test with low ACTH level. Interestingly, all 3
patients were treated by azithromycine 24, 6 and 2 months before the diagnosis of
adrenal suppression. Furthermore, patient 3 had received megestrol acetate for 2 yr
when a first analysis found a low cortisol level of 64 ngyml; 2 months after steroids
and azitromycine were added to itraconazole and megestrol, cortisol and ACTH
were no longer detectable and synacthen test was negative, revealing increased
adrenal suppression. Itraconazole and steroids were then stopped and 2 months later,
only ACTH level normalized, cortisol level remained at 60 ngyml and synacthen
test remained negative. Itraconazole and macrolides inhibit corticosteroids clearance
by inhibition of cytochrome-P450-dependent enzymes. Megestrol could interfere
with pituitary glucosteroid receptor. We hypothesize that the adrenal suppression
by a combination of high dose inhaled corticosteroids and itraconazole could be
increased by association to other drugs frequently given to CF patients. We suggest
regular testing of pituitary-adrenal-axis in CF patients treated for ABPA.
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Altered Bayesian derived tobramycin pharmacokinetics during
prolonged once daily administration in adult cystic fibrosis
N.H. Liao (Presenting), D. Peckham , S. Conway , H. Chrystyn1 2 2 1
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Bayesian analysis is a technique that interprets a single serum drug concentration
with the dosing history to derive revised estimates (RE) of an individual’s phar-
macokinetic parameters (Chrystyn, Drug Intell. Clin. Pharm. 22 (1988) 49–53).
We have used this method to generate these parameters in 27 (11 females) adults
with cystic fibrosis who received once daily tobramycin administration for)7 days.
The REs have been derived from separate serum tobramycin concentrations meas-
ured during days 1–3 (RE1) and 7–10 (RE2) of therapy with no change in their
daily tobramycin dose. Their mean(S.D.) age, weight and height was 24.8(4.7) yr,
56.4(12.5) Kg and 1.67(0.11) m, respectively, and daily tobramycin dose was
547(108.2) mg. Samples for RE1 and RE2 were drawn at 6.6(1.1) and 6.4(0.8)
hours post dose and their respective serum tobramycin concentrations were 2.2(1.2)
and 3.7(2.0) mgyl. The mean(S.D.) RE1 and RE2 for clearance was 6.31(1.47)
and 5.49(1.44) lyh with a mean difference (95% confidence interval) of 0.82
(0.47,1.22) lyh, P-0.001. Similarly, values for the volume of distribution were
13.0(2.7) and 13.8(2.7) l with a mean difference (95% confidence interval) of y
0.78(y1.29, y0.27)l, P-0.01. Half-lives were 1.43 (0.40) and 1.78 (0.51) h,
respectively, with a mean difference (95% confidence interval) of y0.35(y0.18,
y0.52) h, P-0.001. Changes to the volume of distribution cannot be explained.
Decreased clearance is probably due to the effect of prolonged high dose tobramycin
on the renal function. These changes and any long-term effects from prolonged high
dose once daily tobramycin in patients with cystic fibrosis requires investigation.
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Rare renal involvement in cystic fibrosis patients
T. Bolger (Presenting), G. Canny , M. Waldron , M.O. Mahony , A. Awan1 1 2 3 2
Department of Pulmonology, Our Lady’s Hospital for Sick Children, Dublin, Ire-1
land, Department of Nephrology, Our Lady’s Hospital for Sick Children, Dublin,2
Ireland, Department of Paediarics, Limerick Regional Hospital, Limerick, Ireland3
CF patients are frequently colonised with Pseudomonas, which requires chronic
antibiotic therapy, including aminoglycosides. The pharmokinetics of aminoglyco-
sides are different in CF patients compared with normal populations. These prop-
erties suggest that the doses should be increased and given less frequently. Cases:
A 14-year old girl presented with lethargy and anorexia. Initial bloods revealed a
hypokalaemic, hypochloraemic, hypomagnesaemic metabolic alkalosis. Urinary
electrolytes revealed a hypocalciuria and hypermagnesiuria. Renin levels were nor-
mal, while aldosterone levels were elevated on standing samples. A diagnosis of
Gitelman-like Syndrome was made and she was commenced on KCl supplements,
Magnesium and Indomethacin. The onset of this disorder was related to aminog-
lycoside therapy, which she had repeatedly received in the past. A 12-year old boy
presented with anuria, lethargy and anorexia. He had been treated with gentamycin
80 mg tds for 21 days for a chest infection. His most recent gentamycin levels were
markedly elevated. He was dialysed for 10 days but improved slowly. A renal
biopsy was performed which revealed ATN and small amounts of IgA deposition.
In the next 12 months, he had 3 episodes of HSP. It was felt that his renal failure
was due to gentamycin toxicity and the IgA nephropathy was an incidental finding.
A 16-year old girl presented with anuria and epistaxis. She had been treated with
gentamycin for 22 days for a chest infection. Her drug levels had been high on 3
occasions during her treatment course. In the 24 hours before her deterioration, she
received ibuprofen 7.5 mgykg on 3 occasions. A diagnosis of ARF due to aminog-
lycoside and NSAID toxicity was made and dialysis was commenced. Discussion:
Patients receiving large doses of aminoglycosides should be monitored closely for
toxicity and avoidance of other nephrotoxic drugs should be considered. Once daily
dosing should be considered for all CF patients.
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Pharmacokinetics of linezolid in adult patients with cystic fibrosis
P. Flume (Presenting), J. Bosso , S. Gray1 2 2
Department of Medicine, Medical University of South Carolina, Charleston, USA,1
Department of Pharmaceutical Sciences, Medical University of South Carolina,2
Charleston, USA
Background: The pharmacokinetics of many drugs are altered in cystic fibrosis (CF)
patients, often necessitating different dosage requirements than used for non-CF
patients. The objective of this study was to elucidate the pharmacokinetics of line-
zolid, an antibiotic with good activity against Gram-positive organisms such as
methicillin-resistant Staphylococcus aureus, in CF patients so that dosage require-
ment could be established. Methods: Eight adult patients (4 male) ranging in age
from 22 to 39 yr were studied. A single 600 mg dose was administered intrave-
nously over 0.5 h and plasma samples collected at 0 (pre-dose), 0.5, 0.75, 1, 2, 4,
8 and 24 h. Linezolid concentrations were determined with a validated HPLC assay.
Pharmacokinetic parameters were estimated using standard non-compartmental
methods. Blood chemistry and hematologic indices were determined before and
after the study for safety purposes. Results: All patients completed the study without
encountering any adverse reactions. Pharmacokinetic variables were quite variable
among patients with half-lives varying from 1.76 to 8.36 h. Mean ("S.D.) values
for pharmacokinetic parameters of interest were k: 0.21 (0.11) h , t : 4.29 (2.52),y1 1y2
Vss: 0.90 (0.20) lykg, and Cl: 0.12 (0.06) lyhykg. Estimates of 12 h concentrations
at steady state conditions include values below 4 mgyl (maximum MIC considered
susceptible for S. aureus). Conclusions: The pharmacokinetics of linezolid are high-
ly variable in CF patients. In order to maintain plasma concentrations above the
MIC of the least susceptible isolate of S. aureus for the entire dosing interval, some
CF patients may require an every 8 h regimen.
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How to treat antibiotic allergy: experience in CF center of Palermo
M.L. Furnari , M. Collura , G. Traverso , A. Lucania , F. Pardo (Presenting)1 1 1 2 1
Pediatria – Cystic Fibrosis, ‘G. Di Cristina’ Hospital – ARNAS, Palermo, Italy,1
Pediatria – Allergology, ‘G. Di Cristina’ Hospital – ARNAS, Palermo, Italy2
In patients with cystic fibrosis (CF) a high incidence of allergic reactions to anti-
biotics has been reported. The main reason why this hypersensitivity develops could
be the increased usage of intravenous (iv) antibiotics. The etiopathogenetic mech-
anism of adverse reactions in CF is the same as that for the general population.
The adverse reaction has been defined by Edwards and Aronson (Lancet, 2000) as
‘an appreciably harmful or pleasant reaction, resulting from an intervention related
to the use of a medicinal product,«’. These reactions are based on an IgE-mediated
mechanism. The clinical manifestations range from maculo-papular eruptions to
severe anaphylactic shock. But in CF, due to the limited sensitivity of the pathogens,
it is sometimes necessary to use the drug, which caused the allergic reaction; in
this case the desensitization is a good option. Thirteen of our 139 patients chroni-
cally infected experienced an allergic reaction: 7y13 had maculo-papular rush, 4y
13 urticaria angioedema, 1y13 fever and 1y13 anaphylactic shock. Six of them had
multiple antibiotic allergy. Eleven had allergy to ceftazidime, 4 to imipenem, 2 to
piperacillinytazobactam, 2 to cloramphenicol and 1 to ciprofloxacin. For these
patients desensitization was required; this method involves administering tiny quan-
tities of the drug iv and increasing the dose approximately every 15 min until the
patient receives a therapeutic dose. Subsequently, the patient receives his usual
treatment. In this way we haven’t ever had any severe reactions; only once did we
need to stop because of the appearance of severe urticarial rash. We repeat this kind
of desensitisation every time the patients require antibiotic treatment. Desensitiza-
tion is thought to be effective either because increasing doses of antigen neutralizes
IgE or because the mast cells are slowly degranulated. In our experience drug
desensitization is a safe method and a powerful tool for treating allergic patients.
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Pharmacokinetics of amikacin in CF patients: assessment of once daily
administration
M. Halacova (Presenting), J. Ticha , J. Bartosova , V. Vavrova , K. Kotrcova , K.1 1 2 2 1
Kotaska , V. Skalicka , R. Prusa1 3 1
Department of Clinical Biochemistry, Charles University and School of Medicine,1
University hospital Motol, Prague, Czech Republic, Pediatric Clinic, Charles Uni-2
versity and School of Medicine, University Hospital Motol, Prague, Czech Republic,
Pediatric Clinic, Charles University and School of Medicine, University Hospital3
Motol, Prague, Czech Republic
Aim: Successful amikacin dosage regimens are defined as those that achieve a peakyMIC
greater than 8–10 and attain a TMIC of not greater than the duration of the post-antibiotic1
effect (in vivo 10 h). The aim of this study was to compare the predicted pharmacodynamic
(PD) activity of amikacin at 28 mgykgyday administered every 8 h (q8 h), q12 h and q24
h. Methods: Pharmacokinetic (PK) data were derived from the analysis of drug concentrations
(c trough, c peak) in sera from 42 CF patients (age: 12.1"0.8, weight: 33.6"2.2 kg, BSA:
1.2"0.1 m ). Serum amikacin concentrations were determined by EMIT (Advia 1650,2
Bayer). PK analysis was performed for each patient using the MWyPHARM 3.30 program.
Data were fitted to one compartment open model by using Bayesian analysis (Vdykg:
0.4"0.0 lykg T : 2.2"0.1 h, CL: 66.7"5.0 mlymin, CLcr: 118.6"2.8 mlyminy1.73 m .21y2
kel: 0.3"0.0 h ). These individual PK parameter values were used to construct simulatedy1
serum concentration-time curves and to determine various PD indices (peakyMIC, TMIC)
for 3 regimens described above. MIC for P. aeruginosa was 4 mgyl. Results: Significantly
lower peakyMIC, but shorter T, were observed when regimens of q8 h vs. q12 h, q8 h vs.
q24 h and q12 h vs. q24 h were compared (P0.001) (see table).
Administration C (mgyl)peak C yMICpeak TMIC
q8 h 21.3"0.6 5.4"0.2 1.9"0.2
q12 h 29.2"0.7 7.3"0.2 4.7"0.2
q24 h 56.7"1.3 14.2"0.3 14.7"0.3
All values are mean"SEM. Conclusion: This study suggests that the benefit of
achieving a greater peakyMIC with q 24h administration is associated with
significantly greater TMIC in CF patients compared with multiple daily dosing
regimens. Evidence supporting the use of once daily amikacin administration in CF
patients is thus limited. Supported by MSMT 111300003 and IGA MZCR 6568-3.
References:
W.A. Craig et al., Pharmacodynamics of amikacin in vitro and in mouse thigh and1
lung infections. J. Antimicrob. Chemother. 27(Suppl. C) (1991) 29–40.cp7.3,8.7
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An investigation into the synergistic effects of antibiotic combinations
used to treat cystic fibrosis lung infection
M. Tunney (Presenting), S. Kernoghan , J.S. Elborn , C. Goldsmith1 1 2 3
School of Pharmacy, Queen’s University Belfast, Belfast, United Kingdom, Adult1 2
Regional Cystic Fibrosis Unit, Belfast City Hospital, Belfast, United Kingdom,
Microbiology Department, Belfast City Hospital, Belfast, United Kingdom3
Treatment of respiratory infection caused by either Pseudomonas aeruginosa or
Burkholderia cepacia in patients with cystic fibrosis (CF) usually requires the use
of a combination of two or more empirically selected antibiotics. The aim of the
present study was to determine whether the empiric antibiotic combinations used
to treat lung infection in individual patients demonstrated synergy in vitro. The
susceptibility of six P. aeruginosa and three B. cepacia strains to a number of
antibiotics were determined and the effect of antibiotic combinations was interpreted
as synergistic, additive, indifferent or antagonistic. Lung infection in 8 of the 9
patients was treated with a combination of tobramycin and ceftazidime and synergy
testing of this combination against the bacteria isolated from these patients revealed
an indifferent effect for 2 strains, an additive effect for 2 strains and an antagonistic
effect for 4 strains. Infection with B. cepacia in the other patient was treated with
a combination of tobramycin, meropenem and chloramphenicol and synergy testing
revealed that this combination had an indifferent effect for this strain. The results
highlight the importance of using synergy testing to determine which antibiotic
combinations are synergistic prior to commencing antibiotic therapy for the treat-
ment of CF lung infection.
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Development of a colorimetric assay to evaluate tobramycin and
ceftazidime in combination against bacteria causing cystic fibrosis
lung infection
T.F. Moriarty (Presenting), M.M. Tunney , J.S. Elborn1* 1 2
School of Pharmacy, Queen’s University Belfast, Belfast, United Kingdom, Adult1 2
Regional Cystic Fibrosis Unit, Belfast City Hospital, Belfast, United Kingdom
Chronic bacterial colonisation with Pseudomonas aeruginosa and Burkholderia
cepacia and the resulting intermittent pulmonary exacerbations are the major factors
responsible for the morbidity and mortality of cystic fibrosis patients. Existing treat-
ment of pulmonary infection involves the frequent and prolonged administration of
empirically selected antibiotics, which may not be synergistic, therefore resulting
in a less than optimal outcome for the patient. Time-kill assays, which are the
preferred methods for determining antibiotic synergy (Fung-Tomc, Int. J. Antimi-
crob. Agents 20 (2002) 57–60) are time consuming and labour intensive to per-
form. In this study a rapid colorimetric time-kill assay was developed to determine
if there was synergy between ceftazidime and tobramycin, two antibiotics frequently
prescribed to treat CF lung infection. The colorimetric assay described is based on
the bio-reduction of the tetrazolium salt XTT in the presence of an electron coupling
agent, menadione. Synergy tests were performed for a number of clinical Pseudo-
monas aeruginosa and Burkholderia cepacia isolates using both conventional and
colorimetric time-kill assays. There was good correlation between the colorimetric
assay and the conventional plate count method of time-kill analysis. The colori-
metric time-kill technique is less labour intensive and results are available two hours
after sampling. The use of this rapid method to determine which antibiotic com-
binations are synergistic against bacteria isolated from patients should optimise
treatment of CF lung infection in those patients by ensuring that appropriate anti-
biotics are prescribed.
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The results of extensive antibiotic susceptibility testing of multiple
isolates of Pseudomonas aeruginosa correlate poorly with clinical
outcome in acute exacerbation of cystic fibrosis
J. Foweraker (Presenting), C. Laughton , D. Brown , E. Gunn , D. Bilton1* 1 2 3 3
Microbiology, Papworth Hospital, Cambridge, United Kingdom, Microbiology,1 2
PHLS, Cambridge, United Kingdom, Cystic Fibrosis Unit, Papworth Hospital,3
Cambridge, United Kingdom
Patients with acute exacerbation of CF may improve on antibiotics with resistant
Pseudomonas aeruginosa (PA) in sputum and can fail to respond in spite of having
fully sensitive organisms. This poor correlation may be because too few isolates
are analysed. We tested many examples of each morphotype of PA to see if the
results would predict the clinical response. Adults with CF, colonised with PA were
treated for an exacerbation for 14 days. Sputum was taken on day 0, 7 and 14.
Four colonies of each morphotype of PA were tested against 12 antibiotics. Clinical
response by day 14 was measured by change in FEV and daily sputum weight.1
Thirty-one exacerbations were studied in 21 patients, with a mean age (S.D.) of
22.7 yr (5.5) and a mean FEV % predicted of 45.9 (20.15). Most patients had1
tobramycin plus ceftazidime, aztreonam, meropenem or piperacillinytazobactam.
The average number of morphotypes of PA per sample was 4 (range 2–6) with 5.5
(2–11) antibiograms. The mode antibiograms per morphotype was 3 (2–4). If the
predominant isolate of PA was susceptible to one or both of the patient’s antibiotics,
the positive predictive value (PPV) with 95% confidence intervals for improved
FEV was 62% (43, 81) and for reduction in sputum weight was 54% (34, 74). If1
the most resistant isolate was susceptible to one or both antibiotics, the PPV was
64% (44, 84) for an increase in FEV and reduction in sputum. Three patients had1
isolates resistant to both antibiotics, but only one did not respond. The colony counts
of PA over 14 days did not change in most patients and did not correlate with
clinical response. Bacteria of the same morphotype have different antibiograms.
Resistant sub-populations can only be found by extensive testing. Even then, results
poorly predict clinical response. This is unlike any other scenario in diagnostic
microbiology and questions the role of sensitivity testing in exacerbations, using
our present methods.
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Azithromycin in plasma, blood, polymorphonuclear neutrophils and
sputum after chronic administration in CF-patients
E.B. Wilms (Presenting), D.J. Touw , H.G.M. Heijerman1 1 2
The Hague Hospital Pharmacy, The Hague, Netherlands, Pulmonology, Leyen-1 2
burg Hospital, The Hague, Netherlands
Introduction: Chronic use of Azithromycin (AZM) in CF patients is able to reduce or
stabilise clinical symptoms of airway inflammation associated with chronic infection
with Pseudomonas aeruginosa. We investigated the pharmacokinetics of (AZM) after
chronic administration in patients with CF. We therefore optimised an analytical method
for quantification of AZM in different biological matrices: plasma, blood, polymor-
phonuclear neutrophils (PMN’s) and sputum and herewith present the results of the
first subject. Methods: Patients who used AZM 500 mg od during at least 35 days
were included. During the sampling period of 10 days (240 h) AZM therapy was
stopped. At day 10 therapy was restarted. Blood samples were drawn at ts0, 1,2
3,4,6,8, 72–96 and 220–240 h after the last dose of 500 mg and 24 h sputum collec-
tions were collected at day 0, 4–5 and day 10. Blood samples were separated by mass
density separation within 1 h of collection in: blood, plasma and PMN’s. All samples
were kept at y20 8C until assay by HPLC. Results: Patient characteristics: male CF
patient 31 yr.
Table 1. Pharmacokinetic parameters of AZM after chronic dosing of 500 mg od
PRIVATE Plasma Blood PMN’s Sputum (24 h)
Cts0 h 0.102 mgyl 0.695 mgyl 193 mgyl 52 mgyl
Cmax 0.650 mgyl 1.980 mgyl 300 mgyl –
Cts74 h 0.081 mgyl 0.820 mgyl 187 mgyl 30 mgyl
Cts220 h 0.033 mgyl 0.410 mgyl 125 mgyl 27 mgyl
tmax 3 h 3 h 4 h –
T a1y2 1 h 1.8 h 2.3 h –
T b1y2 110 h 121 h 240 h –
V1 210 l 170 l 1,0 l –
V2 5800 l 1950 l 10,1 l –
Conclusion: Chronic administration of AZM 500 mg lead to high levels of AZM
in PMN’s with t of approximately 240 h. Accumulation in blood cells presumably1y2
caused the difference between plasma and blood concentration. A marked
concentration in sputum was seen in this patient, even after 10d. Compared to
kinetic data after short term (500 mg od=3d) dosing of AZM we see no difference
in plasma kinetics but a higher level of accumulation in blood and PMN’s
(Wildfeuer et al., 1994). Further pharmacokinetic studies are necessary to establish
an optimal chronic dosing schedule of AZM.
s48 Journal of Cystic Fibrosis 2 (2003) S31–S48
181
Diagnosis by neonatal screening, segregation of patients and early
airways eradication against P. aeruginosa determine a low prevalence
of P. aeruginosa chronic colonization in CF patients
G. Taccetti (Presenting), F. Festini, S. Campana, N. Ravenni, G. Mergni, S. Farina,
M.L. Cioni, T. Repetto, M. de Martino
Meyer Hospital, University of Florence, Florence, Italy
Neonatal screening improves health outcomes of CF patients in the first decade of
life. Only a few data exists about the acquisition of P. aeruginosa (PA) in patients
diagnosed by screening. Some studies indicate that PA acquisition may be accel-
erated in patients diagnosed by neonatal screening due to interaction with older CF
patients. Other studies indicate that early diagnosis and treatment may delay chronic
PA colonization. Aim: to evaluate the current prevalence of chronic PA colonization
in patients diagnosed by neonatal screening attending CF Center of Florence. Diag-
nosis by neonatal screening was confirmed by sweat test. PA cross-infection pre-
vention policy in our Center is based on patients’ segregation, according to their
microbiological status and intensive daily disinfection. Since 1992, we performed
early eradication treatment with oral ciprofloxacin and inhaled colistin at first PA
isolation. Patients were seen quarterly and microbiological investigations were per-
formed at every visit. CF patients were considered chronically colonized if PA had
been regularly detected for at least 6 months andyor if the value of precipitating
anti-PA antibodies in the serum was G2. Seventy-five patients were diagnosed by
screening from 1984 to 2001 and regularly followed-up since age 2 months. Since
1984 PA first colonization was found in 51 patients (68%), 38 of whom since 1992.
All of the latter underwent early eradication therapy, which succeeded in 29 patients
(76.3%), whereas 9 were chronically colonized. Five patients had been chronically
colonized by PA before the start of our early eradication protocol. The mean age
at chronic colonization was 66.7 months ("57.4 S.D., range 206-8). At the end of
2001 only 14 (18.6%) out of 75 patients were chronically colonized by PA (mean
age: 11.2 yr"4.7 S.D., range 18-2). Early diagnosis by screening allows a better
microbiological surveillance of CF patients, enabling chronic colonization by PA to
be delayed.
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Clearance of first isolate of Pseudomonas aeruginosa in Northern
Ireland. How successful is treatment?
B. O’Connor* (Presenting), N.-A. Henderson, J. McCaughan, A. Reid
Royal Belfast Hospital for Sick Children, Belfast, United Kingdom
Background: Pseudomonas aeruginosa(PA) is the most frequently described oppor-
tunistic pathogen in cystic fibrosis (CF), with chronic infection being associated
with reduction in lung function. Once colonised it is virtually impossible to eradi-
cate, but studies have shown that aggressive treatment of the first isolate of PA can
postpone chronic infection and therefore delay the deterioration of lung function.
Aims: To evaluate the success of clearing the first isolate of PA, using 3 months of
oral ciprofloxacin and nebulised colomycin. Methods: Information from patients
who developed a first isolate of PA between January 1998 and August 2002 were
identified using a database held in RBHSC, which contains details of all the pae-
diatric CF patients in Northern Ireland. The case notes of these patients were ret-
rospectively reviewed. Results: Thirty-five children out of 250 patients were
identified as having a first isolate of PA between January 1998 and August 2002.
Of these 5 patients were excluded. Out of the 30 patients included (13 female).
Median age at first isolate was 7 yr (range 0.5–14). Twenty-nine patients received
eradication therapy as per RBHSC protocol. Twenty-fouryTwenty-nine (82.8%)
treated were successfully cleared. By September 2002, 13 patients remained clear,
6 had further isolates of PA but are currently clear and 11 patients are deemed
chronically colonised. The median length of time to treatment was 10.5 days (range
2–49). Twenty-three (79.3%) were treated within 2 weeks. There was no relation-
ship between length of time to treatment and success of clearance. Conclusion: The
majority of patients with first isolate of PA were prevented from becoming chron-
ically colonised during this study period, using the anti-pseudomonal protocol cur-
rently used in RBHSC.
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Two-year azithromycin treatment in cystic fibrosis patients
M. Cipolli (Presenting), L. Zanolla , D. Trevisanello , G. Cazzola1 2 1 1
Cystic Fibrosis Center, Ospedale Civile Maggiore, Verona, Italy, Cardiology1 2
Department, Ospedale Civile Maggiore, Verona, Italy
Recent controlled azithromycin (AZM) trials in CF patients showed over a 3–6
month period a significant clinical efficacy. Aim of this study was to evaluate
clinical results of AZM in CF patients over a two-year period. Ten CF patients (2
male, mean age: 22.7yr"11.3 S.D.; R: 10.5–40.1 yr) were treated with AZM (500
mg daily, three days a week) for two years. A control group of 10 CF patients (4
male, mean age: 22.3yr"10.8 S.D.; R: 9.8–38.6), was matched for age, P. aeru-
ginosa colonization and respiratory function (FEV 58.3"12.7% predicted and1
65.0"26.4 for AZM and control groups, respectively, p ns). The trend of pulmonary
function (three measurements per year) was studied in both groups for one year
before and during AZM treatment. IV antibiotic courses, persistence of P. aerugi-
nosa and BMI were recorded before and after treatment. In a case-control analysis
there were no significant differences in time per treatment interaction (repeated
measures ANOVA) for CVF, FEV , BMI. However, when the AZM group data1
were computed separately, an improvement in CVF, FEV and BMI was found.1
During treatment CVF increased 11.8% (P 0.004), FEV 7% (P 0.02) and BMI1
4.1% (P 0.02) respect the year before. No improvement was seen in CVF, FEV1
and BMI in the control group. Fewer IV antibiotics were needed during treatment
in the AZM patients vs. the year before (0.8ypt vs. 3ypt; P 0.003). Neither bac-
teriological, nor liver enzyme modifications were recorded in either group. No
adverse events were recorded. Long-term AZM treatment in CF patients does not
seem to modify pulmonary function deterioration in a case control study. This could
be linked to insufficient sample size, as suggested by the fact that the AZM group
on its own did show a significant increase in CVF, FEV and BMI over treatment.1
Moreover the number of IV antibiotic courses decreases in AZM patients.
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Flow measurements in the main pulmonary artery of patients with
cystic fibrosis (CF) using magnetic resonance imaging (MRI)
N. Abolmaali (Presenting), C. Smaczny , H.G. Posselt , C. von Mallinckrodt ,1 2 3 3
T.O.F. Wagner , T. Wolf , T.J. Vogl3 3 3
JW Goethe University, Frankfurt am Main, Germany, Department for Pulmon-1 2
ology and Allergology, JW Goethe University, Frankfurt am Main, Germany,
Department for paediatric medicine, JW Goethe University, Frankfurt am Main,3
Germany
Introduction: Development of a pulmonary arterial hypertension (PAH) is a com-
mon result of CF. This study was performed to evaluate MRI based flow measure-
ments to detect signs of an evolving PAH in patients suffering from CF. Material
and methods: Forty-two patients (median age: 16 yr, range: 9–39 yr) suffering from
CF of different severity (mean FEV : 74.3%"23.7) were examined using MRI1
based flow measurements (in-room-time: approx. 12 min). ECG-triggered flow data
were acquired over the entire cardiac cycle with a high temporal resolution of 10
ms. Flow profile analysis revealed a variety of different information. The assessed
data, especially the acceleration times (AT, (ms)) and the mean blood velocities
during systole (MV, (cmys)) were compared to an age-matched group of 35 healthy
subjects. Results: In healthy subjects the mean AT was 131 ms"14 and the mean
MV was 65 cmys"14. The CF-patients exhibited a mean AT of 125 ms"22 and
a mean MV of 58 cmys"12. Four patients revealed noticeably lower values for
the mean AT (80 ms"10) and the mean MV (45 cmys"12). The mean cardiac
output was 6.3 lymin in the healthy subjects, 6.1 lymin in CF patients and 4.8 ly
min in the four selected individuals. Conclusion: Signs for the development of a
PAH (i.e. reduction of AT and MV) are detectable using MRI based flow meas-
urements. This technique could be a valuable screening tool for CF patients to
identify the development of a PAH.
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Electrocardiography as a marker of pulmonary hypertension and right
ventricular function in adults with cystic fibrosis
R.J. Bright-Thomas (Presenting), M.I. Burgess , M.E. Dodd , S.G. Ray , A.K.1 2 1 2
Webb1
Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals1
NHS Trust, Manchester, United Kingdom, Department of Cardiology, South Man-2
chester University Hospitals NHS Trust, Manchester, United Kingdom
Introduction: Pulmonary hypertension (PH) and right ventricular (RV) dysfunction
occur in patients with CF, but little is known about the relationship between ech-
ocardiographic features and ECG changes in this setting. Methods: Adult patients
were studied prospectively using transthoracic echocardiography and ECG. Pul-
monary artery systolic pressure (sPAP) was measured from the peak velocity of
tricuspid regurgitant jets. RV function was assessed by measuring systolic, diastolic
and global RV function parameters. ECG was performed at the time of echocar-
diography, but analysed independently. Patients were divided into group A (normal
ECG) and group B (ECG indicative of RV dysfunction-right axis deviation, RV
hypertrophy, p pulmonale, right bundle branch block or combination of these).
Results: 109 CF patients (63 male) age 27.1(7.7) yr were studied. Eighty-two
patients were in group A and 24 in group B. Three patients with other ECG abnor-
malities were excluded from analysis. Patients in group B had a higher
sPAP(mmHg) 42.2(13) vs. 32.0(6) (ps0.01), lower FEV % predicted 35.2(17.7)1
vs. 54.8(21.4) (P-0.001) and lower partial pressure of oxygen (mmHg)
63.0(12.1) vs. 72.1(10.1) (P-0.001). RV dimensions were similar between groups,
but group B had reduced TLAM(cm) 1.94(0.44) vs. 2.15(0.38) (Ps0.03), reduced
EyA ratio 1.17(0.34) vs. 1.53(0.48) (P-0.001) and raised RVIMP 0.41(0.15) vs.
0.35(0.12) (Ps0.03) consistent with more deranged RV systolic, diastolic and
global function. The sensitivity of ECG abnormalities to detect patients with sPAP)
s35 mmHg was 34%, specificity was 89% and positive predictive value was 67%.
Conclusion: A significant proportion of CF patients with echocardiographic evi-
dence of raised pulmonary artery pressure or RV dysfunction have ECG findings
indicative of RV dysfunction. Although not sensitive, the specificity and positive
predictive value makes ECG an essential tool when considering the possibility of
PH or RV dysfunction in these patients.
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Clinical correlates of pulmonary artery pressure in adults with cystic
fibrosis
R.J. Bright-Thomas (Presenting), M.I. Burgess , M.E. Dodd , S.G. Ray , A.K.1* 2 1 2
Webb1
Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospitals1
NHS Trust, Manchester, United Kingdom, Department of Cardiology, South Man-2
chester University Hospitals NHS Trust, Manchester, United Kingdom
Background: This study set out to evaluate pulmonary artery pressure and its asso-
ciation with clinical variables and oxygen status in adults with CF. Methods: A
cross-section of adult CF patients attending a large regional centre and healthy
volunteers were studied. Patients were stable at the time of study. Demographic and
clinical data were collected. All subjects underwent a transthoracic 2D and Doppler
echocardiographic examination by a trained operator (RBT). Pulmonary artery sys-
tolic pressure (sPAP) was measured from the peak velocity of tricuspid regurgitant
(TR) jets. Results: 109 CF adults (63 male) age, mean(S.D.), 27.1(7.7) yr and 50
healthy controls (25 male) age 27.0(7.5) yr were studied. Partial pressure of oxygen
(PO )(mmHg) 70.2(11.1) CF vs. 91.0(9.0) controls (P-0.001), FEV percentage2 1
predicted (FEV %) 50.3(22.0) vs. 100.2(10.4) (P-0.001), BMI 20.6(2.9) vs.1
23.4(3.3) (P-0.001), CRP(mgyl), median(range), 5.0(0–237) vs. 0(0–47). Sev-
enty seven patients (70.8%) and 39 controls (78.0%) had analysable TR.
sPAP(mmHg) was 33.9(8.9) in CF patients and 23.3(4.2) in controls (P-0.001).
sPAP was increased ()35 mmHg) in 29 patients and 1 control (P-0.001).
Patient’s sPAP(mmHg) increased significantly with increasing disease severity
(classified according to FEV %): Mild (FEV % )60) 28.1(4.84), moderate1 1
(FEV % 40–60) 34.0(5.7), severe (FEV % -40) 41.3(10.3). Analysis of clinical1 1
characteristics found no association between sPAP and CF related diabetes, liver
disease, sputum colonisation or CF genotype, but identified strong correlations
between sPAP and PO (rsy0.685, P-0.001), and FEV % (rsy0.607, P-2 1
0.001). Significant, but weaker correlations were found between sPAP and BMI
(rsy0.291, Ps0.01) and C-reactive protein levels (rs0.278, Ps0.02). Conclu-
sion: Pulmonary artery pressure is raised in CF adults with relatively mild disease
and rises further as disease progresses. sPAP is correlated with oxygen status,
FEV % and surrogate markers of disease severity.1
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Pneumothorax complicating cystic fibrosis: management dilemmas
H.J. Curtis(Presenting), S.J. Bourke, A.D. Gascoigne
Newcastle upon Tyne, United Kingdom
Pneumothorax (PTX) is a common complication of cystic fibrosis (CF), increasing
with age and deteriorating lung function, with a 19% incidence in adult male CF
patients. Optimal management of PTX is often debated. We retrospectively reviewed
the patients attending the Newcastle Adult CF Centre to establish our incidence of
PTX, the subsequent management and outcome. 143 patients were reviewed; the
130 current attendees and 13 recently deceased. 13 have a history of PTX, 3 with
recurrent problems, resulting in 20 PTX episodes. These patients had severe CF
disease: 75% had a FEV -30% predicted; 85% had Pseudomonas aeruginosa in1
sputum; 75% had an indwelling line for regular intravenous antibiotics; median
BMI was 16 and 50% were receiving supplemental PEG feeding. 3 episodes of
PTX were iatrogenic (porta-cath insertion). The management varied greatly, both
in invasiveness and success rates. Conservative management for asymptomatic PTX
was 100% successful (ns7). Symptomatic episodes were often initially managed
with aspiration, however this was never successful and all required further invasive
procedures (ns3). Although a chest drain was initially successful, if the drain was
removed without medical pleurodesis there was a 100% recurrence rate, with pleu-
rodesis this dropped to 20%. Iatrogenic PTX were successfully treated with chest
drain alone. 3 patients have subsequently been transplanted and 1 remains on the
waiting list. Three patients have died one as a consequence of PTX. Our experience
shows that PTX is a complex problem for patient and physician. Although survival
statistics improve for CF, PTX remains a significant cause of morbidity and mor-
tality. The occurrence of PTX may precipitate a crisis during palliative care of end-
stage CF; alternatively adequate intervention to control a PTX may compromise
future lung transplantation in fitter patients. These extremes highlight the difficult
management choices, and may explain the varying practices.
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Management of pneumothorax in cystic fibrosis and the effect on lung
transplantation outcome
H. Curtis (Presenting), S.J. Bourke , P.A. Corris , J.H. Dark1 2 3 3
Adult Cystic Fibrosis Unit, Durham, United Kingdom, Adult Cystic Fibrosis Unit,1 2
Newcastle upon Tyne, United Kingdom, Cardiothoracic Centre, Newcastle upon3
Tyne, United Kingdom
High post-operative mortality secondary to haemorrhage from pleural adhesions was
reported in the early experience of lung transplantation (LT). This observation led
to previous pleural procedures (PPP) becoming a relativeyabsolute contra-indication
to transplantation in some centres. Has this lead to a more conservative approach
to pneumothorax (PTX) management in patients with Cystic fibrosis (CF)? And
what is the effect of PPP on surgical outcome of LT? We reviewed 3 groups of LT
patients. Group A: 17 CF patients with a previous PTX"PPP. Group B: 17 CF
patients with no history of PTX. Group C: 17 non-CFynon-bronchiectatic patients
with no history of PTX. Main outcome measures: intra-operative blood products;
pleural adhesions at operation; operation and cardio-pulmonary bypass times; post-
op haemorrhage; times to extubation, ITU discharge and hospital discharge and 30
day mortality. Pneumothorax: There were 37 PTX episodes in the 17 group A
patients requiring 28 chest drains. Only 2 patients received medical pleurodesis and
only 2 underwent surgical intervention. Lung transplantation: Packed red cells
transfused intra-operatively showed a small, but significant increase for group A
(P-0.05). Pleural adhesions found at operation were significantly more in group
A, with dense adhesions found only in A (P-0.05). Group C was significantly
more likely to be free from adhesions, with 13 patients clear compared to 7 in B
and 1 in A (P-0.01). Other outcomes showed no significant difference. Patients
with CF and previous PTX"PPP undergoing LT have more pleural adhesions and
higher requirement for transfusion. This does not significantly affect surgical out-
come. Patients with non-CFynon-bronchiectatic were significantly more likely to
be free of adhesions at LT—suggesting that the inflammatoryyinfective component
of CF independently contributes to the increased pleural adhesions. PPP for PTX
should not be considered a contra-indication for LT.
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Transient adrenal insufficiency and growth impairment in cystic
fibrosis patients treated with inhaled and intranasal steroids
V. Pasquasy (Presenting), J.-E. Marcotte , G. Lapierre , M.-C. Quintal1 2 1 2
Pediatric Pulmonology, Hopital Sainte-Justine, Montreal, Canada, ENT, Hopital1 2ˆ ´ ˆ
Sainte-Justine, Montreal, Canada´
Introduction: Transient adrenal insufficiency and inhibition of growth secondary to
inhaled or nasal steroids have been described in patients with asthma or allergic
rhinitis. In CF patients, nasal polyps and bronchial hyperreactivity are common.
Therefore, they are often treated with inhaled andyor intranasal steroids for long
period of time. The possibility of hypothalamic-pituitary-adrenal suppression by
these exogenous steroids and their contribution to growth impairment should be
considered. Patients we report a serie of 5 patients with CF aged 4 to 14 yr (2
females and 3 males) investigated for growth failure in 2001 and 2002. They were
all treated by inhaled fluticasone 250 to 500 mgyday for at least 3 yr. They also
received intranasal fluticasone 100 to 200 mgyday or triamcinolone 200 to 400 mgy
day for a similar duration. Three of them had cushingoid appearance. Results:
Patients showed 8 am serum cortisol concentrations -15 nmolyl or cortisol
response -550 nmolyl 30 min after 1 mg of intravenous synthetic ACTH. There
was recuperation after weaning the exogenous steroids. Conclusions: This serie of
cases illustrates the occurrence of transient adrenal suppression in 5 CF patients
treated by inhaled and intranasal steroids. These patients showed growth impairment
whose etiology could be multifactorial in CF. Poor growth is often associated with
a poor caloric intake or insufficient enzymes dose. Failure to thrive can also be
explained by the pulmonary disease. However, the hypothesis of growth suppression
by inhaled and intranasal steroids should always be kept in mind and investigated
in CF children or adolescents patients.
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The contribution of HRCT to the management of cystic fibrosis patients
M. Fotoulaki (Presenting), F. Charitandi , C. Kouskouras , A. Dimitriadis , S. Nou-1 2 2 2
sia-Arvanitakis1
4th Department of Pediatrics, Aristotle University, Thessaloniki, Greece, Radiol-1 2
ogy Department, Aristotle University, Thessaloniki, Greece
The aim of the study was to investigate the bronchopathology of cystic fibrosis(CF)
patients before and after therapy of pulmonary exacerbations. Material and Meth-
ods: Thirteen CF patients (7 male and 6 female) having an age range of 16 to 26
(mean 21.15"3.64) yr, were included in the study. All the patients had acute pul-
monary exacerbation as indicated by clinical manifestations, leucocytosis with
increased neutrophils, increased C-reactive protein and deterioration of respiratory
function. High Resolution Computed Tomography (HRCT) of the lung(1.5 mm
slice thickness and 10 mm gaps-in deep inspiration and selective scans in expira-
tion) was performed on admission.The following parameters were examined: bron-
chiectasis(severity and extent) mucous plugging, thickening of the bronchial wall,
emphysema, atelectasis-consolidation, saccular bronchiectasis-abscesses, ground
glass appearance, tree-in-bud sign, bullae, thickening of interlobular septae and
mosaic perfusion. According to the severity and the distribution of the pulmonary
lesions, a score of 0 to 20 was calculated where 0 represented no pathology and
20 severe findings. HRCT was repeated after a 14-day course of antibiotic therapy,
which was discontinued or continued for another 7 days according to the findings.
Results: HRCT score was 10.69"1.97 on admission and 8.46"2.40 post-treatment
(Ps0.016). HRCT score improvement was attributed to the changes of mucous
plugging and atelectasis-consolidation. Conclusion: HRCT may recognize reversible
lung lesions and contribute to the appropriate length of management.
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Frequency of allergic bronchopulmonary aspergillosis among Greek
CF patients
S. Doudounakis(Presenting), I. Loukou, M. Liatsis, I. Inglezos, M. Kanariou, G.
Adam
‘Agia Sophia’ Children’s Hospital, Athens, Greece
Introduction: Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease
resulting from the hypersensitivity response to Aspergillus fumigatus. Diagnosis of
ABPA in cystic fibrosis (CF) patients is difficult due to the overlapping clinical,
radiographic and immunological findings. The frequency of ABPA in CF reported
from various centers varies significantly. In this study, we estimated the prevalence
of ABPA in Greek CF patients and studied their characteristics as related to ABPA.
Patients and Methods: Records of 414 CF patients attending regularly the main CF
clinic in Athens were retrospectively examined. Rast for Af as well as measurements
of total IgE and blood eosinophiles were performed at least once per year for each
patient. Results: ABPA was diagnosed in 12 (2.9%) patients (9 males) by the classic
criteria as defined by Rosenberg et al. At the time of diagnosis, the mean age of
the patients was 8 yr (range 1.5–27 yr) and the mean FEV was 73% (range 59–1
81%). All had been colonized with Pseudomonas aeruginosa. Sensitivity to various
allergens other that Af had been confirmed in three of the 12 patients. Two of the
ABPA patients exhibited bronchial hypereactivity to inhaled antibiotics. Conclu-
sions: Frequency of ABPA in Greek CF patients appeared to be low as compared
with frequencies reported in other European countries. Comparison of the ABPA
patients with the rest CF population indicated that occurrence of ABPA was asso-
ciated with allergy and colonization with Pseudomonas.
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International air travel in cystic fibrosis patients with advanced lung
disease
J. Rendall (Presenting), K. Clapperton , J. McCarthy , A.E. Woods , J. Dark , C.G.1 1 1 1 2
Gallagher , J.J. Egan3 1
HeartyLung Transplant Unit, Mater Misericordiae Hospital, Dublin, Ireland,1
HeartyLung Transplant Unit, Freeman Hospital, Newcastle, United Kingdom, CF2 3
Unit, St. Vincent’s University Hospital, Dublin, Ireland
Controversy exits as to the specific criteria, which allows or prevents patients with
lung disease availing of air transport. We present data on cytic fibrosis patients with
advanced lung disease and their outcome following air travel, based on the need
for lung transplantation. In 1999, an international collaboration with the aim of
initiating a lung transplant programme in the Republic of Ireland was initiated in
partnership with the Freeman Hospital, Newcastle, UK. Patients with CF required
air transport to achieve (a) assessment for lung transplantation and (b) urgent trans-
fer to undergo lung transplantation. No patient underwent a hypoxic challenge test.
Oxygen was administered according to routine clinical assessment for oxygen ther-
apy. Patients travelling for assessment were transported in either a commercial 4
engine jet aircraft with a pressurised cabin, at an altitude of 26 000 ft, or a 2 engine
turbo prop jet stream aircraft, at an altitude of 18 000 ft, (ns55, mean age 22,
mean FEV 0.9 L, mean% predicted FEV1 25%, mean PO 9.0 kPa, mean air time1 2
travel 79 min). One patient experienced a spontaneous pneumothorax. Patients
undergoing transplantation were transported via air ambulance, twin engined,
unpressurised aircraft, mean altitude 3 000 ft, (ns13, mean FEV 0.89 l, mean%1
predicted FEV 20.8%, mean PO 8.05 kPa). In conclusion air travel can be under-1 2
taken safely in controlled circumstances in patients with CF with advanced lung
disease.
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Functional status of an adult CF population
L. Lannefors(Presenting), U. Dennersten, L. Eriksson, L. Mared
Lund CF-centre, Department of Respiratory Medicine, Lund, Sweden
The adult part of Lund CF-centre sees all known CF adults in southern Sweden;
69 patients 18–53 yr old. 52% are homozygous and 39% heterozygous for
deltaF508. 84% are pancreatic insufficient, using pancrease enzymes. All parts of
the treatment are in accordance with international guidelines. Individually, adapted
airway clearance programmes and optimised inhalation strategy is focused upon.
Physical exercise and adherence to daily treatment are emphasised. Summary of last
year’s results: The adult population is now larger than the pediatric in the same
area. BMI 22 (17–27), 51% was colonised with Pseudomonas aeruginosa.
Median %p Range
TLC 106 84–151
RV 135 70–284
FRC 120 68–208
VC 94 46–140
FEV1.0 78 23–129
WC 91 44–146
Functional status in our population using our treatment approach with emphasis on
active therapy and physical exercise is good.
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The antinflammatory effect of clarithromycin in CF
S. Sriram (Presenting), J. Young , J.C. Waterhouse , C.E. Bucknall, B.H.R.1 2 3
Stack2
North Glasgow University NHS Trust, Glasgow, United Kingdom, West of Scot-1 2
land Adult CF Centre, Glasgow, United Kingdom, Royal Hallamshire Hospital,3
Sheffield, United Kingdom
Introduction: The role of Azithromycin as an antinflammatory agent in CF has been
established, but the role of other macrolides has not yet been fully explored. Aim:
To assess the possible antinflammatory effect of Clarithromycin in CF with a double
blind randomised control study protocol in Adult CF Patients. Method:- Written
consent was obtained from 22 patients aged 16 yr and above who were colonised
with Pseudomonas aeruginosa.They had pulmonary fuction tests and weight meas-
ured, blood taken for white cell count, CRP and completed a SF 36 question-
naire.They received either modified release Clarithromycin 500 mg once daily or
matched placebo for 3 months and all baseline estimations repeated. They were
then invited to enter the open label phase with active drug for 3 more months.
Results: 17 patients(Ms9, mean age 32.4, range 17–48 yr) completed the study
and 9 entered the open label phase. Analysis of active vs. placebo group for absolute
change in weight percentage predicted FEv, WCC, CRP Sf 36 questionnaire showed
no significant difference at baseline and 3 months. Mean weight gain was 0.7 kg
(96y11 patients) at 3 months and 2 kg(3y6 patients) at 6 months in those on active
Clarithromycin. Conclusion: The study proved no benefit due to insufficient
patients, but may be viewed as a favourable pilot study and Clarithromycin was
well tolerated.
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Diagnosing allergic bronchopulmonary aspergillosis (ABPA) in cystic
fibrosis (CF) by detecting Aspergillus spp. in serum by polymerase
chain reaction (PCR)
A. Verma (Presenting), B. Isalska , A. Fox , A.K. Webb1 2 3 4
South Manchester University Hospital Trust, Manchester, United Kingdom,1
Department of Microbiology, Wythenshawe Hospital, Manchester, United King-2
dom, Department of Microbiology, Manchester Royal Infirmary, Manchester, Unit-3
ed Kingdom, Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital,4
Manchester, United Kingdom
Introduction: Diagnosis of ABPA is difficult in the CF population. Several studies
have shown the value of IgE, RAST to Aspergillus (RAST), IgG and peripheral
eosinophilia. No studies have used PCR to detect Aspergillus in the serum as a
marker of ABPA. The aim of the study was to evaluate the use of PCR in the
diagnosis of ABPA. Methods: Thirty CF patients were recruited for the trial and
divided into 3 groups. Group A had typical ABPA (clinical manifestation, raised
IgE and RAST), Group B had a raised IgE and RAST levels, but no clinical man-
ifestations and Group C had no clinical manifestations and no raised IgEyRAST.
Patients serum and sputum were taken for PCR, IgE and G, RAST, Aspergillus
precipitins and eosinophil count. Patients spirometry, height, weight and treatment
were recorded. Results: There were 7 patients in Group A, 12 in Group B and 11
in Group C. There was no significant difference between the groups for spirometry,
height and weight. Groups A and B had higher IgEyRAST levels than Group C
(P-0.01) and there was no difference between Groups A and B (Ps0.2). There
were no PCR positive patients in any of the 3 groups, however, 5 of the 7 patients
in group A were receiving Itraconazole andyor oral prednisolone for treatment of
their ABPA. Conclusion: In this study serum PCR has no role in diagnosing ABPA,
but a larger controlled study is required to fully evaluate its role.
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The role of selenium on lung function in adult CF patients
S. Pour Schahin (Presenting), S. Lampert , F.S. Fuchs , G.H. Wiest , M.1 1 1 1
Messner , E.G. Hahn , J.H. Ficker2 1 1
Department of Internal Medicine 1, University of Erlangen, Erlangen, Germany,1
Department of Anesthesiology, University of Erlangen, Erlangen, Germany2
Introduction: The trace mineral selenium is essential for many redox-enzymes.
These enzymes are needed e.g. to protect lung tissues from oxidative stress. We
hypothesised that in CF patients there might to be a chronic selenium deficiency
due to intestinal selenium malabsorption. This selenium deficiency might result in
reduced antioxidative activity of selenium dependent redox-enzymes, which again
might contribute to accelerated deterioration of lung function. With this in mind
we studied whether there is a correlation between deterioration of lung function and
blood selenium concentration in adult CF patients. Methods: Selenium concentra-
tions were measured in full blood samples in 17 outpatient CF patients (median
age 33 yr SD 7.3; 12 male, 5 female) and were compared to previously published
reference values (‘normal’: 162–85 mmolyl, ‘low’: 40–80 mmolyl, ‘very low’: -
40 mmolyl). The actual FEV was compared to the first FEV measurement vailable1 1
in the records of the individual patient. For all individuals the rate of deterioration
in lung function was calculated as the mean change in FEV per month over this1
period. Results: All 17 patients showed ‘low’ selenium concentrations (mean 57.7
mmolyl, S.D. 15.9). The mean change in FEV per month was inversely correlated1
with blood selenium levels (Spearmans rsy0.44; Ps0.04). Discussion: All
patients had ‘low’ blood selenium levels when compared to previously published
normal values. In this small study population low selenium levels were associated
with accelerated deterioration of lung function. Further investigations are needed to
confirm these findings. Rayman M: The importance of selenium to human health,
Lancet 356 (2000) 233–241. Anstwurm M: Selenium replacement in patients with
severe systemic inflammatory response syndrom improves clinical outcome, Crit
Care Med. 27(9) (1999) 1807–1813)
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Is tidal breathing analysis (Tpef%Te) useful for detection of airflow
obstruction in children with cystic fibrosis?
S. Filtchev(Presenting), A. Kufardjieva, T. Stoeva, I. Kalev
Clinic of Pediatrics, Alexandrovska University Hospital, Sofia, Sofia, Bulgaria
The aim of the study was to assess the validity of tidal breathing (TB) parameter
such as Tpef%Te (percent ratio of time to reach peak tidal expiratory flow to the
total expiratory time) for detecting airway obstruction in children with cystic fibro-
sis (CF). For TB analysis we used an on-line computer analysis program (Master-
screen, Jaeger). TB and forced expiratory patterns were analysed in 61 healthy
controls and 27 children with (CF) (aged 7–18 yr). The two groups differed sig-
nificantly in forced expiratory volume in 1 second (FEV as percent of predicted,1
mean"SD) (FEV : 118.4"14.6% in controls and 63.9"17.2% in CF patients).1
The Tpef%Te did not differ among groups (Tpef%Te: 34.6"11.6% in controls and
34.2"13.3% in CF patients). Tpef%Te ratios did not correlate with any of anthro-
pometrical parameters in controls (rs0.087 with height) nor with forced expiratory
flow values in children with CF (rs0.211 with FEV ). Children with CF underwent1
measurements before and after bronchodilation with albuterol (FEV 74.4"11.8%1
and Tpef%Te 33.6"10.6% after bronchodilation) (P-0.05 for FEV and non-1
significant for Tpef%Te). We conclude that TB parameter Tpef%Te is highly var-
iable and is not sensitive enough for detecting airway obstruction in children with
CF.
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The rate of change in pre-antibiotic FEV vs. change in post-antibiotic1
FEV as a predictor of outcome of respiratory disease – a cohort study1
S. Javadpour (Presenting), T. Lee , K. Brownlee1 2 2
Respiratory paediatrics Liverpool, United Kingdom, Leeds, United Kingdom1 2
Objectives: The purpose of this study was to investigate the hypothesis that forced
expiratory volume in one second (FEV ) measured prior to the commencement of1
antibiotic therapy was a more sensitive indicator of decline in lung function than
the FEV measured at the end of therapy. Methods: The study cohort consisted of1
54 children receiving full care at the regional St. James’ Hospital cystic fibrosis
unit between 1993 and 1999. FEV pre and post-antibiotic therapy were recorded1
at least annually. The children were divided into five subgroups for analysis; sur-
vived, received lung transplant, died, received lung transplant or died and those
with an FEV -50% at the commencement of the study. Non-parametric t-tests1
and 95% confidence intervals were calculated to detect statistically significant
changes. Results: The absolute decline in FEV was most marked in the children1
who died (y29.5%) while the survivors showed little change in FEV measure-1
ments (y3.2%) over the study period. There was no statistically significant dif-
ference in the rate of decline in FEV measurement pre or post antibiotic therapy1
when the group was looked at as a whole or in subgroups. However, in the subgroup
whose FEV pre-antibiotic therapy at the commencement of the study was -50%1
the rate of decline was three times greater per annum for the FEV pre-antibiotic1
therapy (y3.0% predicted per annum) when compared with the FEV post-anti-1
biotic therapy (y0.8% predicted per annum). This trend was not statistically sig-
nificant. Conclusion: This study failed to show that the measurement of FEV1
pre-antibiotic therapy was a more sensitive indicator of decline in respiratory func-
tion when compared to the FEV post-antibiotic therapy in children with cystic1
fibrosis. It did however, show a trend in children whose FEV is less than 50%1
predicted. This observation warrants further investigation.
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Acquisition and persistence of Pseudomonas aeruginosa: it’s effect on
respiratory function and exercise tolerance in the child with cystic
fibrosis
L. Morrison(Presenting), S.P. Conway, K.G. Brownlee
Adult Regional CF Unit, Leeds, United Kingdom1
Chronic infection with P. aeruginosa and its progression to the mucoid variant is
associated with deterioration in clinical status and respiratory function. It is recog-
nised that a decline in exercise tolerance is linked to deteriorating respiratory func-
tion and has a significant influence on activities of daily living and quality of life.
Formal testing of exercise (using the modified shuttle test), respiratory function
and perceived breathlessness were carried out in 53 children (8–16 yr, mean age
11.1) who had been grouped according to P. aeruginosa status, (ranging from no
infection through to infection with the mucoid variant). Using correlation studies
the data were analysed to determine the possible relationship between the variables
of interest. Despite a tendency for exercise tolerance to decline in accordance with
deteriorating P. aeruginosa status this was not statistically significant (rsy0.111,
Ps0.430). A correlation existed between the Shwachman score and respiratory
function, exercise tolerance and P. aeruginosa status (rs0.430, P-0.0005; rs
0.339, Ps0.013; and rsy0.522, P-0.0005, respectively). Following the test, the
mean change in perceived breathlessness was significant, which suggests the chil-
dren felt they had reached their maximum exercise capacity. The lack of a significant
relationship between exercise scores and P. aeruginosa status may be due to the
small numbers within each specific P. aeruginosa group, reflecting the intensive
management of P. aeruginosa infection that this population has received. By rapid,
aggressive treatment of initial isolates of P. aeruginosa, we may significantly reduce
the numbers of individuals becoming chronically infected with P. aeruginosa thus
potentially preserving respiratory function, exercise tolerance and consequently
quality of life.
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Longitudinal follow up of pulmonary function before and after transfer
of patients from pediatric to adult care at Medical School Hannover
M. Heilmann (Presenting), M. AbdelHamid , C. Lehmann , S. Junge , M.1 1 1 2
Ballmann2
Respiratory and Critical Care Medicine, Medizinische Hochschule Hannover, Han-1
nover, Germany, Pediatrics, Medizinische Hochschule Hannover, Hannover,2
Germany
Introduction: During adolescence and early adulthood many factors influence disease progress.
The aim of this study was to analyse whether CF patients entering a transition programm at
Hannover Medical School between 1992 and 2002 had significant different changes of lung
function deterioration before and after transition to the adult CF center. Treatment changes
regarding antipseudomonal treatment were also evaluated. The transition program started 1992
and since than all patients older than 18 yr moved to the adult CF unit. The same treatment
strategies were used as published in a common CF-manual. Methods: All patients who attend-
ed the pediatric and adult CF Center continuosly between the age of 16 and 21 were included
in the study. A retrospective chart analyses provided information about clinical status, number
of visits and antipseudomonal treatments. Results: 50 patients were seen continuosly at both
centers. Mean number of visits increased from 3.7 with 16 yr to 4.42 with 21 yr, as well as
days of intravenous antipseudomonal treatment from 10.7 days with age 16 to maximum of
29.9 days with age 19. Lung function deteriorated from 74"22.9 to 61.2"27.9% FEV1
predicted within 5 yr (table 1). Neither the individual delta of lung function deterioration nor
the relative lung function change did differ significantly between the age span of 16–18 yr
and 19–21 yr (P)0.5). The mean annual decrease in FEV % pred. was 2.9%. Conclusion:1
Entering the transition program for adult CF patients from Hannover Pedriatic to Adult CF
Center did not reduce the frequency of center visits or antipseudomonal treatments. The
individual delta of decrease in lung function remained unchanged. Careful transition with
well-defined treatment goals identical between pediatric and adult care does not interrupt
previous treatment strategies.
Age 16 17 18 19 20 21
Number of center
visits
3.7 3.9 41 4.5 4.3 4.4
Days of i.v. therapy 14.1"15.6 19.7"17.4 25.1"19.7 28.2"30.2 26.3"16.5 24.6"17.1
Decrease of FEV1 age 16–18
7.15"12.5
age 19
4.07"17.4
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Differences in lung function, growth parameters and frequency of
hospital admissions between adolescents with cystic fibrosis related
diabetes and controls
A. Matson (Presenting), S. McMahon , S. Bell , J. Batch , P. Francis1 2 3 2 4
The Prince Charles Hospital, Brisbane, Australia, Endocrinology, The Royal Chil-1 2
dren’s Hospital, Brisbane, Australia, Adult Cystic Fibrosis Unit, The Prince3
Charles Hospital, Brisbane, Australia, The Royal Childrens Hospital, Brisbane,4
Australia
As survival of patients with CF increases, glucose intolerance and cystic fibrosis-
related diabetes (CFRD), are increasingly recognised common complications.
CFRD may be preceded by a pre-diabetic state. Using markers identified as being
associated with CFRD may improve targeted screening. Aim: To identify features
consistently predicting CFRD in paediatric patients. Patients diagnosed with CFRD
between January 1997–January 2002 were compared with age and sex matched
controls. Clinical, microbiological, and hospitalisation data was collected at time of
CFRD diagnosis, and at six monthly intervals for 3 yr prior to diagnosis. Eight
patients with CFRD were identified, mean age 13.7 yr (S.D. 3.49) at time of diag-
nosis. Control patients underwent OGTT to ensure normal glucose tolerance.
Patients with CFRD had a lower FEV up to 12 months prior to diagnosis however,1
this was only significant at diagnosis. There was no difference in weight and height
z scores between the 2 groups; however, the decrease in weight and height z scores
in the CFRD group over 3 yr prior to diagnosis was significant. Mean number of
days in hospital and admissions per patient significantly increased in the CFRD
group, 6 months prior to diagnosis. No other significant differences were observed
between the 2 groups. Conclusions: This study has shown a difference in lung
function, growth parameters and frequency of hospital admissions between patients
with CFRD and controls. These differences may be utilised as tools for targeted
screening in the paediatricyadolescent population. Further larger scale studies are
required to improve guidelines for targeted screening in this population.
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Hyperreactivity in children with cystic fibrosis
N. Efimova (Presenting), L. Jelenina , T. Gembitskaya1 1
Institute of Pulmonogy of the St-Petersburg’s State Medical University, Saint-
Petersburg, Russia
Introduction: Hyperreactivity is the most important factor, which aggravates the
obstructive syndrome in cystic fibrosis. Aim: We evaluated the level of hyperreac-
tivity with different courses of respiratory syndrome in cystic fibrosis. Methods: We
studied 18 patients aged from 7 to 13 yr and carried out bronchoprovocation tests
with methacholine and histamine on medical device Provotest-2 by ‘Jaeger’ firm.
We defined the degree of hyperreactivity by falling FEV on 20% during the inhal-1
ing different volumes of histamine and methacholine in various concentrations.
Bacterial analyses were performed on all cases. Results: All 18 patients had hyper-
reactivity of bronchial tree. The highest degree was detected in patients with gen-
otype delF508ydelF508 (100%). Frequency of P. aeruginosa infection was 100%
in patients with high degree of hyperreactivity, 62.5% – in average, 25% – in low
degree.
Degree of hyperreactivity
High (%) Average (%) Low (%)
delF508ydelF508 100 68 62
P. aeruginosa 100 62.5 25
Patients with high degree of hyperreactivity had the prolonged persistence of P.
aeruginosa—more than 3 yr. The less degree of hyperreactivity was in the group
of patients who had sowed in their sputum only Staphylococcus aureus and
Str.pyogenes. Conclusion: (1) All patients with cystic fibrosis had hyperreactivity
during the course of infectious process in lungs. (2) The degree of hyperreativity
depended on genotype and character of infectious process (the highest level was at
patients with P. aeruginosa). (3) Hyperreactivity of bronchial tree depended on
prolongation of P. aeruginosa infectious process in the lungs.
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Bronchial hyperreactivity in cystic fibrosis
M. Bielecka-Zylbersztejn(Presenting), A. Milanowski
Department of Paediatrics, Institute of Mother and Child, Warsaw, Poland
Objective: Increased airway responsiveness is not unique to asthma and can be
demonstrated in a number of inflammatory airway diseases. It is related to inflam-
mation, but indirect mechanisms remain unknown. Different mechanisms may
underlie bronchial hyperresponsiveness (BHR) in different diseases. Cystic fibrosis
(CF) is an autosomal recessive disease, caused by mutations of CFTR gene, char-
acterised by progressive pulmonary tissue injury due to chronic bacterial infection
and excessive immune- mediated inflammatory process. The importance of BHR
and treatment with bronchodilators and corticosteroids in management of patients
with CF is poorly understood. The aim of this study was to investigate bronchial
reactivity using bronchial challenge test with carbachol in CF patients and to estab-
lish influencing factors (atopy, prechallenge pulmonary function tests). Methods:
Thirty-three CF patients (14 boys, 19 girls) aged 12.7"3.6 (mean"S.D.) with
mild course of the disease (Shwachman- Kulczycki score)70) were studied. Bron-
chial challenge test with carbachol was performed according to standard guidelines
(tidal breathing method) in all individuals. Patients having PC20-4.8 mgyml were
defined as having BHR. Results: BHR was found in 27 patients (81%), PC20 was
1.46"1.21 mgyml (mean"S.D.). There was correlation between PC20 and base-
line pulmonary function tests (standardised values): SDSFVC-Ps0.001, rs0.53
SDSFEV - Ps0.003, rs0.50 and SDSMEF50- Ps0.007, rs0.46, SDSMEF25-1
Ps0.002, rs0.51. There was no correlation between PC20 and atopy (positive
prick skin tests and total serum IgE.) Conclusion: There was a high incidence of
BHR in studied CF patients. BHR was related to baseline pulmonary function tests,
but was not related to atopy.
s55Journal of Cystic Fibrosis 2 (2003) S49–S60
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Effect of nebulized colistin sulphate and colistin sulphomethate on
lung function in patients with cystic fibrosis
E.M. Westerman (Presenting), P.P.H. Le Brun , H.W. Frijlink , H.G.M.1 1 2
Heijerman3
Central Hospital Pharmacy The Hague, The Hague, Netherlands, Department of1 2
Pharmacy Technology and Biopha, University of Groningen, Groningen, Nether-
lands, Adult Cystic Fibrosis Center, Leyenburg Hospital, The Hague, Netherlands3
Background: Pulmonary administration of colistin is one of the antimicrobial treat-
ments used in Cystic Fibrosis (CF) patients chronically infected with Pseudomonas
aeruginosa (Doring et al., 2000). Dry powder inhalation of colistin may be an¨
attractive alternative to nebulization of colistin (Le Brun et al., 2002). However,
nebulized colistin can cause bronchoconstriction in CF patients. Therefore, in devel-
oping a dry powder formula, the choice of the inhaler and its contents should be
guided by efficacy and least side effects. A side effects study was initiated com-
paring the tolerability of colistin sulphate to colistin sulphomethate per nebulization
in CF-patients. Methods: Nine CF-patients chronically infected with P. aeruginosa
participated in a double blind, randomized cross-over study. On two out patient
visits, patients used either nebulized colistin sulphate or colistin sulphomethate solu-
tion. Lung function tests were performed before and 15 and 30 min after nebuli-
zation. Results: Nebulized colistin sulphate caused a significant larger mean
decrease in lung function compared to nebulized colistin sulphomethate. A signif-
icant decrease in mean changes ("SD) in FEV at 30 min and IVC at 15 and 301
min after nebulization compared to baseline ofy7.3% (8.6%),y9.2% (7.1%) and
y12.1% (7.5%) respectively, was seen after colistin sulphate nebulization com-
pared to colistin sulphomethate (P-0.05). Seven patients were unable to complete
the nebulization of colistin sulphate, because of throat irritation and severe cough.
Conclusion: Nebulized colistin sulphate is unsuitable for treatment of CF patients
chronically infected with P. aeruginosa. Colistin sulphomethate is the drug of choice
for pulmonary administration of colistin.
References:
Doring et al., Eur. Resp. J. 16 (2000) 749–767.¨
Le Brun et al., Eur. J. Pharm. Biopharm. 54 (2002) 25–32.
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HRCT is more sensitive marker of CF lung disease than LFT
H. Kayserova (Presenting), Martin Polakovie , Stanislav Katina1 1 2`
Clinic of Radiology, Natural Institute of TB and Respiratory Diseases, Bratislava,1
Slovakia, Department of Mathematics and Biology, Commenius University, Brati-2
slava, Slovakia
The severity of chronic bronchopulmonary disease is the limited factor for surviving
of CF patients. Lung function testing is an important marker of disorder, but is
seems to be less sensitive in comparison to HRCT of lung in CF. Aims: To evaluate
function (LFT) and morphologic (HRCT) changes over two years interval in CF
patients and its correlation to CF genotype. Methods: Sixty-three CF patients aged
7 to 49 yr (mean age 15.5 yr.) had two HRCT scans (scored acc. Bhalla) in
combination with LFTs. The results were correlating to CFTR mutation. Group A:
18 pts, dF508ydF508. Group B: 25 pts, dF508yother. Group C: 20 pts, otheryother.
Results: In two years period (1)y(2) we can see stability or improvement of mean
yLFT in contrast to worsening of mean HRCT score. Group A: FVC – 77y89%,
FEV : 81y84%, MEF50: 76y72%. HRCT: left – 8.2y9.1, right: 8.4y10.0. Group B:1
FVC – 87y90%, FEV – 90y90%, MEF50 – 81y78%. HRCT: left – 6.0y6.6; right1
– 5.9y6.3. Group C: FVC – 81y89%, FEV – 85y92%, MEF50 – 80y85%. HRCT:1
left – 4.1y4.4; right – 5.0y4.9. Conclusion: HRCT seems to be more sensitive
method of evaluating pathologic process in CF lung (mucus plugging, thickening
of airway wall, bronchiectasiones and inflammation) than LFT is. According to
localisation and type of changes individual segmental physiotherapy, mucolytic and
anti-inflammatory therapy can start. The result of this individual therapy was better
score in HRCT in twenty-two (34.9%) CF patients.
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Non invasive pressure support ventilation (NIPSV) as a bridge to lung
transplantation in cystic fibrosis patients: a case report
S. Quattrucci(Presenting), G. Cimino, A. Grzejdziak(Presenting), F. Alatri, L. Gra-
ziano, P. Porzi, M. Rocco
Department of Paediatrics-Cystic Fibrosis Centre, University of Rome ‘La Sapien-
za’, Rome, Italy
Patients with advanced cystic fibrosis (CF) and chronic respiratory failure with
hypoxia and hypercapnia have been proposed for bilateral lung transplantation
(BLT). Some studies have shown an interest in the non-invasive positive pressure
support ventilation for the treatment of acute decompensation, as well as for the
management of chronic respiratory failure. This ventilation improves the ventilatory
function by resting the chronically overloaded respiratory muscles as well as by
preventing the acute exacerbation of the illness and facilitating physiotherapy. We
report the case of a 26-year-old woman affected by CF with severe chronic lung
disease treated with home non-invasive pressure support ventilation while on the
waiting list for BLT. Case report: Data at the evaluation for BLT: six minutes
walking test (meters 522); FEV (0.97 l); PaO (52 mmHg); PaCO (65 mmHg);1 2 2
pH 7.32; body mass index (BMI) 23; number of acute exacerbations and hospital-
isations during the year before (4 and 2, respectively). Data after 24 months on the
waiting list: six minutes walking test (meters 540); FEV (1.01 l); PaO (621 2
mmHg); PaCO (57 mmHg); pH 7.35; BMI 25; number of acute exacerbationsy2
year (2); number of hospitalisationsyyear (1). The patient was treated with NIPSV
(PSVqPeep) after listed for transplantation. Discussion: An increased waiting time
for double lung transplantation among cystic fibrosis patients has been frequently
associated with the high mortality rates. Domiciliary NIPS improves vital signs and
dyspnea scores, and often avoids intubation. In summary, domiciliary NIPS is very
helpful to reduce the hospitalisation rates and to improve the patient and his family’s
quality of life. This study illustrates the potential utility of NIPS as a rescue therapy
in supporting patients with acutely deteriorating cystic fibrosis and in providing a
‘bridge to transplantation’.
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A role for non-invasive ventilation (NIV) in the management of
respiratory failure in adults with cystic fibrosis (CF)
M. Milross (Presenting), C. Dobbin , A. Piper , G. Willson , J. Regnis , S.1 2 1 1 2
Parsons , R. Grunstein , C. Sullivan , P. Bye2 1 1 2
Centre for Respiratory failure and Sleep Disorders, Royal Prince Alfred Hospital,1
Sydney, Australia, Respiratory Medicine, Royal Prince Alfred Hospital, Sydney,2
Australia
Rationale: Hypercapnic respiratory failure in patients with CF and severe pulmonary
disease is associated with a poor prognosis. We sought to determine the effect of
the systematic introduction of NIV prior to late stage unstable respiratory failure.
Methods: We retrospectively reviewed the outcomes of 56 CF adults with respira-
tory failure treated at our institution between 1989 and 2002. Results: Of 46 hypox-
emic patients using supplemental oxygen (O ), mean FEV 25"8% predicted, 132 1
(28%) were maintained for a median of 14 months until lung transplantation, four
died, two switched to CPAP and 26 developed worsening hypercapnic respiratory
failure requiring NIV after a median of 11 months. The use of NIV allowed an
additional 39% to survive to transplant or achieve long-term stabilisation of their
respiratory failure. Thirteen patients, mostly prior to 1995, with mean PaCO2
77"11 mmHg and mean FEV 15"5% predicted commenced volume preset ven-1
tilation (VPV) for hypercapnia with nine surviving to transplant. Since its intro-
duction, 28 patients, with mean PACO 57"10 mmHg, have commenced bi-level2
ventilatory support (BVS) with 13 receiving transplants after a median of seven
months and six switching to VPV for progressive hypercapnia. In those with wors-
ening hypercapnia on O , introduction of BVS significantly reduced the PaCO2 2
(Ps0.01) for a mean of one month. Of the 56 patients, there were 24 who, at any
stage, on any treatment modality, developed PaCO levels exceeding 55 mmHg.2
The one and two year survival rates were 83 and 53%, respectively. Conclusion:
These results suggest that the introduction of NIV in those with progressive hyper-
capnia on O therapy can, in some patients, temporarily reverse this process, main-2
taining them to transplantation, and in others, offer long-term stabilisation of
respiratory failure and potentially improve survival. HMRC Australia.
s56 Journal of Cystic Fibrosis 2 (2003) S49–S60
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V FRC and functional residual capacity (FRC) in infants with cysticmax
fibrosis (CF) and in infant heterozygous for CFTR gene mutation
G. Tancredi(Presenting), F. Scalercio, F. Midulla(Presenting), S. Cingolani, M. Rol-
la, S. Bertasi, E. Soldi, S. Quattrucci(Presenting)
Pediatrics – University of Rome ‘La Sapienza’ Cystic Fibrosis Centre, Rome, Italy
The aim of our study was to evaluate VmaxFRC and FRC in infants with CF respect
to infants heterozygous of the CFTR gene mutation by an infant respiratory function
testing device (ExhalyzerO Eco medics). In 14 CF infants (8 males) and 12 CFTR`
heterozygous infants (6 males) we measured VmaxFRC with the Rapid Thoraco-
abdominal Tecnique and FRC with sulfur-hexafluoride (SF6) washout technique
using an ultrasonic flow meter. Data for V FRC were expressed as percentage ofmax
predicted values by sex and height for healthy infants and FRC values in mlykg.1
The results are reported in the table:
Cystic fibrosis Heterozygous CFTR gene
Mean"S.D. Mean"S.D. P
Age (weeks) 30.1"21.3 25.5"10.2 -0.01
Height (cm) 63.3"8.9 64.4"3.5 n s
V FRC (% pred)max 80.7"41.4 92.2"34.0 n s
FRC (mlykg) 25.8"10.2 22.6"4.1 -0.02
We observed that mean values of percentage predicted V FRC in CF patients aremax
lower than heterozygous infants for CFTR gene mutation even if there isn’t a
statistical difference (Psn.s.). Mean value of FRCykg was highest in CF patients’
respect to heterozygous infants (P-0.02). Our data demonstrated that air trapping
and early airway obstruction are present in CF subjects, but not in CFTR
heterozygous infants. Our findings evaluate the important questions about the onset
of impaired airways function and natural history in infants and with Cystic Fibrosis.
J. Stocks et al., Am. J. Respir. Crit. Care Med. 165 (2002) 1084–1092.1
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The assessment of the selected spirometric parameters and blood
oxygenation in patients with cystic fibrosis
A. Minarowska (Presenting), M. Kaczmarski , L. Minarowski1 1 2
IIIrd Department of Childrens’ Diseases, Medical University in Bialystok, Bialy-1
stok, Poland, Medical University in Bialystok, Bialystok, Poland2
Cystic fibrosis-conditioned genetically, chronic, multisystemic disease, in which an
advancement of the bronchopulmonary disease is the main cause of death in these
patients. Bronchioli clogged by the thick and viscous mucus lead to the increase of
resistance and in consequence to impairment of the ventilation of the obturative
type. The aim of this study was to evaluate the blood oxygenation and acid-base
balance parameters in comparison with obturation of the large bronchi (FEV ). The1
study was carried out on 18 patients, aged 2–21 yr submitted to the III Department
of Paediatric Diseases of the Medical University in Bialystok. By using the
Schwachmann score, the severity of the illness was assessed and on this ground
two groups were created: -55 pts – respiratory inefficient (9 patients), )55 pts
– respiratory efficient (9 patients). Acid–base balance and blood oxygenation par-
ameters were evaluated in venous blood samples (all values were referred to adults).
Spirometry was performed in 10 cooperative patients (considering age). In the study
the parameters committed in normal oxygen transport were evaluated (sO , ctO ,2 2
O cap) In both groups pCO was lower than average, and only in one case in every2 2
group pCO was increased. In both groups, two patients had decreased pO . ctO2 2 2
in 8 patients in first group and 4 in second group was decreased. O cap in 3 patients2
in first group and 4 in second group was lowered. sO in 7 children in both groups2
was decreased. In group with respiratory inefficiency 6 patients had venous sO2
decreased what correlates with obturation of the large bronchi. In group with res-
piratory efficiency sO and FEV are normal. Obtained results indicate a ventilation2 1
disorder of the obturative type, which leads to sO fall.2
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Effect of nebuliser systems on the in-vitro nebulisation efficiency of
Tobramycin inhalation solutions
A. Balcke(Presenting), M. Keller, U. Schuschnig, P. Stempfle, M. Knoch
Aerosol Research Institute, PARI GmbH, Munich, Germany
Introduction: The eFlow IMP (Injection Moulded Prototype, PARI) an electronic
inhaler is more effective and economic compared to conventional jet nebulisers due
to higher delivered and respirable doses (DDyRD) and shorter nebulisation times.
This study was conducted to investigate the in-vitro drug delivery efficiency of
eFlow IMP upon nebulisation of TOBI (300 mgy5 ml) and higher concentrated
tobramycin solutions compared to the PARI LC PLUS nebuliser. Methods: TOBI
(Chiron, USA) and experimental tobramycin solutions (100–130 mgyml, PARI,
Germany) were used to study the nebulisation performance of the eFlow IMP
and PARI LC PLUS powered by a PARI BOY N (sPRONEB ULTRA) compres-
sor. Nebulisation efficiency was assessed mimicking an adult breathing pattern. All
sample solutions were assayed by HPLC utilising light scattering detection. Droplet
size distributions were measured by laser diffraction. Summary: The fine particle
fraction (FPF, % droplets -5 mm) of the eFlow IMP and the PARI LC PLUS
nebuliser are similar (;60%) when nebulising TOBI, whereas the DD is about
9% higher for the eFlow IMP (45% vs. 36% of label claim). Nebulisation of
higher concentrated tobramycin solutions by the eFlow IMP increases the DD
(56%) and FPF (71%) associated with a decline in the drug residue (11% instead
of 20%) and reduce nebulisation time. Drug delivery performance of the PARI LC
PLUS is independent of the tobramycin concentration. Conclusions: The use of
higher concentrated tobramycin solutions allow the administration of an equivalent
lung dose, compared to TOBI with the PARI LC PLUS, in a much shorter time
when nebulised by the eFlow IMP. It can be expected that the eFlow IMP will
improve both, compliance and quality of life and will reduce drug cost due to better
nebulisation efficacy.
214*
Gas exchange abnormalities during maximal exercise in adults with
cystic fibrosis
J.A. Innes (Presenting), J. Lenney , A.P. Greening1* 2 1
Scottish Adult Cystic Fibrosis Service, Western General Hospital, Edinburgh, Scot-1
land, Respiratory Function Service, Western General Hospital, Edinburgh,2
Scotland
Patients attending our Service undergo annual maximal cardiopulmonary cycle exer-
cise tests as part of their clinical care. Measurements include oxygen uptake
(VO ), oxygen saturation, end tidal CO and ventilation. Exercise responses from2 2
77 adult CF patients without lung transplants were examined. Fourteen patients
showed gas exchange abnormalities (GEA, defined as desaturation G4% and rise
in end tidal CO )10 mm Hg) during maximal exercise. Data from these patients2
were compared with data from the 63 remaining patients who did not show desa-
turation and CO retention. There was no difference between the age, gender mix2
or body mass index of the group with GEA and patients without GEA. There was
also no difference in the maximum workload achieved, (% predicted VO max 73%2
for GEA, 71% for non-GEA). Patients with GEA had more severe airflow obstruc-
tion (% predicted FEV 35% vs. 60% for non-GEA) and consequently reached a1
greater fraction of predicted maximum ventilation (% predicted Ve max 103% for
GEA vs. 66% for non-GEA). At submaximal workloads however, the rise in ven-
tilation with workload was less in patients with GEA than those without, suggesting
GEA is associated with a blunted ventilatory response to exercise. There was no
difference in breathlessness or exertion scores (Borg scales) at peak exercise
between patients stopping with and without GEA. In summary, despite severe air-
flow obstruction, patients with GEA continue exercise to a similar high level to
that achieved by control patients, but with lower ventilatory responses and at the
expense of marked derangements of oxygen and CO levels. The fact that these2
derangements are not associated with greater breathlessness or exertion scores at
peak exercise suggests they may be relatively desensitised to hypoxia and hyper-
capnia. Further research is needed to confirm this desensitisation and to determine
whether it is acquired or congenital.
s57Journal of Cystic Fibrosis 2 (2003) S49–S60
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Time course of walking distance in patients with cystic fibrosis and
severe airway obstruction
C. Braggion(Presenting), M. Dona’, R. Bellini, C. Tartali, L.M. Cappelletti, B.M.
Assael
Cystic Fibrosis Center, Verona, Italy
The six-minute walking test (6MWT) is a useful tool to assess exercise tolerance
in patients with cystic fibrosis (CF). The walking distance (WD) has been shown
to have prognostic value in listing patients for lung transplantation (LT). The aim
of our study was to evaluate the time course of WD in patients with CF and severe
airway obstruction. Sixty-eight patients (31 males)(age: 30.5"6.5 yr; FEV :1
28"7% pred.) were included. Z-score for weight (Wzs), FEV , WD, perceived1
dyspnea (D) and leg effort (LE) ratings by modified Borg scale during 6MWT
were assessed at the inclusion and 1.3 yr after. WD decreased significantly from
608"91 to 559"111 m (P-0.001), whereas there were no significant changes in
Wzs, FEV , D, LE and DyLE ratio during the follow-up. Considering patients who1
died (No. 6) or underwent LT (No. 13), WD decreased significantly from 528"90
to 459"105 m (P-0.001). In conclusion, WD represents a better index of pro-
gression of lung disease compared to FEV and Wzs. A WD below the 500 m1
should be considered a threshold value to include patients in waiting list for LT.
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Beneficial effects of a training program in CF-patients—are there
differences in male and female patients?
W. Gruber (Presenting), D. Kiosz , K. Paul , R. Koelbel , K.M. Braumann1 1 1 2 2
Clinic Sattelduene, NebelyAmrum, Germany, Sports and exercise medicine, Uni-1 2
versity of Hamburg, Hamburg, Germany
Limitation in exercise capacity is one of the common symptoms in CF. However,
beneficial effects of exercise programs have been reported. The aim of this inves-
tigation was to examine the effects of 6 week training program on exercise capacity
in CF-patients and to compare the effects between male and female patients. We
studied 39 male patients aged 12–29 yr and 25 females aged 11–29 yr. All patients
performed an incremental exercise test at the beginning (T1) and at the end (T2)
to determine maximal exercise capacity. Lung function was measured by spirometric
techniques. Duration of training was 6 weeks with a frequency of at least 4 timesy
week. After completing exercise training all patients showed significant (P-0.05)
improvement in maximal workload (P , Watt), maximal oxygen uptake (VOmax 2
max, lymin), oxygen pulse (O pulse, ml) and minute ventilation (VE, lymin) and2
tidal volume (VT, l). Male patients had a higher exercise capacity at T1 but a
greater increase (P-0.05) was seen in female patients (male vs. female: P 5.5max
vs. 12.0%, VO 10.9 vs. 24.4%, VE 10.4 vs. 23.7%, O pulse 12.2 vs. 21.7% VT2 2
10.8 vs. 23.9%). The data suggest that female patients with CF had a lower fitness
compared to the male patients but the beneficial effects of the training program
were greater in this group. This finding could be explained as the result of lower
activity levels in daily live compared to male patients. A similar finding could also
be observed in healthy persons. However, both groups showed an improvement in
exercise capacity and therefore, a regular exercise training program should be
included in the treatment of CF, especially in female patients.
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Bronchial response to the inhalation of high-dose tobramicin (TOBI)
in cystic fibrosis
D. Costantini (Presenting), A. Brivio , D. Brusa , G. Romano , C. Colombo1 2 2 1 1
C.F. Centre Pediatric Department, University of Milan, Milano, Italy, Phisioth-1 2
erapy Department, I.C.P., Milano, Italy
It has been established that inhaled tobramycin has a positive effect on respiratory function
in Pseudomonas aeruginosa positive patients with Cystic Fibrosis. In a previous study low-
dose tobramycin containing phenol is reported to cause significant bronchial obstruction.
Recently, high-dose tobramycin preparations with and without preservativesyphenol have
become available. This study was aimed to assess the airway response to inhalation of high-
dose tobramycin (TOBI 300 mg, 5.0 ml). We studied 29 pts with a confirmed diagnosis of
CF and the ability to expectorate sputum (F 15, M 14); mean age was 14.9 yr, S.D. 5.9
(range 5–32), mean FEV was 76.8% of predicted, S.D. 27.4 (range 28–125). Patients in1
stable clinical conditions were asked to visit the hospital to check tolerability to a test dose
of TOBI. Every single patient inhaled the drug from the same compressor with a LC PLUS
nebulizer (PARI Respiratory Equipment, Labhardt AG, Germany) via mouthpiece. Pulmonary
function was measured using a dry spirometer (SensorMedGraphics, USA); best data out of
three flow-volume curves were considered (as percentage of predicted value). FEV , FVC,1
FEF 75, FEF 25–75 were measured before and 5 min after first dosing. Results: After tobra-
mycin inhalation a significant fall in lung function was detected in 16 pts (55.2%), considering
a decrease )10% in FEV andyor FEF 25–75%. On the other hand, 13y29 patients showed1
no decrease in lung function.
Pts no. Sex FEV % preypost1 FEF 25–75% preypost
16 F 12yM 4 80.4y74.8 58.2y47.6
S.D. 21.9y19.8 S.D. 25.4y21.9
13 F 3yM 10 71.4y74.2 47.1y55.1
S.D. 45.2y47.4 S.D. 36.1y40.3
Treatment with bronchodilators prevented the decline in lung function in our series.
Conclusions: The assessment of bronchial reaction at the first nebulisation of high-
dose tobramycin is strongly recommended for the onset of bronchial constriction is
hardly predictable. Our data suggest an inverse correlation between airway disease
severity and hyperreactivity; more patients are being studied to confirm this
hypotesis. In any case pretreatment with beta agonists is suggested.
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Exercise performance in cystic fibrosis after lung transplantation
C. Braggion(Presenting), A. Borruso, A. Zorzanello, M. Ocampo, U. Pradal, B.M.
Assael
Cystic Fibrosis Center, Verona, Italy
Perypheral muscle dysfunction has been shown to limit exercise performance after
lung transplantation (LT). A suboptimal nutritional status could contribute to this
abnormality. The aim of our study was to assess peak oxygen uptake (VO p) and2
anaerobic threshold (AT) after LT and the relationship between these indices and
the body mass index (BMI) in patients with cystic fibrosis (CF). An incremental
exercise test with a cycle ergometer was performed 1.3"0.4 yr after LT in 11
patients with CF, who underwent LT at the mean age of 26"7 yr. AT was deter-
mined by the V-slope method. The mean VO p and AT were 49"11% pred. and2
27"9% of the predicted VO p, respectively. The breathing reserve was either nor-2
mal or high in all patients. BMI increased significantly from 18.09"2.79 kgym2
to 20.56"3.25 kgym (P-0.05) after LT. We found no relationships between BMI2
before and after LT and either VO p or AT. In conclusion, both VO p and AT were2 2
low after LT in patients with CF. These findings were associated to an improvement
in nutritional status after LT.
s58 Journal of Cystic Fibrosis 2 (2003) S49–S60
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Ergospirometry in children with cystic fibrosis
S. Albinni (Presenting), S. Renner , E. Kampl , I. Eichler1 2 2 2
Children’s University hospital, Wien, Austria, Pediatric Allergy and Pulmonology,1 2
University Children’s Hospital, Vienna, Austria
Introduction: Cystic fibrosis (CF) is associated with reduced exercise capacity. The
aim of our study was to define whether performance limitation was due to cardi-
ovascular, pulmonary or muscular factors and to develop adequate exercise training
programs. Methods: Ergospirometry testing (Oxycon, Jaeger-Toennies, Germany)
was performed in 40 patients with stable CF (median age: 13.3 yr) Watt max%
pred, VO max, EQO , EQCO , RER, HR, VO yHR and BR were evaluated. Anaer-2 2 2 2
obic Treshold (AT) was determined by the ‘Vslope’ method, EQCO and by serum2
lactate. Results: Median FEV % pred was 83.5%. Median Watt max was 94.5%.1
Twenty-twoyForty patients had normal exercise capacity with Watt max)90% pred.
TwelveyTwenty-two showed EQO )35 at peak work capacity. In 7y18 patients2
with reduced exercise capacity (Watt max-90% pred) performance was limited by
a lack of physical fitness; in 11y18 patients limitation was caused by ventilatory
factors (EQO )35) in addition to reduced physical fitness. There was a significant2
correlation between FEV % pred and Watt max (Ps0.0002). There was good1
agreement between Vslope, EQCO and blood lactate concentrations for determin-2
ing the AT. No cardiovascular problems were found. Conclusion: Decreased exercise
capacity was found in 18y40 patients mainly caused by reduced physical fitness.
Respiratory impairment at exhaustion was detected in 23 patients but mostly mus-
cular exhaustion was found before ventilatory limits were reached. Ergospirometry
differentiates between muscular and ventilatory factors limiting exercise perform-
ance in children with CF, necessary to design individual training programs and
goals: Patients with ventilatory limitations will benefit from regular aerobic training
by an increase in the anaerobic threshold but only a modest improvement of exercise
capacity, whereas those with purely muscular performance limitations can expect a
marked improvement of their exercise capacity.
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Asthma bother profile in adult cystic fibrosis patients
M. Al-Aloul, P. Stockton(Presenting), B. Govin, C. Cowperthwaite, M.J. Ledson,
M.J. Walshaw
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom
Many CF adults suffer from bronchial asthma, which may significantly influence
their quality of life. To explore this, we used a 22-item self-administered asthma
‘Bother’ questionnaire (which assesses the 5 domains of activity, sleep, worry,
understanding, and care documented using a visual analogue scale) on 78 adult CF
patients with asthma attending our clinic. Patients were subdivided into compliant
and non-compliant groups on clinical grounds. There was no difference in age, sex,
or spirometry, but those compliant were more likely to accept the diagnosis (P-
0.001), requested more information about the disease (P-0.001), took more treat-
ment (P-0.001), and were more conversant with peak flow measurements (P-
0.05) than the non-compliant group. They perceived more restriction on activity
(paid work, housework, social life, personal life, and leisure) compared to the non-
compliant group (average score of 3.92 vs. 1.51, P-0.001), and more were unem-
ployed due to their symptoms (P-0.05). They also reported more symptoms of
nocturnal cough and wakening, and early morning wakening (P-0.05), and were
more bothered about taking medication (P-0.05), having coughs and colds (P-
0.004), feeling anxious (P-0.0009), visiting new places (P-0.01), letting people
down (P-0.0001), and inability to cope (P-0.006), (average score of 3.51 vs.
1.83 in the non-compliant group). However, they were less sure of how their med-
ication worked (P-0.05) and sought more information (P-0.05), (average score
of 3.23 vs. 1.75, P-0.005). Both groups were equally confident about dealing with
breathless attacks, and satisfied with the level of care they received. Thus, we have
shown that using a general asthma questionnaire in relevant CF patients has allowed
us to better understand patients’ attitudes to their illness, its impact on their life,
and satisfaction with their care. We recommend the use of such tools in the study
of this under-appreciated aspect of adult CF care.
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Autonomic dysfunction in cystic fibrosis (CF): impact of
microbiological status
A. Mirakhur(Presenting), M. Al-Aloul, B. Govin, M.J. Ledson, M.J. Walshaw
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom
We have previously shown that autonomic dysfunction occurs in adult CF patients,
and correlates with a worsening state of CF disease. Colonisation with B cepacia
is associated with a poor prognosis in CF, previously thought to be due to its effect
on pulmonary function. We therefore studied the autonomic nervous system in 14
CF patients colonised with B cepacia (mean age 25.7 yr, range 19–39 yr, 9 male)
and compared it with 34 patients colonised with Pseudomonas aeruginosa (mean
age 23.5 yr, range 17–42, 14 male). We used the technique of power spectral
analysis of heart rate variability during a 15 min modified orthostatic load. This
allows quantification of the parasympathetic and sympathetic systems (high and
low frequency power spectra, respectively), and also an index of global autonomic
tone (total and cumulative power). Lung function was similar in both groups
(FEV % predicted: B cepacia group mean 44 (range 17–88) vs. P. aeruginosa1
group mean 57.8 (range 24–125); PsNS and FVC% predicted (60.1 (29 to 93)
vs. 75.1 (45 to 128); PsNS). Those colonised with B. cepacia had greater auto-
nomic dysfunction, not only for global autonomic tone (mean total power: 874.4
ms vs. 352.3 ms , P-0.01; and mean cumulative power: 2343.6 ms vs. 1144.92 2 2
ms , P-0.05), but also for sympathetic tone (mean low frequency power: 4532
ms vs. 200.4 ms , P-0.01) and parasympathetic tone (mean high frequency pow-2 2
er: 421.1 ms vs. 152.0 ms , P-0.02). Thus, we have shown that patients colonised2 2
by B cepacia have lower values for spectral analysis parameters compared to P.
aeruginosa colonised patients, but this occurs independently of lung function. This
raises the possibility that microbiological status may directly impact on the severity
of autonomic dysfunction in CF.
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Polysomnographic findings in children with cystic fibrosis
R. Rath(Presenting)
Pediatric Pulmonology, University Children9s Hospital, Vienna, Austria
Background: Cystic fibrosis (CF) is characterized by pulmonary inflammation and
deterioration of lung function. Pulse oxymetry is usually used to determine noctur-
nal respiratory disorders Methods: We performed polysomnography (epas 23-som-
no, Schwarzer:video, ECG, 2EEG channels, EMG, EOG, pulse oxymetry, oronasal
air flow, thoracalyabdominal effort, body position and end tidal CO ) in 16 stable2
CF patients. Median age was 14.4 yr (range: 0.8–19.6). Ten are female, 6 male.
Lung function was performed in 15y16 persons, daytime blood gas analysis in all
children. NineySixteen were chronically colonised with P. aeruginosa, 5 of them
were multiresistant. ThreeySixteen had also colonisation with B. cepacia and 2y16
with MRSA. TwoySixteen was afterwards listed for lung transplantation. Twoy
Sixteen showed episodes of snoring during slepp with history of nasal polyposis.
Results: Median FEV was 46.9% pred. (range: 25–112.8), MEF 50:19.1% pred1
(range: 10–154) and MEF 25:14.0% pred. Daytime blood gas analysis: median
pO : 73.5 mm Hg (range: 55–93), median pCO : 39 mm Hg (range 36–87), medi-2 2
an pH: 7.8 (range: 7.3–7.43). Median oxygenation was at daytime and during sleep
higher than 90% (93%). We found nocturnal median ETCO of 45 mm Hg (range2
32–75) and in 9y16 patients median ETCO was higher than 45 mm Hg during2
sleep. All patients showed uncoordinated thoracal and abdominal movements, which
we called paradoxic ventilation pattern (PVP). In correlation analysis, we found
high correlation between quantity of PVP and ETCO (Correlation coefficient:2
0.88). There was also a good correlation between PVP and MEF 50 and MEF 25y
CC: 0.8;0.73). FEV and PVP showed only eak correlation (CC:0.43). Poor cor-1
relation between PVP and daytime pCO and also nocturnal O saturation were seen2 2
(CC: 0.43;0.56). Conclusion: Lung function parameters and daytime blood gas
analysis is poor predictors of nocturnal respiratory distress. We assume that quantity
of PVP and ETCO are early signs of respiratory muscle fatigue.2
s59Journal of Cystic Fibrosis 2 (2003) S49–S60
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Differential evaluation of mucociliary clearance in patients with
mucoviscedosis and other chronic lung pathology with bronchial
obstruction
V. Kobylyansky(Presenting)
State Medical University named after Academician I.P. Pavlov, Saint-Petersburg,
Russia
Mucociliary clearance (MCC) disorder is usually considered to be the main mech-
anism of mucoviscedosis (MV) pathogenesis. At the same time there are diseases,
including Siewert-Kartagener syndrome, COPD, in which development, due to dif-
ferent authors, MCC also plays a significant or main role. This makes it necessary
to determine differentially the role of changes in MCC state in the development of
the obstructive bronchial pathology. The aim of the work was to differentiate the
role and specify MCC state and role of its changes, if any, in mucoviscedosis and
other lung pathology with bronchial obstruction. MCC was studied in 15 patients
with mucoviscedosis, 12 – with allergic bronchial asthma, 14 – with Siewert-Kar-
tagener syndrome and 19 – with COPD using direct non-invasive radioaerosol
method in vivo. The results of the study showed that MCC was changed in all the
groups of patients studied, but the degree of these changes was significantly dif-
ferent. MCC values in the patients with mucoviscedosis and allergic bronchial asth-
ma were 25.2"2.1% and 36.4"3.3%, and moderately differed from the control
group (P-0.05). Most of the MCC values were within the normal ranges. MCC
in all the patients with Siewert-Kartagener syndrome and COPD was significantly
lowered (14.1"1.5% and 16.9"1.6, respectively) and more than 2.5-folds differed
from control and 1.5-2-fold from the previous groups. Thus, MCC disorders in
mucoviscedosis and allergic bronchial asthma plays a significant, but not the main,
role in their pathogenesis. MCC disorders play the main role in Siewert-Kartagener
syndrome and COPD. Similarity of these disorders suggests necessity of genetic
studies in COPD development. Significant differences in MCC state in the groups
studied shows necessity of strict differential approach to the correction mucociliary
insufficiency and treatment depending on obstructive bronchopulmonary pathology.
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Bronchoscopically administered ‘recombinant human DNase’
E. Yalcyn (Presenting), D, Doru , U. Ozcelik , N. Kiper1 2 2 2¨¸ ¸´
Hacettepe University Faculty of Medicine, Ankara, Turkey, Pediatric Chest Dis-1 2
eases Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background: Inhaled ‘recombinant human DNase (rhDNase)’ cleaves extracellular
DNA and causes liquefaction and removal of bronchial secretions. Few studies are
reported concerning the bronchoscopically instillation of rhDNase. Aim: We aimed
to evaluate the effectiveness of intrabronchial instillation of rhDNase by flexible
bronchoscopy. Methods: We performed flexible bronchoscopy in 34 patients (12
with CF, 3 with CF qatelectasis and 19 with atelectasis) for bronchial toilet or re-
expansion of the atelectatic areas and administered rhDNase intrabroncially. The
clinical and radiological outcomes of the patients were reviewed. Results: All the
patients had large volumes of purulent and viscous secretions. Following the admin-
istration of rhDNase (1 mg in 9 ml of normal saline) to the bronchialysegmental
orifices, bronchial secretions were less viscous and were aspirated easily. In 12
patients with CF (mean age 8.9 yr, maleyfemales5y7), we observed short-term
symptomatic relief although the improvement in FEV and oxygen saturation values1
at 3rd and 6th months were not significant. In 3 girls with CF and persistent ate-
lectasis no radiological improvement was evident during a period of 6 months. In
19 patients (mean age 7.6 yr, maleyfemales10y9) who had persistent atelectasis
in the lungs due to causes other than CF, administration of rhDNase resulted in
partial re-expansion of the affected lobes in only two cases after 3 to 18 months of
follow-up. Complete re-expansion was observed in none of the patients. Conclusion:
In patients with CF andyor atelectasis bronchoscopically instillation of rhDNase
resulted in easy aspiration of bronchial secretions, however, did not result in clinical
or radiological improvement. This may be the result of persistent parenchymal dam-
age due to the chronic nature of the underlying disease. Randomized controlled
studies investigating the appropriate timing and dosing of rhDNase administration
is needed to determine the efficacy of the procedure.
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Dornase alfa (Pulmozyme) use in UK cystic fibrosis patients with
early lung disease
Z. Panahloo , M. Hodson (Presenting)1 2
Medical Department, Roche, Welwyn Garden City, United Kingdom, Department1 2
of Cystic Fibrosis, Royal Brompton and Harefield NHS Trust, London, United
Kingdom
Introduction: Life expectancy for patients with cystic fibrosis has improved dra-
matically in recent years. Early treatment with dornase alfa (Pulmozyme) helps
to maintain lung function and reduce respiratory tract exacerbations . This study1
looked at the prescription of dornase alfa in the UK according to the severity of
CF lung disease. Methods: The European Epidemiologic Registry of Cystic Fibrosis
(ERCF) allows longitudinal follow-up of more than 13 000 CF patients receiving
care in nine European countries. UK data from 1 January to 31 December 2000
were compared with data from the five other European countries that were still
submitting data over the whole of this period (codified to maintain anonymity).
Results: Only 25% of UK patients were treated with dornase alfa during 2000
compared with the ERCF average of 44%. Treatment was generally skewed towards
patients with severe lung disease. In UK only 15% of patients with an FEV )1
70% predicted were treated, compared with 40–65% in the other European countries
(Table 1). Conclusion: Early use of dornase alfa for CF patients in the UK lags
behind other European countries. UK clinicians are less likely to prescribe dornase
alfa for patients with moderate and mild lung disease. There may be considerable
scope for UK clinicians to improve outcomes for patients.
Percentage patients in each FEV category who were treated with dornase alfa1
(Pulmozyme) (nsnumber of patients receiving dornase alfa)
UK (ns
320)
I (ns
181)
II (ns
934)
III (ns
932)
IV (ns
206)
V (ns
50)
FEV (%1
predicted)
-40 72 83 50 65 65 58
40–70 42 70 68 60 53 40
)70 15 55 65 48 40 42
J.M. Quan, H.A. Tiddens, J.P. Sy et al. A two-year randomized, placebo-controlled1
trial of dornase alfa in young patients with cystic fibrosis with mild lung function
abnormalities. J Pediatr. 139 (2001) 813–820.
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The efficiency of Fluimucil treatment in CF patients
L. Jelenina(Presenting), T. Guembitskaya, N. Efimova
Research Institute of Pulmonology at Medical University, Saint-Petersburg, Russia
Aim: The efficiency of Fluimucil (Zambon Group) treatment was assessed in CF
patients with the mild form of respiratory disease. Subjects: Fluimucil (Zambon
Group) is mucoactive drug and commonly used for treatment chronic airway infec-
tious in CF patients. All patients (36) mean age 14.6"0.9 were clinically stable
and did not require the antibiotic therapy. CF children have got Fluimucil (300–
600 mg daily depending of age) during one month. Method: All children were
submitted to clinical examination and pulmonary function tests: vital capacity (VC),
forced expiratory volume (FEV ) initially and after 4 weeks of treatment. The levels1
of Protein (P), Elastase (E) and a1-AO have been detected in sputum of CF patients``
before and after treatment. Results:
Protein gyl Elastase cmoly¸
mlmin
a1-AT mgy´
l
FEV %1 VC%
First day 8.60q
0.02*
95.9q5.4* 101.7q
9.1*
60.2q
5.0%*
76.5q3.0%
After
month
6.27q
0.01*
27.7q6.0* 57.9q
8.5*
72.5q5.0% *80.5q
5.0%
Conclusions: After 4 weeks of treatment the FEV was improved significantly in1
CF patients (P-0.05). The levels of P, E were decreased (P-0.01). The
concentration of a1-AO in sputum was decreased twice and the ratio between E``
and a1-AO was 1:1 in the beginning of study and became 1:2 after treatment.``
These findings suggest that Fluimucil may be useful not only as a mucoactive drug
but also leads to normalization of the local inflammatory process in the lungs and
removes dysbalance between protease and antiprotease.in sputum of CF patients.
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In vitro determination of the effect of rhDNase on the physical
properties of adult CF sputum as assessed by texture analysis
D. Trainor (Presenting), S.A. Barker , D.Q.M. Craig , J.S. Elborn1* 1 1 2
School of Pharmacy, Queen’s University, Belfast, United Kingdom, Department1 2
of Medicine, Queen’s University, Belfast, United Kingdom
DNA released from inflammatory cells, bacteria and cell debris has been postulated
to contribute to the increased viscosity of CF lung secretions. RhDNase acts by
cleaving DNA, i.e. reducing its chain length, and hence, reducing the viscosity of
the sputum, as indicated by in vitro studies using the technique of magnetic micror-
heology e.g. . In vivo studies have demonstrated the efficacy of aerosolised rh-1
DNase (Pulmozyme) in improving quality of life and reducing exacerbation
frequency in some patient’s e.g. . We have previously established that texture anal-2
ysis may be used to analyse the physical properties of CF sputum in a simple, direct
and non-destructive manner e.g. . In this work, we have determined the in vitro3
effect of rhDNase on sputum physical properties and assessed the effect of incu-
bation time. Expectorations from adult CF inpatients at the Belfast City Hospital
were refrigerated until use. A TA.XT2 Texture Analyser (Stable Microsystems,
Surrey) was utilised in the adhesion mode, allowing assessment of ‘adhesiveness’,
‘cohesiveness’ and ‘work of adhesion’. Each sputum sample (ns12) was analysed
before and 0.5, 1, 2, 4 and 6 h after addition of 20 mgyml rhDNase (a concentration
similar to that used in previous investigations ). The data indicate that rhDNase1
reduced the adhesive properties of 75% of the samples, indicating that not all
patients may benefit from rhDNase therapy. Additionally, the incubation time
required to elicit maximum effect was often prolonged, in some cases up to 6 h.
Therefore, in the clinical situation, rhDNase may need to be administered several
hours before physiotherapy for maximal efficacy.
J.M. Zahm et al. Eur. Respir. J. 8 (1995) 381–3861
M. Griese et al. Pulm. Pharma. and Therapeut. 10 (1997) 21–272
Trainor et al. Ped. Pulmonol. 24 (2002) 4133
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A novel method to determine deoxyribonucleic acid (DNA) levels in
adult CF sputum
D. Trainor (Presenting), S.A. Barker , D.Q.M. Craig , J.S. Elborn1 1 1 2
School of Pharmacy, Queen’s University, Belfast, United Kingdom, Department1 2
of Medicine, Queen’s University, Belfast, United Kingdom
DNA from inflammatory cells, bacteria and cell debris is considered as major con-
tributor to the abnormally elevated viscosity of CF lung secretions. Reported sputum
DNA concentrations exhibit great variability, presumably due to the variety of tech-
niques used e.g. . We have developed a new, rapid protocol for extracting DNA1,2,3
from whole CF sputum. All sputa samples were expectorates from adult CF patients
in the Belfast City Hospital and were refrigerated at 4 8C until use. For DNA
isolation, sputum was initially dissolved in guanidinium chloride (7.5 volumes) at
37 8C, precipitated out with ethanol and re-dissolved in sodium hydroxide (2%).
DNA concentrations were determined by absorbance at 260 nm and determined
from standard DNA curves. Two sources of DNA were used for the construction
of standard calibration plots: herring sperm and salmon testes (both Sigma). Adult
CF sputum DNA concentrations ranged from approximately 0.5 to 3.0 mgyml spu-
tum, with A260yA280 exceeding 1.75, indicative of a high level of DNA purity.
Our reported DNA concentrations are consistent with those of other researchers ;1,2
however, they were lower than the wide variation reported by Zahm and colleagues,
ranging from 2.4–19.5 mgyml . These results therefore show that the new simplified3
method produces data consistent with previous studies and has the advantage of
being simpler and more rapid.
W.S. Chernick, Pediatrics (1959) 739–7451
R. Picot et al., Thorax. 33 (1978) 235–242.2
J.M. Zahm et al., Eur Respir J. 8 (1995) 381–3863
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Monitoring recombinant human DNase therapy in cystic fibrosis
patients and controls with DNA-quantification and –qualification
J. Riethmueller (Presenting), H. Grassme , Th. Borth-Bruhns , R. Vonthein , R.1 2 1 1
Ziebach , M. Stern , E. Gulbins1 1 2
University Hospital, Tubingen, Germany, Molecular Biology, University of Essen,1 2
Essen, Germany
Aims: In large clinical trials, the positive effect on outcome of inhalative rh-DNase
therapy was usually measured with pulmonary function methods. These studies
showed that only a limited number of patients improved their lung function under
treatment. Therefore, we analyzed if DNA-quantification and -qualification in spu-
tumyBAL is suitable for monitoring rh-DNase-therapy in CF-patients and intubated
non-CF controls. Methods: Aliquots from 43 sputa of CF-patients (group I) without
rhDNase-therapy, 14 sputa of CF-patients with rhDNase-therapy, 138y138 BAL (II)
of intubated pediatric patients and 35 reference DNA-samples of T-lymphocytes
were analyzed by agarose gel-electrophoresis. The qualifications of fractioned DNA
were performed with a gel-analysis-program in each aliquot. Results: Group I: in 5
CF-patients no measurable DNA in sputum was detectable, in 8 CF-patients we
detected intact cells on baseline and in 30 CF-patients we measured mean 0.16 mgy
ml fractioned DNA. In all patients with rhDNase-therapy we found measurable
DNA with a mean amount of 0.36 mgydl. Group II: 149 control-patients showed
only baseline DNA, 78 patients exhibited mean 0.0051 mgyml fractioned DNA
without rhDNase-therapy, 49 patients with rhDNase-therapy revealed mean 0.0031
mgydl. After rhDNase-therapy, we detected a significant shift from high towards
smaller kb-sizes in all measured groups. Gradients of curves of DNA-fragmentated
sputayBAL showed a significant decrease in CF from mean 0.72 to 0.1 and in BAL
from 1.48 to 0.12. Conclusions: (1) RhDNase is effective in decreasing DNA-
concentrations in CF and intubated controls as well. (2) DNA-qualification might
be helpful in monitoring effective DNase-therapy in vivo. All those questions will
be verified in further clinical trials.
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Including serum IgE in the annual assessment
C.A. Steele (Presenting), L.J. Heaf , EF. Burrows , J.J. Cottrell , D.P. Heaf , K.W.1 1 1 1 1
Southern2
Regional Paediatric CF Unit, Royal Liverpool Children’s Hospital, Liverpool,1
United Kingdom, Paediatrics, University of Liverpool, Liverpool, United Kingdom2
Introduction: Raised serum IgE is the most sensitive marker of allergic broncho-
pulmonary aspergillosis (ABPA) in CF. Consensus guidelines suggest a 4-fold
increase in IgE is consistent with a diagnosis of ABPA. We report the first year’s
experience of including serum IgE in our annual assessment; in particular the impli-
cations for clinical practice. Methods: Retrospective audit of change in practice.
Findings: 108 patients had serum IgE measured. Three had IgE)1000. Two had
previously been diagnosed with ABPA; the other was atopic. Six patients had IgE
between 500 and 1000 (two previously diagnosed with ABPA, three atopic and one
with no other clinical or biochemical features of ABPA). Subsequently, 5 patients
with IgE-500 developed clinical features suggestive of ABPA (CXR changes and
respiratory symptoms unresponsive to intravenous antibiotic therapy). A greater
than 4-fold rise in IgE was detected in all these patients, supporting a diagnosis of
ABPA. Other laboratory findings were intermittently positive (raised eosinophil
count, aspergillus precipitins and aspergillus specific RAST). All these patients
responded to steroid therapy (serum IgE used to monitor progress). Conclusions:
Annual serum IgE has been successfully introduced in our clinic. In four patients
a raised IgE was associated with atopy and in one case found in isolation. The
subsequent diagnosis of ABPA in five children in whom the IgE at annual assess-
ment was -500 demonstrates the potential benefit of including this measure in the
annual review.
Journal of Cystic Fibrosis 2 (2003) S61–S68
Physiotherapy
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Non-invasive ventilation prevents inspiratory muscle fatigue and
oxygen desaturation during airway clearance in adults with acute
exacerbations of cystic fibrosis
A. Holland (Presenting), L. Denehy , G. Ntoumenopoulos , M. Naughton , J.1* 1 1 2
Wilson2
School of Physiotherapy, Alfred Hospital and University of Melbourne, Melbourne,1
Australia, Respiratory Medicine, Alfred Hospital and Monash University, Mel-2
bourne, Australia
Background: Airway clearance techniques are essential to the management of cystic
fibrosis (CF). However, adverse effects, such as respiratory muscle fatigue and
oxygen desaturation have been reported. Non-invasive ventilation (NIV) has been
shown to unload respiratory muscles in stable CF. The aim of this study was to
determine the effect of NIV during airway clearance on respiratory muscle strength,
lung function and oxygenation in adults with acute exacerbations of CF. Method:
Twenty-six CF patients aged 27"6 (S.D.) yr with FEV1 34"12% was predicted
who were admitted to hospital with an acute exacerbation of CF was recruited.
Subjects completed a randomized crossover trial on third and fourth day of admis-
sion. The active cycle of breathing technique (ACBT) was compared to ACBTq
NIV. Inspiratory and expiratory muscle strength (PI , PE ) and spirometry were
max max
measured before and after each treatment and pulse oximetry (SpO ) was recorded2
during treatment. Results: There was a significant reduction in PI following
max
ACBT that was correlated with baseline PImax (P-0.001). PI was maintained
max
during the NIV session (P-0.01 vs. ACBT alone). There was no change in
PE with treatment. Oxygen desaturation during treatment was correlated withmax
FEV (P-0.001). Addition of NIV resulted in significant improvement in mean1
SpO (P-0.001) and a reduction in time with SpO -90% (P-0.001). There was2 2
no change in FEV1 or FVC with either treatment, however, a significant increase
in FEF was evident, following NIV (P-0.01). Conclusion: Inspiratory muscle25–75
fatigue and oxygen desaturation occurs during airway clearance in adults with acute
exacerbations of CF and is associated with inspiratory muscle weakness and severe
lung disease. Addition of NIV maintains inspiratory muscle strength improves oxy-
gen saturation and small airway function.
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Non-invasive ventilation in acute respiratory failure in adults with cystic
fibrosis–a retrospective study
T. Hughes (Presenting), P. Agent , A. Brice , M. Chatwin , M. Hodson1* 1 1 1 2
Physiotherapy Department, Royal Brompton Hospital, London, United Kingdom,1
Department of Cystic Fibrosis, Royal Brompton hospital, London, United Kingdom2
Background: In view of the recent BTS guidelines the physiotherapy department
wished to evaluate it’s practise and observe the results of NIV, used during an acute
episode of hypercapnia, on arterial blood gases (ABGs) and on patient survival.
Aim: To carry out a retrospective study looking at the effects of non-invasive ven-
tilation, set up during an acute episode of hypercapnia, on ABGs and survival.
Patient demographics: Twelve patients: 8 male, 4 female. Age: 19–38, mean 26 yr
("6.5). The majority of patients had no pulmonary function tests on admission.
(Patients too breathless). Methodology: All adult CF patients who had been set up
on NIV by the physiotherapy service were identified. Twelve were selected at ran-
dom and data collected retrospectively using the medical notes. Results: Ventilators
at set up: 2 NIPPY, 10 Breas.Ventilators following optimisation: 1 NIPPY, 1 VPAP,
1 Brompton Pac, 9 Breas. Patient survival of admission: 8 patients. Length of
admission: 24.8 days ("9.9). pO increased on first ABG post NIV set-up. pCO2 2
showed no significant change on the first ABG post NIV set-up. There was a
significant decrease in pCO following optimisation of NIV. Discussion: Collecting2
data retrospectively was not ideal in this case as information was missing, we were
unable to standardise timing of ABGs, there were no stable ABGs as comparison
and we were unable to include patients comfort and compliance. In conclusion a
future study would have enhanced accuracy of data with the use of a protocol and
a comprehensive data sheet to gather information prospectively with the results then
re-evaluated. We are currently developing a protocol for the set up of NIV.
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Mechanical in-exsufflation in adults with cystic fibrosis–a physiological
investigation
P. Agent (Presenting), M. Chatwin , E. Ross1 1 2
Physiotherapy Department, Royal Brompton Hospital, London, United Kingdom,1
Respiratory Muscle Laboratory, Royal Brompton Hospital, London, United2
Kingdom
Background: Respiratory infections are associated with decreased inspiratory and expiratory
muscle strength. Currently, there is no evidence to suggest that any one airway clearance1
technique is superior. The ‘cough-assist’ (JH Emerson Co) is a form of mechanical in-exsuf-
flation (MI-E) that aims to improve cough efficacy and is commonly used in patients with
neuromuscular disease. Peak cough flow (PCF) is correlated with expiratory muscle2
strength and it has been suggested that an unassisted peak cough flow)270 lymin is required3
for an effective cough. Aim: To carry out a physiological study to compare the effects of MI-
E on PCF in adults with CF. Method: Four patients (2 female) were familiar in using MI-E.
Patients were assessed with non-invasive respiratory muscle tests. They were then asked to
perform an unassisted cough, followed by an assisted cough—the ‘cough-assist’ provided a
deep breath in (insufflation) and patients were asked to cough with negative pressure (exsuf-
flation), titrated to patient’s comfort. PCF was measured with a pneumotachograph attached
to a full facemask. Results:
Subject 1 2 3 4
Age 26 24 26 38
FEV (lys)1 0.6 0.6 0.4 0.6
FVC (lys) 1 0.9 0.8 1.9
SNIP (cm H O)2 65 63 50 103
PI (cm H O)max 2 87 46 35 95
PE (H O)max 2 125 91 40 143
P (cm H O)moW 2 80 135 110 111
PCF (lymin) 461 443 376 518
PCFqMI-E (lymin) 470 443 323 453
Discussion: All patients had an unassisted PCF adequate to clear secretions with
an unassisted cough. However, greatest PCF was not achieved with mechanical
insufflation-exsufflation. All techniques were tolerated well by the patient and all
reported improved efficacy of airway clearance. The physiological mechanism of
action remains unknown. These preliminary results form part of an ongoing study
and further investigations are required in this group of patients.
References:
Meir 1988., Chatwin et al. 2003 (in press)., Polkey et al. 1998.1 2 3
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Prospective study of the use of inspiratory muscle training in
adolescents with CF
D. Rogers (Presenting), I.J.M. Doull
Child Health, Paediatric CFyRespiratory Unit, Cardiff, United Kingdom
Introduction: Inspiratory muscle function (IMF) is reduced in adult CF patients
when compared to healthy subjects. A recent study has described the use of the
Test of Incremental Resistance (TIRE) as a method of inspiratory muscle training
(IMT) in adults with CF, resulting in improved exercise tolerance and increased
vital capacity. We investigated the effect of using TIRE in a domiciliary setting in
adolescents with CF attending our adolescent clinic. Methods: Five CF patients (3
male), mean age 16.7 yr (range 14.5–18.4 yr) volunteered to take part in a pro-
spective 6 month trial of IMT, using the RT2 device ( Devilbiss Health Care UK).
Patients were instructed to perform TIRE therapy 3 times per week in addition to
their usual physiotherapy management. Measurement of Height, Weight, Body Mass
Index (BMI), SaO , FEV , FVC, FEF50%, Maximum Inspiratory Pressure (MIP),2 1
Sustained Maximum Inspiratory Pressure (SMIP), exercise tolerance, exercise activ-
ity score and adherence to TIRE therapy were made at baseline, 3 months and 6
months, respectively. Results: At both 3 and 6 months no significant difference was
found in lung function, inspiratory muscle function, exercise tolerance or exercise
activity compared to baseline. Patient adherence to prescribed levels of TIRE ther-
apy was a poor mean adherence 28.2% (range 16–38%), despite regular interven-
tion by a physiotherapist. Conclusion: No significant training effect was found in
our small group of adolescent patients with CF. This may be due to poor levels of
patient adherence to TIRE therapy.
s63Journal of Cystic Fibrosis 2 (2003) S61–S68
239*
Thoracic kyphosis in cystic fibrosis. The flexible ruler technique
L. Boyle (Presenting), J.M. Bradley , J. Howard , J.S. Elborn1* 2 1 1
Adult CF Centre, Belfast City Hospital, Belfast, Ireland, Adult CF Centre, School1 2
of Rehabilitation Science, Belfast City Hospital and University of Ulster, Belfast,
Ireland
Postural abnormalities in CF may be related to mechanical back pain. The flexible
ruler may offer a useful, non-invasive method for the quantification of postural
abnormalities in CF. Its reliability and validity have been established in the assess-
ment of lumbar and cervical spinal curvature however, there is no evidence of its
use in the thoracic spine. The aim of this study was to assess if there was any
difference in thoracic kyphosis, as measured by the flexible ruler between patients
with CF and age-matched healthy individuals. A convenience sample of 20 patients
with CF and 20 age-matched healthy individuals were recruited. The ruler was
contoured to the thoracic spine in a relaxed standing posture. Skin marks at T1 and
T11 were transferred to the ruler and paper traces of the shape made. All measure-
ments were made by the same physiotherapist. The angle of curvature was calcu-
lated geometrically. There was no significant difference in age between patients
with CF and healthy individuals (age: mean (S.D.), patients with CFs24.3 (6.9);
controlss24.9 (4.9) yr). There was a significant difference (P-0.01) in thoracic
angle between the 2 groups (angle: mean (S.D.), patients with CFs47.2 (10.0);
controlss38.9 (8.0) degrees). There was no significant relationship between tho-
racic angle and lung function or body mass index. In patients with CF there was a
moderate relationship between thoracic angle and age (rs0.40, Ps0.07). Thoracic
kyphosis is greater in patients with CF compared to healthy individuals. The flexible
ruler is a valuable and simple method to assess thoracic kyphosis.
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Adherence to physiotherapy among children with cystic fibrosis: a
qualitative investigation
J. Coyle (Presenting), B. Williams
Epidemiology and Public Health, University of Dundee Medical School, Dundee,
Scotland
The purpose of the study is to explore children and parents explanations for adher-
enceynon-adherence to home physiotherapy. Although, chest physiotherapy is a
major component in the respiratory management of children with CF, research
shows that only 50% of parents and children fully adhere to their recommended
regimen (Chappell and Williams, 2002). This study therefore sought to explore the
attitudes, beliefs and intentions underpinning adherenceynon-adherence in children
and young people. A sample of 33 children was purposefully selected to take into
account as a wide variety of issues as possible such as age range, symptom severity
and family structure. In-depth, interviews were conducted with the children and
their parents separately, at home. All interviews were audio recorded and tran-
scribed. The findings revealed that time perception, activity perception, fatigue,
boredom, social life expansion, life restriction, and disruption, self-identity and
impact uncertainty were key conceptual categories in explaining adherence and non-
adherence to physiotherapy regimens. The children’s stories of illness illustrated
the complex ways in which the condition permeated their lives, self-identities and
their underlying attitudes towards treatment regimens. The conceptual framework,
which was developed, was firmly grounded in children’s lived experiences. Thus
it can provide a sound basis from which physiotherapists can work with children
and parents to address barriers to adherence. Within this we suggest a key task for
physiotherapists and specialist nurses to assist the child in managing the co-exis-
tence of their CF identity alongside other cherished identities.
F. Chappell, B. Williams, Rates and reasons for non-adherence to home physio-
therapy in paediatrics, Physiotherapy 88(3) (2002) 138–147.
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Positive benefits of school study days for cystic fibrosis–the
Nottingham experience
F. Haynes(Presenting) , H. Holden , A. Smyth1 1 2
Physiotherapy, Nottingham City Hospital, Nottingham, United Kingdom, Depart-1 2
ment of Paediatrics, Nottingham City Hospital, Nottingham, United Kingdom
The Nottingham CF Unit supervises the care of 158 children. Multidisciplinary
School Study Days were introduced in 1996 with the aim of promoting information
about all aspects of CF, fostering contact with staff such as dieticians, who are
primarily hospital based and allowing interactive discussions. In 1996 and 1998
only schools delivering physiotherapy were targeted but in 2000 and 2002, the day
was open to all schools with CF children. Consent was obtained from all parents
before approaching schools. In this study we aimed to assess attitudes towards and
benefits gained by delegates at the 2002 day. From a total of 57 schools in Not-
tinghamshire, attended by 63 CF children, 24 were represented (3 nursery, 14 pri-
mary, 7 secondary) by 28 delegates. A further 13 schools expressed interest but
were unable to attend. All delegates completed questionnaires at the beginning and
end of the day. The majority of delegates were teaching assistants (46%) and 75%
had daily contact with a CF child. Active involvement included physiotherapy
(43%), Creon administration (46%) and inhaler supervision (32%). Prior to the
Study Day, 64% rated their knowledge as poor in all aspects (pathology, nutrition,
medication, physiotherapy and social). At the end, 93% reported good knowledge
in these areas with particular benefit in pathology, nutrition and social. All planned
to cascade information within their school. CF children spend a considerable amount
of time in the school environment and the School Study Day is a valuable tool in
promoting awareness of their physical and emotional needs.
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The impact of an exercise physiologist in an adult cystic fibrosis unit
P. Davies (Presenting), R. Tattersall , I. Rolls , M. Davies , M.J. Ledson , M.J.1 1 1 1 2
Walshaw2
Department of Physiotherapy, The Cardiothoracic Centre, Liverpool, United King-1
dom, Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom2
The therapeutic role of exercise in the Cystic Fibrosis (CF) population has received
much attention in recent years. Although the relationship between regular activity
and decreased mortality for patients with pulmonary disease is inconclusive, the
positive effect on morbidity and quality of life has been well established. Despite
recommendations, physiotherapy staff may not have time to actively direct exercise
sessions during in-patient admissions. In an attempt to increase activity during
admissions and improve adherence to a long-term exercise programme, we
employed a full time Exercise Physiologist to work as part of our multidisciplinary
team. In order to establish any subsequent increase in exercise time during in-patient
stays, we compared the admissions immediately prior to and following the appoint-
ment of an Exercise Physiologist for 16 patients in our adult unit (age range 18–
41 yr, mean FEV1 60% predicted, 6 female). The availability of an Exercise
Physiologist significantly increased the median daily exercise time (DET) by 7.5
min (P-0.005). The median DET prior to the Exercise Physiologist was 0.9 min
with 8 patients (50%) not exercising at all. DET increased to 8.4 min with all 16
patients (100%) exercising at some point in the admission. Furthermore, the most
active 25%, increased their average DET by a median of 6.6 min with the least
active 25% increasing average DET by a median of 6.2 min. This study shows that
the availability of an exercise specialist has had a positive effect on the activity
levels of CF patients during an admission. The role of the exercise physiologist in
our unit is exercise testing, exercise prescription, supervising exercise regimes and
advising on home exercise programmes, thereby the physiotherapist has more clin-
ical time to assess, treat and advise patients on their physiotherapy regimes.
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Exercise capacity in Belgian children with cystic fibrosis
M. Vreys (Presenting), T. Havermans , E. Aertgeerts , M. Proesmans , R.1 1 1 1
Gosselink , K. De Boeck2 1
University of Leuven, Leuven, Belgium, Physiotherapy Department, University of1 2
Leuven, Leuven, Belgium
Aim: To compare the exercise capacity of children with CF (6–13 yr) with normal
values for healthy Belgian children aged 6–13 yr. Method: 25 children performed
exercise capacity tests (endurance run, grip strength and isometric quadriceps
force), lung function tests, and rated Borg scores for dyspnoea. Spearman rank
correlations and chi2 were used for analysis (*P-0.05; **P-0.01). Results: On
the endurance test, 7y25 children scored below P25 and only 2y25 scored above
P75, i.e. worse than the reference group (P-0.01). Mean% predicted FVC (94%
S.D.s15) and FEV (89% S.D.s16) were within normal range. Only 4y25 chil-1
dren had an FEV below 80%. Oxygen saturation was above 90%, both at rest and1
during maximal exercise capacity. Mean body mass index (BMI) score was 16.1
(S.D.s2.1). Eightytwenty-five had a score below P25, i.e. worse than the reference
group (P-0.01). Endurance run results correlated positively with percent predicted
FVC and FEV (rs0.41* and 0.44*, respectively), baseline heart rate (rsy1
0.45*), maximal heart rate (rs0.56**) and peripheral muscle strength (rs0.63**
to rs0.59**). Borg score for dyspnoea was higher in children with lower endurance
(rsy0.47*), lower saturation at maximum capacity (rs0.43*) and higher baseline
heart rate (rsy0.45*). BMI scores correlated with FEV (rs0.42*) and periph-1
eral muscle strength (rs0.55** to rs0.42*). Conclusions: Endurance tests scores
and BMI do differ between young CF children and healthy controls. Endurance is
better in CF children with better lung function. Lung function correlates positively
with BMI and peripheral muscle strength.
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Patient education and adherence to physiotherapy in adults with cystic
fibrosis–a literature review
M. Carroll
Southampton Adult C.F. Unit, Southampton University Hospital Trust, Southampton,
United Kingdom
Iintroduction: As people with C.F. are living longer, more complex and time con-
suming treatment is necessary. Adherence to physiotherapy has been reported in
several studies as being poor, inspite of the recognised benefit of physiotherapy in
reducing lung damage and increasing exercise tolerance (Robinson, 2000). Studies
reveal the significance of health beliefs, locus of control and coping skills in influ-
encing adherence to treatment (Carr et al., 1996, Abbott et al., 2001). Patient
Education: Although physiotherapists spend considerable time teaching and edu-
cating patients to self manage their care, little attention has been given by the
profession into how adults learn (andragogy). The development of a humanistic
educational approach, where the teacher is seen as a facilitator is reflected in the
encouragement given in the National Health Service to empowerment, where
patients take increasing responsibility for their own self care. By fostering an equal
partnership between the patient and the professional, greater emphasis can be given
to patient centred outcomes. If patients participate in their treatment plan they are
more likely to adhere to it. Adherence: The need for evidence based treatment is
paramount. If there is no discernable clinical improvement with physiotherapy treat-
ment then patients are unlikely to adhere to it irrespective of physiotherapy advice
to continue. Adherence can vary over a period of years as the disease process
unfolds. Conclusion: Their needs to be longitudinal research studies on adherence
to physiotherapy and the development of educational strategies to improve patient
care.
References:
Carr et al., Physiotherapy 82(11) (1996) 621–627.
Abbott et al., Disability and Rehab. 23(8) (2001) 315–324.
Robinson Thorax 56(3) (2000) 237–241.
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Community physiotherapy ‘a need or a desire’
P. Singleton(Presenting), F. Hampton, F.J. Lindsay, P.A. Cole
Middlesbrough, United Kingdom
In 2001, community physiotherapy service for Cystic Fibrosis patients was estab-
lished covering two NHS trusts running a combined service in the North of England.
This service was initiated due to a perceived lack of access to physiotherapy in the
home environment. The aims were to provide equal opportunity of access to com-
munity physiotherapy services to meet individual needs. The poster considers how
the service aims equated with family’s needs, the perceived needs of the multi-
disciplinary team and whether the visits were appropriate. Criteria set for home
visits were the following: New diagnosis, Relocating to area, During IV therapy,
Annual review, Increased respiratory symptomsypositive cultures and compliance.
An audit was carried out to consider the source of referral and utilisation of the
service. Results showed 90% of patients accessed the service. Of those using the
service, 55% of referrals came from the MDT and 22% from familiesypatients
themselves. The distribution of visits requested matched the perceived need iden-
tified by the criteria. Patient satisfaction has not been formally audited to date.
Informal discussion with families suggests physiotherapy is an integral part of home
care. There has been a steep learning curve for provider and users of the service
that had been evident over the last year. Results show a real need for the ability to
investigate and monitor respiratory symptoms and parental need to access physio-
therapy directly. The service provided the resource to fulfill this need. Plans are to
formally re-audit the service in two years when community physiotherapy has been
established.
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Status of cystic fibrosis physiotherapy and adherence to physiotherapy
in Poland
T. Orlik (Presenting), D. Sands , L. Kluba , R. Piotrowski1 2 1 2
Physiotherapy Department, Institute of Mother and Child, Warsaw, Poland, Pae-1 2
diatric Clinic, Institute of Mother and Child, Warsaw, Poland
The practical experience of many CF centres is that patients with CF do not do PT.
The frequency and consumption of daily PT time is one of the most important
factors, which may influence the adherence. We believe that the PT Department
having easy access to the home is another reason for compliance with PT, however,
there is little objective evidence to support this supposition. The aim of this study
was to estimate the status of CF physiotherapy care and assess adherence to the PT
in Poland. We studied 441 patients with CF (225 F, 216 M) including 344 children
(177 F, 167 M) of age 3 months to 18 yr and 97 adults (48 F, 49 M) of age 18–
34 yr. Status and compliance with therapeutic regimens among patients with CF
was measured using special questionnaires for parents, children more than 10-years
old and adult patients. We estimated: the kind of PT methods used at home, if
parents and patients are using the PT in compliance with the recommendations of
doctors and physiotherapists, if PT is regularly used at home, which circumstances
influence the use of PT by parents and patients, if PT Departments are easy to
access for patients from their homes. The study shows that in Poland standard
physiotherapy consists of postural drainage with clapping. However, 25.3% patients
use Flutter, ACBT- 9.9%, PEP system- 1.2%. FET during drainage is used by 20.6%
of patients. 77.6% parents and 59.8% adult patients said that they used PT in
accordance with recommendations. On the other hand only 23.5% parents always
use PT, whatever the circumstances. 12.9% of patients take PT Department advice
at home. Among these ones 3.85% take advice regularly, 9.07% occasionally. In
Specialist, CF Centres only 29% of patients take PT advice regularly, 34% occa-
sionally. We suggest that in order to improve adherence to PT in patients with CF
in Poland we should first of all improve the system of PT care based on the Spe-
cialist Centres.
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The Welsh paediatric physiotherapist clinical network: a model of
shared care for paediatric cystic fibrosis (CF) patients
D. Rogers(Presenting), I.J.M. Doull
Child Health, Paediatric CFyRespiratory Unit, Cardiff, United Kingdom
Introduction: The paediatric CF unit at UHW currently has responsibility for the
care of 191 children with CF (70 full care, 121 shared care), spread over a geo-
graphical area of over 4000 square miles. During the past 10 yr a clinical network
of paediatric physiotherapists has been developed to facilitate individual patient care
and provide a seamless service between the specialist CF centre and shared care
CF clinics. Method: The current clinical network is comprised of 22 paediatric
physiotherapists working in 11 hospitals throughout South and Mid Wales, with a
clinical specialist CF physiotherapist based at the specialist CF centre in Cardiff.
At routine CF clinics, 4 levels of physiotherapy care are provided by the specialist
centre, ranging from full patient care to specialist education and clinical advice. At
annual assessment, a home visit is performed by the local physiotherapy service
after which a full medical, physiotherapy and dietetic assessment is carried out at
the following shared care clinic by the CF team and a report fed back to the local
services within 1 month of assessment. Results: In 2002 a total of 43 shared care
clinics were undertaken by the specialist physiotherapist, in 8 District General Hos-
pitals throughout South and Mid Wales, resulting in 166 physiotherapy attendances.
Ninety paediatric CF patients had a physiotherapy annual assessment and patient
reports were communicated between 9 hospitals and 14 paediatric physiotherapists.
Conclusion: We have found that this model of care has been shown to facilitate
patient communication between a specialist physiotherapy team and locally provid-
ed physiotherapy services for children with CF.
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Hospital annual physiotherapy assessment aimed to point out and
improve daily problems in CF children
A. Munck(Presenting), B. Delaisi, A. Vital-Foucher1, V. Leroy, G. d’Acremont, M.
Gerardin, J. Navarro
Hopital Robert Debre, Paris, Franceˆ ´
Efficient chest physiotherapy (CPT) is of recognised benefit in reducing lung dam-
age in CF. Aim: To assess the methods currently used in home CPT, modalities of
aerosoltherapy, adherence, postural dysfunctions and to provide rational advices.
Methods: Prospective study with an annual questionnaire filled during a consulting
session by a senior physiotherapist: CPT techniques (autogenic drainage and active
breathing techniques (ADyABT), oscillating devices (OD), capacity of expecto-
ration, inhalation therapy with optimal inhalation techniques, timing and material
adequacy of aerosoltherapy, morphostatic evaluation (back, shoulders), sports, daily
problems pointed out by home CPT. Results: Sixty-one patients (34 females) were
assessed, Mean age is 8 yr 3 months (range: 15 months–19 yr 3 months), all except
one performed ADyABT and 0 OD. Two were performing physiotherapy by them-
selves. The study revealed that 13 children (7 M, 6 F) were not able to expectorate
while being sputum productor and to benefit CPT advices or psychologic help. Two
ADyABT were not performed with the right technique. EightyThirty-two had inad-
equate timing schedule of inhalation (preypost CPT) or non optimal inhalation
technique. The most interesting results concerned morphostatic abnormalities such
as 2 scoliosis, 2 scoliotic attitudes, 1 kyphosis, 16 kyphotic attitudes, not detected
before this evaluation and necessitating specific active cares. Conclusion: CPT is
time consuming and hard to carry out every day; continuous education and annual
check up is the best tool to find motivation and detect inadequate technique of
morphostatic abnormalities.
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Changing clinical practice–physiotherapy in ‘asymptomatic’ infants
with cystic fibrosis: a consensus statement
M. Dodd (Presenting), A. Parker , S.A. Prasad , M. Dodd1 2 3 1
Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust,
Manchester, United Kingdom, Castle Carey, Somerset, United Kingdom, Cystic2 3
Fibrosis Unit, Great Ormond Street Hospital for Children, London, United Kingdom
Background: Traditionally twice daily chest physiotherapy has been advocated for
infants with cystic fibrosis (CF) from diagnosis irrespective of clinical symptoms.
Nowadays, with neonatal screening and medical advances, babies presenting with
CF are often well nourished and have no respiratory symptoms. A recent review1
revealed the burden of routine chest physiotherapy on families to be considerable.
Furthermore, physiotherapists have become increasingly uncomfortable with pre-
scribing routine treatment in the absence of secretions and minimal evidence of
efficacy. The ACPCF formed a working party to develop consensus guidelines for
the future management of infants with CF using the Delphi technique. Methods:
Eight members of the working party and 16 members of the ACPCF Executive
Committee were asked to rate their agreement with 14 statements and 5 recom-
mendations. These related to concerns regarding changes in practice. Consensus
was assumed when agreement levels were )80%. Results: All statements and rec-
ommendations were agreed at )80%. Respondents agreed that there was a need
for assessment tools, both for physiotherapists (83%) and families (92%). It was
agreed (100%) that minimum standards of care were also necessary with any change
in practice. Discussion: The ACPCF have concluded that any regimen of chest
physiotherapy in infants with CF should be flexible, with an open and honest rela-
tionship between physiotherapists, patients and carers. Emphasis should be placed
on a holistic approach, considering the fitness of the whole child using movement,
exercise and when required appropriate airway clearance modalities. A prescriptive
regimen of routine airway clearance should generally not be advocated. Consensus
guidelines for this change in practice are now being developed.
CF Trust Strategic Review ‘Project Life’ 2000; Cystic Fibrosis Trust, Bromley,1
Kent UK.
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Successful treatment of infants and small children
L. Lannefors (Presenting), U. Dennersten , K. Theander , J. Martensson , R.1 1 2 2˚
Kornfalt2¨
Lund CF-centre, Department of Respiratory Medicine, Lund, Sweden, Lund CF-1 2
centre, Department of Pediatric Medicine, Lund University Hospital, Lund, Sweden
Chest physiotherapy in CF has undergone extensive changes during the last 20 yr.
Many different alternative techniques have been developed. However, modified pos-
tural drainage"clapping and vibration is still considered the only alternative for
children up to the age of 5 yr. In 1983 the airway clearance therapy was totally
changed for all patients at Lund CF-centre. For children, postural drainage with
clapping and vibration was replaced by a locally developed airway clearance tech-
nique based upon physical activityyexercise. This technique is used from the day
of diagnosis. All other parts of the treatment are in accordance with international
guidelines. All patients at Lund CF-centre are tested at the Clinical Physiology lab
for the first time at the age of 7 yr. Static and dynamic spirometry and a working
capacity test is carried out annually. The results from these tests at the age of 7
during the period 1990–2002 are summarised in the table below. Ns38, 22 homo-
zygous and 14 heterozygous for deltaF508.
median% p range
VC 100 70–129
FEV1,0 100 64–135
TLC 100,5 71–134
RV 103 50–200
FRC 100 64–144
WC 110 77–228
The 7-year old, whose airway clearance therapy from the day of diagnosis consisted
of a technique based upon physical activityyexercise show normal lung function
and working capacity.
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Influence of assisted autogenic drainage (AAD) and aad combined with
bouncing on gastro-oesophageal reflux (GOR) in infants under the age
of 5 months
F. Van Ginderdeuren (Presenting), A. Malfroot , J. Verdonk , S. Vanlaethem , Y.1 2 1 1
Vandenplas2
Physiotherapy, AZK-VUB, Brussels, Belgium, Pediatrics, AZK-VUB, Brussels,1 2
Belgium
Gastro-oesophageal reflux can be one of the contributing factors of respiratory
infections in infants. Incidence of GOR in Cystic Fibrosis is very high in the first
month of life, strongly decreasing after the age of 6 months (Malfroot et al., 1991).
GOR potentially impairs pulmonary function and children with CF and GOR have
poorer lung function than those without GOR (Stringer et al., 1988). Conventional
physiotherapy including postural drainage has been associated with a significant
increase in GOR in numerous studies. This is the third and final phase of our study,
looking at the influence of new and efficient airway clearance techniques on GOR.
Assisted Autogenic Drainage is based on the principles of Autogenic Drainage.
Sometimes AAD is combined with Bouncing (a rythmic up and down movement
on a physio ball) to relax the baby. We studied 20 infants (non CF) under the age
of 5 months (mean age: 8.5 weeks) undergoing 24 h pH monitoring for GOR using
Orion (Medical Measurement Systems). All patients had a AAD session and a
BouncingqAAD session of 15 min at least 1 h after breakfast or lunch, given by
an experienced physiotherapist. pH monitoring data (refluxindex and number of
refluxes) were within normal ranges in 19 patients, while in 1 pathologic GOR was
confirmed. For all 20 patients, the refluxindex and the number of episodes with
pH-4 was not significantly higher during both physiotherapy sessions compared
to the results of the same patient 15 min before and 15 min after physiotherapy
(Friedman Two-Way Anova). We conclude that there is no provocation of GOR
during AAD and AAD combined with Bouncing in infants under the age of 5
months.
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Chest X-ray changes in 53 infants and children diagnosed with cystic
fibrosis in a region without newborn screening
P. McCormack (Presenting), A.J. McDonald , K.W. Southern1 1 2
Regional Paediatric CF Unit, Royal Liverpool Children’s Hospital, Liverpool,1
United Kingdom, Paediatrics, University of Liverpool, Liverpool, United Kingdom2
Introduction: A recent randomised controlled trial (RCT) suggests improved res-
piratory condition in CF infants randomised to a modified physiotherapy regime
without head down tilt (B.M. Button et al., Pediatr. Pulmonol. 35 (2003) 208–
213). We reviewed new diagnoses in our clinic over the past 4 yr to establish the
prevalence of lung involvement, as determined by CXR changes, in order to assess
our current practice of initiating postural drainage for basal segments from diag-
nosis. Methods: Retrospective review of case notes and physiotherapy notes. Find-
ings: Fifty-three infants and children were diagnosed in the four-year period (18
following meconium ileus; 10 of whom had some CXR change). Of the remaining
35 (non-MI; median age at diagnosis, 0.7 yr), 31 had CXR changes identified at1
diagnosis (albeit sometimes mild) and in 19 these changes were seen in basal
segments. Twenty-four of these 35 infants and children were assessed as having a
productive cough (including all the patients with basal CXR changes). Twelve
month follow up data from 30 of the non-MI infants demonstrate no significant
difference in the prevalence of respiratory involvement (CXR changes, 26 vs. 23;
basal changes, 16 vs. 18; productive cough, 20 vs. 17). Two infants were treated
for a clinical suspicion of reflux and their physiotherapy regime altered accordingly.
Conclusions: In this region, which does not have a newborn screening programme,
CXR changes and respiratory symptoms were prevalent at the time of diagnosis. In
a significant number these changes were seen in the basal segments (always asso-
ciated with symptoms) supporting the rationale of employing postural drainage to
these areas. Overt reflux was not common, however, persistence of CXR changes
highlights the need for further well-powered RCTs to determine how to best treats
these infants.
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Chest physiotherapy–practical course as follow-up model emphasising
individual adaptation in the use of physical exercise in airway
clearance
S. Gursli(Presenting)
Ullevaal University Hospital, Oslo, Norway
Introduction and aims: A one week course emphasising the use of physical exercise
was offered a group of patients. The aims were to increase the quality of treatment,
increase the degree of self-management, assess working models for the follow-up
of patients and assess feedback and effect. Method: Seven adult CF patients (mean
age 31 yr, range 20–51; (3 female) with Pseudomonas aeruginosa participated.
The patients had two individual treatments indoor and one treatment together out-
doors each day with different kinds of exercise being introduced. The removal of
sputum was observed and amount of sputum was measured. Lung function para-
meters were measured before and after the course. Results: Lung function para-
meters showed no significant improvement when comparing values at the beginning
and at the end of the course. The patients reported that they had expectorated more
sputum than in daily treatments at home. Individual variations were found when
assessing the effect of removing secretions before, during andyor after physical
exercise. Pathophysiology, arena and type of exercise are importent aspects to con-
sider, with power walking and jogging given the best evaluation. All patients report-
ed that they had learned enough to be able to continue at home. Summary: This
pilot work showed the importance of adapting the use of physical exercise in airway
clearance to the individual and to consider type of exercise and the removal of
sputum. It showed benefits of a short-term course on self-management and presup-
positions for implementing treatment in daily routines. Further studies and longi-
tudinal studies are needed to draw conclusions.
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Issues that face undergraduate and post-graduate health care workers
with cystic fibrosis working in clinical settings together with
recommendations relating to duty of care to health care workers and
their patients
B. Button (Presenting), R. Robins-Browne , D. Armstrong , N. Curtis , G. Hogg ,1 2 3 2 2
A. Street4
The Alfred Hospital, Melbourne, Australia, Microbiology, The University of Mel-1 2
bourne, Melbourne, Australia, Respiratory Medicine, Monash Medical Centre,3
Melbourne, Australia, Respiratory Medicine, Royal Melbourne Hospital, Mel-4
bourne, Australia
Health care workers with CF (HCWCF) ask about risk and precautions working in
the health care setting. The University inquired about the duty of care to student
HCWCF and their patients during clinical placements. Aims: (1) To research the
international experience with HCWCF; (2) to determine issues relating to duty of
care to HCWCF and their patients; and (3) to develop practice guidelines. Method:
A University Working Party (UWP) was formed with medical advisors and a phy-
siotherapist (PT) to information. The PT prepared a questionnaire (Qx) to distribute
at conferences in 2001–2002. Questions related to professions chosen; cross-infec-
tion risk and precautions; health and medico-legal issues; confidentiality and pro-
tocols. Results: 100 surveys were distributed to therapists internationally. Twenty
patients were able to complete the Qx. HCWCF trained and worked in most areas
of health care. ‘Universal precautions’ were advised. HCWCF should avoid working
with other CF patients. Cross-infection and medico-legal issues had arisen including
compensation claims. The UWP recommended that individuals with CF should not
be excluded from health care professions; earlyyongoing education about demands,
stresses, risks and other implications of working in health care and strategies to
reduce risks. Disclosure by HCWCF to employers and respect for confidentiality
are necessary to protect themselves and patients. Education regarding infection con-
trol, sputum surveillance, awareness of organisms carried and appropriate actions
should be provided. HCWCF with chronic P. aeruginosa or MRSA should not
attend patients at risk of infection with these bacteria. Patients who can safely be
attended by HCWCF should be determined by the status of the patient and the
HCWCF. Conclusion: Information has been collated and recommendations have
been made that respect the right of adults with CF to work in the health care field
and minimize risks of adverse health or medico-legal outcomes.
s67Journal of Cystic Fibrosis 2 (2003) S61–S68
255
Prevalence of urinary incontinence in male and female CF patients and
its contributing factors
S. Vanlaethem (Presenting), M. Van Nylen , F. Van Ginderdeuren , I. Dab , C.1 1 1 2
Knoop , G. Casimir , L. Van Schil , K. De Sager , K. De Boeck , A. Malfroot3 3 4 4 5 2
Physiotherapy, AZK-VUB, Brussels, Belgium, Pediatrics, AZK-VUB, Brussels,1 2
Belgium, Pulmonology, ULB, Brussels, Belgium, Pediatrics, St. Vincentius,3 4
Antwerp, Belgium, Pediatrics, KUL, Leuven, Belgium5
It is recently reported that the prevalence of urinary incontinence (UI) is higher in
CF patients of both sexes than in the normal population (although females were
mostly studied). The exact mechanism is still unknown, but it is probably multi-
factorial. We sent an anonymous questionnaire in Dutch and French to 250 CF
males and females (age 14–45 yr). A total of 153 (61.2%), 71 males (46.5%) and
82 females (53.5%), replied. There was no difference in the answers between Dutch
and French patients. None of the males reported UI, while it was highly reported
in the females over all age range (in 57 patients or 70%). Most females reported
problems once a week (25.5%), while 23% complained several times a week and
11% reported daily problems. Coughing (49%), laughing (28%) and sneezing
(27%) were the activities that caused UI most frequently. Nineteen (23%) patients
avoided some activities to prevent urinary loss, such as coughing, sports, lifting
things and social activities, while 46% did not. UI was also present in 6 out of 8
women with children (the problems appeared after pregnancy). We concluded that
in our series, using the same questionnaire, UI is a problem in female CF. In 30%
it was clearly related to an infection exacerbation and could hinder correct airway
clearance. Therefore patients should be actively encouraged to report and treat UI,
since shame and fears for more complicated treatments are usually unfounded rea-
sons for non-reporting of their UI. Supported by the Belgian Association of Cystic
Fibrosis.
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The prevalence of urinary incontinence in adults with cystic fibrosis,
and their awareness of role of physiotherapy management
P. Agent (Presenting), F. Alton , S. Madge1 1 2
Physiotherapy DepartmentyAdult CF Centre, Royal Brompton Hospital, London,1
United Kingdom, Adult CF Centre, Royal Brompton Hospital, London , United2 1
Kingdom
Background Prevalence of urinary incontinence in the general population has been
quoted at 5%. Patients with chronic lung disease are thought to be at risk of1
developing urinary incontinence due to repeated coughing causing increased stress
to the pelvic floor. The ‘Clinical Guidelines for the Physiotherapy Management of
Cystic Fibrosis’ recommends the importance of identifying urinary incontinence in2
both children and adults. Other UK Adult Specialist CF Centres have quoted a
prevalence of 68% in women reporting leakage of urine and 4.45% of men . Aims:3 4
A preliminary assessment was undertaken to (1) determine the incidence of urinary
incontinence in adults, (2) discover whether they understood the role of physio-
therapy in the management of this problem, (3) establish whether patients would
prefer provision of a continence service here at the CF Centre or locally. Method:
55 adults (30 female) were randomly surveyed when attending the outpatient CF
clinic. A short, anonymous questionnaire was completed which assessed incidence
of leakage, previous helpysource of help, knowledge of the role of physiotherapy
for continence management, and desired location of management service. Results:
Female % Male % Combined %
Leakage of urine 66.7 (20) 4 (1) 38 (21)
Sought advice 3 (1) 0 2 (1)
Aware of role of physio 20 (6) 8 (2) 15 (8)
Service at RBH 72 (21) 36 (9) 56 (30)
Discussion: This short survey has demonstrated that our prevalence of urinary
incontinence in adults with CF is consistent with other UK centres. A service
requirement has been identified and patients would prefer to attend this CF Centre
for managementytreatment of their urinary incontinence. We are now extending this
study to the entire adult population attending this Centre looking at Quality of Life,
reasons for incontinence and appropriate treatment.
References:
Royal College Physicians (1995)., CF Trust (2002).1 2
Orr et al., (2001)., Gumery et al., (2001 in press).3 4
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Level of inter-communication existing between physiotherapists in
private practice and in hospital practice caring for the same patient with
a serious illness, cystic fibrosis (CF) or neuromuscular disease (NMD)
C. Lejosne(Presenting)
CF Center of Perharidy, Roscoff, France
A patient suffering from a serious and progressive illness spends most of his time
between his home and hospital. He is cared for by professionals in private practice
and hospital practice – ‘dual care’. What level of intercommunication exists
between these two categories of professionals? This study’s aim is to open new
ways to improve quality of care in this professional home-hospital practice. Its
specific objectives are:
– To determine the role of intercommunication in the management of ‘dual care’
physiotherapy.
– To look for links between the level of communication and consensus in care.
Methods: In 2001, a preliminary study on factors facilitating communication was
carried out using a questionnaire sent to private practice and hospital practice phy-
siotherapists caring for the same patient suffering from CF or NMD. The results
were analysed statistically. In 2002, a new questionnaire explored expectations
(regarding information and training) of private practice physiotherapists. Results:
Sixty percentage of respondents declared communication with their colleague (93
out of 170 sent were returned: 54.7%). The main subjects of communication are
the patient and his illness. Then follows work-up and objectives of care. The reasons
why 40% of respondents do not participate in networking and communication is
generally because they do not know their colleague do not feel the need or don’t
have the time. What respondents expect from a network is training (40%) and up
to date information on new knowledge and technical skills. Conclusion: Profes-
sionals are prepared to communicate more if invited to do so. They appreciate
contact with colleagues. Among professionals tending to communicate, we observe
what we call a ‘network effect’: belonging to a network increases tendency to
intercommunicate and increases consensus on care.
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Sputum samples for microbiology-does the timing matter?
B. Rijnbende (Presenting), E. Price , S.B. Carr1 2 2
Children’s Services, Tower Hamlets Primary Healthcare Trust, London, United1
Kingdom, Children’s Services, Barts and the London NHS Trust, London, United2
Kingdom
Much of the improvement in survival for patients with cystic fibrosis has been
attributed to aggressive antibiotic treatment. We are reliant on assessing the presence
of lung bacteria to guide antibiotic prescription. Clinics monitor patients’ sputumy
cough swab samples on a regular basis. There is no data available on the optimum
timing of these samples. We hypothesised that the optimum timing to achieve the
highest rate of bacterial pick-up rate would be in the morning at the end of chest
physiotherapy treatment. Method: Sputum or cough swab samples were taken at the
beginning of a routine chest physiotherapy session, as is our current practice. Repeat
samples were then taken just prior to the end of the session. In-patients also gave
samples at the beginning of morning and afternoon physiotherapy sessions on the
same day. The sample timing was blinded from the laboratory staff analysing the
samples. Results: Twenty children took part in the study (5 months–16 yr 9 months:
11 female), 16 gave sputum samples and 4 cough swab samples. The mean number
of different bacterial strains grown at the beginning of a physiotherapy session was
compared to those at the end: 1.8 (S.D.s1) vs. 1.9 (S.D.s0.9), NS. Fourteen of
the children also gave morning and afternoon samples, they grew 0.9 (S.D.s0.7)
vs. 1 (S.D.s0.7) bacterial strains, respectively, NS. However, despite the similar
numbers of strains of bacteria, 3 children (21%) grew Pseudomonas species in the
afternoon sample that was not present in the morning. Conclusion: There appears
to be no difference in the number of strains of bacteria detected during a single
session of physiotherapy, enabling current practice to be continued. The higher
prevalence in afternoon samples of Pseudomonas species may have a significant
clinical impact and continued work is being done to assess the optimum time of
day to sample these children.
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How to disinfect the nebulizers of cystic fibrosis patients? An in vitro
study
G. Reychler, A. Simon, K. Aarab, C. Van Oosel, J. Gigi, A. Beaudelot, C. Dutran-
noix, P. Lebecque(Presenting)
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Objective: To assess in vitro the efficiency of 5 disinfection methods for nebulizers.
Methods: A standardized technique was used to ensure heavy contamination of 352
nebulizers (maskqmouthpiece) by 16 bacterial strains (St. aureus.: 4, Ps. a.: 8, St.
malt.: 2, Burkh. cep. et Alc. xyl.: 1). The devices were then either disinfected by
5 methods (acetic acid: 3.5%, hypochlorite solution: 225 ppm, Hexanios: 0.5%,
warm waterqdetergent: 0.5% or dishwasher), with or without drying (except for
the dishwasher) (ns208), either used as controls (ns144). Standardized samples
for quantitative bacteriological study were obtained at 1H et 4H for the group
without drying and at 4H for the group with drying. Results: Disappearance of
bacteria and disinfection (defined as a decrease of bacteria count )105) were
observed in 84.1% and 10.6% of the experiments, respectively. Acetic acid was
ineffective against St. aureus, which accounted for most failures (10y11). Conclu-
sion: With the exception of acetic acid, the methods tested in this in vitro study
effectively sterilized or disinfected nebulizers contaminated by usual CF pathogens.
This work was supported by a grant from the Association Belge de Lutte contre la
Mucoviscidose.
Journal of Cystic Fibrosis 2 (2003) S69–S72
Nursing
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Role of the community CF nurse in supporting the CF infant diagnosed
by newborn screening
A. Robinson(Presenting), Phil. Robinson
Royal District Nursing Service, CF Unit, Respiratory Medicine, Royal Children’s
Hospital, Melbourne, Australia
Newborn screening for CF was introduced in Victoria Australia in 1989. In the
same year a community based support program including 2 clinical-nurse-consult-
ants (CF CNC) and a physio was established. This team, in conjunction with the
hospital-based team established a support program for newly diagnosed families.
At diagnosis parents spend a 5-day period in the hospitals ‘care-by-parent’ unit.
During this period CF education is given to parents in conjunction with tests such
as CXR’s and fat balance studies conducted to document the infant’s phenotype.
The community team is introduced at the end of this period and follow-up visits
are planned weekly for the first month and second weekly for 2 further months. In
that period the CF CNC also contacts the local general practitioner to provide
information about CF care. If required, grandparents and other family members are
also provided with information and education. Discussion with hospital team mem-
bers concerning issues raised in such sessions are fed back to hospital based prac-
titioners at weekly meetings. In families where childcare is being used, the CF CNC
visits these centers and provides education on CF care. In a group of 18 families
who received this support overall parental confidence in CF knowledge and ability
to provide CF care was significantly higher than that found in a group of 12 families
who did not receive this post education week support. Intensive support of newly
diagnosed families in the community has long-term benefit for the CF family.
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Supporting newly diagnosed cystic fibrosis patients and families in the
home
J. Burton(Presenting)
Great Ormond Street Hospital, London, United Kingdom
Introduction: A nurse led homecare service commenced at our centre in 1998; we
care for 200 children in the south east of the UK. Aim: A retrospective review of
home visits in the first year after diagnosis was carried out. Results: Fifty-three
newly diagnosed patients have been referred in the 4-year period since 1998. Thirty-
oneyFifty-three (58%) have been seen by the CF Homecare Nurse Specialist
(CFHNS). In total 127 visits were carried out in the first year after diagnosis, with
an average of 4 visits per patient. For various reasons 20 patients were not referred
to the CFHNS and 2 families declined home visits. On 32y127 (25%) visits the
CFHNS was accompanied by 39 various community health care professionals (com-
munity nurses, health visitors, physiotherapists and psychologists). Discussion: The
aims of the service are to help families care for, cope with and adjust to having a
child with CF. The CFHNS plays a vital role in the education and clinical man-
agement of a newly diagnosed patient. Meetings in the patient’s own home allows
time to facilitate discussions on various issues. The CFHNS is well placed to take
on the role of coordination and communication between the multi-disciplinary team
(MDT) and community agencies. Informal feedback from parents about visits has
been very positive and it is felt to be a useful and important link for them following
diagnosis. In the future a satisfaction survey is planned to formalise this feedback.
The CFHNS has a challenging, varied and multifaceted role within the MDT.
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A change in transition services for young people with cystic fibrosis
J. Cowlard*(Presenting), G. Attard
Paediatric Research, Royal Brompton Hospital, London, United Kingdom
Introduction: The purpose of this study was to evaluate whether the introduction
of a transition service was of benefit to the patient and family. At present the
caseload of children with Cystic Fibrosis at the Royal Brompton Hospital is approx-
imately 350, with an adult population of over 600. There are one hundred young
people aged 13 to 18 yr that will transfer to adult care over the next five years.
The transfer process between services was identified to be in need of review. The
initial objectives were to review current practice for young people ready to transfer
from paediatric to adult care, and to establish the professional, patient, and caregiver
needs at this time. Methodology: Discussions were held between all members of
the paediatric and adult multidisciplinary teams to identify areas for development.
The young adult population and their families were questioned about their feelings
towards moving to a new team and service. In June 2000 a standard for transition
was approved and subsequently a new system was introduced, this included offering
joint transfer consultations with both teams. In June 2002, the service was audited
from the patient and caregiver perspectives. Results: For all patients the transition
process was only discussed within a year of the final transfer. Written information
about transfer given was adequate for all patients but communication, documenta-
tion and meeting the adult team were areas for improvement. Conclusion: The audit
of the transition process highlighted that there had been an improvement in the
process of transfer from paediatric to adult care. Nevertheless, further service devel-
opment is required to cater for the needs and challenges of this population.
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Crossing the nurse-patient relationship boundary
B. Govin*(Presenting), C. Cowperthwaite, H. Miller, M.J. Ledson, M.J. Walshaw
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom
We have previously shown that nurses working on general wards can become more
emotionally involved with patients who have CF compared to other medical
patients. We were interested to investigate whether nurses working in an exclusive
CF environment are more likely to cross nurse-patient relationship boundaries than
their peers from a non-CF environment. We therefore constructed a questionnaire
containing scenarios and asked nurses to indicate, which they believed to be accept-
able or unacceptable. The scenarios varied from ‘holding hands to comfort a patient’
to ‘having a romantic relationship with a patient’. We compared the responses of
35 nurses working in a dedicated adult CF ward (opened in January 2002) with
those of 35 working on general wards, where CF patients were unlikely to go.
Eighteen nurses (51%) from the CF ward stated that it is acceptable to attend a
patient’s personal social function compared to 12 (34%) from a non-CF environ-
ment. Eleven (31%) CF ward nurses indicated that it is acceptable to smoke in the
presence of patients, whilst only 6 (17%) stated this from the general wards. Six
(17%) from the CF ward would visit a patient in hospital, whilst off duty compared
with a surprising 19 (54%) from the general wards. Six (17%) CF ward nurses
said it is acceptable to drink alcohol to excess in the presence of patients compared
to only 2 (6%) nurses from a non-CF ward. Only 1 nurse from any area stated that
it was acceptable to have a romantic relationship with a patient. In all of the sce-
narios raised, many of the staff indicated that they were unsure of when the bound-
aries were crossed. This study shows that nurses from all areas struggle with
nurse-patient boundaries. However, nurses working exclusively with patients who
have Cystic Fibrosis were more likely to cross the nurse-patient boundary than those
working in a non-CF environment. We intend to use these results to promote dis-
cussion and education within our Cystic Fibrosis Unit.
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Anaphylactic reactions to intravenous antibiotics in cystic fibrosis
inpatients: education of nursing staff
L. McIntosh, E. Bowman*, A. Balfour, J.A. Innes
Scottish Adult Cystic Fibrosis Service, Western General Hospital, Edinburgh, Unit-
ed Kingdom
Introduction: Anaphylaxis is a rare but serious medical emergency and requires
immediate treatment. A small number of our Cystic Fibrosis (CF) adults have
reported symptoms such as urticaria, lip tingling and wheeze, but not developed
acute anaphylaxis. However, over the last 2 years we have experienced 3 episodes
of what we believe to be acute anaphylaxis during a course of inpatient intravenous
antibiotics. The CF sister was instrumental in the management of these episodes.
Following discussion with the CF team and ward sister, it was acknowledged that
an action plan was necessary to deal with the increasing issue of anaphylactic
reactions in our CF inpatients. Methods: The action included: assess the knowledge
of ward staff using a questionnaire, discuss with the hospital resuscitation nurse
educational needs of nursing staff, review the ease at which adrenaline 1:1000
solution is accessed and place treatment algorithms for anaphylactic reactions in
key areas within the ward. Results: To date 12 staff has completed a questionnaire.
The pre-education questionnaire, issued to staff revealed that while most nurses
knew the basics about anaphylaxis, they were very keen to know more about the
presentation and treatment. Only 7 out of 12 nurses correctly identified all the signs
and symptoms of anaphylaxis. Only 3 out of 12 knew the correct sequence of
management in agreement with the UK Resuscitation Council guidelines. All 12
staff wanted formal, ongoing education. Discussion: We have identified a need for
continuing education and documented guidelines for management of anaphylactic
reactions at ward level. As a result, algorithms are now positioned in strategic
places. An education pack with 30 min teaching sessions is planned and will be
implemented in March 2003. This will be followed by a second questionnaire to
the nurses to audit the training.
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Capillary blood gas sampling–the painless alternative?
B. Whitlock (Presenting), D. Bilton
Adult Cystic Fibrosis Centre, Papworth Hospital, Cambridge, United Kingdom
Arterialised blood gas analysis via a capillary sample from the earlobe provides an
alternative, less invasive method of obtaining samples than an arterial stab. Patients
who have had arterial samples are often reluctant to have further samples taken this
way because it can be painful and the pain could last for a few days due to bruising
and trauma. In addition, patients are fearful of the varying technical skills of the
medical staff. The CF Unit nursing staff wished to eliminate these barriers to best
care by introducing a capillary blood gas service. The Cystic Fibrosis Unit at Pap-
worth Hospital decided to introduce capillary blood gas analysis for routine baseline
assessment of respiratory function at annual review and as an alternative to arterial
gas analysis for patients with deteriorating oxygen saturation (sy-92%) and as
an indicator of patients’ response to oxygen treatment. The reasons for the decision
to use capillary samples were that they are less invasive, more patients friendly and
nurses could provide a rapid service to enable early therapy for patients. After
obtaining specialist equipment, formulating guidelines and protocols and training
nurses to undertake the task we undertook a small study to establish patients’ views
and acceptability to the medical staff. Over 4 months, 61 capillary samples were
obtained. Of the 61 patients, 21 completed a patients’ opinion survey. Seventeen
patients had previously had arterial samples taken, 14 of whom retrospectively
scored the pain on a Likert scale (0–5))3. All 21 scored pain from earlobe cap-
illary sampling -2. Oxygen saturation of samples was always comparable to pulse
oximetry, with the medical team expressing high satisfaction. In conclusion arteri-
alised blood sampling from the earlobe is acceptable to patients, less traumatic and
increases patient satisfaction. Acquiring these skills has enhanced the nurses’ ability
to deliver holistic care.
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Evaluation of the cystic fibrosis clinic summary note
L. Semple* (Presenting), E. Foulkes, M. Montgomery
Alberta Children’s Hospital, Calgary, Canada
A summary note, prepared by the clinic nurse with input from C.F. team members
is sent to the families after each clinic visit and provides information about the
health of their child, and instructions regarding the next step of care. The rationale
for the summary is that enhanced awareness of the CF team concerns and recom-
mendations will maintain the family role as active participants and positively influ-
ence adherence to treatments and recommendations. The purpose of this study was
to determine the utility of the clinic summary as perceived by families and the
attributes of the note of greatest value. Ninty-one surveys were mailed. Respondents
were asked to rank components of the clinic note and to answer open ended ques-
tions. Forty-five were returned and were analyzed for content. Results: Overall
families perceived benefit from the clinic note and all the components of the note
were deemed useful. Physician’s comments and recommendations were ranked most
useful, followed by nursing comments and culture results. The summary note was
of greatest value by providing the family with organized documentation, allowing
longitudinal review of a child’s progress. The note was also considered a good
means of communication. Families recommended increasing the detail included in
the physician comment component and requested receiving the note sooner after
the appointment. The clinic summary is a valuable tool for families of children
with CF. Modifications in the clinic summary have resulted from the survey. Regular
assessment of the communication tool by the users is essential to maintain positive
benefits.
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Developing a palliative care service for children and adults with cystic
fibrosis
K. Thomas (Presenting), K. Oakley , E. Simmonds1* 1 2
Child and Family Health Services, Coventry Primary Care Trust, Coventry, United1
Kingdom, Paediatric Unit, University Hospitals Coventry and Warwickshire NHS2
Trust, Coventry, United Kingdom
The Coventry Community Children’s Nursing Service (CCNS) comprises specialist
nurses caring for children at home with life-limiting conditions, including CF.
Although, a tertiary McMillan service existed for children with oncology conditions,
it was recognised that a similar palliative care service was required locally for all
children requiring terminal care at home. A comprehensive symptom control pack-
age was developed for home use. This included a drug box containing a range of
medication including oral and parental opioids and anti-emetics, individually pre-
scribed detailing starting and maximum doses. Symptom control flow sheets are
now used to aid assessment and promote communication. A terminal care hold all
contains practical items such as bed protectors and tissues. A comfort care chart
highlights simple measures and has proved an invaluable adjunct to complex med-
ical regimes. A team death certificate book has enabled home certification by the
paediatrician. Liaison with undertakers has facilitated individualised aftercare. The
team has cared for )40 children dying at home over 9 years. Although only 2 had
CF, care delivery evaluation has demonstrated this to be an effective model of home
terminal care. Evaluation of the care packages following the Kennedy report and
Shipman recommendations, has led to new developments and progression of the
service. Tracking systems which ensure staff safety, whilst lone visiting at night
also enable patient safety by providing a retraceable clinical trail, where practice
can be monitored. Future developments include the adaptation of the paediatric
package for use with adult CF patients and promotion of this model locally for
other adult groups.
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An audit of inpatient nebuliser cleaning: patients practice in an adult
cystic fibrosis centre
A. Bowling(Presenting), J. Milnes, A.K. Webb, A.M. Jones, M.E. Dodd
Adult Cystic Fibrosis Centre, South Manchester University Hospitals NHS Trust,
Manchester, United Kingdom
Introduction: The Cystic Fibrosis Trust guidelines and our local infection control
guidelines recommend that nebulisers are washed, rinsed, dried thoroughly and
stored in a sealed container away from the sink area. Instructions for cleaning and
the facilities provided are displayed in each room. Aim: We report an audit of patient
practice before and after the introduction of a signed information sheet which rein-
forced nebuliser cleaning practice and asked if the patients were happy to adhere.
Method: The nebuliser cleaning practice was observed (AB) in each patient’s room
at the same time of day once weekly for a six-week period. Before and after obser-
vations were made of 3 areas: (1) has the nebuliser been stored in the sealed
container, (2) has the nebuliser been left in an unclean state, (3) has the nebuliser
been left on the side to dry. The method of observation in the two audits was
identical Results: There were 58 observations for 33 patients in audit 1 and 60
observations for 30 patients in audit 2. The results for areas 1, 2, and 3 before and
after the introduction of the information sheet were: (1) 39y58 (67%) vs. 35y60
(58%), (2) 9y58 (16%) vs. 10y60 (22%) and (3) 10y58 (17%) vs. 12y60 (20%).
There was no significant difference between the two audits, for each of these areas
or for an individual patient practice. In audit 2, 28y30 patients signed that they
were happy to adhere to the instructions. Conclusion: These audits have identified
poor patient adherence with nebuliser cleaning both before and after further infor-
mation was given. This was despite patients’ agreement with the instructions given.
We need to review our existing policies and identify methods of improving our
clinical practice.
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Implantable venous access devices: effect of insertion on efficiency of
in-hospital treatment
Alex Robinson (Presenting), Phil Robinson1 2
Royal District Nursing Service, Melbourne, Australia, CF Unit, Respiratory Med-1 2
icine, Royal Children’s Hospital, Melbourne, Australia
Implantable venous access devices (IVAD) are inserted in CF patients who expe-
rience significant difficulty with venous access when faced with a clinical need for
frequent periods of in-hospital treatment. The aim of insertion is to optimize these
periods of in-hospital treatment. In order to assess whether insertion of an IVAD
does improve efficiency of in-hospital treatment we examined the CF epidemiology
of 18 children who had IVAD implanted in the past 7 yr in our clinic of 350
pediatric patients. The average age of the 18 patients at insertion was 12.7 yr. Prior
to insertion, the average number of admissions in the preceding two years was 5.2
with an average length of time in hospital for each treatment period being 18.3
days. The average length of follow-up time post insertion was 3.4 yr. In the two
years post insertion (ns14) the average number of admissions was 4.5 and the
average length of each treatment period was 11.3 days (P-0.05). Average FEV1
at insertion was 67.5% predicted. The average drop in FEV1 in the month post
insertion was 10.8%. Fifteen of the patients took an average of 3 months to obtain
pre-insertion FEV levels. Four patients have not yet returned to pre-insertion spi-1
rometry levels (average time since insertion 5.9 months). Insertion of implantable
venous access devices is associated with an improved efficiency of period of in-
hospital treatment, despite a short-term reduction in pulmonary function.
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A national Swedish survey of totally implantable venous ascess
devices (TIVAD) in patients with cystic fibrosis (CF)
Eva Gronowitz (Presenting), Kathe Strandner , Kerstin Herlitz , Asa Peters-1 1 1 ˚¨
son (Presenting), Vivi Adermark , Berit Widen , Inger Erwander , Kristina2 3 4 5
Agardh , Elisabeth Naas , E, Gronowitz6 7˚ ¨ ¨˚
West Swedish CF-center, The Queen Silvia Children’s Hospital, Goteborg, Sweden,1 ¨
CF teamet, Barn och Ungdomssjukhuset, Huddinge sjukhus, Huddinge, Sweden,2
CF centret B59, Huddinge sjukhus, Huddinge, Sweden, CF centret B59, Huddinge3 4
sjukhus, Huddinge, Sverige, CF teamet, Barn och Ungdomssjukhuset, Universi-5
tetssjukhuset, Lund, Sverige, CF teamet, Barn och Ungdomssjukhuset, Universi-6
tetssjukhuset, Lund, Sweden, Uppsala CF center, Akademiska Barnsjukhuset,7
Uppsala, Sverige
Background: The TIVADs are considered to be a safe and effective way to admin-
istrate antibiotics andyor nutritional supplements in patients who need repeated i.v
treatment. Our aim was to investigate the prevalence and the survival time of the
TIVADs in the Swedish CF population and what kind of complication that occurred.
Patients and Methods: 187 CF patients (119 females) with a mean age of 16 yr
(range 2 months–48 yr) attending the four national Swedish CF centers (Goteborg,¨
Lund, Stockholm and Uppsala) had TIVADs implanted between November 1986
and June 2002. The TIVADs were inserted surgically under general (infants) or
local anaestesia. All patients were educated to manage i.v treatment at home. Ini-
tially the TIVADs were not used for blood sampling but over time 36% was used
for blood sampling 1–2 times a year. Results: Two-hundred and sixty-six TIVADs
were inserted in 187 patients during this period (approx. 34% of all CF patients in
Sweden). The total number of years with TIVADs was 1171 year (TIVADyear),
96 complications were registered that makes 12.2 TIVADyearycomplication. The
complications that occurred were infection (39%), ocklusion (32%), mechanical
problems (19%), and thrombosis (10%). There was no significant difference in
survival time between TIVADs used for blood sampling or not, or between gender,
genotype and center. According to Kaplan-Meyer survival statistics of the first
TIVAD implanted in all patients (ns187), 50% were still working at 7.9 yr and
25% at 13.1 yr. Conclusion: TIVAD is a good alternative for patients needing
intravenous treatment regularly. The complication rate is low.
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Totally implantable venous access devices in patients with cystic
fibrosis
E. Eber (Presenting), B. Oberwaldner , D. Dacar , M. Zach1 1 2 1
Paediatric Department, Respiratory and Allergic Disease Division, Graz, Austria,1
Department of Surgery, Graz, Austria2
Background: The implantation of a venous access device may provide a solution
to difficult venous access in patients with cystic fibrosis (CF). In the few published
series on totally implantable venous access devices (TIVADs) in CF patients, how-
ever, a number of complications were recognized. We report our experience with
two systems in the last 15 yr. Methods: The medical records of CF patients who
underwent insertion of a TIVAD at our centre from December 1987 to August 2002
were reviewed to record the details of TIVAD insertion, duration of function, and
complications. Handling of and care for these TIVADs followed a strict predefined
protocol, with regular renewal of the heparin lock, adherence to an aseptic handling
technique, and strict avoidance of blood sampling through the device. Results: Six-
teen devices (8 PORT-A-CATHz , Pharmacia Deltec Inc., USA, and 8 Celsite , 
B. Braun Medical SA, France) were inserted in 16 patients (age 16.6"6.8 yr, range:
6.1–29.8). All catheters were inserted in the right subclavian vein and portals were
placed on the anterior chest wall under general anaesthesia or sedationylocal anaes-
thesia. In 14 patients (88%) there were no complications until now or patient death.
One patient developed symptomatic venous thrombosis 3 months after insertion;
this complication could be managed successfully without removal of the device. In
one patient, catheter dislocation to the jugular vein was observed after 10 months;
subsequently, the catheter was replaced leaving the portal in situ. The mean duration
of function was 783 days (range: 190–2354). TIVADs were used only for inter-
mittent intravenous antibiotic therapy and parental nutrition. Conclusion: TIVADs
provide effective long-term intravenous access in CF patients if they are inserted
and cared for in accordance with a standardized surgical approach and a strict long-
term maintenance protocol.
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The gastric emptying of a solid meal in cystic fibrosis (CF) patients
assessed by 13C-octanoic acid breath test
D. Neumann(Presenting), O. Pozler, H. Vanicek, V. Vorisek, J. Bures
Department of Pediatrics, University Hospital, Hradec Kralove, Czech Republic
The 13C-octanoic acid breath test (13C-OABT) is the most precise breath test for
the assessment of the gastric emptying. The presented study concentrates on gastric
emptying of solid meal in CF patients. Method: The test solid meal (cake) was
doped with 65 ml of the 13C-octanoic acid. Patients collected breath samples
throughout 4 h period. The air samples were examined by the mass spectrometry
to obtain delta values, which were transformed to the elimination pattern of 13C.
The gastric half-emptying times (T GE) were counted by MOMENT 4 pro-1y2
gramme modelling elimination as incomplete gamma function. The incomplete
gamma parameter estimation was done by the moment method. The T1y2GEs were
compared with the reference data obtained by Van Den Driessche. The 13C-OABT
was performed in 20 patients, median age 13.5 yr. Results: 13C-OABT was ana-
lyzed in 16 patients. In 69% of them T1y2GEs were in the reference range, in 25%
below and in 6% prolonged. The difference in delta values remained in CF 13C-
OABT is mainly low. Conclusion: The gastric emptying rate in CF patients does
not differ on principle from healthy population.
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Oesophageal Dysmotility and Autonomic Dysfunction in Cystic
Fibrosis (CF)
A. Mirakhur (Presenting), J. Tran , H. Miller , M.J. Ledson , M.J. Walshaw1 2 1 1 1
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom, Depart-1 2
ment of Pulmonary Physiology, The Cardiothoracic Centre, Liverpool, United
Kingdom
Oesophageal dysfunction is common in patients with CF. Whilst it has been sug-
gested that this is due to acid reflux, the concept of oesophageal autonomic neu-
ropathy as a cause has not previously been considered. We have already shown that
cardiovascular autonomic abnormalities occur in adult patients with CF, and since
these could reflect wider changes in autonomic function, we postulated that auto-
nomic neuropathy may play a role in oesophageal dysmotility in this patient group.
To explore this further, we undertook oesophageal manometry in 12 adult CF
patients using a Synectics Medical PC Polygraph with a standard 6 lumen catheter
connected to a minimally compliant Arndorfer hydraulic infusion pump. Using wet
swallows, we measured motility by assessing propagation and amplitude of peri-
staltic contractions throughout the oesophageal body. We also assessed the lower
oesophageal sphincter (LOS) by measuring barrier pressure and relaxation prop-
erties. Only 4 patients (33%) had completely normal oesophageal manometry. Of
the remainder, 3 (25%) had evidence of upper oesophageal dysmotility (reduced
or tertiary wnon-propagativex contractions), 3 (25%) demonstrated reduced contrac-
tions in the lower third associated with a weak LOS, and 2 (17%) abnormalities
of both. Four patients with abnormal oesophageal manometry underwent cardio-
vascular autonomic testing and 3 of these were abnormal. Of these, 1 demonstrated
reduced contractions throughout with only partial LOS relaxation, whilst the remain-
ing 2 had abnormal motility yet normal LOS relaxation. Thus, we have shown that
CF patients may have oesophageal dysmotility yet normal LOS function indicating
that acid reflux is not the causal mechanism. Furthermore, 2 of these patients had
abnormal cardiovascular autonomic reflexes, suggesting autonomic dysfunctionmay
play a part. Further work needs to be done to assess the contribution of autonomic
neuropathy to oesophageal dysmotility in CF.
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Symptomatic and silent gastroesophageal reflux (GOR) in adults with
cystic fibrosis: the usefulness of a structured symptom questionnaire
compared to 24 hr oesophageal pH monitoring in identifying GOR
B. Button (Presenting), S. Roberts , T. Kotsimbos , J. Wilson1* 2 1 1
Respiratory Medicine, The Alfred Hospital, Melbourne, Australia, Gastroenter-1 2
ology, The Alfred Hospital, Melbourne, Australia
Gastro-oesophageal reflux (GOR) is well-described in children with CF. Sympto-
matic GOR has been described in adults with CF. There is no data to indicate
whether adults with CF have silent GOR. Aims: (1) To establish the usefulness of
a valid symptom questionnaire (Qx) in CF to identify GOR using 24 h oesophageal
pH monitoring; (2) To establish whether adults with CF experience silent GOR.
Method: Adults with symptoms of GOR and without symptoms of GOR were
studied. Each patient completed a symptom Qx. Weighted scores of )4 out of a
total of 18 indicating GOR. Each patient then undertook dual probe 24 h oesopha-
geal pH monitoring. Results: Results representing the mean, S.D. and range from
29 subjects: Age: 28.6"4(19–45.5) years; FEV : 50.4"21.4(21–87)% predicted;1
FVC: 64.4"16.3%(44–93.9)%; Symptom Score: 8.8"5.5 (0–18); DeMeester
Score (DMS)wnormal-14.72x: 35.7"20.9 (4–89.2): number reflux episodes prox-
imal probewnormal-4x 50.8"44.3 (4–147);distal probewnormal-50x: 182.2"90.7
(28–404); fractional reflux time proximal probewnormal -0.1%x: 2.11"2.1 (0.1–
6.8); distal probewnormal-4.5%x: 7.9"5.3(0.7–21.8).Silent GOR was identified
in 6 (21%) subjects with DMS of 53.7, 53.1, 46.7, 37.6, 31.2 and 28.4, respectively.
Four of these subjects had multiple long episodes of GOR while asleep – the longest
episode for each subject lasting for 22, 82, 33 and 15 min, respectively. Results to
date suggest that the symptomatic GOR is common in adults with CF, however,
symptom scores do not correlate with DMS (ns29; r s0.015; ps0.53). Patients2
with high DMS had significantly lower FEV (Ps0.03). Conclusion: CF adults1
with high symptom scores tend to have high DMS, however, some adults with CF
and asymptomatic GOR also have high DMS. This is the first study to demonstrate
silent GOR in adults with CF. Therefore, patients with declining lung function
without symptoms of GOR should undergo 24 h oesophageal pH monitoring to
establish whether GOR is present.
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Distal intestinal obstruction syndrome in adults with cystic fibrosis
X. Dray , T. Bienvenu , N. Desmazes-Dufeu , D. Dusser , P. Marteau , D.1 2 3 3 1
Hubert (Presenting)3*
Service d’Hepato-Gastro-Enterologie, Hopital Europeen Georges Pompidou, Par-1 ´ ´ ´
is, France, Service de Biochimie Genetique, Hopital Cochin, Paris, France, Ser-2 3´ ´
vice de Pneumologie, Hopital Cochin, Paris, France
The frequency of distal intestinal obstruction syndrome (DIOS) is believed to
increase with age in cystic fibrosis (CF) patients. The possible relationship of DIOS
with CF transmembrane conductance regulator (CFTR) genotypes and clinical fea-
tures has not previously been studied in adults. Objectives: To determine the prev-
alence and clinical features of DIOS, and its relationship with the CFTR genotype,
in an adult CF population. Methods: Cross-sectional study of an adult CF cohort.
Results: Among 171 adults with CF (mean age 28.9 yr), 27 patients (15.8%) report-
ed 43 episodes of DIOS. The first episode of DIOS occurred in adulthood in 15
cases (55.5%). DIOS recurred in 13 patients (48.1%). All patients who developed
DIOS had pancreatic insufficiency (PI). Pulmonary function was significantly more
altered in patients with DIOS than in other patients. DIOS occurred in 21.9% of
patients with a severe CFTR genotype and in only 2.4% of patients with a mild
CFTR genotype (P-0.005). This association remained significant in the sub-pop-
ulation of patients who developed DIOS after the age of 18 (Ps0.04). Conclusions:
DIOS is frequent in adults with advanced-stage cystic fibrosis. Our data suggest
that any impact of PI replacement therapy on the risk of DIOS be offset by the
enhanced life expectancy of patients with CF. They also support the hypothesis that
other factors than PI, such as impaired intestinal fluid secretion due to severe CFTR
dysfunction, are involved in the onset of DIOS.
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The treatment of distal intestinal obstruction syndrome with a modified
antegrade continence enema (ACE) operation
I.J. Clifton (Presenting), A.M. Morton , N.S. Ambrose , D.G. Peckham , S.P.1 1 2 1
Conway1
Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, LEEDS, United Kingdom1
, Department of Colorectal Surgery, St James’s University Hospital, LEEDS, Unit-2
ed Kingdom
Distal intestinal obstruction syndrome (DIOS) results from an accumulation of vis-
cous mucous and faecal material in the terminal ileum, caecum and ascending colon.
It causes recurrent abdominal pain, bloating and nausea, which may lead to intes-
tinal obstruction. Conventional treatment is with oral or rectal laxatives. We report
a young woman who had a modified ACE operation as treatment for severe recur-
rent DIOS. Miss Y was born with duodenal atresia. She was diagnosed with CF in
the neonatal period, is homozygous delta F508 and pancreatic insufficient. She had
a 2nd laparotomy for adhesions and appendicectomy in 1997. Miss Y had recurrent
episodes of DIOS, requiring repeated admissions to hospital. Treatment included
gastrografin, n-acetyl cysteine, Klean prep and Picolax. Quantitative assessment of
absorption was not performed but faecal fat microscopy was negative and faecal
chymotrypsin 633 mcgyg. PERT was taken at a dose of 4800 IU lipaseykgyday
and omeprazole 20 mg bd. A low fat, low residue diet was temporarily introduced
until the bowel was cleared. Barium enema showed no structure or obstruction.
After five admissions with DIOS in three months she was referred for surgical
advice. Following counselling by Specialist Stoma Nurses a modified ACE proce-
dure was performed. As there was no appendix, the terminal ileum was used to
create the irrigation conduit and the proximal end of the ileum was anastomosed
to the ascending colon. There were no perioperative problems. Miss Y performs
irrigation every two to three days and has good bowel movements. She had one
episode of constipation, but no further episodes of DIOS. The ACE procedure can
be considered for patients with DIOS that does not respond to conventional
treatments.
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Altered bowel sounds in adult patients with cystic fibrosis (CF)
A. Mirakhur (Presenting), J. Earis , M.J. Ledson , M.J. Walshaw1 2 1 1
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom, Depart-1 2
ment of Chest Medicine, Aintree University Hospital, Liverpool, United Kingdom
Adult CF patients suffer from constipation, when severe presenting as distal intes-
tinal obstruction syndrome (DIOS). Whilst this may be due to increased viscidity
of bowel mucus, it may also be due to abnormal gut motility. However, this is
difficult to investigate because the few tests available are indirect. We had noticed
that bowel sounds (BS) in CF patients appear different in character and frequency
to normal individuals. We have developed a method of digitally analysing BS, and
applied this to CF patients. BS signals, collected by a high gain microphone (con-
nected to a DAT recorder) sealed to the abdominal wall, undergo low pass filtering
at 22 kHz, A to D sampling at 44 kHz, down-sampling to sets with spectral band-
widths of 4, 2 and 1 kHz, and then spectral analysis based on wavelet and time-
frequency techniques. Using this, we analysed BS in normal controls and compared
them to those from normal CF patients and those with constipationyearly DIOS. In
normal controls, BS have a frequency of -1 kHz and a Gaussian envelope or
exponential decay pulse shape, both with a duration of 10–25 ms with a mean
frequency of 351–400 Hz. Whilst BS in CF patients have many similar character-
istics, they have a higher mean frequency (457–500 Hz) and a high motility index.
Furthermore, in a study of 16 CF patients and 16 controls, they had more frequent
BS (log10 BSymin: 7 constipated CF mean 0.99 vs. controls 0.48, P-0.01; all CF
patients 0.77 vs. controls 0.48, Ps0.06). These preliminary data suggest that BS
differ in CF patients compared to normal individuals, a phenomenon not previously
investigated. We postulate that this may be due to a change in intestinal motility
rather than mucus impaction, perhaps due to abnormal neural control of the CF gut.
We are currently investigating further the clinical impact of these findings.
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Meconium ileus–early clinical manifestation of CF
D. Sands(Presenting), D.S. Sands, A.M. Milanowski, R.P. Piotrowski
CF department, Institute of Mother and Child, WARSAW, Poland
Meconium ileus (MI) was present in 17 out of 313 children monitored at the
Warsaw CF centre in the years 1993–2002. The aim of our study was to analyse
retrospectively, the clinical course of CF with MI in infancy. Only 3 infants were
managed non-operatively. Fourteen children were treated surgically, 3 with MI com-
plications (perforation, peritonitis). MI equivalents occurred in 3 children with MI
in infancy. Average age of CF diagnosis with MI was 3,4 months, in CF cases
without MI-42 months. A family history of CF was present in 3 cases. Molecular
analysis was performed in all the cases. Del F508ydel 508 was found in 10 patients,
del F508yother known mutation in 5 patients, one other mutation in one child, and
one child with no mutations. In 11 children with MI there were no pulmonary
symptoms at the time of diagnosis. 9 children characterised mild pulmonary disease,
1 moderate and one variable. No child was colonised with Pseudomonas aeruginosa.
Current clinical status in the Shwachman score was very good or good in 10
patients. In 6 children with MI, symptoms from the pulmonary system were present
at the time of diagnosis (4 children characterised by serious pulmonary disease
colonised with Pseudomonas aeruginosa.) In this group clinical Shwachman scoring
was lower than in patients without pulmonary symptoms (3 died, 4-moderate, 2-
mild disease). Conclusions:
1. Infants with MI need to be followed up in CF specialised centre.
2. Manifestation of pulmonary symptoms at the time of MI is a risk factor for CF
disease severity.
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An investigation to assess the intake of dietary fibre and fluids and the
incidence of Distal Intestinal Obstructive Syndrome in adults with CF
S. Collins(Presenting), G. Pinnock, ME, Hodson
Royal Brompton Hospital, London, United Kingdom
Aims: To assess the intake of fluid and dietary fibre and the incidence of DIOS in
adults with CF. DIOS is characterised by recurrent attacks of abdominal distension,
pain, constipation and occasionally complete intestinal obstruction. The incidence
of DIOS has been reported between 10–47%. Aetiology includes pancreatic insuf-
ficiency, dysmotility, dehydration and thickened mucus. Objectives: (1) To calculate
and compare dietary fibre and fluid intake amongst patients with a history of DIOS
(2 or more episodes of DIOS in the past 3 yr) and controls (no history of DIOS).
(2) To ascertain whether there is an association between low dietary fibre and fluid
intake and the incidence of DIOS. Results: 16 (out of 45 contacted) patients com-
pleted a five-day unweighed food diary, a bowel history and symptom questionnaire
and a lifestyle questionnaire. Mean dietary fibre intakes were 15.4 g per day in
subjects vs. 13.5 g per day in controls (psNS). Estimated fluid requirements were
exceeded in 60% subjects and 83% controls. Conclusions: Dietary fibre intake was
marginally higher in the subject group contray to the hypothesis low fibre intakes
are associated with DIOS. However, both groups had fibre intakes less than the
current recommendations of 18 g per day. It appears therefore from this small group
that patients with DIOS have a higher dietary fibre intake but fewer exceed their
fluid requirements when compared to those without DIOS. It would be useful to
carry out a similar study on a larger sample size to improve the significance of
these findings.
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Reduced bone mineral density in cystic fibrosis patients is associated
with radiological abnormalities in the lumbar spine and a higher
occurrence of traumatic fractures
S. King (Presenting), D. Topliss , T. Kotsimbos , J. Wilson1* 2 3 3
Alfred Hospital, Melbourne, Australia, Department of Endocrinology and Dia-1 2
betes, Alfred Hospital, Melbourne, Australia, Department of Respiratory Medicine,3
Alfred Hospital, Melbourne, Australia
It is well-recognised that reduced bone mineral density (BMD) is common in CF
patients. However, few studies have examined the associations between reduced
BMD, fractures and other radiologically detectable features of osteoporosis. Meth-
ods: Eighty-eight adults with CF (60% male; mean age 29.9(S.D. 7.7)years; mean
FEV % predicted 58.2(S.D. 21.5)%) were studied. None were on treatment for1
reduced BMD or had sustained an atraumatic fracture. Subjects underwent DEXA
scanning to measure BMD at the lumbar spine (LS). Seventy-five subjects also
underwent LS X-ray to determine the presence of features of osteoporosis, including
crush fractures or reduction in vertebral height. Subjects were asked to recall any
previous bone fractures they had sustained. Results: Abnormalities associated with
osteoporosis were observed in 25 of the subjects who had an X-ray (33%). Mean
LS Z-score was significantly lower in the group with abnormal LS X-rays (y
1.0(S.D. 1.16) vs.y0.28(S.D. 1.33), Ps0.02). 35 of the 88 subjects (40%) report-
ed a total of 86 previous bone fractures. All fractures were associated with
significant trauma. A greater proportion of males than females reported fractures
(49% vs. 26%, Ps0.03). Mean LS Z-score was significantly lower in the group
with previous fracture(s) (y1.08(S.D. 1.37) vs.y0.26(S.D. 1.16), Ps0.004), and
remained significant when the influence of gender was taken into account. Conclu-
sions: The presence of radiological abnormalities associated with osteoporosis in
the LS was common, and was correlated with lower LS BMD Z-scores. A history
of traumatic fractures was also associated with lower LS BMD Z-scores. These
findings suggest that patients with reduced BMD may be at greater risk of both
osteoporotic and traumatic fractures. This emphasises the importance of:
1. Strategies to optimise BMD;
2. Regular monitoring of BMD; and
3. Lifestyle education as well as physiological and pharmacological interventions
to prevent fractures in CF patients with reduced BMD.
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Is bone turnover slightly elevated in cystic fibrosis (CF) patients with
mild lung disease?
G. Loeuille (Presenting), M. Dherbomez , I. Devaux , X. Marchandise , F.1 2 1 2
Delepoulle , A. Sardet1 1
Cystic fibrosis center, Dunkirk Hospital, DUNKERQUE, France, Department of1 2
nuclear medicine, University hospital, LILLE, France
Reduced bone mineral density (BMD) occurs commonly in young CF adults. In
order to understand the evolution and the pathophysiology of an abnormal bone
metabolism, the status of bone mineralisation is studied in 36 CF patients (20
females) aged 3–24 yr (mean"DS, 11.6"5.7). Bone mineral content (BMC) and
BMD are measured using dual energy X-ray absorptiometry (DEXA; ns32).
Serum concentrations of osteocalcin (OC; ns44), bone alcaline phosphatase (BAP;
ns43), C telopeptide 1 (ICTP; ns43) and C telopeptide 2 (CTx; ns44) are
determined. The mean whole body BMD score is normal but 10 patients (6 children,
2 adolescents and 2 adults) have a lumbarspine BMD score below y1 S.D. The
total body BMC and BMD scores are positively correlated with weight and body
mass index (BMI) (P-0.03). The whole body BMC is significantly related to
Shwachman (S) score (Ps0.009). The bone marker profile is similar to healthy
control subjects. We observe slightly elevated OC levels correlated with weight
(Ps0.03) and BMI (Ps0.007), but we discover also a good correlation between
OC, BAP, ICTP and albuminemia (P-0.01). Correlations with disease severity are
observed: all the bone markers with S score (PF0.05) and FEV-1 (P-0.05); OC,
BAP and ICTP concentrations with FEF25–75 (PF0.03) and at last, OC, ICTP
and CTx concentrations with radiological score (P-0.04). Inflammatory variables
are inversely proportional to serum OC, BAP and ICTP levels (PF0.02). Moreover,
bone marker levels decrease in CF patients with allergic aspergillosis (PF0.02)
and inhaled corticosteroid use clearly lowers OC concentrations (Ps0.008). CF
patients with an abnormal OGTT also have a significant decrease of serum OC,
BAP and ICTP concentrations (PF0.05). Bone mineral accretion may begin to
decrease during childhood. A tendency to a slightly exaggerated bone turnover is
present in midly affected CF patients (S scores82"8). Some groups have a more
significant risk for depressed bone formation.
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Gender differences in CF phenotype associated with low bone mineral
density
R. Greer (Presenting), P.K. O’Rourke , H.M. Buntain , J.A. Batch , P.W. Francis ,1 2 3 4 3
S.C. Bell5
University of Queensland, Brisbane, Australia;, School of Population Health, Uni-1 2
versity of Queensland, Brisbane, Australia, Respiratory Medicine, Royal Children’s3
Hospital, Brisbane, Australia, Endocrinology and Diabetes, Royal Children’s Hos-4
pital, Brisbane, Australia, Thoracic Medicine, The Prince Charles Hospital, Bris-5
bane, Australia
Adolescents and adults with CF have lower bone mineral density (BMD) than
normal, but its relationship with phenotype is not well understood. Point FEV1%
predicted (FEV) and rate of change of FEV are biased estimates of disease severity,
because progressively older subjects represent a selected survivor population, with
females at greater risk of death than males. To investigate the relationship between
BMD and phenotype we used an index (predicted age at death) derived from Bay-
esian estimates of slope and intercept of FEV, age at last measurement and survival
status. Predictive equations for the index were derived from 97 subjects (78 sur-
vivors) from the RCH CF clinic, and applied to a group of 102 comparable subjects
who had BMD measured, classified as having ‘mild’ ()75th), ‘moderate’ (25–
75th), or ‘severe’ (-25th centile) phenotype. Total body (TB) and lumbar spine
(LS) BMD z-scores (Z) were compared, adjusting for gender effects, using 2-way
ANOVA. Annual mean change in FEV segregated, as expected, according to phe-
notype, ‘severe’ (ns25), ‘moderate’ (ns51) and ‘mild’ (ns25) y3.01(y3.73
to y2.30)%, y0.85(y1.36 to y0.35)%, 2.70(1.92 to 3.46)%, respectively, with
no gender difference. LS and TB BMDZ were different in each phenotype (P-s
0.002), LS BMDZ for ‘severe’, ‘moderate’ and ‘mild’ y1.63(CI: y2.07 to y
1.19), y0.86(CI: y1.17 to y0.55), y0.06(CI: y0.54 to 0.41). Males had lower
LS BMDZ than females overall (y1.22 (CI: y1.54 to y0.91) vs. y0.48(CI: y
0.84 to y0.12) Ps0.002). In the ‘severe’ group, males had lower TB BMDZ and
LS BMDZ (PF0.002). Low BMD is associated with ‘moderate’ and ‘severe’ phe-
notypes, with relative preservation in females in the ‘severe’ group. Female biology
(reproductive fitness) might promote resistance to bone resorption at a critical level
of BMD loss.
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Long-term measurement of the bone mass in children with cystic
fibrosis
A. Minarowska (Presenting), J. Konstantynowicz , M. Kaczmarski , L.1 2 3
Minarowski1
Medical University in Bialystok, Bialystok, Poland, Department of Auxology, Med-1 2
ical University in Bialystok, Bialystok, Poland, IIIrd Department of Children’s3
Diseases, Medical University in Bialystok, Bialystok, Poland
Introduction: Both in Polish and world standards, nutrition of patients with CF takes
up a crucial position, because regular body mass and growth inhibition is one of
the clinical characteristics of this disease, often accompanied by malnutrition.
Regarding the lifestyle quality handicap associated with CF, limited spontaneous
mobility (frequent hospitalisations, constant physiotherapeutic procedures) and
application of steroid therapy, there is a potential disorder of bone tissue minerali-
zation. The crucial elements of osteoporosis prevention include optimal conditions
for bone mineralization and development. Aim: The aim of the study was quanti-
tative assessment of bone mass in children and adolescents with CF and establishing
whether there is any risk of osteopenia and whether any preventive actions in this
field are effective. Material and methods: The study was carried out on 14 children
aged 5–21 yr (mean age – 9.3 yr), submitted to the III Department of Pediatrics
of the Medical Academy in Biaystok (Center for CF Therapy for the North-East
Poland). Total bone mineral density (TOTAL BMD) and lumbar spine bone mineral
density of L2-L4 region (Spine BMD) was evaluated with dual energy X-ray
absorptiometry (DEXA) using DPX-L apparatus (LUNAR Radiation Corp., Mad-
ison, WI) at regular interval at least one year from the first examination. Results
and conclusions: Expressed percent extent of changes ranged for TOTAL BMD–
3.6–5.9% (aver. 1.55%); for SPINE BMD –1.3–10.9% (aver. 5.4%). Observed
changes during densitometry monitoring correlated with age and different rate of
growth in all subjects. Because of that fact average values of BMD were used. Most
of the children demonstrated a characteristic rate of changes and decreased values
of BMD, lower than population average. The results of the study were presented
on the original centile grids.
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Prevalence of osteopaeniayosteoporosis in an adult CF centre
J. Roberston (Presenting), K. Liddle , M. Richardson , JA. Innes1 1 1 1
Cystic Fibrosis Office, Ward 54, Western General Hospital, Crewe Rd, Edinburgh,1
Scotland
Bone loss is a recognised complication of CF. Risk factors include severe lung
disease, low BMI, oral steroid use, immobility, and low vitamin D and K (Aris et
al., 2002). We hypothesised that there would be a high prevalence of bone disease
in those patients in our clinic identified as at risk. Aims: (1) To identify the group
of patients at most risk of bone disease in our adult clinic (ns120). (2) To inves-
tigate the prevalence of bone disease in those patients at risk. (3) To highlight
inconsistencies in the current treatment of bone disease. Methods: Patients were
classified according to the known risk factors; we also included age )40 yr, dia-
betes and previous fracture as additional risks. 42 patients, (36% of the clinic) were
identified as at risk by the above process. DEXA scans were requested on all at
risk patients who had not previously been scanned. Patients who had been scanned
previously had their treatment reviewed. Results: To date DEXA scans have been
performed in 31 patients. Of these, 17 (55%) have osteopaenia, 12 (39%) have
osteoporosis, and 2 (6%), have normal scans. In the osteoporotic group, patients
had at least 3y8 risk factors, (range 3–6), compared to 2y8 risk factors (range 2–
5) in the osteopaenic group. 60% of patients had vitamin D levels -37 nmolsyl.
Of the cohort of patients with previous DEXA scans, treatment varied considerably
and monitoring the effects of treatment was inconsistent. Conclusions: There is a
high prevalence of bone disease in our adult CF population. Patients with bone
disease have multiple risk factors. Vitamin D deficiency is almost universal in
patients identified with bone disease in our centre. There is a need to implement
clear guidelines for the detection and management of bone disease in adults with
CF.
Reference:
R.M. Aris, Pathogenesis of CF bone disease Pediatric Pulmonology, Supp. 24
(2002) 177.
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Prevalence and characteristics of liver disease in a screened CF
population
M. Mitchell(Presenting), A. Reid, J. McCaughan, A. Leavy, M. Macfarlane
Allen Ward, Royal Belfast Hospital for Sick Children, BELFAST, United Kingdom
Introduction: Liver disease is a recognised complication of cystic fibrosis and may
lead to eventual cirrhosis with portal hypertension. Its onset may be insidious and
difficult to detect clinically. CF liver disease has been defined by Colombo et al.
as having 2 out of the following 3 criteria;
● Hepatomegally;
● Persistently raised liver function tests; and
● Abnormal liver ultrasound scan.
Methods: Cystic fibrosis in our centre is diagnosed by IRT neonatal screening. All
patients receive an annual assessment, which now includes a liver ultrasound as
well as liver function test. We looked retrospectively at all 217 patients case-notes
to establish risk factors and prevalence of CF liver disease. Results: 200 patients
received a liver ultrasound scan with LFT measurements. 24 patients (12%) fitted
the above criteria for having CF liver disease-7 of these had meconium ileus, all
24 were pancreatic insufficient, 12 were female and 12 male. 14 were homozygous
Delta F508, and 9 had Delta F508, other, 1 had 621 and 87T homozygous. 20 had
abnormal LFT’s. A further 21 patients showed evidence of either hepatomegaly or
fatty infiltration on ultrasound scan, but did not fit the full criteria for CF liver
disease. Age range of those with ultrasound abnormalities was from 6-18 yr. Con-
clusions: The incidence of CF liver disease in our population is 12%. We did not
note a male preponderance, but all patients were pancratic insufficient with severe
mutations. 7 out of 24 had a history of meconium ileus. We have still not established
if fatty infiltration is an early sign of the onset of CF liver disease or if ultrasound
scanning is required in patients under 6 yr. Future Work: To ensure all patients with
CF liver disease are adequately treated with Ursodeoxycholic Acid and to establish
the most effective method for detection of CF liver disease.
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Liver transplantation for adults with cystic fibrosis–when and how?
D. Mckeon(Presenting), J. Collier, E. Bateman, A. Lyons, A. Gimson, G. Alex-
ander, D. Bilton
Cystic Fibrosis Unit, Cambridge, United Kingdom
Background: Biliary cirrhosis and portal hypertension complicate a minority of
those with cystic fibrosis leading to liver failure, often requiring liver transplanta-
tion. The severity of the associated cardiorespiratory disorder varies, so that some
patients are suitable for liver transplantation alone, others require heartylungyliver
grafting and others are too ill to undergo any surgical procedure. Method: Audit of
a 10-year experience in adults referred to a single tertiary referral centre for con-
sideration of liver transplantation with patient survival as outcome. Results: Twelve
patients accepted for liver transplant alone underwent grafting after a median 9
weeks (range 1–27). Nine are alive and well at 10–112 months and one further
patient is alive, but with chronic rejection at 26 months. One patient underwent
heartylung transplantation 23 months after liver transplantation and is well at 46
months. Eleven were listed for heartylungyliver grafts. Three died after prolonged
periods on the waiting list (4,126 and 171 weeks) and one is waiting at 98 weeks.
Seven underwent heartylungyliver transplantation after a median 66 weeks (range
4–176). Two are alive and well at 16–30 months. Four patients were not accepted
onto the programme for varied reasons. Conclusion: The results for liver transplant
alone were excellent with acceptable waiting times. The results for heartylungyliver
grafting were less satisfactory, with unacceptable waiting times. One possible solu-
tion may be to offer liver transplantation at an earlier stage with a view to subse-
quent heartylung transplantation. Routine surveillance for the presence of chronic
liver disease and the evolution of portal hypertension should be undertaken and
would allow early assessment for liver transplantation.
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Cystic fibrosis related liver disease: frequency, risk factors and
treatment with ursodeoxycholic acid
T. Kapustina(Presenting)
Research Centre for Medical Genetics, Moscow, Russia, Podolsk, Russia
The study is aimed at establishing the frequency and kind of LD in the Russian
patients with CF, assessing risk factors for its development and defining benefit of
UDCA treatment. Methods: We analysed case histories of 570 children with CF (1
month–18 yr old) before the UDCA treatment (25 mgykgyday), after 12 and 24
months of treatment, using the following criteria: genotype, sex, haemoglobin con-
centration, thrombocytes level, liver size and characteristics at each clinic visit, liver
US, liver enzymes (ALT, AST, GGT), alkaline phosphatase, liver biopsy, meconium
ileus, splenomegaly. To confirm necessity of UDCA treatment we studied lipid
metabolism at the patients receiving (group 1–42 patients) and not receiving UDCA
(group 2–18 patients) in serum by liquid chromatography. Results: Frequency of
liver cirrhosis (LC) in CF-children in Russia is 7.5%. Risk factors to develop LC:
male gender, meconium ileus and severe genotype. After 1 yr of UDCA treatment
serum level of albumin, haemoglobin concentration and thrombocytes level
increased to normal values (P-0,05). Increased levels of ALT (50%), AST (70%)
were normalized after 24 months (P-0.05). Alkaline phosphatase level became
normal in 70% patients after 12 months. On ultrasound we noticed decreased ech-
ogenicity of biliary tract and content of gall bladder (P-0.05) after the 1-year
treatment in patients with LC. Before UDCA treatment 92% patients without LC
had ultrasound signs of hepatobiliary tract damage: 39% had abnormalities of gall
bladder, 53%-increased echogenicity of liver parenhime. We revealed improvement
of liver ultrasound after the UDCA treatment in 60% patients without LC. Changes
in serum lipid content and composition (group 1 had increased phosphatidylcholine
level and decreased phosphatidylethanolamine level compared to group 2) might
partly explain both cytoprotective action of UDCA and their effect on membrane
fluidity in patients with CF.
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Prevalence of cystic fibrosis-related liver involvement (CFLI) and
provision of routine abdominal ultrasound (AUS) in the south-west of
England
K. Giles (Presenting), R. Scott-Jupp , J. Tyrrell1 2 2
South and West Cystic Fibrosis Database, Bath, United Kingdom, Paediatric1 2
Department, Salisbury District Hospital, Salisbury, United Kingdom
Liver involvement in CF is relatively common, mostly as mild or sub-clinical dis-
ease. A small proportion progress rapidly to severe liver disease. Criteria for diag-
nosis are often difficult to interpret, and the effects of milder CFLI on clinical
progress and mortality vary between studies. The usefulness of the only available
treatment–—ursodeoxycholic acid (UDCA)—is disputed, although Nousia-Arvan-
itakis et al. (2001) 10-year follow-up study indicates that it may reverse early
pathological changes. Data have been collected annually since 1995 on all patients
in the south-west of England for a regional database. These data include results of
abdominal examination, presence of oesophageal varices, and since 1997 ultrasound
scan results and UDCA use. Data on the population as at 31st December 2001 were
analysed (ns750), excluding 8 patients who were post-liver transplant. Patients
were classified as having unequivocal, mild or no liver involvement. Biochemical
disease (i.e. raised liver enzymes with no other indicators) was not considered. 77
(10%) were categorised as unequivocal liver disease (65% male), and 94 (13%)
as having mild liver involvement. The distribution shows a peak during adolescence.
These findings match earlier studies in different populations (e.g. Scott-Jupp et al.,
1991), which suggests that the distribution is not due to a cohort effect. Forty-two
percent of patients have had at least one AUS during 1997–2001. Older patients
had fewer scans, suggesting that the low prevalence in this group may be partly a
consequence of poorer availability of diagnostic data. AUS provision by sex does
not differ. Rates of prescription of UDCA vary (0–52%) by clinic, and do not
necessarily match CFLI prevalence. The adolescent prevalence peak is still a feature
of CFLI. Clinics vary in their practice regarding diagnosis and treatment of CFLI.
This reflects the lack of consensus in the literature, and is unlikely to change until
these questions are resolved.
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Early diagnosis of cystic fibrosis may protect against development of
cystic fibrosis-associated liver disease: population based case
controlled study
K. Corbett (Presenting), S. Kelleher , M. Rowland , L. Daly , G. Canny , P. Greal-1 1 1 2 3
ly, R, Hayes , B. Drumm , B. Bourke4 1 1
Children’s Research Centre, Our Lady’s Hospital for Sick Children, Dublin, Ire-1
land, Faculty of Medicine, Earlsfort Terrace, Dublin, Ireland, Paediatrics, Our2 3
Lady’s Hospital for Sick Children, Dublin, Ireland, Radiology, Our Lady’s Hospital4
for Sick Children, Dublin, Ireland
Liver disease is an important cause of morbidity and mortality in cystic fibrosis.
Early identification of patients at risk for the development of cystic fibrosis-asso-
ciated liver disease (CFALD) might allow the timely introduction of preventative
measures. However, risk factors for developing CFALD are ill-defined. Methods:
This was a case controlled study of all children (age 5–18 yr) with established
CFALD in the Republic of Ireland between January 1999 and June 2000. Each
child was pair-matched for age and sex with a CF patient without liver disease.
Only children with clinically overt liver disease and portal hypertension (confirmed
ultrasonographically or endoscopically) andyor fibrosis on liver biopsy were
enrolled in the disease group. Data collected included current clinical and pulmonary
status, degree of nutritional impairment, age of diagnosis of CF and history of
disease complications. Findings: Forty-two patients (26 boys) with established
CFALD were enrolled. Children with CFALD had worse FEV than those without.1
However, chest X-rays and clinical scores did not differ between groups. Height
(mean difference y4.2 cm w95% CI-7.14 to 0.9.x, ps0.014), weight (mean dif-
ferencey3.21 kg (y6.03 to y0.40), ps0.026) and mid-upper arm circumference
(mean differencey1.23 cm (y2.35 toy0.12.), ps0.031) were significantly low-
er among children with CFALD. Measures of skin-fold thickness were also lower
among children with liver disease but did not reach significance. Children with
CFALD were diagnosed later than children without liver disease. There were no
differences between groups with regard to genotype, distal ileal obstruction syn-
drome, or glucose intolerance. There were more children with meconium ileus in
the control group (14 vs. 4) than among those with CFALD. Interpretation: Chil-
dren with established CFALD have impaired growth and nutrition, altered body
composition and worse FEV values. CFALD is associated with later age of diag-1
nosis of CF.
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Post prandial glucose measurement in the assessment of CF related
diabetes mellitus (CFRDM)
M. Al-Aloul(Presenting), S. Pandya, C. Cowperthwaite, M.J. Walshaw, M.J. Ledson
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom
A complication of pancreatic damage in CF is glucose intolerance, and up to 25%
of adult CF patients develop frank diabetes. However, the nature of CFRDM means
that fasting glucose and glycosylated haemoglobin estimations are unreliable as
indicators of disease control, and the pre-meal BM estimations used to gauge insulin
needs in classical diabetes mellitus may not be appropriate. Therefore, to assess
which daytime estimations provide the best indication of glycaemia, we assessed
paired pre and 2 h post prandial glucose in 11 patients (mean age 24 yr (range
20–32), mean FEV1 61% predicted (29–87), mean BMI 21.6 (18.5–24.8), 6 male)
with established CFRDM being considered for insulin therapy. As expected, only
18 of 84 (21%) fasting glucose estimations in 6 patients and 2 of 11 (18%) HbA1c
estimations were abnormal. Based on WHO criteria, we used a BM stix value of
8.0 mmolyl as the abnormality threshold for daytime glucose level. There were 76
paired results (mean 7 per patient, range 3–11). Postprandial values were higher
(premeal: mean 7.6 mmolyl (range 3.5–18.4) vs. postprandial: 13.3 (5.4–25.5);
P-0.001). Furthermore, only 25 (32%) premeal values were )8.0 mmolyl com-
pared with 69 (91%) postprandial values (P-0.001). In 7 pairs of data (8%), both
results were within the normal range, in 44 pairs (59%) there was a normal pre
but an abnormal post level, and in the remaining 25 (33%) both values were abnor-
mal. Thus, in two third of cases, the traditional method of glucose assessment by
premeal BM measurement would have missed significant daytime glycaemia there-
by underestimating the requirement for insulin therapy. However, postprandial BM
assessment revealed significant hyperglycaemia in )90% of cases. These results
suggest that postprandial blood glucose estimation is the best way of assessing the
need for insulin therapy in those patients with CFRDM.
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Early insulin treatment in insulinopenic CF patients improves body
composition and stabilizes pulmonary function
S. Kolouskova (Presenting), D. Zemkova , J. Bartosova , M. Macek Jr. , Z.1 1 1 2
Sumnik , J. Vavrinec , V. Vavrova1 1 1
Pediatric Clinic, Charles University Prague-University Hospital Motol, Prague,1
Czech Republic, Institute of Biology and Medical Genetics, Charles University2
Prague-University Hospital Motol, Prague, Czech Republic
Introduction: Screening of CF-related diabetes (CFRD), including the first phase
insulin response in patients with impaired glucose tolerance (GT), identifies cases
with severe insulinopenia (IP) prior to the onset of typical symptoms. Our aim was
to elucidate the influence of severe IP in asymptomatic CF patients on their body
composition, pulmonary function, including monitoring of their changes during
treatment by small dosage of intermediate insulin. Patients and methods: IP was
assessed by i.v.GTT as a sum of insulin response in 1 and 3 min. -1 percentile in
healthy controls (48 mIUyl). Body composition was assessed by anthropological
parameters (height, weight, mid-arm circumference-S.D.s). Controls were sexyage
matched to cases. Results: IP was found in 31y144 CF patients (11.1–28.5; med–
16.5 yr). IP patients were diagnosed significantly earlier (1.8"3.2 vs. 3.6"3.6;
Ps0.04) likely due to the higher prevalence of ‘severe’ (Class I–III) mutations
(Ps0.04). In controls pancreatic insufficiency appeared later. We did not find any
differences in sweat chloride concentrations, occurrence of MI and chronic bacterial
infection. Body height and weight did not differ in both groups. Mid-arm circum-
ference in IP-CF cases was significantly lower (y1.2"0.9 S.D. vs. controls y
0.8"0.9 S.D.; Ps0.02) and worsening of the mid-arm circumference 1 yr prior to
the diagnosis of IP (Ps0.05) was observed. During the first year of insulin treat-
ment nutritional status (NS) has improved (P-0.01) and pulmonary function tests
(PFTs) became stable (FEV 72.4"18.4 vs. 71.9"19). However, in controls the1
NS did not change, but PFTs deteriorated (74.3"22.4 vs. 67.6"18.9; Ps 0.006).
Conclusion: Early detection of IP by i.v.GTT and its early treatment improves NS,
stabilizes PFTs and improves life expectancy. Supported by IGA MZCR: 6464-3,
6461-3, 00000064203 and MSMT: LN00A079, 111300003.
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Outcomes of patients with hypoglycaemic glucose tolerance tests an
adult cystic fibrosis centre
A. Verma (Presenting), R. Hoare , M. Dodd , J. Biesty , A. Webb , A.M. Jones1 2 2 2 2 2
Wythenshawe Hospital, Manchester, United Kingdom, Manchester Adult Cystic1 2
Fibrosis Centre, Wythenshawe Hospital, Manchester, United Kingdom
Introduction: Annual oral glucose tolerance testing (OGTT) has been our practice
since 19991. A group of patients were identified, who did not fit the WHO criteria
and were found to have a glucose -3.6 mmolyl at 120 min. These were classified
as hypoglycaemic glucose tolerance (HGT). In a previous audit, we found 30% of
OGTTs performed to be HGT2 and wished to explore the outcomes of this group
in comparison to patients with an impaired glucose tolerance (IGT). Methods: Cas-
enotes were examined for OGTT results over the 4 yr period to identify the two
groups (HGT and IGT) and subsequent management noted to 24 months. C reactive
protein was used to validate clinical stability. Results: 133 OGTTs were performed
on 57 patients. 4 patients were excluded: death (ns3) or transfer (ns1). 21y53
patients had a HGT and 19y53 IGT. In the IGT group at 24 months, 2y19 had a
diabetic glucose tolerance test (DGT), 11y19 remained IGT, 1 had a HGT and 5y
19 became normal. In the HGT group at 12 months follow up: 2y21 developed a
DGT, 10y21 became normal, 3y21 IGT and 4y21 HGT. At 24 months: a further
2y19 developed DGT, 6y19 returned to normal, 2y19 IGT, 1y19 HGT. There was
no difference in the number of patients developing a DGT in the two groups (Ps
0.66). All patients with DGT, HGT or IGT went onto home blood sugar monitoring.
1 patient with DGT was subsequently treated with oral hypoglycaemics and 5 were
commenced on insulin. Of the OGTT results that were HGTyIGT at any time (ns
82), 61 (74%) had a CRP in the normal range and 12 (15%) were raised. Conclu-
sions: Patients in the HGT group may be just as likely to develop a DGT as the
IGT group. Annual OGTTs are therefore recommended to identify these patients
and optimise their care.1. Verma et al., Thorax 20022. Verma et al, Journal of Cystic
Fibrosis 2001
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48 h-Continuous interstitial glucose monitoring in non-diabetic cystic
fibrosis patients: a pilot study
A. Sauty (Presenting), J. Mazza-Stalder , J., Ruiz , M. Hofer , M. Roulet1 1 2 1 3
Service of Pneumology, University Hospital, CHUV, Lausanne, Switzerland, Ser-1 2
vice of Endocrinology, CHUV, Lausanne, Switzerland, Department of Pediatrics,3
CHUV, Lausanne, Switzerland
Introduction: Impairment of glucose tolerance increases with age in cystic fibrosis
(CF) and may be associated with clinical deterioration and higher mortality. Oral
glucose tolerance test (OGTT) is still considered the best test to detect glucose
tolerance abnormalities, but the right time to treat glucose intolerance or diabetes
is still debated. Early treatment, before clinical deterioration occurs, might be ben-
eficial to delay complications. In this pilot study, we ought to assess whether con-
tinuous interstitial glucose monitoring, in non-diabetic CF patients, could bring
additional information on their glucose tolerance. Methods: 5 CF adult patients who
were not taking insulin (3 Fy2 M, 22–34-year-old, VEMS 32–89% predicted val-
ues, BMI 18.4–24.8 kgym ), were compared to 5 non-healthy volunteers matched2
for sex, age, weight and height. A needle-type glucose sensor (Glucosensora, Med-ˆ
tronic) was implanted in the abdominal wall subcutaneous tissue of the subjects
and connected to an electronic system that determined interstitial glucose levels
every 10 sec.. At 24 h, an OGTT was performed and blood glucose level determined
every 30 min. At 48 h, the system was removed. During the 48 h of the study,
capillary glucose levels were measured 3–4 times daily by the subjects and record-
ed. Results: 2 CF patients had impaired glucose tolerance according to OGTT. In
one of these patients and in 2 with normal OGTT, interstitial glucose profiles
showed important daily fluctuations mainly related to meals. In the other patient
with glucose intolerance, glucose profile looked normal due to defective glucose
detection. Discrepancy between capillary or blood levels, and interstitial glucose
levels were noted in some subjects and will be discussed. Conclusions: Continuous
interstitial glucose monitoring in addition to OGTT may help to assess insulin
response in non-diabetic CF patients and suggests that, even when OGTT is normal,
the insulin response may be abnormal.
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Conventional measures underestimate glycaemia in cystic fibrosis
(CF) patients
L. Dobson (Presenting), A.T. Hattersley , C.D. Sheldon1 2 1
Royal Devon and Exeter Hospital (Wonford), Exeter, United Kingdom, Diabetes1 2
and Vascular Medicine, Peninsula Medical School, Exeter, United Kingdom
The diagnosis of diabetes in the CF population has relied upon the adoption of
conventional measures such as the fasting level and 2 h glucose in an oral glucose
tolerance test (OGTT). It has not been established if these values in the non-CF
population are equivalent to the same values in the CF population. We compared
21 non-diabetic CF subjects with 21 matched non-CF controls using the OGTT and
a subcutaneous continuous glucose monitoring system (CGMS) to investigate the
glucose profile over 72 h. The CGMS relies on the short-term insertion of a small
sensor that electrochemically determines interstitial glucose levels. These subjects
were matched for weight, height, and BMI. OGTT Results: Conventional measures
of glycaemia were similar in the two groups for {mean (S.D.), CF vs. Controls}
HbA1c 5.5(0.6)% vs. 5.3(0.3)%, fasting glucose 4.8(0.5) vs. 4.7(0.3) mmolyl and
2 h glucose 6.4(1.7) vs. 6.0(1.2) mmolyl. No patients had diabetes and the pro-
portion of subjects with impaired glucose tolerance was similar, 25% v 9.5% Ps
0.24. However, at 30, 60 and 90 min the CF subjects had markedly higher glucose
values than controls (P-0.01). The areas under the OGTT curves were higher in
the CF group compared to controls (891.9(135.0) vs. 745.2(115.0) mmol hr, Ps
0.004). CGMS Results: The mean value recorded on the CGMS was higher in the
CF subjects {6.0(0.8) mmolyl} over a 24 h period than the controls {5.2(0.7)
mmolyl} (Ps0.001). In addition, the proportion of subjects with peak CGMS
glucose values )11.1 mmolyl was higher in the CF group compared to the control
group (50 vs. 9.5%, Ps0.004). Conclusions: Overall glycaemia, as shown by both
the average glucose value in an oral glucose tolerance test, and by continuous
glucose monitoring is higher in CF patients who have similar HbA1c and fastingy
2 h glucose values. These results question whether it is appropriate to use the same
criteria for a diagnosis of diabetes in a patient with cystic fibrosis.
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Longitudinal follow-up of clinical and laboratory data in patients with
cystic fibrosis related diabetes mellitus (CFRD) after initial treatment
with glibenclamid
M. Ballmann(Presenting), Ch. Mueller-Brandes
Paediatric, Medical School Hannover, Hannover, Germany
The treatment of CFRD with insulin is a safe and effective treatment, but an addi-
tional burden especial on young patients. Therefore it is still controversially dis-
cussed whether oral antidiabetic drugs e.g. glibenclamid are an alternative initial
treatment of CFRD for at least some years. Patients with CFRD defined by WHO
criteria were followed for two years after diagnosis and initial treatment with gli-
benclamid regarding nutritional status (body mass index (BMI) Z-score), lung func-
tion (FEV1%pred) and HbA1c in a single paediatric CF-center. From 1.1.1993 to
12.31.2002 19 (7male, 12 female, age at diagnosis (mean"S.D.) 13.7"3.7 yr) out
of 41 patients with CFRD were initially treated with glibenclamid and had com-
pleted follow-up. In 6 patients treatment was changed to insulin (group 1) after 14
to 24 months, whereas 13 patients were still on glibenclamid after two years
(group2). Follow-up of clinical and metabolic data are shown in the table below.
PRIVATE Group1
Initial
Group1
Starting insulin
Group 2
Initial
Group 2
After 2 yr
BMI Z-score y1.7"1.2 y2.1"1.5 y0.8"1.0 y0.87"1.0
FEV1% pred 68"22 58"23 76"26 73"29
HbA1c % 5.7"0.5 8.2"0.4q 5.2"0.6 5.5"0.8
P-0.05 (vs. initial)q
In this retrospective evaluation more than 68% of those started with glibenclamid
were in a stable clinical condition (BMI Z-score and FEV1% pred) and good
metabolic control (HbA1c) after two years. This emphasizes the importance of
controlled randomised prospective studies comparing insulin vs. oral antidiabetic
treatment of CFRD already started in USA and Europe.
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Cystic fibrosis-related diabetes mellitus (CFRD) and oral glucose
tolerance testing (OGTT) in the south-west of England
K. Giles (Presenting), C. Sheldon , A. Prendiville , R. Clifford , J. Tyrrell1 2 3 4 5
South and West Cystic Fibrosis Database, Bath, United Kingdom, Respiratory1 2
Department, Royal Devon and Exeter Hospital, Exeter, United Kingdom, Paedia-3
tric Department, Royal Cornwall Hospital, Truro, United Kingdom, Paediatric4
Department, Dorset County Hospital, Dorchester, United Kingdom, Paediatric5
Department, Royal United Hospital, Bath, United Kingdom
CFRD is an increasingly important complication of CF, particularly in older patients.
We investigated the prevalence of CFRD in a regional population, and audited the
use of OGTT against the standard of annual test for patients )10 yr. Data have
been collected annually since 1995 on all patients in the south-west of England for
a regional database. These data include CFRD (by clinician diagnosis) and since
1999, OGTT results. Data on all patients aged )s11 yr on 31st December 2001
were analysed (ns516). Overall, there are 88 patients (17%) who have been diag-
nosed with CFRD. Prevalence was unrelated to gender. The proportion of diabetics
rises with age. A further 28 patients (5%) have reported glucose tolerance abnor-
mality on OGTT but are not yet diagnosed with CFRD. The rate of use of OGTT
is low, and variable between clinics. Overall 223 (45%) patients have had at least
one OGTT during 1999–2001–indicating that clinics would need to address this in
order to meet the 2001 care standard above. The prevalence of CFRD by clinic
varies widely (0–100%), even when only larger clinics ()20 patients in sample)
are considered (9–39%), as does the rate of abnormal OGTT without firm diagnosis
of diabetes (0–13% for larger clinics). The degree of OGTT usage does not predict
the incidence of diabetes diagnosis during the same period. Some clinics have tested
100% of patients but have no diagnosed diabetics; others have tested no patients
but have one or more diabetics receiving treatment. These results suggest variation
in diagnosis threshold between clinics. Given the complexity of CFRD and the lack
of established consensus on its diagnosis, they may also indicate limitations in the
sensitivity of OGTT as a routine screen and raise questions about its clinical inter-
pretation. Research is needed into the clinical effects of CF-related insulin defi-
ciency and how they differ from non-CF-related diabetes, and development of
sensitive diagnostic criteria.
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Prevalence of diabetes and nutritional status in patients with cystic
fibrosis: Results of a multicenter diabetes screening program
Ch. Muller-Brandes (Presenting), R. Holl , R., Goldner , M. Ballmann1 2 2 1¨¨
Paediatric Department I, Medical School Hannover, Hannover, Germany, ZIBMT,1 2
University of Ulm, Ulm, Germany
Cystic fibrosis related diabetes mellitus (CFRD) has been reported to be the second
most prevalent form of diabetes in children and the third most common type in
adults. It is also associated with increased morbidity and mortality. Prevalence rates
range from 3–25% depending on age and diagnostic criteria all derived from rel-
atively small cohorts. As part of a prospective randomised multicenter study based
on an initiative of the German Cystic Fibrosis Foundation, an annual oral glucose
tolerance test (OGTT) following standard WHO recommendations was conducted
as a screening test in order to identify patients ()10 yr) with CFRD. As an age-
independent parameter of nutritional status we used body-mass-index (BMI)-Z-
scores based on the recent German reference data, using LMS transformation. The
Kruskal-Wallis-Test was performed to compare the groups with different OGTT-
results. Up to now 618 patients (54% males, 46% females aged 10–64 yr, median
16.6 yr) were screened by an OGTT. A prevalence of 71% with a normal (n), 6.3%
with an impaired fasting glucose (IFG), 14.1% with an impaired–(IGT) and 8.6%
with a diabetic glucose tolerance was calculated. Out of the 53 patients with a
diabetic response 56% were without fasting hyperglycaemia. There was no signif-
icant difference among the groups concerning the BMI-Z-scores (mean"S.D.; n:
y0.65"1.15, IFG: y0.56"1.28, IGT: y0.95"1.30, CFRD: y0.83"1.21). In
this large cohort CFRD has a prevalence of 8.6%. With this screening approach we
could not see any age independent difference regarding nutritional status between
the early diagnosed patients with CFRD and other CF patients.
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A longitudinal study of body composition, leptin levels, insulin
sensitivity and clinical status in children and adolescents with cystic
fibrosis
L. Ahmed(Presenting), K. Ong, D. Dunger, A. Thomson
Oxford, Cambridge, United Kingdom
Body weight is an important prognostic indicator in children with cystic fibrosis
(CF), but the relationships between body composition and clinical outcomes are
less clear. The roles of evolving insulinopenia and variation in leptin levels (a
potential satiety factor) have not been fully evaluated. 143 children (77 boys) with
CF, age: median, range: 5.99 y, 2.27–17.98 were followed for a median of 3.48 yr
(1–8.5) with annual measurements of height, weight, subcutaneous skinfolds and
a fasting blood sample. Clinical assessment included the Shwachman score and
measurement of forced expiratory volume (FEV1). Age and sex adjusted S.D.
scores for height, weight and BMI decreased (P-0.0005) with age; and fat mass
and fat free mass were lower in both sexes compared to controls. Shwachman score
decreased with age in both sexes, P-0.0005 and it was related to fat free mass in
the girls and both fat free mass and fat mass in the boys. Insulin levels were lower
and insulin sensitivity was greater in the CF children compared to controls, whereas
leptin levels for fat mass were higher in CF children. In summary, despite contem-
porary management, children with CF gained less body fat and fat free mass and
were lighter and shorter than controls. We postulate that higher leptin levels, in
spite of lower fat mass and insulinopenia, may be due to stimulatory effects of
inflammatory cytokines. The insulinopenia andyor high leptin could contribute to
anorexia, poor weight gain and growth in CF children. Keywords: Body composi-
tion; Insulin sensitivity; Leptin
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Renal Damage in CF: Impact of Tobramycin Therapy
M. Al-Aloul(Presenting), A. Mirakhur, B. Govin, C. Cowperthwaite, M.J. Ledson,
M.J. Walshaw
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom
We have correlated renal damage in CF with long-term use of tobramycin and
colomycin. To investigate this, we measured creatinine excretion and urinary protein
loss in 10 CF patients with renal damage (creatinine clearance -60 mlsymin)
undergoing 14 days IV tobramycin therapy, and compared them with 10 CF patients
with normal renal function (creatinine clearance )60) having the same treatment.
IV tobramycin was given tds with protocol based dose adjustment. All had normal
serum biochemistry; none had toxic levels. Measurements were made at baseline,
14 days and 28 days. In those with renal damage, creatinine clearance improved at
14 days and then did not change (mean: pre-treatment 41.4 mmolyl, 14 days 63.1,
28 days 63.4; P-0.003), but did not reach the unchanging values of the remainder
(84.2, 84.4, and 95.0, respectively; all PsNS). Urine output improved in both
groups after 14 days (mean: 1.25 l to 1.96 l and 1.85 to 2.51, both P-0.04). Total
daily creatinine excretion improved in the renal failure group (mean: 5.01 mmoly
day, 6.82 and 6.88, respectively, P-0.005), but was still less (P-0.0002) than the
unchanging values in the remaining group (11.06, 11.63 and 12.46 respectively, all
PsNS). In the latter group urinary protein loss increased after 14 days (mean: 0.04
gyl and 0.16, P-0.004), due to the renal insult of tobramycin, returning to baseline
at 28 days (0.04, P-0.02). In the renal damage group urinary protein loss remained
high (0.12, 0.13 and 0.05, respectively, P-0.05), indicating ongoing renal damage.
This study shows that short-term renal sequelae to tobramycin therapy are better
withstood by patients with normal renal function. The improvement in creatinine
clearance in those with renal damage was due to better hydration with intensive
therapy that occurred in both groups. Nephrotoxic antibiotics should be used with
caution in CF patients, who may require repeated courses over many years, with
subsequent cumulative renal damage.
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Investigation into the knowledge of pancreatic enzyme
supplementation (PERT) and impact of a higher strength pancreatic
enzyme preparation in adult patients with CF
D. Mc Cann (Presenting), P. Kelly , J.S. Elborn1* 2 3
Belfast City Hospital, Belfast, Ireland, Pharmacy, Belfast City Hospital, Belfast,1 2
Ireland, Adult CF Centre, Belfast City Hospital, Belfast, Ireland3
The majority (90%) of patients with CF is pancreatic insufficient requiring pan-
creatic enzyme replacement therapy (PERT). Aims: To investigate current knowl-
edge, use and compliance with a pancreatin preparation containing 25 000 IU lipase
(Creon 25 000, Solvay Healthcare) and patients opinions on changing to a higher
strength preparation (Creon 40 000). A convenience sample of 25 adults with CF
and pancreatic insufficiency completed an interview administered questionnaire on
PERT. ElevenyTwenty-five patients reported taking enzymes with all meals and
snacks. Patients are advised to take enzymes before and during eating but only 7y
25 reported doing so. Mean (S.D.) daily Creon 25 000 dose was 7447 (3084) units
lipaseykgyday and 5 patients exceeded the maximum recommended daily dose
(10 000 units lipaseykgyday). Patients were shown a specified meal plan contain-
ing 3 meals and 3 snacks of varying fat contents. 10y25 patients made no variation
in number of enzymes for the 3 meals; 5y25 made no variation for the 3 snacks;
2y25 varied for all 3 meals; no patients varied for all 3 snacks. It is estimated that
patients would take 7 (3) fewer capsules per day if they were changed from Creon
25 000 to Creon 40 000 (P-0.01) however, this mean (S.D.) difference (280
(1137)units lipaseykgyday) does not translate to a significant change in the esti-
mated daily dose of lipaseykgyday (Ps0.23). 23y25 patients perceived that they
would benefit from changing to Creon 40 000. This study highlights the need for
ongoing nutrition education. The main patient perceived benefit in changing to
Creon 40 000 is the need for fewer capsules.
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Enteric coated pancreatic enzyme dosage and growth in cystic fibrosis
infants who are breast fed
George Davidson*(Presenting),
Pediatrics, BC Children’s Hospital, Vancouver, Canada
Pancreatic insufficient (PI) cystic fibrosis (CF) patients require pancreatic enzyme
therapy to achieve satisfactory nutrition and growth. Enzyme dosage recommen-
dations for CF children are established, but for young infants who are breast fed
there is little data to support enzyme dosage recommendations or use of enteric-
coated preparations. Older recommendations for use of non-enteric coated enzymes
in infancy are not satisfactory for breast fed infants because of the resultant exco-
riation of mother’s nipples as well as of the infant’s lips and mouth. We report our
experience with breast fed PI CF infants who were treated with enteric coated
pancreatic enzymes. Seventeen infants were successfully breast fed for a mean dura-
tion of 30 weeks (range 18–58 weeks). An 8000u lipaseycapsule enteric coated
preparation was used. Enteric coated microspheres from the capsule were given by
teaspoon in applesauce or equivalent, just before each feed. NaCl supplement (2
meqykg) was given to all breast-fed infants, and solid food was started according
to standard recommendations (at 4–6 months). Enzyme dosage at time of weaning
ranged from 250–1600 u lipaseykgyfeed (1400–8000 u lipaseykgyday). Nutritional
markers were satisfactory, with body weight at time of weaning being 75 percentile
or greater for 5 infants; 50–75 percentile for 3; 25–50 percentile for 4; 5–25 per-
centile for 4; while, 1 infant was just below 5 percentile. Enteric coated pancreatic
enzymes allow successful breast feeding and growth of CF infants with PI, at dos-
ages within or slightly below current maximal recommendations for older patients.
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Help for daily management of pancreatic enzyme supplementation in
cystic fibrosis patients
B. Santini(Presenting), T.S.A. Palmas
Camarda, Lezo, Scienze Pediatriche e dell’Adolescenza, Gastroenterologia–Nutri-
zione Clinica, Torin, Italy
In Cystic Fibrosis (CF) the nutritional status plays a determinant role. Along with
the pulmonary function, it is undoubtedly responsible of the patients quality of life
and prognosis. Considering that lipid intake is not a real problem any more, the
diet results tasty and fits to the nutritional requirements; the higher intake of lipids
permits to meet the caloric needs. Therefore, a good dietetic management requires
a good knowledge of the bromatologic profile of foods. The use of high strength
pancreatic enzymes has simplified food-choosing even though for optimal digestion
could be necessary adding other pharmacological agents. Actually there is a wide
variability of prescription modalities of pancreatic enzymes referring to the patient’s
age or weight, to the meals or the total daily dose. Excessive doses could result
useless and harmful. Calculate the enzyme dose to be administered according to
the lipid content of the food or the meal represents the ‘‘gold-method’’. It is not
always feasible to realise the real lipid content of certain foods and thus the relative
dose of enzymes sometimes results to be excessive or insufficient. All considering,
it seems useful drawing-up an easy to use manual giving information on: The
pancreatic enzymes and their correct use
● Foods and their principal groups with relative descriptions of the caloric and fat
content per 100 g The caloric and lipid content of different courses and complex
foods
● Transforming lipid content in lipid Units*
● Grouping various foods and courses according to the lipid Units contained
● How to use lipid Units in accordance to the entity of pancreatic insufficiency
in order to have the enzyme doses correctly distributed
Some pages of this manual will be introduced.
References:
*Solvay Pharmaceuticals
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Development of z-score for height and weight in a pediatric CF
population between 1993–2000
E. Karlge-Nilsson(Presenting), A. Lindblad
Department of Pediatrics, The Queen Silvias Children’s Hospital, Goteborg,¨
Sweden
Aim: To evaluate if children with CF improved their nutritional status during the
period 1993 to 2000 and relate their z-score for height with their target height
predicted by the height z-score of their parents. Patients and methods: All children
18 yr and younger attending the center between 1993–2000 were included. Z-score
for height and weight for each year was calculated at the annual check-up. The
mean z-score for height for each child’s’ parents were calculated. FEV was meas-1.0
ured in all patients 7 yr and older. The number of patients with pancreatic suffi-
ciency were 18% 1993 and 17% 2000. No child below the age of 19 died during
the study period. Results: Forty-five children (9.2"5.2 yr) were included 1993 and
66 (10.2"4.4 yr) in year 2000. FEV improved significantly (1993 84"17% and1.0
2000 96"17%, Ps0.0009) while there was a trend towards improvement in z-
score for height (1993: y0.55"1.1 and 2000 y0.25"1.1, Ps0.16) and weight
(1993 –0.65"1.0 and in 2000 –0.23"1.3, Ps0.08). The mean weight and height
z-score for the CF population differed significantly from zero (the normal reference
population) in 1993 (P-0.001 and P-0.001) but not in year 2000 (P-0.12 and
0.06, respectively). 1993 the z-score for height was significantly different from
target height (0.26"0.85, P-0.001) but in 2000 this was barely not significant
(0.19"0.86, Ps0.05). The results were similar when excluding the children with
pancreatic insufficiency. Conclusion: An improvement in FEV , z-score for weight1.0
and height was noticed over the study period. Despite normalization of the nutri-
tional parameters in 2000, the target height was barely reached indicating a possi-
bility of further improvement.
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Body composition in 9 to 11 year-old children with cystic fibrosis
assessed with a reference four-component model
C. Benden (Presenting), A. Jaffe , J.E. Williams , C. Wilson , N.J. Fuller , J.C.K.1 1 2 2 2
Wells2
Portex Respiratory Medicine Unit, Great Ormond Street Hospital for Children,1
London, United Kingdom, MRC Childhood Nutrition Research Centre, Institute of2
Child Health, London, United Kingdom
Background: Bone disease is an increasingly recognised complication of cystic
fibrosis (CF). However, it is not known when pathological changes might occur in
the mineral flux affecting bone mineral content (BMC) or structure. Methods: Ten
pre-pubertal CF subjects, aged 9 to 11 yr, were age- and sex-matched with healthy
controls for body composition assessment using a reference four-component model.
Results: Acceptable assessments were obtained in 8 of 10 CF subjects (2 male, 6
female) due to technical difficulties with air displacement plethysmography
(breathing patterns) and collection of saliva for total body water. Although, differ-
ences were not significant (paired t-test) between CF subjects and controls, respec-
tively, for weight (mean (S.D.); 31.1 (6.6) vs. 34.4 (8.2) kg) and height (1.39
(0.05) vs. 1.36 (0.08) m), the lower weight in CF subjects was due entirely to less
body fat (18.3 (8.4) vs. 26.9 (9.2)% weight, P-0.05). Despite no significant dif-
ference for BMC (1.12 (0.17) vs. 1.18 (0.29) kg), the lower mineral content of
FFM in CF subjects (5.68 (0.43) vs. 6.08 (0.66)% FFM) reached significance for
the protein:mineral ratio (3.57 (0.54) vs. 3.18 (0.52), P-0.01). Conclusion: CF
subjects in this age group have less body fat. Although, BMC for the CF subjects
was apparently within the healthy range, these preliminary data (ns8)may indicate
early signs of lower mineralisation in relation to FFM. This is currently being
followed up with more subjects.
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Update on Wisconsin study: pulmonary and cognitive function in
children with cystic fibrosis after prolonged malnutrition associated
with delays in diagnosis
P. Farrell (Presenting), R. Koscik , M. Kosorok , K. Zaremba , A. Laxova , H-C.1 1 2 1 1
Lai , J. Douglas , M. Rock , M. Splaingard1 2 1 1
Pediatrics, University of Wisconsin Medical School, Madison, USA, Biostatistics,1 2
University of Wisconsin Medical School, Madison, USA
Patients with cystic fibrosis (CF) who experience delayed diagnosis by traditional
methods have prolonged nutritional deficits compared to infants diagnosed via neo-
natal screening. Our evaluations of pulmonary function show only modest abnor-
malities throughout childhood; however, there is an apparent relationship between
the degree of malnutrition and pulmonary outcomes. To evaluate cognitive function
in children with CF and the influence of both early diagnosis through neonatal
screening and the potential effect of early malnutrition, we obtained cognitive
assessment data for 89 patients (ages 7.3 to 17 yr) during routine clinic visits.
These children had been enrolled in either the screened or traditional diagnosis
(control) group of the Wisconsin CF Neonatal Screening Project. The Test of Cog-
nitive Skills, 2nd Edition (TCSy2) was administered to generate the Cognitive
Skills Index (CSI) and cognitive factor scores. Cognitive scores in the overall study
population were similar to normative data (CSI mean (S.D.)s102.5 (16.6) 99.1–
105.9 (95% c.i.)). In patients without meconium ileus, mean (S.D.) CSI scores for
the screened and control groups were 104.4(14.4) and 99.8(18.5), respectively (Ps
.24). Significantly lower cognitive scores correlated with indicators of malnutrition
and unfavorable family factors. Our analyses also revealed lower cognitive scores
in patients with low plasma alpha-tocopherol levels at diagnosis. In addition,
patients within the control group who also had vitamin E deficiency at diagnosis
showed lower CSI scores in comparison to sufficient controls and both deficient
and sufficient subgroups of screened patients (P-0.05). Our results show a dele-
terious effect of prolonged malnutrition, especially vitamin E deficiency, on cog-
nitive function.
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Adult males with cystic fibrosis (CF) have greater deficits in lean tissue
mass than adult females with CF
S. King (Presenting), I, Nyulasi , T. Kotsimbos , J. Wilson1 1 2 2
Nutrition Department, Alfred Hospital, Melbourne, Australia, Department of Res-1 2
piratory Medicine, Alfred Hospital, Melbourne, Australia
Poor nutrition and low body mass index (BMI) are associated with poor survival
in CF. Aim: To compare body composition in adults with CF with a group of healthy
adults of similar age and height. Methods: Eighty-six adults with CF (52 males, 34
females; mean age 30.0 yr (S.D. 7.7)); and seventy healthy controls (35 males, 35
females; mean age 31.1 yr (S.D. 7.2)) was studied. Subjects had body composition
measured to calculate fat mass, lean tissue mass (LTM) and bone mineral content
(BMC) using DEXA (Lunar DPX-IQ, Lunar Radiation Corporation). Results:
Results are shown in the table. Data are mean (S.D.). Significance estimates are
for comparisons between CF subjects and controls for each gender, using unpaired
t-tests (*P-0.05, **P-0.005). Males with CF had significantly lower mean total
weight, fat mass, LTM and BMC than control males. In comparison, females with
CF had lower mean total weight, fat mass and BMC than control females, but
similar mean LTM. Generalised linear models showed that the deficits in mean
LTM and total body weight found in CF males relative to controls were significantly
greater than those observed in CF females, but that there were no significant gender
differences in deficits in fat mass or BMC.
PRIVATE Parameter Control males CF males Control females CF females
Height (m) 1.76 (0.06) 1.73 (0.07)NS 1.63 (0.07) 1.61 (0.07)NS
Weight (kg) 78.5 (12.6) 64.8 (10.1)** 59.9 (9.9) 55.7 (7.1)*
Fat mass (kg) 15.7 (9.0) 8.3 (5.3)** 17.4 (8.0) 13.2(4.9)*
LTM (kg) 58.2 (7.0) 52.3 (7.0)** 39.0 (4.1) 39.0 (3.5)NS
BMC (kg) 3.1 (0.5) 2.7 (0.5)** 2.5 (0.3) 2.3 (0.3)*
Conclusion: Males with CF have a significantly greater deficit in LTM relative to
their healthy peers than do females with CF. It is unknown whether this finding
reflects the better survival of males into adulthood, or is a consequence of greater
nutritional imbalance in males during growth and development. It highlights the
need for further study of (1) the accretion of body tissue during childhood and
adolescence and (2) the relationship between lean tissue mass and survival.
Supported by the Australian Cystic Fibrosis Research Trust.
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Total energy expenditure in cystic fibrosis: comparison of
measurement by doubly labelled water vs. heart rate monitoring
R. Greer (Presenting), M.L. Richards , P.S.W. Davies , S.C. Bell1 2 2 3
Paediatrics and Child Health, University of Queensland, Brisbane, Australia,1
Children’s Nutrition Research Centre, University of Queensland, Brisbane, Aus-2
tralia, Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia3
Assessment of total energy expenditure (TEE) in CF is important, because body
weight and BMI are lower in CF than in the normal population, but it is not known
whether TEE is increased. Also, there are conflicting reports as to whether TEE is
related to fat free mass (FFM) in CF. TEE can be measured using doubly labelled
water (DLW), or by heart rate monitoring (HRM). The DLW method, while well
validated in health, is expensive and requires mass spectrometer analysis. HRM is
relatively simple, requiring calibration of heart rate and VO (oxygen consumption)2
during graded exercise, and heart rate monitoring. We compared TEE by DLW vs.
HRM in 9 adults with CF (5 M, age 19–35 yr), using the Bland-Altman method.
Weight, height, FEV % predicted (FEV) were recorded and BMI calculated. Sub-1
jects received 180 (0.1 gykg) and 2H (0.05 gykg) on day 1, urine samples were
collected over 10 days and TEE calculated. Subjects performed a treadmill exercise
test for calibration of HR and VO , and wore a heart rate monitor for 3 days. FFM2
was calculated from the 180 dilution space. Mean body weight was 66.3(13.3) kg
and mean FFM 50.2(11.5) kg, 75.4(6.0)% of body weight. DLW differed from
TEE by a mean 521.2(1314.9) kcal compared with HRM. All measurements were
within 2 S.D. of the mean difference between the two methods, although the dif-
ference was higher in those with higher TEE. Mean TEEyFFM was similar (dif-
ference 8.7(12.1) kcalykg, Ps0.06) by either method. TEE by either HRM or DLW
was correlated with FFM (rs0.87, Ps0.002, rs0.97, P-0.0001). HRM provides
an adequate measure of TEE in CF, and has the advantages of being well accepted
by subjects, useful in the field and economically practical. TEE measured by either
method was strongly correlated with FFM.
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Resting energy expenditure in cystic fibrosis
T. Moudiou (Presenting), A. Galli-Tsinopoulou , C. Mandroukas , S. Nousia-1 1 2
Arvanitakis1
Fourth Department of Pediatrics, Aristotle University of Thessaloniki, Thessalon-1
iki, Greece, Ergometry Laboratory, Aristotle University of Thessaloniki, Thessa-2
loniki, Greece
The aim of this pilot study was to relate resting energy expenditure (REE) to the
clinical status in Cystic Fibrosis (CF). Material and Methods: Twenty-three CF
patients, 13 males and 10 females, ranging in age from 12–34 yr, were investigated.
Their clinical scores ranged from 74 to 96. REE was measured by indirect calorim-
etry. Forced vital capacity (FVC), forced expiratory volume in one second (FEV )1
and peak expiratory flow rate (PEFR) were measured by spirometry. Clinical con-
dition was expressed as Shwachman score. Results: REE(mean"SEM) was higher
than predicted in CF patients on the basis of the Schofield Equation: 1662"59 vs.
1505"45 kcalyday (ts4.3445, Ps0.0003). REE was higher in males than in
females (1805"78 vs. 1449"78 kcalyday, tinds2.080, Ps0.02). The linear
regression analysis of the data demonstrated that REE increased as Shwachman
score, FEV , FVC and SatO (x) decreased (REEsy28.5430xq4177, y1 2
4.8448xq2039, y6.7881xq2214, y6.0663xq2217 kcalyday, respectively, and a
95% confidence interval), showing clear correlation between them. Correlation was
also documented by the Pearson coefficient: rsy0.5712, y0.4520, y0.5473, y
0.4189, respectively. It is worth mentioning that the correlation between REE and
Shwachman score was significantly higher in females (rsy0.793 vs. y0.428).
PEFR did not correlate with REE. Conclusion: Our data support the concept that
REE is higher in CF than expected. REE increases as the clinical condition and
pulmonary function deteriorates in CF.
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Energetic cost of physical activity in cystic fibrosis children during
Pseudomonas aeruginosa pulmonaryexacerbation
B.L. Beghin (Presenting), G.F. Gottrand , M.L. Michaud , W.N. Wizla-1 2 3
Deramlbure , V.H. Vodougnon , H.R. Hankard , T.D. Turck4 5 6 3
Gastroenterology and CIC-9301-INSERM-CHU, Jeanne De Flandre Hospital1
CHRU, LILLE, France, Gastroenterlogy Unit Paediatric Department, Jeanne De2
Flandre Hospital CHRU, LILLE, France, Gastroenterlogy Unit and Cystic Fibrso-3
sis Center, Jeanne De Flandre Hospital CHRU, LILLE, France, Cystic Fibrosis4
Center, Jeanne De Flandre Hospital CHRU, LILLE, France, CIC-9301-INSERM-5
CHU, Cardiologic Hospital CHRU, LILLE, France, CIC-9202-INSERM-AP-HP,6
Robert Debre Hospital AP-HP, PARIS, France´
Chronic pulmonary infection by Pseudomonas aeruginosa is observed in Cystic
Fibrosis (CF) patients in whom intravenous antibiotic therapy (IVAT) are often
necessary. Our aim was to assess the evolution of ECPA after home IVAT in lab-
oratory conditions as in free living conditions. Sixteen CF patients (9 boys) with
a mean age of 12.1"2.3 yr were studied before and after IVAT. Physical activity
energy expenditure (PAEE) in laboratory conditions was first measured by indirect
calorimetry (IC) during a standardised physical exercise. PAEE was calculated as
‘PAEEsTEEyREE’ and was expressed in kJyminykg of fat free mass. ECPA in
laboratory conditions was compared using area under the curve (AUC) of the linear
regression between PAEE and power braking force of a cycloergometer. Energy
expenditure was then assessed in free living condition using the 24 h heart-rate
monitoring technique (HMRT) calibrated against IC. Physical activity (PA) was
simultaneously recording using triaxial-accelerometer (TA). ECPA in free living
condition after and before IVAT were compared using the ratio PAEEyPA. AUC
between 60 and 90 W in laboratory condition decreased significantly by y15.4%
after IVAT (median 14.9, range 8.8–30.3 vs. median 12.6, range 8.5–17.6; P-
0.05, Wilcoxon rank test). In free living conditions, ECPA did not vary significantly
(PAEEyPA controled by TA in free living condition decreased byy19.8%: median
3.4, range 1.6–6.4 vs. median 2.8, range 1.4y4.8: NS). The present data clearly
demonstrate a decrease of ECPA in laboratory condition for moderate level (60y
90 W) and probably also in free living conditions after IVAT. The decrease of both
REE and ECPA after IVAT could contribute to improve aerobic fitness, well being
and weight gain in CF patients.
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Comparison of growth status of CF patients with or without a positive
history of meconium ileus
I. Loukou(Presenting), P. Vogli, A. Tzouganatou, G. Adam, S. Doudounakis
Aghia Sophia Children’s Hospital, Athens, Greece
The study was designed to compare the growth status of CF children with or without
a positive history of meconium ileus (MI) and to determine if CF infants presenting
with MI have a more severe clinical course than those who do not. Subjects and
methods: Group 1 (MI group) consisted of 26 CF patients who presented with MI
and a control group (non-MI group) consisted of 52 CF patients without meconium
ileus (diagnosed following clinical presentation). Nutritional status was evaluated,
based on anthropometric assessments. All participants (ns78) had their weight
(kg), height (cm) and weight—for—height index% (Index) measured at age 6, 12
and 36 months. Results:
PRIVATE MI group (ns26) Non-MI group (ns52)
Boyss16 Girlss10 Boyss32 Girlss20
Weight 6y12 6.38"0.35 6.45"0.55 6.40"0.21 6.08"0.28
Weight 12y12 9.04"0.42 8.95"0.36 9.08"0.23 8.46"0.27
Weight 36y12 14.37"0.39 14.26"0.55 14.64"0.30 14"0.37
Index 6y12 91.55"2.73 89.72"3.80 88.6"2.48 90.72"3.28
Index 12y12 100.09"3.94 103.35"2.70 102.66"1.89 102.31"3.57
Index 36y12 105.59"2.25 102.62"2.43 103.39"2.07 102.33"2.56
Data are presented as mean"SEM. There was no significant difference in any
parameter between the two groups. Conclusion: Growth status is similar in CF
patients who present with meconium ileus and those who do not. Appropriate and
adequate medical and nutritional management of MI allows similar nutritional status
in comparison with other CF patients.
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Assessment of oral calorie supplements in children with cystic fibrosis
I. Loukou(Presenting), P. Vogli, A. Tzouganatou, S. Doudounakis
Aghia Sophia Children’s Hospital, Athens, Greece
Poor growth and malnutrition are major problems for a lot of patients with cystic
fibrosis. Oral calorie supplements are commonly prescribed as an effort to increase
weight gain. Aim: The aim of the study was to assess the efficacy of Scandishake,
a concentrated energy (2.0 kcalyml) oral supplement, specifically designed for CF
patients. Subjects and methods: 11 CF patients (5 male and 6 female) aged between
3.5 yr and 18 yr ( mean age 10.5 yr) were included in the study. Criteria for entry
to the study was that the participants had to have a recent weight loss of more than
5% of their usual weight, or had to be at the same weight for at least the last 6
months. All participants had their weight (kg), height (cm), BMI (body mass
index) and weight—for—height index% (Index) measured on entry to the study at
week 0.Then they received a daily supplement of Scandishake for a period of 6
months and their nutritional status was re-evaluated, based on the same anthropo-
metric assessments, at week 24. Results:
PRIVATE Week 0 Week 24 Difference Statistical analysis
Weight (kg) 29.17 32.03 q2.86 P-0.005
Height (cm) 134.5 135.7 q1.27 Ps0.008
Index 86.64 93.82 q7.18 P-0.01
BMI 15.16 16.34 q1.17 Ps0.005
Kcal 2072.73 2581.82 q509.09 Ps0.008
Statistical analysis showed significant difference between weight, height, index and
BMI before and after the supplemental period. Conclusion: The concentrated energy
formulation of Scandishake promotes significant weight gain in CF patients.
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‘Weighed 3 day food records’ in children with cystic fibrosis (CF) and
healthy controls: are the calculations of mean daily intake
reproducible?
M. Proesmans (Presenting), L. Vanharen , K., De Boeck1 1 1
University Hospital Leuven, Leuven, Belgium1
Introduction: Several methods are used to evaluate mean daily dietary intake in CF
patients but few studies validate the reproducibility of the obtained data. At our
centre we use ‘weighed 3 day food records’. The Aim of this study is to assess the
reproducibility of dietary calculations obtained with the ‘weighed 3 day food
records’. Methods: We performed the 3-day food record twice with 1 month interval
in CF patients and healthy controls (HC) and compared the respective calculations.
Out of 160 CF patients, 16 patients aged 8–13 yr were contacted and 14 finished
the evaluation. 15 healthy children of the same age category were evaluated as well.
For each food-record, daily intake of energy, proteins, fat, carbohydrate (CH), fibre
and calcium was calculated. Coefficients of variation (CV) in CF and HC were
compared by unpaired t-test. Results:
PRIVATE Cal1 Cal2 CV% Fat1
(g)
Fat2
(g)
CV% Prot1
(g)
Prot2
(g)
CV% CH1
(g)
CH2
(g)
CV
CF 2240 2390 8.3 90 96 17 84 90 11.1 270 290 9.7
HC 1970 2080 9.7 76 81 13 69 69 11.5 250 270 9.7
NS NS NS NS
Mean values and CV’s for intake of calories, fat, protein and CH are represented
in the table. For daily caloric intake mean CV was 9.7% for CF (min 1%–max
30%) and 8.3% for HC (min. of 1%–max 17%). For calcium intake CV is 14.6%
vs. 24.0% and for fibre intake CV is 17.3 vs. 15.5%. CV’s do not differ between
CF’s and HC’s for all of the above calculations. Conclusion: Overall, mean
variability of dietary calculations obtained with 3 day food records are around 10–
20% and thus acceptable. However, in individual patients CV’s are as high as 30-
40%. This may reflect fluctuations in dietary intake or incorrect noting. Therefore,
dietary calculations have to be interpreted with care. There are no differences in
reproducibility between CF patients and HC’s.
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Are nutritional intakes in children with cystic fibrosis (CF) adequate for
weight gain and growth?–a comparison with healthy controls
H. White(Presenting), S.P. Wolfe, S.P. Conway, K.G. Brownlee
Regional paediatric cystic fibrosis unit, St James’s University Hospital, Leeds, Unit-
ed Kingdom
High energy, high fat diets have been promoted in our clinic for the past 15 yr. The
aim of this study was to assess its impact on dietary intakes, nutritional status and
growth in children and adolescents with CF in comparison to healthy controls.
Method: Sixty-nine children with CF (38 male, mean 11.0 yr) were compared to
45 controls (24 male, mean 10.9 yr). Weight, height and body mass index (BMI)
were recorded and standard deviation scores (SDS) calculated. Five day unweighed
food diaries were completed by 58(CF) and 31(control) and analysed using Micro-
diet Computer Software (University of Salford, UK). Nutrient intakes were com-
pared to the estimated average requirement (EAR) for energy and reference nutrient
intake (RNI) for all other nutrients. Results: Children with CF consumed more
energy (116% vs. 94% EAR, P-0.0001), protein (221 vs. 184% RNI, P-0.01),
dietary fat (98.9 g vs. 74.9 g, P-0.0001) and fatykg body weight (3.1 g vs. 2.1
g, P-0.001) than healthy controls. Intakes of calcium, iron, zinc, vit. B2, vit. B12
and vit. E were also significantly higher (P-0.01). Increased intakes of vit. A, vit.
C, vit. D, folate and dietary fibre were also observed in the CF group, but were not
significant. Chidren with CF met current dietary recommendations for protein
(221% vs. 200% RNI recommended) but not for energy (116% vs. 120–150%
EAR recommended). Mean weight SDS (y0.62 vs. 0.15, P-0.001), height SDS
(y0.48 vs. 0.1, P-0.01) and BMI SDS (y0.49 vs. 0.11, P-0.01) were all lower
in children with CF. Conclusion: Children with CF attending our clinic achieve
significantly higher intakes of energy, protein, fat and some micronutrients than
controls. Despite this we fail to attain optimal growth and nutrition in some children.
Keywords: Children; Nutritional intake.
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Body mass index (BMI) improves after transfer to the adult specialist
cystic fibrosis (CF) centre at Papworth Hospital (UK)
R. Hartley(Presenting), H. Watson, E. Gunn, D. Bilton
Adult Cystic Fibrosis Centre, Papworth Hospital, Cambridge, United Kingdom
The role of nutritional status in cystic fibrosis is known to be highly significant in
terms of long term outcomes, with patients above 85% of ideal body weight having
a significantly better prognosis than patients less than 85% of ideal body weight,
independent of lung function . The Papworth Adult CF Centre receives patients1
from the paediatric service at age 16. On transfer a detailed dietetic assessment is
undertaken in order to optimise nutritional status and to address deficiencies in
patient knowledge with regard to pancreatic supplementation. We aimed to study
the impact of the transfer to adult centre care on nutritional status. Initial BMI for
new patients transferred between 1999 to 2001 was recorded on transfer and at
subsequent annual review assessments. Analysis of variance was used to evaluate
the change in BMI over time. Eighty-five new patients were transferred from the
paediatric clinics during the study. The mean BMI of new patients at transfer was
19.3 kgym significantly lower (P-0.01) compared with a mean BMI of 20.5 kgy2
m in the resident population. Post transfer there was a significant rise in BMI over2
all visits. The mean difference (95% CI) at first annual review from BMI at transfer
was 0.65 (0.22–1.09) kgym . In conclusion transfer to adult care with full nutri-2
tional assessment and attention to detail in terms of pancreatic supplementation and
dietary intake facilitates significant gains in BMI.
R. Sharma et al., Wasting as an independent predictor of mortality in patients with1
cystic fibrosis. Thorax 56 (2001) 746–750.
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Cystic fibrosis nutritional game
A. Cazenave (Presenting), D. Feeza, Pediatrie generale , I, Sermet-Gaudelus , C.1 1 1´ ´ ´
Kouhaiz , I. Jarrier , J. Besnard , S. School teachers , M. Burguiere , A. Laffitte ,1 1 1 1 2 3`
G, Lenoir1
Pediatrie generale, Hopital Necker, Paris, France, Artist, Hopital Necker, Paris,1 2´ ´ ´ ˆ ˆ
France, Dietetique, Hopital Necker, Paris, France3 ´ ´ ˆ
Introduction: Proper nutrition is a determining factor for a good overall status for
Cystic Fibrosis (CF) patients. We have noted that CF children don’t seem to be
greatly involved in their daily nutritional care. In order to sensitise CF children so
that they understand the importance for a good diet, a nutritional game has been
created by a workshop involving a dietician, a medical doctor, nurses and other
health professionals together with the pedagogic help of a teacher and 2 artists.
Materials: This board game has 48 boxes referring for questions classed according
different topics: families of food including notions on nutriments and equivalencies;
balanced diet with different types of meals and criticism of menus; general culture
underlining the pleasure of eating taking into consideration the 5 senses and 4 taste
groups; different types of traditional food and the origin of some typical expression;
getting into litigious situations. Results and Conclusion: The aim of the game is to
move forward on the board while throwing dice and to answer questions. The
winner is the one who arrives the first to the central star. This game is used through
a setting where 4 to 6 children are gathered, with a brief introduction teaching the
basics on nutrition is given and then after the game a brief conclusion while cooking
a simple culinary item is done.
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Training teenagers to nutrition and sports during an internship
C. Poisson (Presenting), M. Brechu , A.S. Haennig , I. Sermet-Gaudelus , A.1 2 1 1
Cazenave , C, Karila , A. Perrin , L. Brienne , I, Jarrier , C. Kouhaiz , M,1 3 1 1 1 1
Claricia , G. Lenoir1 1
Pediaitrie generale, Hopital Necker, Paris, France, Association Etoiles des neiges,1 2´ ´ ´ ˆ
Hopital Necker, Paris, France, Pneumologie pediatrique, Hopital Necker, Paris,3ˆ ´ ˆ
France
Introduction: Regular physical activity is essential in Cystic Fibrosis (CF) in order
to optimize bronchial draining and a good nutritional state. With this aim in mind,
a partnership has been developed between our Departments in Necker Hospital and
the association ‘Etoile des Neiges’. This association is made up of high level ath-
letes. They sponsor CF children and take them to important sporting events. More
recently, a new project is being set up where children follow an internship to reha-
bilitate to effort, in order to encourage them to undertake regular sports activity.
This internship also includes nutritional education. Materials: This internship has
recently involved 8 teenagers, all of them infected with the same germ in order to
avoid cross-contamination. These patients had recently stopped all sport activity
due to the worsening of their respiratory function and often of their nutritional
status. The group is supervised by health professionals, athletes for the effort reha-
bilitation, a cook, and the department’s nutritionist. Before the internship, the teen-
ager and his family meet the health professionals, athletes in order to define the
nutritional and sports aims. Results: During the internship the teenager does 2 to 4
h of physical activity, adapted to his respiratory capacities. He is also taught to
apply specific CF nutritional concepts while participating to ‘cooking activities’.
Following the internship, regular evaluations are done in order to follow the evo-
lution of his training to effort. Conclusion: This kind of internship encourages
teenagers in caring for their disease. It allows a therapeutic education using the
group dynamics as well as the identification to a high level champion.
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Auxological evolution of the French cystic fibrosis patients: a national
survey
F. Huet (Presenting), G. Bellis , J.V. De Monleon , M. De Braekeleer , S.1 2 1 2
Ravilly3
Hopital D’Enfants, Dijon, France, INED, Paris, France, Vaincre La Mucovis-1 2 3ˆ
cidose, Paris, France
Clinical, biological and social data of a French cohort of cystic fibrosis patients are
annually collected in a national registry since 1993. Each and every French patient
treated in a cystic fibrosis center (n s 87) is included in this transversal survey.
3149 patients (mean age: 14.9; range: 0–75) are regularly followed (sex ratio My
F: 1.12). In this study, the auxological data extracted from this registry are reported.
The data used to analyze our results are taken out from the French auxological
standards published by Sempe in 1997. Analyzed year by year, the results showed´
an optimal height velocity (HV) during the first 10 yrs of life (HV: y0.30"1.3
SDS at 10 yr of age). The height velocity’s peak during puberty (which appears
without delay) was characterized by low amplitude and a long duration. In 2000,
the mean CF adult’s height was 171.5"7 cm (y0.48"1.24 SDS) in male and
161"6 cm (y0.47"1.27 SDS) in female. The impact of the disease was impos-
sible to evaluate since patient’s target height was not available. We observed a
dramatic weight deficit at the end of the first year of life (y1.21"1.7 S.D. in both
sex). The intensive nutritional supplementation and pancreatic enzyme treatment
allowed to obtain, during the first 10 yr of life, a substantial weight catch-up (y
0.43"1.9 at 10 yr of age). During the puberty, the weight evolution bent (y
1.2"1.3 at 16 yr of age). Then, the bias induced by the patients’ overmortality
after 20 yr of life (best life expectancy for the patients with optimal weight),
involved in an amelioration of weight after 25 (y0.75"1.72 DS). The results of
the French national survey showed that the cystic fibrosis patients afford an accept-
able auxological evolution, even thought it is still under the average. Puberty
seemed to be a key period and needs particular care.
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Phospholipid and thiol metabolism in children with Cystic Fibrosis
Sheila M. Innis , A G F, Davidson , A. Chen , Y.P. Lillquist , R. Dyer , S.1 1 2 1 1
Melnyk , J. James1 3
Pediatrics, University of British Columbia, Vancouver, Canada, Nutrition, B C1 2
Children’s Hospital, Vancouver, Canada, National Center for Toxicological3
Research, Jefferson, Arizona, USA
Abnormalities in membrane phospholipid turnover in CF have long been speculated
and there is considerable information regarding altered concentrations of essential
fatty acids (which are predominantly esterified in phospholipids). We used a novel
approach based on the intersection of thiol and phospholipid metabolism at the
sequential methylation of phosphethanolamine (PE) to form phosphotidylcholine
(PC) to study potential alterations of phospholipid metabolism in CF. Plasma PC,
PE, methionine, S-adenosyl methionine (SAM), S-adenosylhomocysteine (SAH),
and homocysteine were quantified and plasma and red cell phospholipid fatty acids
were determined in 53 CF (mean age 10.6 yr) and 18 control (mean age 9.8 yr)
children. Of the CF children, 69% were homozygous and 25% heterozygous for
dF508 mutation. Plasma homocysteine and SAH was higher (P0.001) in children
with CF (9.3"0.2 mM, 35.8"1.4 nM, respectively) than in controls (5.2"0.2 mM,
20.0"nM) while plasma methionine was lower (P0.001) in CF (19.5"0.6 vs.
28.5"1.4 mM). Plasma methionine was inversely (P0.05) and SAH and homo-
cysteine were positively (p0.001) correlated with plasma phospholipid PE. Plasma
and rbc folate and plasma B12 were normal in all subjects. Children with CF had
consistently lower 22:6n-3 in plasma phospholipids and triglycerides and rbc PC
and PE than controls children. These results suggest altered turnover of PE via
sequential methylation to form PC, with subsequent decreased methionine and
increased homocysteine. The increase in SAH in CF could inhibit PEMT (PE meth-
yl transferase) leading to increased PE and decreased PC formation. Altered
membrane lipid and thiol metabolism may contribute to the clinical complications
associated with CF.
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Gastrostomy in patients with cystic fibrosis: a commentary
T. Havermans*(Presenting), K. De Boeck, L. Vanharen
Pediatric Pulmonology, University of Leuven, Leuven, Belgium
In this commentary a short literature review is presented with regard to positive
and negative aspects of gastrostomy. The lack of psychosocial research is apparent
and although we can learn from studies done with illnesses other than CF, there is
a need for better understanding the impact of gastrostomy on young adults with CF.
Experiences with patients from the University Hospital of Leuven who have (had)
a gastrostomy show that patients realize very well the positive aspects of a gas-
trostomy. They acknowledge that it helps them with their weight problem. However,
the perceived pressure by doctor or family, the perceived inconvenience of gastros-
tomy, the hindrance and feelings of shame or embarrassment often result in non-
compliance. Few patients are able to really integrate gastrostomy feeding into their
lives. In addition to these negative experiences, it seems that the age at which the
gastrostomy is placed is an important contributing fact to success or failure of the
gastrostomy. From our experience we conclude that gastrostomy placed at a young
age has a better chance of success than gastrostomy placed during teenage years.
Teenage years are not an ideal stage to recommend gastrostomy feeding: adolescents
are concerned with their body esteem and a gastrostomy button has been described
by our patients as an ‘ugly sight’. We conclude by discussing how health care
professionals can support patients with a gastrostomy taking into account the impor-
tance of personal experiences and life phase of individual patients.
s86 Journal of Cystic Fibrosis 2 (2003) S73–S90
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Are gastrostomies useful in cystic fibrosis
R. Jayaram (Presenting), H. Vaindirlis, T. Salerno, A. Bush, M. Rosenthal
Peadiatric Respiratory Medicine, Royal Brompton Hospital, London, United
Kingdom
Aim: To assess whether gastrostomy and overnight feeding was of benefit to growth
and lung function. Methods: Casenotes with a minimum of 4 years lung function
data were reviewed. 23 of 136 CF patients born between February 1977 and October
1986 underwent gastrostomy. There had been prior dietetic input and exclusion of
other causes of poor weight gain. Height, weight and spirometric data were collected
and z-scores (corrected for gender, age and size) calculated. Results: Median age
at gastrostomy was 13.5 years (range 8.3–20.8). Fifteen were male. Fifteen were
homozygous for dF 508. There were no significant improvements in z-scores for
weight (zW) or FEV1 (zF) 6 months after gastrostomy compared with the prior 6
months. Median zW at insertion wasy1.68 (rangey0.34 to 5.1), 6 months before
was y1.64 (y0.13 to y3.8) and 6 months after was y1.46 (y0.08 to y5.03).
Median zF at insertion wasy4.92 (y0.62 toy7.69), 6 months before wasy3.67
(y2.9 to y5.81) and 6 months after was y4.76 (y1.53 to y5.46) zW improved
in 11 patients. In these, median zW at insertion was y1.57 (y0.51 to y3.09), 6
months before was y1.64 (y0.75 to y2.74) and 6 months after was y1.17 (y
0.62 to y1.44). zF improved in 5 patients, 6 months after gastrostomy insertion.
Of these, 1 did not show an improvement in zW in the same period. No significant
differences in sex, genotype or age at gastrostomy were found between children
whose zW and zF improved and those whose did not. Conclusion: The overall
group response to gastrostomy feeding in CF was poor but with wide individual
variation. No single antecedent variable was a predictor of outcome; this may be
related to compliance, which was not assessed in this study. Benefit seems likely
to be on an individual basis; as outcome is not predictable, we see no alternative
to gastrostomy as yet in a severely malnourished CF child.
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Cyproheptadine is an effective appetite stimulant in patients with cystic
fibrosis
D.N. Homnick (Presenting), B.D. Homnick , C.D. Brooks , A.J. Reeves , K.L.1 2 1 3
Hare , J.H. Marks , R.S. Pimentel , S.K. Bonnema4 1 5 6
Pediatrics, Michigan State University, Kalamazoo Center for Medical Studies, Kal-1
amazoo, USA, Kalamazoo Area Math and Science Center, Kalamazoo, USA, Phar-2 3
macy, Michigan State University, Kalamazoo Center for Medical Studies,
Kalamazoo, USA, Pediatric Research, Michigan State University, Kalamazoo Cen-4
ter for Medical Studies, Kalamazoo, USA, Statistics, Western Michigan University,5
Kalamazoo, USA, Nutrition, Bronson Methodist Hospital, Kalamazoo, USA6
Chronic infection, poor appetite, and intestinal malabsorption lead to malnutrition
in cystic fibrosis (CF) patients. Cyproheptadine hydrochloride (CH), a first gen-
eration antihistamine with a secondary effect of appetite stimulation, has been used
to stimulate appetite in patients with asthma, AIDS and cancer with variable results
but with an excellent safety profile. We undertook a 12-week, double blind; placebo
controlled trial of CH with the objective of determining its safety and efficacy as
an appetite stimulant in CF patients. Methods: Eighteen subjects were randomized
to receive CH (2 mg QIDX1 week, 4 mg QIDX11 weeks) or placebo. Eight subjects
in each group completed the study. Measures included weight, height, BMI, % ideal
body wt.yht., skin folds, body composition by bioelectric impedance analysis
(BIA), Shwachman score, spirometry, days of PO and IV antibiotic use, and a
satisfaction questionnaire. Results: There was no significant difference between CH
and placebo groups at baseline in Shwachman score, age, or most anthropometirc
measures. There was a significant increase in weight from 0–12 weeks in both
groups but substantially more in the CH than placebo groups (3.45 kg or 9.3% of
baseline wt. vs. 1.1 kg or 2.6% of baseline wt.). BMI and skin folds increased
significantly only in the CH group, A significant difference in baseline FEV and1
FEF25-75 was noted between groups but no changes occurred in either measure
over the 12 weeks of the trial nor were there differences in IV or PO antibiotic
use. Side effects were mild consisting of 1–2 days of mild fatigue at study start.
Two subjects were withdrawn (1 placebo, 1 CH) for transient elevation of liver
enzymes (probably not drug related) and poorly controlled diabetes. Summary: CH
appears to be an effective appetite stimulant with few side effects in CF patients.
Supported by the MSUyKCMS CF Center Grant and the Bronson Community
Research Fund.
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Use of megestrol acetate to improve body weight in malnourished adult
cystic fibrosis (CF) patients
J. Crawley (Presenting), S. Pandya , M.J. Ledson , M.J. Walshaw1 2 3 3
Department of Pharmacy, The Cardiothoracic Centre, Liverpool, United Kingdom,1
Department of Dietetics, The Cardiothoracic Centre, Liverpool, United Kingdom,2
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom3
Low body weight in CF is associated with a poor prognosis. CF patients have high
nutritional requirements, but ill individuals often have a poor appetite, which inhib-
its weight gain. Megesterol acetate (Megace) is a progestogen that has been used
as an appetite stimulant in patients in palliative care, but there are few reports of
its use in CF. We decided to investigate its effect in our adult CF patients with low
body mass index (BMI) and failure to gain weight due to a poor appetite. Nine CF
adults (age range 17–30, average weight 44.4 kg (range 31–66), average BMI 16.1
kgym (range 13–23), 5 females) were commenced on megestrol acetate 160 mg2
od (average treatment length 3 months (range 2–9 months)). All had pancreatic
insufficiency and 7 (78%) CF related diabetes mellitus. All were prescribed nutri-
tional supplements and 4 (44%) overnight enteral feeding. Subjective response to
treatment was assessed by monitoring patients’ appetites and satisfaction with food,
and all patients were weighed monthly to calculate BMI. Seven patients (77%) did
not show any significant weight gain, including one who took therapy for 9 months.
However, 2 patients (23%) showed weight gains of 8.6% and 16% (3.2 and 6 kg)
after 4 and 3 months of treatment, with their BMIs increasing by 1.6 and 2.0,
respectively. All 9 patients reported increased appetite during the treatment period
and the drug was well tolerated with no adverse effects. This study shows that
megesterol 160 mg daily may have a beneficial effect in improving appetite and
thus preventing weight loss and aiding weight gain. We speculate that increasing
the dose used may see further improvements in BMI. Further studies are merited
to assess the use of this drug in the treatment of poor body weight in CF.
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Adult cystic fibrosis (CF) patients show considerable deficits in their
antioxidant status: what is the implication?
E.I. Back (Presenting), M. Stern , D. Nohr , H.K. Biesalski1 2 1 2
Institute of Biological Chemistry and Nutrition, University of Hohenheim, Stuttgart,1
Germany, University Children’s Clinic, Tuebingen, Germany2
CF-patients have to cope with a high free radical load due to chronic inflammation
and infection. They often suffer from a lack of fat-soluble antioxidant vitamins due
to chronic malabsorption as well. Our study aims to investigate whether there is a
discrepancy between antioxidant vitamin-requirements and -availability with age,
i.e. with increasing severity of the clinical picture. Furthermore, we investigate
whether the potential lack of fat-soluble antioxidants causes a rise in oxidative
damage (TBARS, F2a-isoprostane). CF-patients and healthy controls were divided
in 4 age groups (-6 yr, 6–12 yr, 13–18 yr, G18 yr). Vitamin concentrations (vit.
E, carotenoids, vit. C), and the level of oxidative stress were measured in plasma
and buccal mucosal cells (sBMC). Plasma vit. C (P-0.05) and BMC-vit. E (Ps
0.015) decreased significantly with age in patients, but not in controls. Vitamin E
and carotenoid levels in plasma and tissue of CF patients in groups 2 and 4 were
sign lower when compared to controls. In age group 4, sign more (P-0.01) controls
than patients reached preventive plasma levels (H.K. Biesalski et al., 1997) of vit.
C ()50 mmolyl), vit. E ()30 mmolyl) and b-carotene ()0.4 mmolyl). Overall,
sign more patients than controls had vit. E and b-carotene plasma levels indicating
a deficit. There were no significant differences in the level of oxidative stress
between either patients or controls or the 4 age groups. Most CF-patients sufficiently
covered their vitamin requirements via diet andyor supplements. Yet their vitamin
status was less satisfactory than the one of healthy controls. The differences between
patients and controls were most pronounced in age group 4. Having an adequate
antioxidant status is important in order to avoid chronic degenerative diseases later
in life. New strategies in supplying vit. E and C as well as b-carotene (nutritar-
geting) might help to better balance the vitamin status of CF-patients.
s87Journal of Cystic Fibrosis 2 (2003) S73–S90
338
Micronutrients; relationship with nutrition and disease in children with
cystic fibrosis
K. van Niekerk, S.B. Carr (Presenting)
Paediatrics, The Royal London Hospital, London, United Kingdom1
Better nutritional status in CF is said to be related to lower morbidity and increased
survival; little hard research evidence confirms this. Research suggests a link
between lung function and micronutrients, especially vitamin E and selenium1.Aim:
To show an association between micronutrients and health status, with the question:
do low micronutrient levels predict poorer lung functionygeneral health? Methods:
104 children with CF mean age 9.5 yr (range 0.9–17.9). Plasma levels of selenium,
copper, zinc, vit. E and vit. A were measured. Lung function (FEV ) was recorded.1
Z-scores for height, weight and BMI calculated. CXR Northern score and IgG as
extra indicators of disease statusyhealth. Results: Z-scores means (S.D.): BMI –
0.29 (1.14), Ht – 0.48 (0.91), Wt – 0.53 (1.07). Micronutrient means (S.D.): Cu
17.2 (3.9), Se 0.85 (0.21), Zn 16.7 (4.5), Vit. E 19.9 (8.1), Vit. A 1.33 (0.32).
CXR score 6.9 (3.5), IgG 10.3 (4), FEV 78% (21). Two regression models with1
BMI z-score and FEV as the dependent variables and all 5 micronutrients as inde-1
pendent variables showed no correlation. A larger model with age, CXR score and
IgG showed no relationship. Bi-varient analysis showed a correlation between lung
function and Vit. A and a negative correlation between lung function and Cu.
Applying the linear regression model with these two kept their significant, but weak,
correlation with FEV . (Beta: Cu – 0.3 (Ps0.03) and Vit. A 0.3 (Ps0.03)).1
Discussion: This study failed to link low micronutrients with poorer lung function.
There was no relationship between nutritional status and micronutrients. Copper is
known to be toxic in lungs but useful when bound in antioxidant enzyme systems.
This new finding of copper’s negative association in CF is worth further review.
The benefits of micronutrients and antioxidants on the respiratory system have long
been postulated, but still no strong clinical evidence supports this.
L. Wood, Am. J. Clin. Nutr. 77 (2003) 150–159.
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Evaluation of vitamin supplement use in a cohort of adults with CF
J. Al-Siaidi (Presenting), N. Jarad1 2
Bristol Royal Infirmary, Bristol, United Kingdom, Respiratory Medicine, Bristol1 2
Royal Infirmary, Bristol, United Kingdom
Introduction: Malabsorption of fat-soluble vitamins is common in most patients with
CF. It is routine practice to supplement patients with vitamins with A, D and E and
to monitor plasma level annually. Serum levels of vitamins A, D and E were found
to be sub-optimal in 30%, 21% and 40% of patients, respectively, at recent annual
review of patients at the Bristol Adult CF Centre. This is consistent with findings
at other CF centres. Aim: The aim of this study was to evaluate the adherence with
vitamin supplementation and determine associated factors in this group of patients.
Methods: An anonymous questionnaire is given to all patients attending the adult
CF clinic over a period of 4 months. It is completed and returned during clinic.
Results: To date, (1 month in) 21 patients were issued questionnaires, 20(95%)
completed them (10 female), 19 were pancreatic insufficient (PI). All patients had
been advised to take vitamins. Seventeen (85%) had been prescribed vitamins,
9(45%) used a pre-payment ‘season ticket’, 8(40%) received free prescriptions and
3(15%) paid for all their prescriptions. 25% purchased vitamins – 25% vitamin C,
and 15% multivitamins. Seventeen (85%) of patients thought they knew why they
needed to take vitamins. Sixteen (80%) took their vitamins at least 6 daysyweek,
the remainder took them 4–5 timesyweek, ‘forgetting’, being the most common
reason for not taking them. Of the PI patients, 10(52%) took their vitamins most
regularly with a drink and enzymes"food, 9(47%) usually took them with a
drink"food and no enzymes. Fourteen (74%) were unaware that taking vitamins
with food and enzymes is likely to improve uptake. Ten (50%) were interested in
receiving more information about vitamin supplements and their health. Conclu-
sions: Reported adherence to vitamin supplementation was good. Resources are
needed to better inform patients about their vitamins.
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Vitamin A is associated with the inflammatory marker CRP in cystic
fibrosis
R.M. Greer (Presenting), H.M. Buntain , C.E. Wainwright , J.A. Batch , P.W.1 2 2 3
Francis , J.M. Potter , S.C. Bell2 4 5
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bane, Australia, Thoracic Medicine, The Prince Charles Hospital (TPCH),5
Brisbane, Australia
We have observed that vitamin A levels, deficient in patients with severe disease,
returned to normal post lung transplant independent of oral supplementation or
pancreatic sufficiency. We hypothesised that vitamin A is associated with disease
severity and the inflammatory marker C-related peptide (CRP). Data from RCH
paediatric and TPCH adult CF clinic subjects (ns138 CF, 138 control, aged 5–56
yr), who had participated in a study of bone mineral density (BMD) in which
vitamins A, E, D, and CRP, height, weight and lung function had been measured
was used. Groups were compared using t- or Wilcoxon-tests, and predictors of
vitamin A examined using multiple regression. Vitamin A was lower in CF subjects
(1.23"0.5 vs. 1.80"0.6 mmolyl, P-0.0001), increasing with age in paediatric
subjects but to a lesser extent in the CF group (Ps0.0007). CRP was correlated
with age (rs0.6, P-0.0001). FEV % predicted (FEV) (57.93"23.0 vs.1
70.63"21.8, Ps0.0014), weight z-score (WTZ) (y0.76"0.9 vs. y0.12"1.0,
Ps0.0002), lumbar spine BMD z-score (y1.08"1.3 vs. y0.50"1.2, Ps0.009)
were lower, and CRP higher (median 7.0, IQR 2–4 vs. median 1.0, IQR 1–3 mgy
l, P-0.0001) in vitamin A insufficient CF subjects (61 insufficient vs. 71 suffi-
cient). In all subjects, control status (P-0.0001), WTZ (Ps0.02), vitamin E (Ps
0.0003), CRP (Ps0.001), 1,25 dihydroxy vitamin D (1,25 vit. D) (Ps0.0007),
and child, adolescent or adult grouping (all P-0.0001) were predictive of vitamin
A. In the CF group, CRP (Ps0.01), Vitamin E (P-0.0001) and 1.25 vit. D (Ps
0.006), but not FEV, were predictive. The normal increase in vitamin A with age
was not observed in CF subjects, who had lower levels at any age. This failure of
normal increase in vitamin A had a consistent association with increasing CRP,
supporting the hypothesis that increased inflammation may result in increased vita-
min A consumption.
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Altered availability and mobilisation of vitamin A in CF
A.L. Cawood (Presenting), J.L. Murphy , M.P. Carroll , G. Connett , P.1* 1 2 3
Afolabi , J.M. Jackson , S.A. Wootton1 1 1
Institute of Human Nutrition, University of Southampton, Southampton, United1
Kingdom, Department of Respiratory Medicine, Southampton University Hospitals2
Trust, Southampton, United Kingdom, Department of Pediatrics, Southampton Uni-3
versity Hospitals Trust, Southampton, United Kingdom
High dose supplements of retinyl palmitate (RP) are routinely prescribed in the
belief that availability is compromised with the maldigestion of lipid. However,
there is concern that chronically high intakes will accumulate in the liver particularly
if mobilisation is constrained. We have used tracer techniques to directly determine
(i) availability of exogenous vitamin A from faecal losses along with post-prandial
changes and (ii) mobilisation from the liver, from plasma retinol (R) tracer:tracee
ratios. Six adult CF patients and 6 age-matched healthy adults (HA) received an
oral dose of (10,19,19,19) H-retinyl palmitate within an emulsion, with a breakfast2
and usual PERT. Baseline and post-prandial bloods were drawn at 2, 5, 10, 24 h
and 7, 14 and 28 days. Faeces were collected for 3 days. Plasma and faecal R and
RP were determined by HPLC; w H xR was determined by GCMS. Despite greater2 4
excretion of total and labelled vitamin A in the faeces of CF patients compared to
HA, they were still able to absorb over 70% of the administered dose. Post-prandial
excursions of plasma RP were not different between groups (AUC over 10 h (medi-
an (range)): CF 1.54 (0.41–2.98) vs. HA 2.26 (1.28–4.62) mmolyl 10 h). Whilst
plasma w H xR declined in HA (4.4%, 2.87%, 1.76% at 7, 14 and 28 days, respec-2 4
tively), it was not possible to detect enrichment in CF patients. These results suggest
that whilst GI dysfunction may impair vitamin A availability, the additional increase
in intake required to overcome these modest losses is considerably less than that
achieved with routine supplementation. The inability to detect labelled retinol may
reflect a large store of vitamin A within the liver andyor a constraint in mobilisation.
Taken together, these findings highlight the need to review current practice in order
to prevent potential harm through hepatotoxicity from excessively high intakes.
s88 Journal of Cystic Fibrosis 2 (2003) S73–S90
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Vitamin A supplements in children with CF – are we giving too much?
J. Gavin (Presenting), J. Murphy , G. Connett , M. Carroll , A. Cawood , S.1 2 1 1 2
Wootton2
CF Centre, Southampton University Hospitals Trust, Southampton, United King-1
dom, Institute of Human Nutrition, University of Southampton, Southampton, Unit-2
ed Kingdom
Current CF guidelines recommend prophylactic vitamin A supplementation to all
pancreatic insufficient patients with the dose adjusted according to circulating ret-
inol concentrations. It is not well recognised that the level of supplementation has
progressively increased over recent years and that even relatively modest increases
in intake might cause harm over prolonged periods, particularly in terms of damage
to liver and bone. Children are believed to be more sensitive to the toxic effects of
retinol than adults and at greater risk from chronic exposure. The aim of this study
was to explore the dose of vitamin A supplement given to children with CF in
relation to current guidelines and prevailing circulating retinol concentrations. Clin-
ical records and plasma retinol concentrations were available from 158 children
attending the CF centre since 2001 for annual assessment. Of these, 148 children
were apparently consuming between 1200–4800 mgyd RE from their vitamin A
supplement in addition to that available from the diet-equivalent to between 5 and
10 times the Reference Nutrient Intake. Infants and young children appeared to be
at greatest risk of excess vitamin A with 15y16 of children under 3 years having
total vitamin A intakes in excess of the daily Safe Upper Limit (900 and 1800 mgy
d for -1 yr and 1–3 yr, respectively). Plasma retinol concentrations ranged from
0.4–3.0 mmolyl (mean 1.20 mmolyl). Of these, 25 children (17%) had values that
were below the UK reference range for plasma retinol in healthy children despite
supplementation; 21 children (14%) had values above the reference range. Even
allowing for possible increased faecal losses, the evidence base to support such high
intakes is not forthcoming. There is a need to review the current approach to vitamin
A supplementation, with more attention directed towards the factors that underlie
altered retinol concentrations in these patients.
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Vitamin D status in children with cystic fibrosis in Republic of
Macedonia
T. Jakovska (Presenting), S. Fustik , N. Slavevska , K. Jakovski1 1 1 2
Department of Pediatrics, Clinical Center, Skopje, Fyrom, Institute for Pharma-1 2
cology, Clinical Center, Skopje, Fyrom
Patients with cystic (CF) are at risk for malabsorption of fat-soluble vitamins and
those with low 25-OH vitamin D levels have a higher risk of low bone mineral
density and long-term skeletal complications. Routine supplementation of liposo-
luble vitamins is part of management in our CF Center. We assessed vitamin D
status for the first time in children with CF who had attended our Center. Methods:
We examine 30 patients with CF (14 girls), mean age 11.6"4.50 (S.D.) yr and
control group with mean age 12.73"4.71 (S.D.) yr. We assessed them for serum
levels of 25-OH vitamin D with RIA method. Results: Nine (30%) of 30 patients
had marginal or low levels of 25-OH vitamin D (reference range 15–60 ngyml),
mean level for 25-OH D was 25.75"14.7 ngyml, median 24.74 with min. level
6.86 ngyml and max. 63.96 ngyml. Mean level for 25-OHD for the control group
was 43.56"14.8 ngyml, median 43.01 ngyml, with min. level 18.72 and max. 65.79
ngyml. Median 25-OHD was significantly lower between CF and control group
(P-0.05) despite supplementation with 800–1200 IE vitamin D routinely in chil-
dren with CF. Conclusion: Vitamin D, a fat-soluble vitamin, is important in regu-
lating bone accretion 25-OHD was lower in children with CF compared to healthy
children. We conclude that the widespread practice of oral supplementation with
800 IE of vitamin D is ineffective in maintaining normal vitamin D stores in many
patients with CF so closer monitoring of vitamin D status in children may be
warrant.
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Vitamin D deficiency in pancreatic sufficient and insufficient adults
attending a Scottish CF centre
M. Richardson (Presenting), J.A. Innes
Adult Cystic Fibrosis Service, Western General Hospital, Edinburgh, Scotland
Background: Sub-optimal serum 25-hydroxyvitamin D (25OHD) levels have been
reported in Cystic Fibrosis (CF) patients and may contribute to low bone mineral
density. Risk factors for vitamin D deficiency include mal-absorption, poor dietary
intake, inadequate vitamin D supplementation and insufficient sunlight exposure.
Sunlight exposure is limited in Scottish CF patients and our aim is to determine
prevalence of vitamin D deficiency in our unit and review current practice for
vitamin D supplementation. Methods: Case note review documented 25OHD levels,
prescribed vitamin D dose and pancreatic sufficiency status in 87 adults aged 18–
54 yr. Our laboratory reference range for 25OHD is 15–100 nmolyl, but a value
of -37 nmolyl is recognised as vitamin D deficiency in the literature and -15
nmolyl indicates severe deficiency. Vitamin adherence was determined by dietetic
review. Twenty-sevenyEighty-seven (31%) provided 3-day food diaries and vitamin
D intake was quantified using Microdiet software. Results: Vitamin D deficiency
was identified with equal prevalence in pancreatic insufficient (PI) and pancreatic
sufficient (PS) patients. Forty-twoySeventy (60%) PI and 9y17(53%) PS had
25OHD-37 nmolyl. ElevenySeventy (16%) PI and 2y17(12%) PS had 25OHD-
15 nmolyl. Vitamin D was prescribed in 65y70 PI and 5y17 PS patients at a
mean"SD dose of 1000"400IU. Of 70 patients prescribed vitamin D, 19 reported
complete non-adherence. In these, 63% had 25OHD-37 nmolyl and 26% were-
15 nmolyl. In the 27 patients who completed food diaries, mean dietary Vitamin D
was 140IU(25-289IU) per day. The mean"SD 25OHD was 38"19 nmolyl (April–
September) and 29"17 nmolyl (October–March). Conclusions: Vitamin D defi-
ciency is prevalent in PS and PI CF adults. Minimal seasonal difference suggests
inadequate sunlight exposure. These results suggest that all CF patients including
those with pancreatic sufficiency should be monitored and treated aggressively to
prevent vitamin D deficiency.
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Vitamin K status in children with CF and its relationship to bone
turnover
S.P. Conway (Presenting), B. Oldroyd , S. Wolfe , K.G. Brownlee , J.G.1 2 1 1
Truscott , M. Shearer , J. Harvey , W. Fraser , H. White2 3 3 4 1
Paediatric CF Unit, St. James’ Hospital, Leeds, United Kingdom, Centre for Bone1 2
and Body Composition Research, University of Leeds, Leeds, United Kingdom,
Haemophilia Reference Centre, St. Thomas’ Hospital, London, United Kingdom,3
Clinical Chemistry, University of Liverpool, Liverpool, United Kingdom4
Vitamin K is a cofactor necessary for post-translational carboxylation of glutamic
acid residues in vitamin K dependent proteins e.g. prothrombin and osteocalcin.
Incompletely carboxylated proteins are functionally defective. Osteocalcin is syn-
thesised by osteoblasts and has a regulatory role in bone formation and mineralis-
ation. The aim of this study was to quantify the prevalence of vitamin K deficiency
in children with CF and to assess the effect of a potential undercarboxylation of
osteocalcin on their bone turnover. The following were measured in 102 children
from 5–16 years old: Serum vitamin K (phylloquinone; K1) by HPLC, undercar-
boxylated prothrombin (PIVKA-II) by in-house Mab-based ELISA, undercarbox-
ylated (Glu-OC) and carboxylated (Gla-OC) osteocalcin using separate Takara
Mab-based ELISA kits; plasma BSAP, P1CP, (bone formation markers), fPYD and
fDPD, (bone resorption markers). BMD and BMC were measured at the lumbar
spine and total body using a GeyLunar Prodigy densitometer in 93 of the 102
children. Sixty-eight of 102 children showed sub-optimal vitamin K status (low-
serum K1 levels andyor raised PIVKA-11 levels). Mean (S.D.) levels of Glu-OC
and Gla-OC were 43.6 (27.4) and 21.6 (12.6) ngyml. Glu-OCyTotal OC (%)s
62.7 (23.7). BMD age-matched Z scores were -y1.0 in 41% of the children.
Significant correlations were seen between Glu-OC and bone turnover markers;
BSAP & P1CP, P-0.0001, fPYD & fDPD, P-0.03. There were no such significant
correlations for Gla-OC or for Glu-OC or Gla-OC with BMD or BMC. The majority
of children with CF in this study had sub-optimal vitamin K status. This may be
associated with increased bone turnover.
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A pilot study to assess iron supplementation in cystic fibrosis (CF)
using soluble transferrin receptors (STfR) as a measure of functional
iron deficiency
A. Verma (Presenting), Brummell Zoe , B. Keevil , J. Redfern , A.M. Jones , A.K.1 1 2 1 1
Webb1
Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester,1
United Kingdom, Biochemistry Department, Wythenshawe Hospital, Manchester,2
United Kingdom
Introduction: Iron deficiency has been found to be relatively common in CF. The
causes of iron deficiency are increased losses and requirements, a decreased absorp-
tion and insufficient intake. Consequences of iron deficiency include anaemia,
decreased physical capacity and reduced immune function. STfR is recognised as
an accurate method of measuring functional iron deficiency in CF patients . Aim:1
The aim of this pilot study was to assess the effect of iron supplementation in iron
deficient patients with CF using STfR. Method: Thirty-three patients were randomly
selected (mean age 29 yr, 17 men). Group 1 were patients with an initial high STfR
(G1.7 mgyl) who were supplemented with 400 mg of ferrous sulfate (130 mg
iron) once daily for 14 days. Group 2 had normal STfR and was not supplemented.
STfR and other blood assays were measured before and after iron supplementation.
Results: Twelve patients were in Group 1 and prescribed ferrous sulfate 4 experi-
enced side effects and were withdrawn from the study. Mean STfR, mean corpus-
cular volume and mean corpuscular haemoglobin content were significantly
different (P-0.05) between the 2 groups. There was no significant difference
between pre- and post-treatment STfR levels in the 8 patients who completed the
trial. There was a significant difference (P-0.05) between pre- and post-treatment
haemoglobin. Conclusions: The results of this study show that iron supplementation
with 400 mg of ferrous sulfate (130 mg iron) once daily for 14 days does not
significantly correct functional iron deficiency as determined by STfR however does
improve haemoglobin concentration.
B. Keevil et al., Ann. Clin. Biochem. (2000).1
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Transfer from pediatric to adult care: patients’ experiences before and
after a program was implemented
T. Havermans (Presenting), K. Colpaert , L. Dupont , K. De Boeck , M.1 2 2 2
Proesmans , E. Aertgeerts2 2
CF Team, University of Leuven, LEUVEN, Belgium, University of Leuven, Leuven,1 2
Belgium
Aim: The evaluation of a transfer program developed to assist patients in their
transfer from pediatric to adult CF care. A study was conducted to compare young
adult CF patients who transferred before the program (group 1) to those who trans-
ferred after the program (group 2) was implemented. Method: Patients were asked
to fill out a questionnaire during an outpatient clinic. The questionnaire focused on
the following topics: the preparation for transfer, information about the CF clinic,
the outpatient clinic and hospitalization. Results: 33 (82%) patients completed the
questionnaire. Patients from group 2 were significantly more satisfied with the prep-
aration than patients from group 1: they talked to more people about the transfer
and they considered different options that were available within the program (e.g.
visiting the adult ward or opting for a gradual transfer). All patients reported con-
siderable emotions during the preparation, with patients from group 2 being signif-
icantly more worried about transfer. Transfer at the age of 18 was the preferred
option by most patients. Approximately 83% preferred the pediatric location for
their outpatient clinic, although some older patients preferred a location for adults
only. Patients considered information during outpatient clinic sufficient (86%), but
were less satisfied with hospitalization. Conclusion: The transfer program led to
patients from group 2 being more satisfied about the preparation than patients from
group 1. Further staff training and improvement of conditions on the ward are
essential. Important aspects for future transfers are the provision of sufficient infor-
mation about the structure of the adult CF clinic, about adult CF issues and about
the functioning of the CF adult ward.
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Cystic fibrosis: transition from pediatric care to adult care: a
retrospective study about 15 patients
S. Blivet , D. Hubert , N. Dufeu , B Delaisi (Presenting)1 2 1 3
Hopital Ambroise Pare, Boulogne, France, Pulmonology, Hopital Cochin, Paris,1 2ˆ ´ ˆ
France, CF center, Hopital Robert Debre, Paris, France3 ˆ ´
Introduction : In France, national register (ONM) reported in 2000 that 34.5% of
patients with cystic fibrosis were more than 18 yr old. For young patients with
cystic fibrosis, transition to adult care is a difficult period. The goal of our study
is too precise how patients with cystic fibrosis transferred in adult care had lived
through the transition and to collect their suggestions for improvement. Patients
and methods: It is a retrospective study including patients from hospital Cochin
pulmonology department with cystic fibrosis and transferred from pediatric care in
2000 and 2001. Patients answered in April 2002 to a questionnaire on the way the
transition was carried out as well as to a life quality questionnaire CFQ14q. Clin-
ical data of patients at the moment of their arrival in adult care were collected:
revelation mode and genetic of the cystic fibrosis, body mass index, functional
respiratory data and bacterial bronchic colonization. Results and discussion: 15
patients (9 women and 6 men) aged in average of 20.6"3.5 yr at the moment of
the transition have accepted to participate to the study. Their clinical characteristic
were the following: mean CVF s71.3"21.1% from theoretical, mean SaO s2
95.5"1.2%, IMCs19.03"1.8 kgym , 73.3% of patients were colonized with2
Pseudomonas aeruginosa. Seven patients (46.7%) lived through the transition with
anguish, 4 of them as a constraint. As a matter of paradox, the 4 patients who were
the most anguished had a very moderate respiratory form with a mean CVF at 82%.
For the moment of the transition: it was optimal for 66.7% of patients, 33.3%
thought it was to late, but no patients thought it came to early. Sixty percent of
patients thought the accompanying procedures were relevant, including a joint con-
sultation with both pediatric MD and adult care MD. Conclusion: After this study,
the implementation of carefully designed transition programs from pediatric care to
adult care would be relevant.
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Education of parents with young cystic fibrosis children less than 5-
year old
M. Clairicia (Presenting), I. Sermet-Gaudelus , P. Canoui , B. Thouvenin , J.P.1* 1 1 1
Delaunay , C. Kouhaiz , D. Folio , B. Madras , G. Lenoir1 1 1 2 1
Pediatrie generale, Hopital Necker, Paris, France, CFTDE, Hopital Necker, Paris,1 2´ ´ ´ ˆ ˆ
France
Introduction: A number of parents with Cystic Fibrosis (CF) children have told us
about their feeling of isolation at the announcement of their child’s diagnosis as
well as the difficulties in coping with daily care. This has led us to organize meet-
ings with parents of recently diagnosed CF children. The aim of these meetings
was to answer to their questions, to organize meetings with experts and to allow
exchange between families. Materials: Following the first gathering, requested by
the families, we continued to organize regular meetings with topics chosen by them.
Appropriate experts to the chosen fields of discussion were invited. The whole
health team involved in the care of the CF children also participates. These meetings
take place during 1 whole day, allowing the possibility to lunch together. Results:
The following topics have been discussed: physiotherapy, home hygiene, dietary
care, school, dealing with healthy brothers and sisters, psychological aspects, con-
sidering a pregnancy after having had a CF child, living with 2 CF children, meeting
with an adult patient. The participation of the families increased regularly. Conclu-
sion: These meetings allow an exchange at a different level among families and
with the nursing staff. The interaction with the expert allows families to better
understand the issues and thereafter get more deeply involved in the daily care. For
the health team, it allows better relationships with the child environment and better
therapeutic management. These meetings have allowed us to sense the intensity of
the problems—often underestimated—that these families encounter in their daily
life.
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The impact of cystic fibrosis (CF) on family functioning and parenting
A. De Temmerman (Presenting), I. Dab , G. Loots1 2 1
Department of psychology, Brussels Free University, Brussels, Belgium, Depart-1 2
ment of Paediatrics, CF Clinic, Academic Hospital, Brussels Free University, Brus-
sels, Belgium
Abstract: Approximately 160 CF-families undergo multidisciplinary follow-up in
the Academic Hospital in Brussels (A.Z.-V.U.B.) as CF influences the medical
domain as well as the social and psychological domains. These follow-ups brought
into attention the linking between Cystic Fibrosis, family functioning and parenting
and resulted in a study on the relationship between the family context and the
emotional and physical well being of patients and course of the illness. From clinical
observations, we noticed that children and adolescents with CF mean an extra pres-
sure for the whole family, importantly affecting family functioning. The way fam-
ilies are coping with this parental and family stress seems to influence the course
of the illness. If this statement can be confirmed by research, it is important to
improve family functioning to optimise physical well being. Starting this study, we
asked both parents of approximately 35 Flemish patients’ aged between 3 and 13
yr, to fill in two questionnaires. The Dutch version of the Family Environment
Scale and the Parenting Stress Index to determine the kind of difficulties, which
parents experience when taking care of a child with CF. The family functioning
and its climate were assessed. In this presentation we discuss the results of the
questionnaires, focussing on differences in perception between mothers and fathers.
In the future, depending on our findings, we intend to study more profoundly the
effect of family interaction and parenting on the course of illness.
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Disease knowledge among cystic fibrosis families in Brittany (France)
M. De Braekeleer (Presenting), G. Bellis , G. Rault1 2 3
Laboratoire de Cytogenetique, Universite de Bretagne Occidentale, Brest, France,1 ´ ´ ´
INED, Paris, France, Centre de Perharidy, Roscoff, France2 3
Cystic fibrosis (CF) has an incidence of 1 in 2636 live births and a carrier rate of
1 in 26 inhabitants in Brittany. A questionnaire was distributed through the partic-
ipating centres from Brittany and Loire Atlantique to the French Cystic Fibrosis
Registry; it contained 6 questions on general knowledge of hereditary disorders, 10
on the knowledge of CF and 8 on the genetic transmission of CF. At the time of
the study, 506 patients (children, adolescents and adults) were followed by the CF
centers in Brittany and Loire-Atlantique. Overall, we received 207 completed ques-
tionnaires (40.9%). The return rate was 42.3% (124y293) for the parents with a
CF child, 40.3% (27y67) for CF adolescents, and 38.4% (56y146) for CF adults.
The knowledge of clinical signs was rather good among patients and their parents
(50–68.7%) with important differences regarding some specific manifestations of
the disease. The knowledge of genetics in general was much better (81.4–93.7%);
all three categories were well informed of the genetic transmission of CF (74.3–
89.4%). Comparison with the high risk population of Saguenay Lac-Saint-Jean
(SLSJ) in Quebec for CF showed similar results. However, the return rate of the
questionnaires in the SLSJ region was much better (80.6–88.9%) than in Brittany
and Loire Atlantique. Therefore, we cannot exclude that only those who thought to
be well informed answered the enquiry, making the comparison of the results dif-
ficult. Supported by grants from the ‘Fondation du Centre Helio-Marin’ in Roscoff´
and the ‘Programme Hospitalier de Recherche Clinique (PHRC)’
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Living with cystic fibrosis – perception of impact of disease, hope and
quality of life
B. Hanestad (Presenting), Eva Gjengedal , Tone Rustøen , Astrid Klopstad Wahl1 1 2 2
Department of Public Health and Primary Health Ca, University of Bergen, Ber-1
gen, Norway, Faculty of Nursing, Oslo University College, Oslo, Norway2
Introduction: The fact that cystic fibrosis (CF) patients are surviving longer raises
psychosocial and spiritual issues. Therefore, the aim of the present study was to
assess impact of disease and perception of hope and quality of life in adults suffering
from CF. Methods: The sample consisted of 86 adults (48% female, mean age 29
(SD 9.0) yr, age range 17–54) with CF recruited from the Norwegian Competence
Centre for Cystic Fibrosis (84% response rate). The patients filled in a questionnaire
consisting of: (1) demographic data; (2) single items measuring symptoms and
perceived impact of disease; (3) Herth Hope Index (HHI), score range from 12–
48 with higher scores indicating greater hopefulness and (4) Quality of Life Scale
(QOLS), score range 16–112 with higher scores indicating better quality of life.
Mean FEV % was 57.7 (S.D. 23.2), range 21–120. Mean BMI was 21.3 (S.D. 3),1
range 15.6–32.2. Results: Ninety one percent reported treatment to impact their
daily life activity. The patients perceived coughing, mucus plugging and fatigue as
the most bothering symptoms. Those with lower FEV % reported significantly more1
symptoms. Although 72% of the sample experienced living with CF as difficult,
75% stated that they were satisfied with life and had a positive outlook in life.
Mean score on HHI was 36.1 (S.D. 4.1), range 25.1–45.6 and mean score on QOLS
was 86.1 (S.D. 12.8), range 44–110. Conclusion: Scores on the standardised ques-
tionnaires show similar level of hope and quality of life compared to the Norwegian
normal population norms, indicating that perception of bothering symptoms is not
contradictory living a good life with CF.
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Health-related life satisfaction of adolescents and adults with cystic
fibrosis: impact of pulmonary function, daily time for therapy and
partnership
L. Goldbeck (Presenting), T.G. Schmitz1 2
Child and Adolescent PsychiatryyPsychotherapy, University Clinic Ulm, Ulm, Ger-1
many, Children’s Hospital Schwabing, Technical University Munich, Munich,2
Germany
Objective: Quality of life (QoL) and objective health parameters correlate only
moderately. To learn more about risk and protective factors influencing subjective
health, this study investigates the relative impact of pulmonary function, expenditure
of time for daily therapy and partnership on QoL in an adolescent and adult cystic
fibrosis (CF) population. Methods: 243 patients with CF (mean age 25.5 yr, range
16–47 yr) answered the Questions on Life Satisfaction (FLZ-CF). This multidi-
mensional instrument measures general life satisfaction, general health-related life
satisfaction and CF-related satisfaction. The participants reported on their recent
FEV %, their time for daily therapy, and whether they lived in a partnership.1
3=2=2 MANOVAs were performed with FEV % (-40% of the predicted; 40–1
70%; )70%), therapy time (- or )90 min per day), and partnership status as
factors and the three dimensions of life satisfaction as dependant variables. Results:
General life satisfaction is influenced significantly by therapy time (Fs24.4, P-
0.001), and partnership status (Fs14.4, P-0.001), but not by FEV %. General1
health-related satisfaction is influenced significantly by therapy time (Fs35.0, P-
0.001) and FEV % (Fs5.3, Ps0.005). CF-related satisfaction is associated with1
therapy time (Fs5.5, Ps0.02), FEV % (Fs3.9, Ps0.021), and partnership status1
(Fs3.1, Ps0.079). Discussion: Partnership and the expenditure of time for daily
therapy contribute significantly to the life satisfaction of adolescents and adults with
CF. In our model, these factors explain more variance of life satisfaction than
FEV %. Patients without partner and with time demanding therapy procedures are1
at risk to get dissatisfied with their life. They might need special psychosocial
support.
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Routine computer-based evaluation of quality of life in outpatient
clinics for cystic fibrosis
T.G. Schmitz (Presenting), L. Goldbeck1* 2
Department of pediatrics, Technical University of Munich, Munich, Germany,1
Child and adolescent psychiatry, university Ulm, Ulm, Germany2
Quality of life (qol) is an important outcome criterion of therapy effectiveness,
especially regarding diseases with a time-consuming therapy such as Cystic Fibrosis
(CF). Standard measures of subjectively perceived qol should be implemented as
a routine procedure in outpatient clinics for CF. In a pilot-study we examined the
feasibility of a computer-based assessment with the Questions on Life Satisfaction
FLZM-CF. In five German CF-outpatient clinics qol was evaluated longitudinally
for 135 patients (16–47 yr of age, 47% female, FEV 20–125% of predicted, mean1
65.6%) parallel to every pulmonary function test. Additional medical parameters,
recent changes of objective health and sociodemographic factors were recorded.
The self-report data were collected with a computer-based questionnaire. The com-
puter-based assessment facilitates an immediate evaluation of individual qol, a prin-
tout of the results including a graphical representation of the longitudinal data of
the patient is offered. In the mean the FLZM-CF took 10 min. Ninety percent of
patients eligible for our study participated. During the follow-up assessments the
acceptance of the instrument remained on a high level, only one patient dropped
out of the study. The computer-based FLZM-CF is a simple, time-saving instrument
for measuring qol as a standardized parameter in daily clinicale practice. The assess-
ment is easy to integrate into the daily routine of outpatient clinics. Another advan-
tage of this method compared with paper-pencil questionnaires is the completeness
of data. The implementation of the FLZM-CF asa a screening method supports the
communication between physician and patient and integrates the subjective per-
spective of patients with CF into the process of planning their therapy.
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Social status of adults with cystic fibrosis in a specialist unit
I. Inglezos (Presenting), E. Panitti (Presenting), M. Mani , F. Apostolopoulou1 1 1 1
Pulmonology, Sismanoglio General Hospital, Athens, Greece1
The aim of this study was to describe the social status and some demographic
characteristics of adults with cystic fibrosis, aged over 17, attending a specialist
unit in Athens-Greece. From the data of our 67 adult patients with cystic fibrosis
(38 men and 29 women) aged over 17 (range 17–39 yr, mean 32) results that 11
were married (16.4%) with fewer men than women (3 men and 8 women) and
only one married woman had a child. Eighteen percent lived alone and the great
majority (82%) was still living with their parents regardless of their age. Fourty-
nine percent was working and 33% of them working part time. We didn’t note any
significant medical difference between working and non-working adults except for
the number of hospital admissions (i.v. treatment or other medical emergency). Of
our adults 25% had higher qualification and 46% (in the range of 19–26 yr) were
studying to a higher education. In Greece the large majority of young adults is still
living with their parents so don’t differ cystic fibrosis patients. A great number of
them have many difficulties to find a job due to their ilness.
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A survey to determine the prevalence of sleep disturbance in patients
with cystic fibrosis
B. Govin (Presenting), C. Cowperthwaite , H. Miller , M J. Ledson , M J.1* 1 1 1
Walshaw1
Adult CF Unit, The Cardiothoracic Centre, Liverpool, United Kingdom1
Members of the multi-disciplinary team at the Cardiothoracic Centre in Liverpool
noted that there were a significant reports of disturbed sleep patterns by patients
attending the Cystic Fibrosis clinic. We therefore surveyed 40 adult patients to
determine the prevalence of the problem in the clinic population. An interview took
place with each patient using a structured questionnaire technique. Overall, different
sleep problems included 25 patients (63%) waking during the night, 32 (80%)
feeling tired on waking, and interestingly 20 (50%) reported regularly sleeping
during the day. Eighteen (45%) commented that they had difficulty falling asleep
and 13 (33%) complained of early wakening. Of 26 patients (65%) who were
particularly troubled with sleeping, 10 (38%) had experienced problems for greater
than one year. Fourteen of these (54%) identified worry as the main cause, includ-
ing issues surrounding end of life, the family, the future and living with Cystic
Fibrosis. Whilst only 12 of them (30%) had tried oral sedation, 11 (92%) found it
effective. Fifteen patients (58%) had tried alternative methods to help them sleep,
but only 7 of these (47%) found these methods useful. Patients were asked about
common medications used in the management of Cystic Fibrosis that are known to
cause sleep disturbance. Of those on steroids, 22% attributed the treatment to the
cause of sleep problems. Whilst only one patient commented that bronchodilator
therapy caused a problem, 12% stated that they do not take their bronchodilator
late in the day as it may prevent them from sleeping. Sleep disturbance is common
in patients who have Cystic Fibrosis and may be caused by physical and psycho-
social triggers. Members of the Cystic Fibrosis multi-disciplinary team are in a key
position to identify problems and instigate appropriate intervention.
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Newborn screening for CF in a regional paediatric centre: psychosocial
effects of false-positive results on parents and re-evaluating service
provision
J. Moran (Presenting), K.L. Quirk , A.J.A. Duff , K.G. Brownlee , S.1 1 2 2
McLaughlin2
Academic Unit of Psychiatry and Behavioural Science, Doctorate in Clinical Psy-1
chology Course, Leeds, United Kingdom, Regional Paediatric CF Unit, St James’s2
University Hospital, Leeds, United Kingdom
Introduction: Routine neonatal screening for CF has been established in Leeds since
1975. The current method is IRT and genotyping. National false positive rates are
0.3 to 0.6% . Such results can cause parents emotional distress and the quality1 2,3
of service provision is crucial. This study aimed to explore parents’ experiences of
receiving an initial false-positive IRT result. Method: Parents (Ns21) completed
a semi-structured interview about: knowledge of CF and neonatal screening,
psychosocial impact of the experience, service provision and potential improve-
ments. Descriptive statistics and a content analysis identified several common
themes. Results: Anxiety, distress and upset were commonly reported at the initial
raised result. Parents described a greater range of emotions and hypervigilence
whilst waiting for repeat test results. For most, the final ‘all clear’ result brought
relief. Current good practice included; health visitors informing of initial raised
result in person and CF nurses performing repeat test at home. Information provision
and the professional conduct of CF nurses rated positively. Service improvements
included; reviewing information provided on routine neonatal screening, developing
protocols to improve consistency and accuracy of information given at initial raised
result and reducing waiting time for repeat results. Conclusions: Parents supported
neonatal screening for CF. Receiving initial false-positive results is associated with
parental anxiety and emotional distress. Although many aspects of the service were
evaluated positively, there are implications for practice-improvement.
References:
D.J.H. Brock, Cystic Fibrosis. in: N.J. Wald, I. Leck (Eds.), Antenatal and Neo-1
natal Screening (2nd Edn.), Oxford: OUP, 2000.
Tluczek et al., J. Dev. Behav. Peds. 13 (1992) 181–186.2
Baroni et al., Ped. Nursing 23 (1997) 143–151.3
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Evaluation of a 5 day residential education program for parents of
newly diagnosed infants with CF
Judith, Glazner*(Presenting), Susan, Sawyer, Phil, Robinson
CF Unit, Respiratory Medicine, Royal Children’s Hospital, Melbourne, Australia
The diagnosis of Cystic Fibrosis (CF) is a major event for families. Initial parental
emotional responses include sadness, shock and severe grief. At the same time
parents are required to learn skills that enable them to perform complex tasks
required to care for their child. Newborn screening for CF was introduced in Vic-
toria in 1989. At that time a 5-day in-patient based approach to CF education was
conducted. More recently with the establishment of a care-by-parent unit within the
hospital a 5-day residential CF education program was developed. This program
aims to provide an opportunity for baseline assessment, information and support to
families, to establish rapport and facilitate an ongoing partnership with members of
the CF team and to promote the development of a co-coordinated care partnership
with community health professionals. Parents are introduced to a CF physician and
the CF Psychologist and clinic coordinator on the day of diagnosis by the genetic
counselor. Following an initial discussion with the parents concerning CF, the family
is the invited to begin the 5-day residential program. Baseline tests performed
include faecal fat analysis, chest X-ray and blood tests for vitamin levels and gen-
otyping. Older siblings are routinely sweat tested. 17 families who underwent this
educational program were interviewed regarding their experience. All families
endorsed the timing and content of the program. Over 50% identified the major
benefit being able to concentrate on CF education without having to travel or being
distracted by other factors present in the home environment.
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Using patient’s views to develop and improve a CF service
A. Nicholas(Presenting), H. Oxley, M. Dodd, A.K. Webb, A. Jones
Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester, Unit-
ed Kingdom
Introduction: For the last four years our annual User Satisfaction Survey has asked
patients what they think about our service. We wanted to see if we could use the
information gathered to address their concerns and complaints in a way that would
improve our service. Method: Taking the results from the User Satisfaction Survey
(described elsewhere) we grouped patients’ comments according to themes. We
then discussed these as a team and found a solution wherever possible. We explained
to patients those issues we could not resolve. We published the solutions, expla-
nations and results in a regular newsletter and sent it to all patients. We also dis-
played the same information in poster format in the out patient waiting room.
Results: Recurring themes were admissions procedures, inequalities in the service,
out patient facilities, ward facilities, courtesy, and communication with the team,
car parking, appointment times, annual assessments and continuity of care. We used
the information we gathered to find solutions to some problems and to improve our
service. Here are just two examples: We made the hospital Trust aware of patients’
comments on car parking and as a result now we have two new disabled car parks
adjacent to our unit. Patient’s comments on the hospital catering service prompted
more detailed research into this problem. Patients then met with catering to try to
improve the service. The patients chose their own menus for the new hot trolley
service. This consultation process has continued. Conclusion: Patient’s views and
ideas can be a powerful influence on service development. They can enable teams
to target those areas that are of greatest concern to patients and provide a practical
way to reach solutions. They can also be used to make patient led improvements
to the service.
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Patient satisfaction with an adult CF service
A. Nicholas(Presenting), H. Oxley, A.K. Webb, A. Jones, M. Dodd
ManchesterAdult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester, Unit-
ed Kingdom
Introduction: Patient satisfaction has a central role in the NHS (DHSS 1983). We
have developed a questionnaire to assess what patient’s think of our service, to
highlight those areas we need to develop or improve and to ensure that when we
make changes they are patient led. Method: The survey has an anonymous semi-
structured self-completion format based on a five point Likert scale. There are 17
questions with additional space for patients to make comments. The questions relate
to standards of service. We have administered it annually for four years. We give
it to the first 60 patients attending clinic or admitted to the wards in November
each year. Results: Our patients report high levels of satisfaction with the service
year on year. Between 98 and 100% are satisfied or very satisfied with the quality
of care. Patient comments from the survey also reflect these high levels of satis-
faction. The comments reflect recurring themes from year to year. These include
admissions procedures, inequalities in the service, out patient facilities, ward facil-
ities, courtesy and communication with the team, car parking, appointment times,
annual assessments and continuity of care. Conclusion: The format gives us valuable
information about our patient’s views. This illustrates our patients concerns with
practical issues and emphasises the importance of user involvement in getting this
right. We use the survey as a starting point for more sensitive consultation on
specific issues raised.
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Adult cystic fibrosis patients’ perspective on their social support:
interactions and satisfaction
A.J. Crossan , T. McCarthy (Presenting), S. Elborn1 2 3
Clinical Psychology, Windsor House, Belfast City Hospital, Belfast, United King-1
dom, School of Psychology, Queen’s University Belfast, Belfast, United Kingdom,2
Adult Cystic Fibrosis Unit, Belfast City Hospital, Belfast, United Kingdom3
This pilot study focuses on the social support available to a sample of the CF adult
population in Northern Ireland. Social support is composed of two components
supportive interactions and the individual’s perception of being supported. Both
supportive transactions and satisfaction with the support are explored in this study.
The four types of support are examined: (i) social-emotional; (ii) instrumental; (iii)
crisis and (iv) daily support. Eighteen adults participated in the study. Six patients
were sampled from each of the three microbiological subgroups within the CF
population: (i) Burkholderia cepasia; (ii) Pseudomonas aeruginosa and (iii) non-
Pseudomonas aeruginosa. Participants completed four standardised questionnaires:
(i) Social Support Questionnaire for Transactions and Satisfaction; (ii) Social Sup-
port Questionnaire Short Form; (iii) Rosenberg Self-esteem Questionnaire and (iv)
Hospital Anxiety and Depression Scale. The patients’ social support interactions
and satisfaction with support were also explored using semi-structured interviews.
Analysis revealed that social interactions were relatively low, but patients’ satisfac-
tion with the social support provided was high. Preliminary analysis of the semi-
structured interviews revealed that several patients sought independence and a
normal life, but were wary of over-dependence on others for support. A comparison
between psychological adjustment and social support was not possible as all par-
ticipants were in the normalymild range for anxiety and depression. Our findings
suggest that in general adults with CF in Northern Ireland are satisfied with the
social support provided and are experiencing no significant psychological morbidity.
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Satisfaction of adolescent and adult cystic fibrosis patients with
rehabilitation programmes
T.G. Schmitz (Presenting), L. Goldbeck1 2
Department of pediatrics, Technical University of Munich, Munich, Germany,1
Child and adolescent psychiatry, University Ulm, Ulm, Germany2
Rehabilitation is an essential element of therapy in Cystic Fibrosis (CF). The sat-
isfaction with inpatient rehabilitation programmes was investigated in a multicenter
study. Patients of six German CF-rehabilitation centres filled in a questionnaire
about satisfaction with different offers and aspects (scale from 1 to 5) four weeks
after the end of their rehabilitation programme. 55 of 75 patients (76.4%) eligible
for the study (16–62 yr of age, 62% female, FEV 22–85% of the predicted) sent1
back the follow-up questionnaire. The expectations of 47 participants (85.4%) were
completely met. Among the different therapeutic aspects that contribute to the pos-
itive effect of rehabilitation satisfaction with physiotherapy (4.0), with the oppor-
tunity to meet other CF-patients (4.0) and with the distance from daily problems
(3.7) was in the upper range of the scales. Satisfaction with i.v.-therapy (2.3),
psychoeducational interventions(2.6), nutritional advice (2.7) and psychosocial care
(2.5) was less pronounced. The most frequent reason for dissatisfaction was the
lack of health improvement due to a severe infection. The results of the study
indicate a high satisfaction of CF-patients with inpatient rehabilitation treatment. A
potential response bias should be considered, as 24% of the patients did not partic-
ipate in the study. Psychosocial aspects such as socializing with other persons affect-
ed and distance from daily conflict contribute to the satisfaction of the participants.
The study will be continued to describe medium-term effects of rehabilitation on
different dimensions of qol in adolescents and adults with CF.
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CF adult: education, job or anticipatory pension?
L.D. Lund (Presenting), C. Koch , E. Wendel1* 1 2
CF Center-Copenhagen, Department of Pediatrics GGK-5003, Rigshospitalet,1
Copenhagen, Denmark, Danish Cystic Fibrosis Association, Viborg, Denmark2
Introduction: An increasing number of patients now reach adulthood and integration
in society becomes a dominant issue for the individual patient, and for the CF social
worker dealing with problems related to education, job and anticipatory pension.
Aim: To perform a cross-sectional analysis of social status of adult patients and of
the obstacles encountered. Methods: A questionnaire was sent to all 196 patients
-18 yr corresponding to 403 all living patients in Denmark. Results: 131 patients
responded. 88 were under education, had a job or a ‘flexjob’, which allows flexible
working hours with compensation of the employee for non-working hours. 40 were
receiving-or had received pension, which had been granted at an average age of 23
yr. The ‘flexjob’ was not in existence when the majority of these 40 patients applied
for pension, and today several of these have started working again in a ‘flexjob’
with their pension pending. Three were currently unemployed. Upon the question:
‘Did you have to stop or extend education because of CF?’ 32 said yes, 95 said
no, and 4 were unanswered. Common reasons in the yes-group encompassed general
illness, poor lung functions, frequent hospitalisations for antibiotic treatment, and
a few underwent double lung transplantation. Upon the question: ‘Did you have to
stop or change job because of CF?’ 23 said yes, 94 said no, and 14 were unan-
swered. Common reasons encompassed too much dust and smoke, no airing, too
many hours at work resulting in too little time for daily PEP physiotherapy and
medication, and that the work was physically too hard. Discussion and conclusion:
It is encouraging that large proportions of adult patients were integrated in society
with respect to education and job. An optimistic CF team, which includes a social
worker with expertise for individual study and vocational guidance, is essential for
proper guidance of the individual patient aimed at securing social integration, an
essential part of quality of life.
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Stressors and needs of the support person involved in a lung
transplant program
G. Ullrich (Presenting), H. Jansch , H.J. Bartig , J. Niedermeyer1* 2 1 2¨
Pediatric Pulmonology, Medical School Hannover, Children’s Hospital, Hannover,1
Germany, Pulmonology, Internal Medicine, Medical School Hannover, Hannover,2
Germany
Most transplantation (Tx) programs stress the importance of a relative or friend to
support the Tx-patient during the endeavour. Yet, there are only a few articles
dedicated to their situation. Methods: We developed a questionnaire with questions
related to the situation of the support person (stressors and strains), his or her
evaluation of professional support (related both to the actually received support as
well as to unmet needs). The survey was part of a larger retrospective study on
psychological aspects of double-lung Tx in adults with CF (ns28) or other end-
stage lung disease (ns20). Twenty-two relatives of CF patients and 17 relatives
of patients with other diseases participated. Results: During the acute (in patient)
period 80% of the relatives felt ‘very’ strained, during the waiting period this was
slightly less frequent (54%) and even more so during the rehabilitation period
(33%). The latter period was considered more stressful by relatives of CF patients
(36% ‘very’ strained vs. 29%). Relatives reported both somatic (53–68%) as well
as emotional complaints (50–73%). Unfortunately, professional suppport frommed-
ical staff was considered insufficient by at least 20–35% of respondents and was
worse both during the waiting period as well as during the rehabilitation period.
Psychosocial staff was not available for most of the respondents even though 52–
65% would have been interested in respective support at least during the in patient
period. As regards suggestions to improve the situation of the support person a wide
range of aspects was mentioned (housing conditions during the acute period, a
person to relate to, information giving from medical staff, formal psychosocial sup-
port). Conclusions: It should therefore stand without question that the support per-
son needs to be supported, too. The minimum should be that one member of the
multidisciplinary team acts as the person-to-relate-to.
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Depression occurring in family members of patients with cystic fibrosis
(CF) undergoing lung transplantation (LT)
M. Intermite(Presenting), S. Bertasi, M. Rolla, E. Soldi, S. Quattrucci
Department of Paediatrics – Cystic Fibrosis Centre, University of Rome ‘La Sap-
ienza’, Rome, Italy
Objective: LT is currently the only valid therapeutic option for patients with CF
who have end stage pulmonary disease. LT is a complex procedure in which the
whole family environment is fully involved. Methods: We have observed 44 CF
patients who underwent 45 bilateral sequential lung transplantation and who sur-
vived more than 12 months after the transplant; we followed clinically their families
for a period of 12 months. Results: we have observed the emergence of significant
depressive symptoms in the closer parent within 3y8 months from the transplan-
tation. The rate of depression is higher among those parents who are directly
involved in the daily care of the patient before transplantation. The change in
patients life, and the suddenly acquired autonomy seems to be leading to a depres-
sive-anxious response in parents involved in cures for several years and unable to
adopt a new behavior after the BLT. These sudden changes elicit in patient severe
feelings of guilt and sorrow and an unconscious tendency to reduce hisyhers auton-
omy. This may lead to severe behavioural interferences with the therapeutic treat-
ment in the post transplantation period, and affects seriously the compliance level.
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Eating disorder symptomatology in adults with cystic fibrosis
N. Brager*(Presenting), L. Meloff , H.R. Rabin, M. Atkinson, C. Dang1
Department of Psychiatry, Foothills Medical Centre, Calgary, Canada
Chronic illnesses such as cystic fibrosis (CF) have been proposed as being precur-
sors to eating disorder symptomatology due to the emphasis on food and diet. Eating
and weight attitudes may impede the nutritional gains, which are essential for the
health of these individuals. The objectives of this study were to examine (1) the
nature and scope of eating disorder symptomatology in patients with CF; (2) the
importance of shape and weight in determining self-esteem for patients with CF;
(3) the validity of three standardized instruments in the assessment of eating dis-
order symptomatology in CF and (4) compare the findings to a control group. The
study was broad based and followed a cross-sectional survey design. CF adults
completed the Eating Attitudes Test (EAT) and the Eating Disorder Inventory-2
(EDI-2) and a semi-structured interview: the Eating Disorder Examination. In addi-
tion, the Shape and Weight Body Self Esteem Questionnaire and a chart review
were completed. Controls completed the EAT and EDI. Results indicated that the
CF patients exhibit eating disorder symptoms with some, particularly pancreatic
sufficient patients, demonstrating pathology that may be indicative of an eating
disorder. Different eating behaviors were exhibited including: ‘normal’ eating pat-
terns, disordered eating, ‘normal’ eating disorder symptomatology and disease-spe-
cific eating disorders (Food Avoidance Emotional Disorder). A significant portion
of the patients were found to evaluate themselves based on their body weight and
shape with levels approaching those exhibited by eating disordered patients. Varied
factor structures for the instruments did not support the constructs originally posited
for eating disordered populations. In conclusion, the study was exploratory and
supports the presence of eating disorder symptomatology in patients with CF. There
is a need for further investigation and for the development of a disease specific
instrument.
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Supporting staff in a cystic fibrosis centre – the value of an annual staff
stress survey administered for four years
H. Oxley*(Presenting), M.E. Dodd, A.M. Jones, A.K. Webb
Manchester Adult Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester, United
Kingdom
Introduction: Working in the area of chronic ill health and terminal disease can be
potentially stressful for the staff involved. A survey of staff stresses has been devel-
oped (HO) for use with the multidisciplinary team at the above adult CF centre
(approximately 250 patients and 40 staff).Methods: A short, self-completion, semi-
structured, anonymous survey was administered annually to staff four times. The
survey comprised some quantitative rating scales, but particularly invited further
comments, to give more specific information about work related stresses and sug-
gestions for what might help alleviate these. Each year the results of the staff stress
survey were discussed by the CF multidisciplinary team, to plan possible changes
to working practices. Results: On average, over the 4 yr, 7% of staff surveyed had
not felt stressed at all, 65% had felt stressed occasionally, 25% frequently and 2%
felt stressed all the time. The specific sources of stress identified by staff fell into
three main categories, patient, team and resource related issues. Many suggestions
were made about what would be helpful to the team in addressing these issues.
These included requests for further training in several different areas. Following
annual discussion of survey results by the team, a variety of initiatives have been
introduced in the unit to address issues raised, including a programme of teaching
sessions, and measures to improve team working. Conclusion: A short annual sur-
vey of staff stresses within a CF unit has identified specific sources of work related
stress, generated suggestions for changes in working practices, and highlighted
training needs for the CF team. Use of such a survey provides a means of consulting
and supporting staff in a CF multidisciplinary team.
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Does the severity of the illness reflect the care allowance paid?
S. Hall(Presenting), I.J.M. Doull
CFyRespiratory Unit, Department of Child Health, Cardiff, United Kingdom
Aim: To determine whether the care component of the Disability Living Allowance
(DLA) is related to the severity of the illness in CF patients attending the pediatric
CF unit in Cardiff. Background: In UK the DLA offers financial assistance towards
the extra costs of bringing up a child with Cystic Fibrosis. For a child under 16 yr
of age to receive DLA care requirements must be ‘substantially in excess’ of what
is usually required by a healthy child of the same age. Methods: Details on entitled
allowances were collected on all 69 full care CF patients attending UHW in 2002.
Nine patients were excluded—2 no annual review, 2 CFTR related disease, 1 non-
UK resident, 3 not applied for benefits and 1 has had benefits refused. Results: Of
the 60 families receiving DLA, 23 (38%) receive high rate, 30 (43.5%) receive
middle rate and 7 (4.8%) receive low rate. Of the 23 families receiving high rate
DLA, 9 do not require nebulised drugs, overnight feeds or regular intravenous
antibiotics. Only 4 of the patients receiving high rate DLA require nebulised drugs,
receive regular courses of intravenous antibiotics and receive overnight feeds. Two
families receiving middle rate require nebulised drugs, receive regular courses of
intravenous antibiotics and receive overnight feeds. Conclusion: There is inconsis-
tency in the degree of extra care required for the different levels of the DLA. The
criteria necessary to merit the different levels of DLA in CF are not clearly defined.
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Staying connected: optimising the educational opportunities for the
child with cystic fibrosis
B. Emblin (Presenting), Alex Robinson , Phil Robinson1 2 2
Education Institute, Royal Children’s Hospital, Melbourne, Australia, CF Unit,1 2
Respiratory Medicine, Royal Children’s Hospital, Melbourne, Australia
The continuity of educational opportunities for children, including those with Cystic
Fibrosis is imperative as a key developmental pathway. Fundamental to these oppor-
tunities is the recognition that health and well being are inseparable from learning
and developing for a future. The Royal Children Hospital Education Institute, The
Royal District Nursing Service CF community support team, and the CF unit at the
Royal Children’s Hospital have developed an innovative service to assist young
people, families and school communities to manage Cystic Fibrosis within the con-
text of their daily lives. This service is specifically tailored to address age related
challenges including school commencement through vocational opportunities. The
program encompasses school commencement information days for parents, annual
teacher’s seminars, school based information sessions for teachers and staff, infor-
mation packages and class-room visits if requested. If hospitalisation occurs, edu-
cation advisers facilitate school links through the use of information and
communication technologies such as desk top video conferencing. Active consul-
tation with members of the CF team, family and education communities are strongly
encouraged throughout the school life. Educational opportunities, even for CF chil-
dren who have not required periods of in-hospital treatment, may be threatened by
the day to day challenges of maintaining health in the face of a chronic disease
such as CF. An innovative and pro-active intervention into each child’s educational
program ensures that the child experiences optimal opportunities for education and
development.
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Do patients with cystic fibrosis (CF) find annual assessments
stressful? The results of a postal survey at an adult centre
A. Verma*(Presenting), H. Oxley, J. Biesty, A. Nicholas, A.K. Webb
Manchester Adult Cystic Fibrosis Centre, South Manchester University Hospital
Trust, Manchester, United Kingdom
Introduction: Annual assessments are now part of clinical practice at most CF cen-
tres. Some patients have told staff that they found the whole process ‘stressful’.
Our aims were to survey the patients who had undergone the annual assessment
process, to determine the extent of this problem and to highlight any areas that we
could improve or change. Methods: A postal anonymous, semi-structured, self-com-
pleted survey was sent to 120 patients who had completed their annual assessment.
14 questions were asked about how stressful patients found the various components.
To compare their responses to other issues, patients were asked if they were stressed
about other life events and hospital visits. Results: 84 (70%) responses were
obtained. 25 (30%) were very stressed or stressed quite a lot by the annuals, 34
(40%) were a little stressed, 25 (30%) were not at all stressed by the annual
assessment. Comparing those who were very stressed to those who were not
stressed, 44 and 19%, respectively, were stressed by other life events (Ps0.02),
16 and 2%, respectively, by attending other hospital visits (Ps0.19). Of those
patients who were stressed, 72% found organising time off workyeducation stress-
ful, 40% having the investigations and 20% waiting for the results. Conclusion: A
minority of patients found the annual assessment process very stressful (30%). It
may be that this small group of patients is also having stresses from other areas in
their life and would benefit from further intervention. We are using the information
about the most difficult aspects of the process to make changes to our annual
assessments.
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Microbiological colonisation in UK CF children–a comparison with
international databases
J. McCormick(Presenting), E.J. Sims, M.W. Green, G. Mehta, F. Culross, A. Mehta
University of Dundee, Dundee, Scotland
Introduction: The proportion of patients whose respiratory system is colonised with Staphy-
lococcus aureus (S.a.), Pseudomonas aeruginosa (P.a.) or Burkholderia complex (B.c.) can
be measured by national CF databases. This study aims to analyse the health of the paediatric
UK CF population in terms of its prevalence rates of microbiological colonisation and com-
pare it to three other major national CF registries; the French (Rapport sur la situation de la
mucoviscidose en France en, 2000, Vaincre la Mucoviscidose, 2002), the AustralianyNew
Zealand (Cystic Fibrosis in Australia and New Zealand, 2000: Annual Report from the Aus-
tralasian Cystic Fibrosis Data Registry. Cystic Fibrosis Australia 2002) and US CF registries
(Cystic Fibrosis Foundation Patient Registry Annual Data Report 2000. CFF 2001). Methods:
Data from 2001 was collected on microbiological colonisation (at least 1 isolateyyear) with
P.a., S.a., and B.c. from 2370 children registered in the UK CF Database (www.cystic-fibro-
sis.org.uk.). Results:
UK vs. France UK vs. US (CFF) UK vs. AustralianyNew
Zealand
Age P.a S.a B.c Age P.a S.a B.c Age P.a S.a B.c
0–4 28 vs.
21
19 vs.
50
0 vs.
0
0–5 28 vs.
30
20 vs.
47
0 vs.
1
0–4 28 vs.
9
19 vs.
30
0 vs.
2
5–9 35 vs.
28
32 vs.
63
1 vs.
2
6–
10
37 vs.
42
35 vs.
50
2 vs.
2
5–
17
50 vs.
22
40 vs.
42
3 vs.
5
10–
14
53 vs.
44
47 vs.
64
4 vs.
3
11–
17
62 vs.
63
46 vs.
53
4 vs.
4
15–
19
69 vs.
55
45 vs.
60
6 vs.
4
Discussion: P. aeruginosa prevalence appears to be lowest in the AustralianyNew
Zealand report (differences in methods of data collection will be discussed), slightly
lower in France than the UK, but at similar levels to that found in the US. The UK
has lower prevalence rates of S. aureus than any of the other countries. Prevalence
rates of B.c. colonisation are similar in UK CF children to those rates reported in
other countries. UK data on chronic colonisation with S. aureus and P. aeruginosa
are also collected when )3 isolatesyyear are found, and this may reflect morbidity
more accurately. Greater collaboration on streamlining data collection should exist
between national CF databases to facilitate data comparison.
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The health of UK CF children–a comparison with international
databases
J. McCormick(Presenting), E.J. Sims, M.W. Green, G. Mehta, F. Culross, A. Mehta
University of Dundee, Dundee, Scotland
Introduction: National CF databases allow comparisons of clinical parameters
between paediatric CF populations. We analysed clinical parameters within the pae-
diatric UK CF Database (UKCFD) and compared them to three other CF registries;
the French (Rapport sur la situation de la mucoviscidose en France en, 2000. Vain-
cre la Mucoviscidose, 2002), the AustralianyNew Zealand (AyNZ; Cystic Fibrosis
in Australia and New Zealand, 2000: Annual Report from the Australasian Cystic
Fibrosis Data Registry. Cystic Fibrosis Australia, 2002) and US CF registries (Cys-
tic Fibrosis Foundation Patient Registry Annual Data Report, 2000. CFF, 2001).
Methods: Age, age at diagnosis, height, weight and lung function was taken from
the UKCFD (www.cystic-fibrosis.org.uk.). Results: In 2001, the total registered
population on the UKCFD was 6558 patients (around 85% of estimated UK pop-
ulation). Meanymedian age were 16.5y15.0 yr, respectively. 51% were aged -16
yr, meanymedian, 8.6y9.0 yr, respectively. Meanymedian age at diagnosis was 4.1
yry4 months, respectively. For those diagnosed -16 yr, meanymedian age at diag-
nosis were 11y2 months. 68% of children had heightyweight recorded; respectively,
71y61% of children were -50 centile; 23y19% were -10 centile. Median FEV1
% at age 6, 11, 16 is shown with best estimates of corresponding data from the
other reports (see Table).
PRIVATEAge
(yr)
UK Median
FEV %1
French Median
FEV %1
US Median
FEV %1
AyNZ Median
FEV %1
6 84 90 97 77
11 82 81 86 82
16 75 69 77 67
Discussion: UKCFD patients have an older meanymedian age compared to the
French, AyNZ or US population. Patients from AyNZ have a lower mean age at
diagnosis due to national neonatal screening programmes. All reports demonstrate
deterioration in lung function with age. Differences in patient selection, data
recording and FEV % calculations may account for other variations. Increasing1
collaboration between national CF registries would allow greater interpretation of
the internationally collected patient data.
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Call for standardisation of national CF registry reports–the problem
outlined
E. Sims(Presenting), J. McCormick, M.W. Green, G. Mehta, F. Culross, A. Mehta
University of Dundee, Dundee, Scotland
Introduction: National CF patient registries collect data, which is presented in the form of an annual
report. Comparison of reports between countries could facilitate the identification of differences in
treatment practices. We ascertained whether the current format of the UK (2001 UK CF Database
report), US (Cystic Fibrosis Foundation Patient Registry Annual Data Report, 2001; CFF, 2002),
French (Rapport sur la situation de la mucoviscidose en France en, 2000. Vaincre la Mucoviscidose,
2002) and AustralianyNew Zealand (AyNZ; Cystic Fibrosis in Australia and New Zealand, 2000:
Annual Report from the Australasian Cystic Fibrosis Data Registry. Cystic Fibrosis Australia, 2002)
reports would facilitate comparison of data. Methods: Reports were compared in terms of paediatric
age limit, age split categories and whether the number of total registered patients for whom clinical
data were received for the year (active patients), the number of positive culturesypatient and equation
for calculation of FEV % predicted were defined.Results:1
PRIVATE UK French US AyNZ
Registered population Yes Yes Yes Yes
Active patients Yes Yes No No
Paediatric age limit (years) -16 -18 -18 -18
Age categories Always: At least:* Variable Mostly:
0–4 0–4 0–4
5–9 5–9 5–9
10–14 10–14 10–14
15–19 15–19 15–19
20–24 20–24 20–24
25–29 25–29 25–29
30–34 30–34 30–34
35q 35q 35–39
40q
Positive culturesypatient G1 and G3 positive
cultures in 12 months
No No No
FEV % predicted equation1 No No No No
*Some figures presented additional groupings of 35–39 and 40–44 or 40q.
Conclusion: Comparison of the reports was hindered by the use of a graphical
instead of tabulated format (particularly US report, and to a lesser degree in the
French report), differences in the paediatric age limit (UK has lower limit) and age
split categories (particularly US report, and to a lesser degree in the AyNZ report)
and by a lack of clarity (only the UK report defined the number of positive bacterial
culturesypatient). Clarity across reports could be improved by a standardised
presentation format.
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Call for standardisation of national CF database reports–an interim
solution
E.J. Sims(Presenting), J. McCormick, M.W. Green, G. Mehta, F. Culross, A. Mehta
University of Dundee, Dundee, Scotland
Introduction: National CF patient registries collect data, which is presented in the
form of an annual report. Comparison of reports between countries could facilitate
the identification of differences in treatment practices. Currently, different presen-
tation formats make comparisons of data between reports difficult or in some
instances impossible (see abstract titled ‘Call for Standardisation of National CF
Database Reports–the problem outlined’). To facilitate comparison of national
reports we propose a standardised reporting format. Methods: The UK (2001
report), US (Cystic Fibrosis Foundation Patient Registry Annual Data Report, 2001;
CFF, 2002), French (Rapport sur la situation de la mucoviscidose en France en,
2000. Vaincre la Mucoviscidose, 2002) and AustralianyNew Zealand (Cystic Fibro-
sis in Australia and New Zealand, 2000: Annual Report from the Australasian Cystic
Fibrosis Data Registry. Cystic Fibrosis Australia, 2002) reports were reviewed and
a consolidated presentation format was developed. Results: We established that com-
monality is best achieved as follows: (1) a paediatric age limit of -18 yr. (2)
splitting ages into bands: 0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39
and 40q yr. (3) Clarification of patient numbers for whom data were collected
(and on which the figures and tables are based) as opposed to those registered. (4)
Stating the number of positive bacterial cultures (G1 or G3 ) within a 12-month
period. (5) Stating the equation for calculation of % predicted lung function meas-
urements would provide additional clarity. Conclusion: In the absence of a common
registry, comparison of national reports is essential to the evolution of CF patient
care. The format we propose would require only minimal modification of the current
report presentation formats. Further discussion is required to clarify the definition
of chronic bacterial colonisation.
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Oral glucose tolerance testing for cystic fibrosis related diabetes–poor
staffing alone cannot explain failure to meet the standards of care
E. Sims(Presenting), J. McCormick, M.W. Green, G. Mehta, F. Culross, A. Mehta
University of Dundee, Dundee, Scotland
Introduction: For UK patients ()12 yr), an annual oral glucose tolerance test
(OGTT) is recommended to exclude CF related diabetes (CFRD; Standards for the
Clinical Care of Children and Adults with Cystic Fibrosis in the UK, 2001. Cystic
Fibrosis Trust). However, for 2001, we found -50% of the expected number of
OGTTs performed when the UK CF Database was analysed (www.cystic-fibro-
sis.org.uk). We tested the hypothesis that under provision of UK CF-trained staff
(medical, nursing and paramedical) is a determinant for the proportion of OGTTs
performed. Methods: Staffing at CF centres were recorded at the time of enrolment
into the UK CF Database between 1995 and 2001. Patients )12 yr in 2000, with
data recorded for both 2000 and 2001 were identified. Results: Only 709y1385
(51%) patients had an OGTT either performed or recorded as not necessary (as
patient was known to be diabetic) in 2001. Of these 709, 233 (33%) were diabetic
but 189 (27%) were already known to be diabetic in 2000. Therefore, only 520y
1196 (43%) OGTTs was actually performed in the target population. For all clinics
with greater than 20 OGTT eligible patients in 2001, we calculated the number of
CF nurse specialists, medical (registrar level and above), dieticians and total par-
amedical staff to 100 OGTT eligible patients. When staff to patients ratios were
plotted against % OGTTs performed, we found no correlation for any staff disci-
pline. Some clinics with lower staffing ratios performed close to the CF Trust’s
recommended standards in contrast with other Centres with better staff ratios. Con-
clusion: We found that percentage completion of OGTTs in UK CF clinics was not
determined by CF nurse specialist, medical, dietician or total paramedical staff
provision. Variable clinic policy towards targeting the resources available and tai-
lored to the individual clinic population, is the most likely explanation for the low
number of OGTTs performed.
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The health of UK cystic fibrosis adults–a comparison of international
databases
E.J. Sims(Presenting), J. McCormick, M.W. Green, G. Mehta, F, Culross, A. Mehta
University of Dundee, Dundee, Scotland
Introduction: National CF databases allow comparisons of clinical parameters between adult CF
populations. We analysed the adult UK CF Database population and compared them to the adult
populations reported in the US (Cystic Fibrosis Foundation Patient Registry Annual Data Report,
2001; CFF, 2002), French (Rapport sur la situation de la mucoviscidose en France en 2000. Vaincre
la Mucoviscidose 2002) and AustralianyNew Zealand (A and NZ; Cystic Fibrosis in Australia and
New Zealand, 2000: Annual Report from the Australasian Cystic Fibrosis Data Registry. Cystic Fibro-
sis Australia, 2002) reports. Methods: Data were collected on height, weight, body mass index (BMI)
and lung function from the UK CF Database (www.cystic-fibrosis.org.uk). Results: In 2001, data
were received for 4689y6739 patients registered with the UK CF Database.
PRIVATE UK French US A and NZ
Meanymedian age of national
population
16.9y15.0 14.9y13.0 16.9y14.8 15.3y13.8
Patients G18 yr of age 43% 34% 39% 34%
Meanymedian height z-scores y0.57yy0.57 y0.54yy0.59 NR NR
Meanymedian weight z-scores y0.78yy0.68 y0.78yy0.90 NR NR
Meanymedian BMI 21.2y20.9 19.6y19.3 NR 21.7y21.4*
Meanymedian FEV (% predicted)1 55y54 55y52 58y55* 63y66*
PRIVATE FrenchyUK USyUK A and NZyUK
Respiratory severity FEV (%)1 Adults (%) FEV (%)1 Adults (%) FEV1 Adults (%)
Normal G80 18.4y16.3 G90 15.0y7.4 NR 18.2y?
Mild 60–79 20.0y25.1 70–89 21.4y21.1 NR 26.5y?
Moderate 40–59 28.0y27.7 40–69 38.7y40.6 NR 37.9y?
Severe -40 33.7y30.9 -40 25.0y30.9 NR 17.6y?
NR: data not reported; *: results estimated from reported data; ?: unable to calculate
UK % populations as respiratory severity FEV categories not defined in A and Z1
report.
Conclusion: As none of the reports explicitly state that their data is representative
of their national CF population, the exact interpretation of these results are open to
question. However, the UK has the highest proportion of adult patients and the
respiratory severity of UK and French populations are comparable. Further
interpretation would be aided by a standardised reporting format.
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Registry of Urals CF centre (Russia)
G.V. Pavlov(Presenting), N.V., Nikitina
Registery of Urals CF centre, Russia
We created the Registery of CF patients watched from 1972 to 2003 yr. Now the
Registery has data approximately252 of patients in the age of 0–44 yr (male – 144,
female – 108). The Registery allows estimating the survivel and quality of life as
integral parameters. The survival median has estimated by Kaplan-Meier method.
Mutation delF508 is observed in approximately 42% of all cases. The majority of
CF patients will grow into adulthood. If the current trend of improved survival
continues, it is estimated that half of CF patients will be over 30 yr by 2003.
Advances in the technologies of drug pharmacology and chest physiotherapy con-
duced towards more effective treatment combinations and increase the patient’s
chance for long-term survival. Survival male median is 20.8 yr, female – 19.26 yr.
Log–Rank Test (0.1595, Ps0.873) and Coxe F-criteria (Fs1.084, Ps0.345)
shows no difference between this groups. We used PedsQL (Pediatric Quality of
Life Inventory, Version 4.0) for child’s of age 8–2 yr (average 10.11 yr). We used
SF-36 QoL test for patients in age of 14–33 yr (averages19.7 yr, average CF
symptoms manifestation of the group is 16.5 yr). Teenagers of the group had lower
valuation in 6 of 8 parameters of SF-36 scale in comparison with their healthy
coevals. Thus, our Registery shows us the survival picture of our CF patients. It is
close to situation in some European countries.
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A managed clinical network–a novel method of care delivery in a non-
metropolitan area
A. Prendiville (Presenting), C. Sheldon , P. Oades , J. Myers , A. Bosley1 2 3 4 3
RCH Treliske, Truro, United Kingdom, Medicine, Royal Devon and Exeter Hos-1 2
pital, Exeter, United Kingdom, Paediatrics, Royal Devon and Exeter Hospital,3
Exeter, United Kingdom, Medicine, RCH Treliske, Truro, United Kingdom4
The Peninsula is a geographically isolated rural area in South West England. Three
large hospitals (each with approximately 1000 beds) and two slightly smaller hos-
pitals serve a cystic fibrosis population of 200 patients. When audited 97% of cystic
fibrosis patients and their carers wanted care delivered at their local hospital. In
order to (a) reduce patient travelling time and (b) help minimise potential for cross
infection a proposal for a Peninsula wide managed clinical network was drafted.
The model includes the facility for care to be delivered by locality, based clinicians
and PAMs (professionals allied to medicine). Two monthly clinical meetings are
held where patients with difficult CF related problems are reviewed, state of the art
topics and Peninsula CF research are presented and joint clinical guidelines are
formulated by PAMs and clinicians. The proposal also includes the facility for
obligatory joint clinics by visiting clinicians and PAMs from other Peninsula loca-
tions in order to (a) increase exposure to a wide range of CF pathology (b) enable
peer review as a component of clinical governance and (c) provide patients with a
second opinion when faced with difficult decisions regarding potential treatment
options. The CF specialist commissioners and purchasers of care have approved the
model and have committed to providing new annual funding of 300 K to the net-
work. The clinical directors, clinicians and nursing components of the network are
fully funded. Two monthly clinical meetings and joint clinics are in progress. Own-
ership of the model has been enthusiastically taken up by the clinical staff. This
model aims to provide agreed standards of high quality care, education of staff,
regular clinical meetings, joint specialist clinics, shared guidelines, audit and
research. Results from the national database will assess whether this model meets
national standards and improves patient outcomes.
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Pregnancy and motherhood in women with CF: the financial cost to the
health service and the health cost to the mother
I. Clifton (Presenting), S. Bodey , G. McIntosh , S.P. Conway , D.G. Peckham ,1 2 2 1 1
C. Etherington1
Adult CF Unit, Leeds, United Kingdom, University School of Medicine, Leeds,1 2
United Kingdom
Preservation of health in pregnancy and early motherhood may require a greater
therapeutic input. The aim of this study was to assess increases in treatment during
pregnancy and the pre-school years and any increased health service costs. Data
were retrospectively collected for nine women from 2 yr before pregnancy to up to
4 yr after who delivered healthy infants between 1993 and 2000. Mean % predicted
FEV in early pregnancy was 55%. Control patients were identified. There were1
significant differences in the number of OP visits, P-0.05, IV antibiotic courses,
P-0.01, and days of IV treatments, P-0.001, during pregnancy. Mothers required
more, P-0.001, and longer, P-0.001, courses of IV treatments at 2 yr after deliv-
ery. They had significantly more inpatient IV treatments during pregnancy and at
years 1–4 after delivery, while control patients had significantly more IV treatments
at home, increasing the cost differential between the two groups. Total treatment
costs per year were significantly greater during pregnancy, P-0.03, and at 2, P-
0.001, and 4, P-0.01, years after delivery. At 4 yr the total annual cost of care
was £51 000 (mothers) vs. £25 000 (controls). There was no significant difference
in change in weight or FEV between the groups. By 4 yr there was a significant1
difference in FVC %, P-0.001. Two mothers died at 10 months and 3 yr 9 months.
Preservation of maternal wellbeing during and after pregnancy is achieved only by
increased clinical and pharmacological input. Despite this the demands made on
the mother by a toddler may impact upon her own health. Women planning a family
should be counselled about the greater level of treatment that pregnancy and moth-
erhood will require.
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The cystic fibrosis(CF) pharmacist’s annual review recommendations
have a significant impact on adult CF care
C. Bateson(Presenting), A. Lyon, E. Gunn, D. Bilton
Adult Cystic Fibrosis Centre, Papworth Hospital, Cambridge, United Kingdom
The UK CF Trust has recognised the role of a dedicated pharmacist in the multi-
disciplinary team caring for patients with CF. At our adult centre the pharmacist
carries out a detailed assessment of the patient drug history including patient knowl-
edge of dose and frequency, adherence to prescribed medication and a review of
non-prescription medication. At the end of the review the pharmacist makes rec-
ommendations to be considered by the physician. In developing this aspect of the
annual review we wished to prospectively study the recommendations made and
classify them as to the nature of the recommendation e.g.: advice on dose or fre-
quency, an alert to knowing non-adherence, or an alert to non-adherence because
of lack of knowledge. Furthermore the pharmacist was asked to grade the effect of
the recommendation as having minor, moderate or major clinical significance. The
physician was then asked to record their assessment of the pharmacist’s intervention.
Forty-five adult CF patients were reviewed in the sixth month period. Only 6
patients had no recommendations from the pharmacist. In 39 patients a total of 80
recommendations were made of which 74 were classified of moderate or major
clinical significance. The pharmacist highlighted 18 cases of lack of adherence
despite adequate knowledge, which prevented the physician initiating new or
changed medication without an exploration of adherence issues. In conclusion the
role of the pharmacist in performing a detailed check of medication at annual review
is crucial in ensuring optimum care for CF adults.
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Anaphylaxis in cystic fibrosis adults self-administering intravenous
antibiotics in the community: incidence and management
E. Bowman(Presenting), L. McIntosh, J.A. Innes, A. Balfour
Scottish Adult Cystic Fibrosis Service, Edinburgh, United Kingdom
Introduction: Anaphylaxis is a rare but serious allergic reaction requiring immediate
medical treatment. Our Cystic Fibrosis (CF) centre of 115 adults has seen 9 cases
of anaphylaxis during courses of intravenous (IV) antibiotics in the past 7 yr (639
patient years and 1270 courses of antibiotics.) As a result, we decided 18 months
ago to provide all patients self-administering antibiotics in community with an Epi-
pen (Adrenaline1: 1000 solution 0.3 mg intra-muscular injection). Of the 9 episodes
we saw 4 were in hospital, 5 in the community. One patient self-administered adren-
aline. It continues to be the responsibility of the CF Nurse Specialist and CF Phar-
macist to educate the patients on recognition of symptoms of anaphylaxis and use
of an Epipen. An Epipen is always demonstrated on first issue. Patient information
leaflet is also issued. On each subsequent course of IV antibiotics the patients were
asked if they were able to locate their Epipen at home and reminded of symptoms
of anaphylaxis and the use of the Epipen. Patients have the chance to use the
placebo Epipen at all times. Methods: After 18 months use of Epipens we were
keen to hear the views of our patients. A questionnaire was developed to focus on:
location of Epipen at home, identification of anaphylaxis, action to take and how
to keep patients informed. So far 18 patients have completed a questionnaire.
Results: 83% of patients reported that they could locate their Epipen .72% of
patients knew to stop their antibiotic injection immediately and then use their Epi-
pen. Conclusion: Despite stating that they felt confident and well educated about
the Epipen, the patients felt it was important to have ongoing education as 56%
stated they had forgotten some information. Only 1 patient to date has used an
Epipen to self-treat a reaction at home.
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An audit of treatment costs for adult cystic fibrosis patients with
chronic Pseudomonas infection
S. Conway (Presenting), J. Holmes , C. Etherington , L. Hemmett , D.G.1 2 1 2
Peckham1
Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, Leeds, United Kingdom,1
Beaufort International Health Economics, London, United Kingdom2
The aim was to identify patterns of drug use for patients with pseudomonas infec-
tion and estimate costs for selected drug ‘packages’. Audit of clinic and prescribing
records for patients 1997–2000, categorised by level of respiratory impairment in
each year. Drug costs were based on constant prices using the British National
Formulary March 2002. All drugs except intravenous (iv) treatments and TOBI
were assumed to be taken all year round. Costs for iv treatment did not include
hospital ‘hotel’ costs. The mean annual drug cost per patient overall grew by 27%
between 1997 and 2000. There was an increase in the proportion with mild respi-
ratory impairment ()69% FEV ) from 24% to 32%, and a decline in the proportion1
with severe respiratory impairment (-41% FEV ) from 31% to 27%. Within each1
category of respiratory impairment, the mean drug cost per patient increased by
approximately a third.
Mean Annual Drug Cost per Patient (£)
PRIVATE 1997 (ns
115)
1998 (ns
167)
1999 (ns
150)
2000 (ns
154)
% change 2000 vs.
1997
)69%
FEV1
5098 6059 7,656 6,786 33
41–69%
FEV1
8945 10 666 10 396 11 871 33
)41%
FEV1
13 669 15 833 17 031 18 443 35
There was a shift away from low cost packages for mild patients (with increased
use of pulmozyme) and a shift towards higher cost packages for moderateysevere
patients (with increased use of iv antibiotics and TOBI). The implications of this
rise in costs, and the changing patterns of treatment that it reflects, need to be fully
understood in order for CF treatment services to be adequately funded in the future.
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Parent and patient satisfaction questionnaire to assess dietetic and
physiotherapy services currently provided to CF paediatric patients
J. Lowdon(Presenting), D. Rogers, I. Doull
Cystic Fibrosis Unit, University Hospital of Wales, Cardiff, United Kingdom
Aim: To assess the level of parent and patient satisfaction with the physiotherapy
and dietetic services currently provided to CF paediatric patients and to identify
any areas of unmet need. Method: A questionnaire was mailed to 69 full care
patients. Clinical audit anonymised responses on receipt. Data was collated and
analysed via an access database. Results: 41 responded. Mean age was 10 yr (0.5–
18). Seven were completed by the patient, 2 by both the parent and patient and the
remaining by the parent alone. Ninty-eight percent felt the physiotherapy service
and 95% the dietetic service to be useful or very useful. Thirty-seven percent of
respondents attend the adolescent clinic. Of these, 100% felt that the services were
provided at a time to suit their needs. However, 40% felt that more time should be
spent on adult issues, in relation to physiotherapy and dietetics. Current educational
material for physiotherapy was felt to be either useful or very useful by 90% and
83% for dietetics. With regard to possible educational aids at home, response was
very mixed. However, cassette tapes were the least popular option overall. Alto-
gether, 15% felt the physiotherapy service could be improved and 10% the dietetic
service. Summary: The majority of parents and patients felt that there was no
improvement necessary in the current service provision. Several respondents who
felt there was room for improvement did provide some useful suggestions. Current
educational material used was thought to be helpful but opinion regarding possible
educational aids at home was very mixed.
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Acute allergic reaction following midline catheter insertion in two
patient with cystic fibrosis
R. Sundar(Presenting), C. Etherington, D.G. Peckham, S.P. Conway
Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, Leeds, United Kingdom
Patients with Cystic Fibrosis require frequent courses of intravenous antibiotics
commonly administered via midline catheters (longlines). We report two cases of
an acute allergic reaction following insertion of the Becton Dickinson (BD)midline
catheter. Case 1: A BD long-line was sited in the right antecubital fossa of a 37-
year old female without subcutaneous anaesthetic. Immediately after insertion she
became breathless, tachycardic and distressed with audible wheeze. Oxygen satu-
rations dropped to 78%. Blood pressure remained stable. This patient had several
months previously had a similar line inserted without any problems. Case 2: An
18-year old female had a BD catheter inserted into the left antecubital fossa without
any subcutaneous anaesthetic. Immediately post insertion she became breathless and
complained of chest tightness and nausea. Examination revealed clinical cyanosis,
tachycardia and widespread wheeze. Oxygen saturation dropped to 60% with no
fall in blood pressure. In both cases rapid recovery occurred within minutes with
administration of high flow oxygen and nebulised bronchodilators. The longlines
were not removed and remained in situ with no further complications. Discussion:
Systemic reactions to peripheral venous catheters have been reported with the
Ohmeda midline catheter. (1) These were anaphylactic reactions characterised by
facial swelling, hypotension, tachycardia and bronchospasm. In all cases the lines
were immediately removed. All physicians involved in CF care should be aware of
these complications and have appropriate resuscitation facilities at time of insertion.
C.S. Haworth, R. McL Niven, A.J. Moorcroft et al., Acute anaphylaxis following1
midline catheterisation in a patient with CF. Thorax 54(8), 747.
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Intelligent distance patient monitoring program optimizes CF children
patients follow-up
V. Pasquasy (Presenting), G. Lapierre , J.-E. Marcotte , M. Dumont , N, Bureau ,1* 1 1 2 3
P. Lehoux , L. Poitras , S. Froissart4 5 5
Pediatric Pulmonology, Hopital Sainte-Justine, Montreal, Canada, Biostatistics,1 2ˆ ´
Hopital Sainte-Justine, Montreal, Canada, Research, Hopital Sainte-Justine, Mon-3ˆ ´ ˆ
treal, Canada, Health administration, Universite de Montreal, Montreal, Canada,4´ ´ ´ ´
Professional Services, Hopital Sainte-Justine, Montreal, Canada5 ˆ ´
Introduction: The frequency of follow-up visits at CF clinic is a major determinant
of disease control. Frequent visits to the hospital may however, represent a major
source of physical and financial stress for patients and their family. Distant patient
monitoring can allow for multiple contacts between caregivers at the hospital and
CF patients in their home environment. The main objective of our study was to
evaluate the effects of an Intelligent Distance Patient Monitoring (IDPM) program
over a 6 month-period on the overall health of CF children. Methods: 20 CF patients
were randomly recruited and assigned to the IDPM group. Exclusion criteria were
age -8 yr and FEV -35% predicted. Through the IDPM program, participants1
provided (1) daily information about their symptoms and adherence to treatments,
(2) weekly measures of their FEV and weight, (3) monthly assessments of their1
respiratory microbial flora. A control group of 20 CF patients were paired according
to gender, age and genotype and disease severity and were followed according to
the standard protocol at the CF clinic. Results: At study’s onset, the IDPM patients
(8 My12 F) aged 13.4"2.6 (M"S.D.) had a FEV of 77.7%"15.0 and a body1
mass index (BMI) of 19.2"3.1. At study’s end, FEV was 75.9%"14.4 and BMI1
19.5"3.4. Five of the 20 patients required intravenous antibiotics for a total of 150
days. Compared to those of controls, these values showed no significant difference.
Discussion and conclusion: This 6 months IDPM program is not related to signif-
icant change in clinical status of the 20 CF children. A follow-up with weekly
spirometry and weight measures in combination with microbiological sampling done
at home and regular communication with pediatric patients is therefore, feasible
and allows for reasonably accurate distant monitoring and less frequent CF clinic
visits without being associated with any detectable clinical deterioration.
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Vaccination status in CF patients
D. Tjesic-Drinkovic(Presenting), D. Tjesic-D, A. Votava-Raic, J. Kelecic, T.
Voskresensky
Department. of Pediatrics, University Hospital Center Zagreb, Zagreb, Croatia
Bacterial and viral infections, especially in early life, can trigger pulmonary disease
progression in CF patients. The aim of this study was to analyze the vaccination
status in Croatian CF patients. Data were collected from 30 CF patients (1y3 of
the recognized CF population: 12 boys and 28 girls, aged 6 mo to 25 yr, median
age: 6 yr; genotype: 25 dF508ydF508, 5 heterozygots dF508). Croatia’s national
immunization program covers BCG, DTP, Polio and MMR in the first 18 mo of
life. Hep B vaccination is given the age of 12 yr, and HiB vaccination is in the
program since 2003. Other available vaccines are against Hep A, varicella, pneu-
mococcus and Influenza. All CF patients (100%) had vaccines following the nation-
al program, but they were behind the schedule for approximately 4 mo. Forty
percent had HiB vaccination (the vaccine is available last 4 yr). Immunization
against Hep B is relatively low, because it is given at school age. No child was
given Hep A vaccine. Only one patient was vaccinated against varicella and one
against penumococcus. 70–86% of children had influenza immunization, 21 of them
both in 2002 and 2003. Analyzing their medical charts 2 yr prior to influenza
immunization and in the last 2 yr, a 25% decline in the incidence of respiratory
infection was observed during the winter period (November–March). Conclusion:
The coverage of the national immunization program is 100%, although vaccination
is often delayed due to frequent hospitalization. However, immunization strategies
should be modified for the CF population, especially for hepatitis. Hep B should
be given in infancy and Hep A vaccination should also be considered, because of
frequent (evident or subclinical) liver disease. Therefore, fatal hepatitis is more
likely to occur. In CF patients vaccinated against influenza, a significant decrease
in respiratory exacerbations has been observed during winter in comparison to the
pre-vaccination stage.
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Prediction of survival in adult patients with cystic fibrosis treated in a
Moscow centre, Russia
E. Amelina(Presenting), A. Tcherniak, A. Cherniaev
Research Institute of Pulmonology, Moscow, Russia
Our purpose was to predict 2-year survival in adult cystic fibrosis (CF) patients on
basis of lung function and nutritional status, using time dependent proportional
hazards regression analysis. The study population comprised 36 adult patients (age
20.1"0.7 yr, 22 males, FEV 49.6"4.2 % and BMI 17.4"0.4 kgym ) with CF21
who were treated at the Research Institute of Pulmonology, Moscow, in 1992–2002
and whose lung function was evaluated at least once before 1999, thus allowing
two years of follow-up. The diagnosis of CF was confirmed with an abnormal sweat
sodium test ()60 mmolyl) andyor genetic test together with typical pulmonary or
digestive disease, or a positive family history. Measurements of pulmonary function
and nutritional status were routinely performed in all the patients. There were 10
deaths during the 9 yr study period. Univariate proportional hazards regression with
time dependent covariates revealed that FEV (a decline in the FEV of 5% pred1 1
is associated with a 1.9-fold increase in risk, 95% CI 1.0 to 3.6, Ps0.039) and
BMI (a decline in the BMI of 2 kgym is associated with a 2.7-fold increase in2
risk, 95% CI 1.1 to 6.8, Ps0.026) were significant predictors of survival. Our data
demonstrate that in adult CF patients BMI and FEV correlate with 2-year survival.1
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Regional comparison of survival of cystic fibrosis patients in Russia
E. Amelina(Presenting), A. Tcherniak, A. Cherniaev
Research Institute of Pulmonology, Moscow, Russia
Introduction: The past 30 yr have seen an improvement in diagnostics, general
concepts and practical treatment of cystic fibrosis and spectacularly prolonged life
expectancy in patients aflicted with that hereditary disease. Thanks to these achieve-
ments, underage patients now have a considerable chance to live into adulthood.
By now more than 20 CF centres have been created in Russia, half of them though
are just starting their activity. Aims and Methods: The aim of the multicentre study
was to evaluate survival of patients with cystic fibrosis in Russia and analyze the
difference in life expectancy between regions of residence, if any. Data were pro-
vided from the eight special cystic fibrosis clinics and were used for national reg-
ister. Nine hundred and forty eight patients (422 females and 526 males) were
analysed. Results: Two hundred and fifty one patients were over 15 yr (26%). In
the beginning of the analysis, 243 patients (26%) were registered dead. Survival
analysis has demonstrated that the mediana of expectant life is 25 yr. Median life
expectancy in patients, affiliated to the CF centres of the Central region (Moscow,
St.-Petersberg, Yaroslavl; ns599, 316 males) is 25.04 yr, while for the patients of
Siberia and the Urals (ns349, 210 males) this parameter is a mere 19.96 yr (table).
The difference in life expectancy between the Central region and Siberia-Urals
region is statistically significant (P-0.0001), while there was no significant dif-
ference between centres of the Central region or between centres of Siberia and the
Urals. Conclusion: Our data demonstrated that median life expectancy in Russia
for cystic fibrosis patients are 25 yr. However, significant difference in survival of
cystic fibrosis patients persists between regions of residence in Russia.
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Anthropometric differences in Lithuanian children with cystic fibrosis
and other obstructive lung diseases
I. Skurvydiene (Presenting), L.I. Indrejaityte , A. Valiulis1 2 2
Taurage regional hospital, Taurage, Lithuania, Pediatric pulmonology, Vilnius1 2
University Clinic of children diseases, Vilnius, Lithuania
Cystic fibrosis (CF) makes a great impact on child’s growth and nutritional state.
The aim of the study was to compare anthropometric data from children with CF
and other obstructive lung diseases with those from healthy children. Measurements
of height and weight were taken from 50 children with CF (in 17 genotypes con-
firmed), 50 children with other obstructive lung diseases, and 50 healthy children.
Percentiles for age were calculated from national growth charts , and results were1
compared between groups. Results were expressed as mean (Mean"S.D.), data
were analyzed according paired t-tests, differences between groups considered sig-
nificant when P-0.05. Height for age percentiles from CF patients with confirmed
genotypes (delF508ydelF508 and delF508yR553X, ns17) were significantly lower
than in CF patients with unidentified genotypes (23.7"14.7 vs. 45.8"11.5).
Weight for age percentiles in CF patients with confirmed genotypes were signifi-
cantly lower than in CF patients with unidentified genotypes (20.5"13.6 vs.
47.6"15.8). Any significant differences in anthropometric data between CF chil-
dren with unknown genotypes and healty or diseased controls were not found.
References:
J. Tutkuviene, Assessment of children growth and maturity (in Lithuanian lan-1
guage). Vilnius, (1995) pp. 1–24.
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Prospective evaluation of physical activity and clinical status in
children with cystic fibrosis (CF)
S. Junge(Presenting), H. Stobbe, M. Ballmann
Pediatrics Department, Medical School, Hannover, Germany
Background: Various studies detected positive effects of sports in CF-patients. The
aim of this study was to evaluate the seasonal physical activity of children with CF
in relation to their clinical status. Methods: In a prospective longitudinal study we
evaluated the physical activities of children in a single CF-centre in spring and in
autumn 2002 using a questionnaire including activities engaged in at school (A),
in a team (B), as individual training (C) or as physical activities during leisure
time (D). 146 questionnaires were sent off two times. Each time clinical parameters
(FEV , CN-score, weight for height) were collected during the clinical visit.1
Results: 63 out of 146(43%) patient aged 9.4"3.8 yr (mean"SD) had complete
data sets. There were no differences in total time of physical activities (AqBq
CqD: 12.8"8.6 vs. 11.7"9.4 hyweek) between the two surveys, but the time in
leisure activities (D: 8.5"8.0 vs. 5.8"7.9 hyweek) and the FEV (97"21 vs.1
92.4"20%) decrease significant from spring to autumn, while the time in individual
training (C: 1.5"2.8 vs. 3.0"3.7 hyweek) increases. The time of total physical
activities (AqBqCqD) decreases significant from younger to older children.
There were no significant correlations between clinical parameters (FEV , CN-1
score, weight for height, delta FEV %) and physical activities. Conclusion: The1
reported physical activity of children with CF is very high, 67% of CF-patients vs.
47.4% of age matched healthy children are active in sports teams. Seasonal varia-
tions of sports activities have to be considered in studies of physical activity. It
could be speculate that a professional training is necessary to demonstrate a clinical
profit.
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The study of expectant life of patients with cystic fibrosis (CF) in St-
Petersburg
A. Tchermenski (Presenting), A.V. Molodtsova , T.E. Gembitskaya , L.A.1 1 1
Jelenina , L.F. Kovaleva , A.V. Orlov1 1 2
Research institute of Pulmonology, the St.-Petersburg’s State medical university,1
St-Petersburg, Russia, Department of pulmonology, St.-Petersburg’s municipal2
children hospital of St. Olga, St-Petersburg, Russia
The aim of the study was to evaluate survival of. 74 CF patients observed in St-
Petersburg’s CF center (32 males (43.2%) and 42 females (56.8%)) were analyzed.
The mean age of CF patients (MeanqSE) has made 13q0.9 yr. 26 CF patients
(35.1%) were over 15 yr. In the beginning of the analysis, 25 CF patients (33.8%)
were registered died. The mean age alive CF patients have made 10.4q1.2 yr, died
CF patients—14.3q1.3 yr. Among the alive CF patients there was 40.8% females
and 59.2% males, among died CF patients—48% females and 52% males. Survival
analysis has demonstrated that the mediana of expectant life of St-Petersburg’s CF
patients is 21.8 yr. It has demonstrated tendency to difference exists in expectation
of life of St-Petersburg’s CF patients between sexes, but has not showed significant
difference between sexes (Cox’F test Ps0.25). The mediana of expectant life in
men is 23.7 yr, whereas this parameter in women is 21.8 yr. Thus, cystic fibrosis
is not only paediatric problem any more and is actual problem of pulmonology.
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Atypical CF: experience of the Prague CF centre
V. Vavrova , D. Zemkova , J. Bartosova , L. Fila , S. Kolouskova , M. Macek1 1 1 2 1
Jr.3
Pediatric Clinic, Charles University Prague – University Hospital Motol, Prague,1
Czech Republic, Clinic of Tuberculosis and Respiratory Diseases, Charles Uni-2
versity Prague – University Hospital Motol, Prague, Czech Republic, Institute of3
Biology and Medical Genetics, Charles University Prague – University Hospital
Motol, Prague, Czech Republic
Introduction: Due to improved dg. possibilities in CF problematic cases have been
identified and we often face the question: ‘Is this CF or not?’. Such a decision is
important for therapy and has prognostic, psychological and legislative conse-
quences. The aim of this report is to show our atyp. patients or unclear diagnoses.
Case reports: Case 1: male (M)-49 yr was dg. at 7 yr due to rec. mild resp. sympt.;
Cl : 88 mMyL, panc. sufficient (PS); had in childhood mild obstruction of smally
airways with currently normal PFTs requiring no treatment; azoospermia; CFTR:
CFTRdele2,3(21 kb)yunk. Case 2: M 32 yr was dg. at 12 yr due to pansinusitis
and nasal polyposis; Cl : 75 mMyL and is PS. He stopped treatment since he hady
no resp. problems and came back only when CFRDM appeared; CFTR: 3272-26
A-)Gy3600q2insT. Case 3: F 12 yr was dg. by family screening since her young-
er stepbrother was a F508del homozygote. At dg she had mild resp. problems that
subsided with therapy; she is PS; Cl : 39 mMyL; CFTR: R117HyF508del. Casey
4: M 61 yr came to our centre with his own suspicion of CF; had chr. sinusitis,
expectorated thick sputum and suffered from diabetes. Initial Cl : 93 mMyL, buty
repeatedly varied from 47.4 to 85.5 mMyL. None of the most common CFTR alleles
were detected. Case 5: F 42 yr with rec. pancreatitis, variable Cl : 7.7–49.6 mMyy
L according to the clin. status; she has no resp. problems; CFTR: R117H-IVS8-
(T)7yL997F. Case 6: F 26yr with diff. bronchiectasis infected by mucous P.
aeruginosa; Cl : 21.9 and 36.9 mMyL; CFTR: F508delyunk; is PS; has clubbingy
with FEV : 60% p.v. Conclusion: Individual approach to atyp. CF cases are1
required, since in many instances their prognosis is much better. Moreover, some
of them never develop classical CF complications and do not need standard therapy.
Nevertheless, careful monitoring and appropriate treatment is still necessary. Sup-
ported by IGA MZCR: 6464-3, 00000064203 and MSMT- LN00A079, 111300003.
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Predictors of survival in two adult cystic fibrosis populations in Ireland
J. Courtney (Presenting), J.M. Bradley , J. McCaughan , C. Shortt , C. Bredin ,1 2 3 4 4
J.S. Elborn1
Adult Cystic Fibrosis Unit, Belfast City Hospital, BELFAST, United Kingdom,1
School of Rehabilitation Science, University of Ulster, BELFAST, United Kingdom,2
Department of Microbiology, Queen’s University, BELFAST, United Kingdom,3
Adult Cystic Fibrosis Unit, University Hospital, Cork, Ireland4
In cystic fibrosis (CF) populations the ability of variables such as FEV , body mass1
index (BMI), and microbiology to predict survival is uncertain. The aim of this
study was to examine, which factors could be used to significantly predict survival.
Two adult populations were studied from 1996–2000. Full data was available on
183 adult CF patients from Belfast (ns128) and Cork (ns55) in December 1995.
Of the 27 patients (20 M) who died in the following 5 yr the mean (S.D.) FEV1
was 38 (12.2)%, mean BMI was 18.6 (3.1) kgym and mean age at death was 24.72
(6.9) yr, range 15–42 yr. Those patients who remained alive (79 M) had a mean
(S.D.) FEV 66.9 (23.8)% and BMI 20.6 (3.4) kgym . Of those who died, 16y2721
patients were infected with Pseudomonas aeruginosa alone, 4y27 with Burkholderia
cepacia alone and 7y27 with both P. aeruginosa and B. cepacia compared with 72y
156, 9y156 and 12y156, respectively, of patients who remained alive. No patients
from the Cork population were infected with B. cepacia. 63y156 of patients who
remained alive was dF508 homozygous compared to 12y27 of those who died.
Survival analysis was used to predict survival at 5 yr. The only factors that signif-
icantly predicted survival were FEV , Ps0.001 (odds ratio 0.986) and whether or1
not they were infected with B. cepacia, Ps0.035 (odds ratio 0.42) although BMI
(Ps0.09) and infection with P. aeruginosa (Ps0.077) approached significance.
This study confirms that in these populations lung function and infection with B.
cepacia are the strongest predictors of survival.
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Death from cystic fibrosis in childhood: a registry based longitudinal
study
L. Viviani (Presenting), S. Milani , A. Bossi , R. Padoan , V. Raia , L. Giglio1 1 1 2 2 3
Istituto di Statistica Medica e Biometria, Universita degli Studi di Milano, Milano,1 `
Italy, C.R.R. per la Fibrosi Cistica-Milano, Milano, Italy, C.R.R. per la Fibrosi2 3
Cistica-Trieste, Trieste, Italy
Introduction: Although survival of patients with Cystic Fibrosis (CF) has improved
in recent years, several deaths within the first 5 yr of life are still reported. This
study aims at estimating the effect of some risk factors on early mortality from CF.
Subject and Methods: All CF patients born between 1988 and 2001 and recorded
in the Italian CF Registry were analysed. The diagnosis was suspected on symp-
toms, positive neonatal screening or family history and confirmed with an abnormal
sweat test ()60 mmolyl) or molecular analysis. Results: Among 1742 patients
(51% male), 38 (2.2%) died, because of CF before their 14th birthday. The survival
was 99.0% (1 yr), 98.8% (3 yr), 98.7% (5 yr) and 98.6% (7 yr), with negligible
differences between genders. Among the 474 patients without symptoms at diag-
nosis only 2 deaths (0.4%) were observed, whereas 36 deaths (2.9%) occurred
among the 1261 patients with symptoms (ORs6.9, 95% CI 1.7 to 28.9). In par-
ticular, 24 deaths (2.5%) in the group of 976 patients with symptoms other than
meconium ileus (ORs6.0, 95% CI 1.4 to 25.3) and 12 deaths (4.2%) in the group
of 285 patients with meconium ileus (ORs10.4, 95% CI 2.3 to 46.7). At 1 yr the
survival was 99.4% in the first group and 94.5% in the second one. Discussion
Patients presenting meconium ileus were earlier diagnosed and had lower survival,
when compared to the general CF population. This fact is probably due to post-
surgical complications.
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Aging with CF: organization of an international project
W. Warwick (Presenting), C. Milla , J. Dodge1 1 2
Pediatrics, University of Minnesota Medical School, Minneapolis, USA, Child1 2
Health, University of Wales, Swansea, United Kingdom
Aging with CF presentations have been made three times at CF meetings in two
years. All emphasized the need to study the risks for CF associated diseases of
aging before CF Centers are filled with geriatric patients who have new or different
responses to diseases of aging. All stated the need for a prospective study of all
patients age 40 and older re problems before age 40 and starting age; plus annual
review of health, nutrition, life style, physiotherapy and alternative treatments; ill-
nesses, physical health, pulmonary function, lung and other infections, hospitali-
zations, surgery, height and weight, medicines as well as self-medications, plus
quality of life; new diagnoses; and new symptoms even if no diagnosis has been
made. The comprehensive survey will be repeated once a year. For confidentiality
individual data will require only birth date, sex and the first two letters of the first
name. Data will encrypted and kept in a secure, off line, computer with access only
to an international study committee of adult physician CF caregivers, database
experts and epidemiologists. Coordination, Database, Epidemiology, Stakeholders,
Caregivers and Sponsor groups will be needed. The Coordination group to include
a WHO observer, one or more CF patients, epidemiologists, database specialists,
physicians providing care to CF adults, physicians who have cared for over 1000
patients, and representatives of the ECFS and the NACFF. Progress will be reported
at the ECFS and the NACFF conferences and published in journals related to CF
associated diseases and to diseases of aging. Other Physicians will be permitted to
ask questions of the database with Coordination Group approval and database safe-
guards for confidentiality. For success, the patients’ organization, CF Worldwide,
must give full support to recruit CF patients.
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Analysis of prognostic factors of survival after lung transplantation
(LT) for cystic fibrosis (CF) in France: a 10-year experience
Y. Chalem (Presenting), E. Gautier-Le Roux , M. Stern , M. Reynaud-Gaubert , P.1 2 3 4
Tuppin , J. Navarro1 5
Etablissement Francais des Greffes, Paris, France, Vaincre la Mucoviscidose,1 2¸
Paris, France, Groupe Transplantation pulmonaire, Paris, France, Groupe Trans-3 4
plantation pulmonaire, Marseille, France, Groupe Transplantation et Mucovisci-5
dose, Paris, France
A collaborative retrospective cohort study was conducted in order to identify the
factors that might explain the low early post-transplant survival rates observed in
France (59% at one-year) in CF patients. Patients and methods: Between
01.01.1990 and 31.12.1999, 263 patients underwent LT in France and 242 (92%)
of them were included for the analysis. Data concerning donors and recipients
(before, during and after LT) were collected directly from patient files. The asso-
ciation between potential risk factors and two main criteria (3 months and 1-year
survival for patients still alive after 3 months) were analysed through univariate
logistic regression. All factors linked with each criteria with P-0.2 were included
in a multivariate logistic regression selected by a backward procedure. Results: LT
were performed in 13 centres (1 to 60 patientsycenter). Recipient characteristics
were age 25.7"12.3 yr; weight 41.3"10.9 kg; Pseudomonas aeruginosa and cepa-
cia colonisation, respectively, 95 and 9%. Centre effect was found as the only
independent significant factor to predict survival at 3 months. Nevertheless, a model
including the following factors, year of transplantation, recipient age, previous tho-
racic surgery, Aspergillus fumigatus colonisation and donor-recipient O blood group
match, was significantly better than the former according to the likelihood ratio
test, although none of these factors were significant at P-0.05. This could be
explained by a lack of power of the study. For 1-year risk of death within patients
still alive after 3 months, the multivariate model included 4 significant independent
factors: year of transplantation, type of transplant, donor age and recipient gender.
LT results have significantly improved with time, offering a true therapeutic option
to CF patients.
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Using electronic data acquisition and analysis system for nasal
potential difference measurement in cystic fibrosis
Z. Ergonul (Presenting), G. Yilmaz Gokhan , Z.D. Balkanci , N. Kiper , E.1 1 1 2
Yalcin , D. Dogru , U. Ozcelik , A. Gocmen2 2 2 2
Physiology, Hacettepe University, Ankara, Turkey, Pediatrics, Hacettepe Univer-1 2
sity, Ankara, Turkey
Nasal potential difference (NPD) measurement keeps its importance for diagnosis
of patients with atypical cystic fibrosis (CF). Measurement techniques commonly
vary between centers and different study personnel. In order to alleviate standard-
ization problem of measurement techniques, electronic data acquisition and analysis
has been suggested (1). In this study, NPD was measured using an adaptation of
the method described by Middleton et al. (2). Data were recorded and evaluated
with DA100B differential amplifier module of MP100 computer based data acqui-
sition and analysis system (Biopac System, Inc.). Thirty-one CF patients (16
females 15 males, mean age 8.83 yr, range 2–21 yr) and 43 normal or non-CF
controls (18 females and 25 males, mean age 16.02 yr, range 2–35 yr) were eval-
uated. CF group’s NPD was y39.71"2.30 mV; control group’s NPD was y
21.11"1.62 mV (mean"SEM). NPD values of CF group were found higher than
control values (Student’s t-test, P-0.001). This is the first study that evaluates
NPD data of Turkish pediatric CF population. Our findings are consistent with
published NPD results of CF patients and healthy subjects. Commonly, high impe-
dance voltmeters have been used for NPD measurement in previous studies. The
results of these voltmeters depend on readings and comments of the person who
performs the tests. In order to eliminate subjectivity, we used computer based data
acquisition and analysis system in our measurements. We suggest that electronic
data acquisition may help standardization of NPD measurements.
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Nanoduct sweat analysis system measuring sweat conductivity is a
reliable test for cystic fibrosis
J. Barben (Presenting), A. Metlagel
Children’s Hospital, St. Gallen, Switzerland
Introduction: Sweat test analysis measuring chloride is the current gold standard
for diagnosing cystic fibrosis (CF). The collection of a sufficient amount of sweat
can sometimes be difficult, especially in young children. Measuring chloride is time
consuming and the results are often not available immediately. Nanoduct is a new
sweat analysis system to measure sweat conductivity. It needs only 3 ml sweat and
results are available within 30 min. Methods: On the same day, Nanoduct sweat
analysis system (Wescor, Utah, USA) measuring sweat conductivity was tested in
comparison with the macroduct sweat test (Wescor, Utah, USA) measuring chlo-
ride and osmolarity. Results: Seventy-six subjects aged 6 weeks to 60 yr were
investigated. Eight children had insufficient sweat production and only conductivity
could be measured. In the remaining 68 subjects, Nanoduct sweat test reliably
identified all patients with CF and differentiated them from healthy subjects within
a mean time of 20 min.
Conductivity Chloride Osmolarity
Healthy subjects
(ns53)
35 (5–56) 14 (6–25) 95 (47–156)
Typical CF (ns14) 114 (92–133) 105 (90–126) 247 (222–294)
Atypical CF (ns1) 60 54 193
Fourteen patients aged 2–24 yr had typical CF (chronic lung disease and pancreas
insufficiency) and one aged 14 yr had atypical CF (chronic rhinosinusitis with nasal
polyps). Conclusion: Measuring sweat conductivity using the Nanoduct sweat test
reliably differentiated all diagnostic groups. This suggests the Nanoduct could be
used as a diagnostic test in addition to its screening value. The system is simple,
quick and the results are available within a short period of time.
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The role played by the nasal potential difference in the diagnostic of
cystic fibrosis patients, with the negative sweat tests
M. Bosque (Presenting), Christian Domingo , Helena Larramona , Teresa1 2 1
Casals , Oscar Asensio , Conchita Monton , Laura Valdesoiro , Teresa Marco3 1 2 1 1
Pediatric Pulmonology, Hospital De Sabadell, Sabadell, Spain, Pulmonology,1 2
Hospital De Sabadell, Sabadell, Spain, Genetic, Iro, Barcelona, Spain3
Introduction: The diagnosis of Cystic Fibrosis (CF), is doubtful in some cases.
Objective: Describe the technique of the Nasal Potential Difference (NPD) and its
application for the CF diagnostic especially in mono-symptomatic patients with
evidence of negative sweat tests.Methods and material: A total of 84 patients were
studied using a determination from PDN, in both nostrils by way of a non-invasive
(THOLY, Medicap) normal value: approximately y20 millivolts (mV); value in
CF)y50 mV. The value of NPD used is the mean obtained from the value in each
of the nostrils. A sweat test was carried out with Macroduct; (positive result of)
to 80 mEq) and genetic study. The patients were grouped into 5: Group 1: 15
healthy controls, without clinical manifestations, non-smokers, PF. chest radiographe
normal, negative both sweat tests and genetic study. Group 2: 13 CF patients. Group
3: 4 adult patients affected by non-diagnosed bronchiectasis, with negative sweat
tests and carrier with 1 CF mutation. Group 5: 22 adult and pediatric patients,
healthy carrier with 1 CF mutation. STATISTICAL TREATMENT; ANOVA, deter-
mination of the predicted positive value (PPV), predicted negative value (PNV),
specificity (E) and sensitivity (S) of the NPD. Results: expressed in the mean value
of NPD."S.D. Group 1: 29.5"22.1. Group 2: 62.1"16.7. Group 3: 63.4"7.9.
Group 4: 46.7"16.02. Group 5: 2.5"15.6. The comparison of the results between
the different groups: Non-significant: 2y3, 4y5 and significants: 2y5 and 2y4 (P-
005). E80%; S 91.7%; PPV 78%; PNV 92.3%. Conclusions: (1) There were no
complications during the carrying out of the test. (2) As (S) as the E of the NPD
are elevated. (3) A normal NPD value allows the ruling out any CF diagnostic due
to the high PNV from the test. (4) The NPD resulted as sensitive as the sweat test
to diagnostic. (5) In the patients with some CF findings the NPD was more sensitive
than the sweat test.
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Cystic fibrosis (CF) diagnostic procedures in Warsaw CF centre
D. Sands (Presenting), A.N. Nowakowska, K.Z. Zybert, R.P. Piotrowski, A.M.
Milanowski
CF Department, Institute of Mother and Child, Warsaw, Poland
Four hundred and Seventy CF patients are registered in our CF centre, which has
been working since 1966, 250 CF children are under our care. Our objectives have
been early diagnosis and efficient diagnostic procedures. We consider 3 situations
in which CF is suspected, using specific diagnostic procedures in each case:
1. Clinical symptoms suggesting CF. For these patients classical sweat tests are
performed. Results with chloride ion concentration bigger than 60 mmolyl (40
mmolyl for babies) confirm the diagnosis. For confirmed cases molecular diag-
nosis follows. Parents are directed to genetic counseling. In 2002 this procedure
identified 12 newly diagnosed patients aged from 2 months to 14 yr mean 87
months. In atypical cases with changeable sweat test values nasal PD tests are
performed. According to our own analysis values bigger than 25 mV are highly
specific for CF.
2. CF patients’ families, especially their siblings. In 2002, 2 children were diag-
nosed by this method.
3. Neonatal screening programme for CF. Since 1999 a neonatal screening pro-
gramme has been operating in Poland (1y4 of the population). Different methods
have been used, with IRTyIRTydelF508 with confirmation by sweat test being
the method finally preferred. Infants with positive test results are consulted in
our centre by a CF clinician and two types of sweat tests are performed: classical
and conductometric (immediate result). In the case of positive sweat tests and
none or one AF508 mutation known, further mutations are checked. Parents are¨
directed to genetic counseling. In 2002 year 13 newly diagnosed infants. Age
of diagnosis range from 1 to 47 days, mean – is 1 month.
Conclusions: 1. Neonatal screening for CF enabled earlier diagnosis and the intro-
duction of profilaxis and complex therapy in comparison to symptomatic diagnosis.
2. For non-classical CF phenotype patients several additional diagnostic tests (PD,
elastase) and longer clinical observations are needed.
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Characteristics of patients diagnosed with cystic fibrosis as adults
M. Ferrin (Presenting), D. Holsclaw , D. Lipson , J. Shinnick , C. Robinson1 2 3 3 4
University of Pennsylvania Medical Center, Philadelphia, USA, Presbyterian1 2
Medical Center, University of Pennsylvania Medical Center, Philadelphia, USA,
Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania3
Medical Center, Philadelphia, USA, EpiGenesis Pharmaceuticals, Princeton, USA4
An ever-increasing number of adult diagnoses of cystic fibrosis are being made.
Literature supports that differences in health status and life expectancy exist. Some
are diagnosed by genotype and have normal sweat chloride. The shift in age at
diagnosis has potential to instruct caregivers about signs and symptoms that should
suggest pursuing a cystic fibrosis diagnosis. A retrospective review of all medical
records in our Adult Cystic Fibrosis program over the past 20 yr was performed to
identify patients diagnosed after 18 yr. Forty-two patients were diagnosed as adults.
The average age of onset of symptoms was 13.7 yr (range 0.1–44). Average age
at diagnosis was 30.9 yr (range 18–56). Four were DF508 homozyzous, 15 were
DF 508 heterozygous, while 8 did not carry the DF508 allele. Thirty-nine (93%)
presented with a history of recurrent respiratory infections; 35 (85%) with bron-
chiectasis; 10 (24%) with hemoptysis; 15 (30%) with nasal polyps; 36 (88%) with
chronic sinusitis; 3 (7%) with pancreatitis. Fourteen (36%) were pancreatic insuf-
ficient. Referral sources included general pulmonary (15), primary care provider
(9), Lung Transplant program (3), Allergy (3), 5 were self-referred, and other.
Only 7 had a positive family history of CF. Four had a sweat chloride-60 mmoly
l. Thirty-seven (88%) had sputum colonized with Pseudomonas aeruginosa.
Patients diagnosed with CF as adults may have a different phenotypic expression
of their disease compared with CF patients diagnosed younger. They are more likely
to be DF 508 heterozygotes. The age of onset of symptoms predates age of diag-
nosis by many years. Symptoms of respiratory infections and advanced lung disease
are common; these patients are colonized with similar organisms as younger
patients. Sweat chloride and pancreatic function may be normal. The index of sus-
picion remains the responsibility of the referring health care provider.
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Missed diagnosis or mis-diagnosis?...characteristics of paediatric
patients not diagnosed on the Northern Ireland neonatal screening
programme. 15 years experience (1988–2002)
A. Leavy (Presenting), H. Leslie , C. Graham1 2 3
Royal Belfast Hospital for Sick Children, BELFAST, United Kingdom, Department1 2
of Clinical Biochemistry, Royal Group of Hospitals, BELFAST, United Kingdom,
Department of Clinical Genetics, Belfast City Hospital, BELFAST, United Kingdom3
Introduction: Babies born in Northern Ireland between 1988–2002 (363811) have
been screened for CF using a 2 tier IRT system with referral for sweat test and
molecular genetics. Thirteen were missed on screening. Do these children have
cystic fibrosis? Method: Retrospective case analysis and initial IRT result was
checked. Age, symptoms on presentation, sweat test and molecular genetics were
collated. Results: All had an IRT, which was - the cut-off point for repeat testing.
Two of the children (both male), were diagnosed in the neonatal period by molec-
ular genetics due to family history. One had (Sodium 25 mMyl, Chloride 22 mMy
l) and molecular genetics Delta F508yR117H. The other has Delta F508y2789G)
A, and is pancreatic insufficient. Age – The remaining 11 presented clinically, mean
age 22.75 months (Range 6 months–12.6 yr). Symptoms – 9y11 had failure to
thrive, 10y11 had respiratory symptoms and 2y11 had diarrhoea. Sweat Test – All
had sweat tests in the positive range, mean sweat Sodium and Chloride 65 mMyl
and 72 mMyl, respectively. Molecular Genetics – Tested for Northern Ireland’s 29
most common CF mutations and 4y11 had CF mutations identified. 1y11 Delta
F508yDelta F508, 1y11 Delta F508yR117H and 2y11 Delta F508yNot identified.
Discussion: SevenyEleven in whom no CF mutations are identified, blood will be
sent for rare mutation screening. All now appear to be pancreatic sufficient (normal
faecal elastase, normal growth pattern established, no clinical or biochemical evi-
dence of malabsorption), although 1 still has diarrhoea. All have normal spirometry
and no significant respiratory pathogens. Repeat sweat testing has been done on 3y
11 and was normal. Conclusion: The screening programme has ‘missed’ only 2
cases of Typical Cystic Fibrosis. Diagnosis of Atypical Cystic Fibrosis can be very
difficult!
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Issues of cystic fibrosis late diagnosis in Lithuania
Sigitas Dumcius (Presenting)
Kaunas University of Medicine, Kaunas, Lithuania
The diagnosis of CF in Lithuania often is established late: only approximately 50%
of children CF is diagnosed before age 5 yr and mean age of patients with CF is
less than 15 yr. The aim of this study was to understand possible connections
between uncommon modes clinical presentation and other factors of children with
CF when disease was diagnosed late. Study presents data of personal observation
of 57 children with CF in Kaunas University hospital. Prospective evaluation during
the period of 6 yr included history, physical evaluation, chest radiographs, sputum
culture and results of genetic counselling. Mean age was 5.1 yr when CF was
diagnosed first. The classical symptoms of CF (a mixture of both respiratory and
gastrointestinal symptoms) were found in 32 (56.1%) of the patients. Atypical
modes of presentation were observed in 6 (10.5%) cases, while the disease mani-
fested either with respiratory or gastrointestinal symptoms in 19 (33.3%) cases.
Increased sweat chloride concentration was determined for 35 (61.4%) patients. In
5 (8.7%) cases bacteriological isolates were negative during all period of obser-
vation. The molecular characterization of the defects underlying CF in 29 patients
resulted in determination of 63.3% (37y58) of the CF chromosomes. Five different
CFTR mutations were identified during the course. It is interesting to emphasize
that delta F508 mutation was present only in 51.7% (30y58) of the chromosomes.
In most cases we faced diagnostic difficulty because of uncommon modes of clinical
symptoms and normal or borderline ranges of sweat test. The results of our study
also enable us conclude that S. aureus and H. influenzae are most frequently recov-
ered from children with CF even if disease was diagnosed late.
415
Evaluation of the announcement procedures, their psychological
impact, and parents’ adaptation following diagnosis of cystic fibrosis
(by neonatal screening or on alert symptoms)
L. Gueganton (Presenting), G. Rault , M. De Braekeleer1 1 2
Centre de Perharidy, Roscoff, France, Faculty of medicine, Brest, France1 2
Neonatal screening reduces the diagnostic delay and improve the medical follow-
up, but raises questions about the optimal announcement modalities, the psycho-
logical impact for parents, and the necessary means to make the parental adaptation
easier. Our study evaluates the announcement procedures, their psychological
impact and the accompanying measures. Specific aims are to draw a parallel
between regions which practice neonatal screening and regions that do not yet;
between fathers and mothers; between physicians and parents; to study the reactions
evolution; to think about the possibilities of psychological help for families and
medical teams; to help and incite teams to improve their modalities of announce-
ment and accompaniment. The method is based on national questionnaires send to
announcers and to parents, in the month after the announcement and one year after.
The investigation will be achieved in May 2004. So, we are just presenting few
preliminary results (39 children concerned). Significant differences between parents
show that: mothers use an emotional coping, they are more anguish and more
disposed to meet a psychologist. Fathers use a coping centred on the problem
resolution. Significant differences between diagnosis show that: after screening,
parents are shocked, but, little by little, they will familiarize with illness; after
diagnosis on symptoms, they are relieved because they have a verdict, but they
discover illness in an urgency climate. Our questionnaire, restructured, could be
used as an evaluation material of the benefits of the waited implemented announce-
ment and accompanying modalities. We would like to spread this study to the
international level, and call for participation. To finish, our investigation, our results
and our reflexion could be applied to all diagnosis announcement of a disease after
screening.
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Neonatal screening for cystic fibrosis in Northern Ireland – 15 years
experience (1988–2002)
H. Leslie (Presenting), G. Roberts , A. Leavy , A. Redmond , A. Reid , C.1 1 2 2 2
Graham1
Department of Clinical Biochemistry, Royal Group of Hospitals, Belfast, United1
Kingdom, Allen Ward, Royal Belfast Hospital for Sick Children, Belfast, United2
Kingdom
Introduction: Screening for Cystic Fibrosis in Northern Ireland is performed by 2
tier immunoreactive trypsinogen testing, using a fluoroimmunoassay DELFIAmeth-
od supplied by Wallac, Turku, Finland. The first blood card is taken at 6–8 days
of age with a second card at 4 weeks if the IRT is elevated. Those babies with a
second elevated IRT are referred for clinical examination and sweat testing at the
Royal Belfast Hospital for Sick Children. Blood is taken for molecular genetics
from babies with positive or equivocal sweat tests. Results: Over the reported period
363811 babies were screened. The percentage of babies requiring a second blood
spot screening card for IRT has varied over the years and is currently set at 0.7–
8%. In this period 175 children were diagnosed as having cystic fibrosis, giving an
incidence of 1 in 2021. Thirty-one presented with meconium ileus, and all of these
had elevated IRT on the first card. 131 were identified by the screening programme.
Their mean sweat Sodium and Chloride was 80 mMyl and 106 mMyl, respectively.
Of the remaining 13 whose screening was negative, 11 were identified with a pos-
itive sweat test having been referred with clinical symptoms. Their mean sweat
Sodium and Chloride was 66 mMyl and 89 mMyl, respectively. Two were diag-
nosised by molecular genetics because of a known family history. The four major
CF mutations identified in this population were Delta F508, R117H, G542X and
G551D, with respective frequencies of 68, 4, 2 and 2%. Conclusion: Neonatal
screening in Northern Ireland identifies the majority of patients with cystic fibrosis
and this, combined with education of health care professionals, results in a well
accepted screening programme which ensures that all patients are cared for in a
large cystic fibrosis centre.
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Strong parental support in Sweden for neonatal screening for CF
I. de Monestrol (Presenting), A. Bergsten-Brucefors , L. Hjelte , B. Sjoberg1 2 1 1¨
Stockholm CF Centre, Huddinge University Hospital, Stockholm, Sweden, Depart-1 2
ment of Public Health Sciences, Social Medicine, Karolinska Institutet, Stockholm,
Sweden
Aim: To find out the parental attitude towards including CF in the neonatal screening
programme in Sweden. Methods: A questionnaire was mailed to the parents of 143
CF patients born 1968–2000 and attending Stockholm CF centre (48)18-years
old, 95-18-years old). The parents were asked to anonymously complete questions
about their attitude towards neonatal screening for CF and about their experiences
when their child received the CF diagnosis. Each CF patient had three diabetic and
three healthy controls matched for gender, year of birth and birth region. Results:
Response rate: CF parents 85%, diabetes parents 71%, parents with healthy children
66%. Whish for their child to be screened for CF in the neonatal period; yes: CF
parents 86%, diabetes parents 70%, parents of healthy children 77%; no: 4, 11 and
8%. Wish for knowledge of CF carrier status before giving birth; yes: CF parents
47%, diabetes parents 45%, parents of healthy children 50%; no: 28, 27 and 24%.
Timing of CF diagnosis: CF parents thought the diagnosis was delayed in 60%
(doctor’s delay 58%, parents’ delay 2%), given at the right time in 25%, too early
0%. 15% answered other with descriptions such as: both early and late, delayed
but understandable, delayed due to the parents not being taken seriously. Well-being
of CF child at time of diagnosis: good 20%, neither good nor bad 8%, bad 72% –
and one year later: 77%, 8%, 14%, respectively. There was no correlation between
the well-being of the CF child at diagnosis and the wish for neonatal screening.
Conclusion: A majority of the parents of CF patients in Sweden want CF to be
included in the neonatal programme, as well as the control parents. More than half
of the CF parents thought their child received the CF diagnosis too late. About half
of all the parents would have wanted to know their CF carrier status before giving
birth. These results should be taken into consideration when deciding about neonatal
screening for CF in Sweden.
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Evaluation of a novel conductometric device for the diagnosis of cystic
fibrosis
H. Losty (Presenting), H. Wheatley , A. Gupta , I. Doull1 1 2 2
Medical Biochemistry, University Hospital of Wales, Cardiff, United Kingdom,1
Cystic Fibrosis Unit, University Hospital of Wales, Cardiff, United Kingdom2
Conductivity has been demonstrated to be a robust analytical parameter in the UK
National External Quality Assurance Scheme for sweat electrolytes. However, there
are concerns that sweat conductivity is inferior to sweat chloride in diagnostic
discrimination particularly for atypical cases of Cystic Fibrosis (CF). We evaluated
a novel micro-flow cell conductometric device, which measures sweat conductivity
in situ. We compared the diagnostic discrimination with that of sweat chloride using
a contemporaneous Quantitative Pilocarpine Ionotophoresis Test (QPIT) in a cohort
of 86 patients – of whom 34 had CF – referred to our Regional CF Unit. Using
an upper limit of normal of 60 mmolyl, conductivity had a specificity of 96% in
ruling out CF. However the diagnostic sensitivity, using conductivity in excess of
80 mmolyl, was only 69%. The excessive false negative rate was demonstrated on
photographic examination to be due to an occluded flow path in a faulty batch of
sensors. Repeat conductivity determinations using liquid sweat collected into
Macroduct coils were diagnostic. We found the equipment robust and easy to use
and eminently suitable for point of care testing as it dispenses with the need for
separate analytical facilities and specialist laboratory personnel. This device would
appear to be suitable for use in secondary health care facilities for ruling out CF.
However refinements of design and quality control of sensor production are required
to enable further comparative studies before the device could unequivocally be
recommended as an alternative to the QPIT for the diagnosis of CF.
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Paranasal sinuses pathology in cystic fibrosis early childhood
M. Di Cicco (Presenting), C. Castagna , R. Padoan , D. Costantini1 2 3 3
E.N.T. Department, University of Milan, Milan, Italy, E.N.T. Department, Univer-1 2
sity of Milan, Milano San Felice (MI), Italy, C.F. Centre, University of Milan,3
Milan, Italy
Mucoceles are frequently found in the sinus mucosa of CF patients: the congenital
epithelium alterations causing excessively viscous mucus, bacterial overgrowth and
infection, lead to paranasal sinuses obstruction. The routinary ENT evaluation of
CF patients with nasal endoscopy and CT scan, led us to a correct early diagnosis.
We treated 9 CF patients with mucocele (4 male and 5 female), the age of the
patient’s ranges from 6 months to 6 yr (mean age 3.50 yr). All patients presented
with persistent rhinorrhea, snoring since birth with SaO decrease, respiratory dis-2
tress in absence of other rhino-oro-pharyngeal pathologies. Diagnosis was per-
formed by means of CT scan of paranasal sinuses and fibroscopy. In two patients
the neoformation was located at the nasolacrymal duct, five had maxillary muco-
celes and two had monolateral ethmoido-maxillary mucocele. Since that the gold
standard in nasal surgery is actually ESS, we consider external sinus procedures
inappropriate to approach CF mucoceles. We haven’t been faced with particular
intraoperative complications during surgery and it has been always possible to
remove completely the neoformation. At surgery of nasolacrymal duct mucoceles
only thick fibrous tissue separated the content of the mass from orbital fat showing
that in these cases ESS is essential to avoid orbital involvement. All symptoms and
particularly SaO decrease dramatically regressed after mass removal and no recur-2
rency was observed after 24 months at endoscopic follow up. Pediatric sinus pathol-
ogy with this kind of clinical aspects occurs almost exclusively in CF patients and
an early diagnosis with an otorhinolaringoaiatric endoscopic evaluation and CT scan
in our opinion is the gold standard for the best medical or surgical treatment of this
CF complication.
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Patients’ concerns and problems with central venous access devices
related to their site of insertion
C. Sheldon , S. Elworthy , W.B. Campbell , I. Peerlinck , K. Vanslembroek , R.1 1 2 2 3
Bangur , D. Stableforth4 4
Respiratory Medicine, Royal Devon & Exeter Hospital, Exeter, United Kingdom,1
Vascular Surgery, Royal Devon & Exeter Hospital, Exeter, United Kingdom, Gen-2 3
eral Surgery, Royal Devon & Exeter Hospital, Exeter, United Kingdom, Cystic4
Fibrosis, Birmingham Heartlands, Birmingham, United Kingdom
Central venous access devices (CVADs) have been increasingly used for adminis-
tration of antibiotic therapy in patients with cystic fibrosis (CF). There are few data
to guide clinicians about the best site for CVAD placement and patients may not
be offered a choice. This study examined patient experiences and aimed to provide
guidance. Fifty-four patients, (39 female, median age 24), who had received one
or more CVAD in two CF units were sent structured questionnaires about potential
problems or concerns (12 questions) and use of their CVADs (4 questions). A
separate questionnaire was used for each CVAD. The response rate was 54 of 69
patients (78%) relating to a total of 86 CVADs. Responses were analysed by Chi
squared for differences between CVADs placed on the upper chest (67), lower chest
(13) and elsewhere (6). Patients were given a choice of insertion site for 46% of
CVADs. Forty two percent of patients with CVADs reported 0–2 areas of concern
and only 3% reported)10 areas of concern. Similar concerns were expressed about
devices placed in the upper and lower chest except that unspecified problems on
the lower chest were less common than on the upper chest (0y13 vs. 23y65 Ps
0.006). Problems with lying in bed or sleeping were higher in devices on the lower
chest (9y12 lower chest, 27y67 upper chest, Ps0.05). Fewer patients with lower
chest devices reported problems with sports but this did not achieve statistical sig-
nificance, 1y10 vs. 20y66. No differences were reported for cosmetic appearance,
driving or sex life. Thirty one percent of CVADs could be accessed and flushed by
the patients themselves. Of those who could not access the device themselves, 56%
would have liked to do so. This study draws attention to the different sites available
for CVAD placement and potential areas of patient concern. All sites are generally
well tolerated. Most patients would like to access CVADs and this may be an area
for future patient education.
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Polycystic ovaries in cystic fibrosis female adolescents
A. Galli-Tsinopoulou , T. Moudiou , A. Mamopoulos , M. Karamouzis , S. Nousia-1 1 2 3
Arvanitakis1
Fourth Department of Pediatrics, Aristotle University, Thessaloniki, Greece, Third1 2
Department of Gynecology and Obstetrics, Aristotle University, Thessaloniki,
Greece, Department of Biochemistry, Aristotle University, Thessaloniki, Greece3
Introduction: Women with Cystic Fibrosis (CF) are known to have menstrual irreg-
ularities and reduced fertility. Polycystic ovary syndrome (PCOS) presents with
menstrual dysfunction, anovular cycles, hyperandrogenism, inappropriate gonado-
tropin secretion and insulin resistance. The aim of this study was to investigate
gonadotropins and gonad steroids in CF. Patients and methods: Eighteen female CF
adolescents, 12–23 yr, and 18 healthy females, matched for age, were examined.
Results: The following hormones (mean value standard deviation) were investigated
in CF and controls during the follicular phase: Follicle stimulating hormone
(3.601"54 vs. 5.22"1.75 mUyml), androstendione (237.55"116.7.1 vs.
140.73"38.04 ngyml), lutenizing hormone (8.417.0"6 vs. 3.61"1.7 mUyml) and
estradiol (10.63"7.95 vs. 8.02"2.63 ngyml), sulfate dehydroepiandosterone
(128.84"75.43 vs. 174.96"45.936 ngyml), prolactin (16.40"6.78 vs. 8.5"2.96
ngyml), testosterone (1.22"0.66 vs. 2.77"0.42 ngyml). Body mass index
(19.79"4.52 vs. 23.25"0.90) and fatness index (%) calculated by Bioelectrical
Impedance Analysis (20.71"6.51 vs. 25.63"2.30) were used as parameters of
growth and nutrition. EightyEighteen (40%) CF adolescents had menses irregular-
ities and ovarian cysts on US examination, 6y8 had LHyFSH ratio )3 and 3
patients were operated for ovarian torsion. Nine older CF adolescents (50%) had
diabetes. Obesity, hirsutism or acne was not observed and menarche occurred within
normal range. Conclusions: Polycystic ovaries are frequent in our CF adolescent
population. Although androstendione (produced by the ovaries) is high, testosterone
is normal (not converted in the reduced fat tissue) and prolactin is higher in CF
(cytokine). Although high levels of insulin and insulin resistance characterize clas-
sic PCOS, all CF related cases of PCOS, in our study have diabetes. The mechanism
of PCOS development may be different in CF.
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Urolithiasis in cystic fibrosis
M. Fotoulaki (Presenting), S. Giourdzis, V. Lafazanis, A. Makedou, S. Nousia-
Arvanitakis
Fourth Department of Pediatrics, Aristotle University, Thessaloniki, Greece
The aim of this study was to determine the potential risk factors for renal stone
formation in cystic fibrosis (CF). Material and methods: Thirty CF patients (16
male and 14 female), 5 to 34 (18"7) yr, were investigated by renal ultrasonography
and X-Ray of the abdomen. Blood levels of creatinine (Cr), calcium (Ca), phos-
phorus (P), parathormone (PTH), potassium (K), uric acid, bicarbonates (HCO )2
and hydrogen ion concentrations were obtained. Twenty-four-hr urine collections
for uric acid, Ca, oxalates, magnesium (Mg) and cystine were examined. Glome-
rular filtration rate (GFR), the ratio of uric acid per 100 ml GFR and the ratio Cay
Cr in a urine sample were calculated. Fresh urine samples were examined for
crystals and erythrocytes. Results: Four adults (13%) 2 males and 2 females were
found to have urolithiasis. No hypercalciuria, hyperuricosuria, hyperoxaluria or cys-
tinuria were detected in 3 of these patients. Fresh urine samples were negative for
crystals or erythrocytes. By contrast, hypercalciuria, hematuria, crystaluria (Ca oxa-
late) and mild hydronephrosis were detected in a 23-year old female. Her Ca exre-
tion was 4.57 mgykgy24 h and the ratio CayCr in every urine sample was high ()
0.45) PTH was normal. Hypercalciuria persisted during starvation and after a meal,
while on Ca-rich and Ca-free diet. The final diagnosis was idiopathic hypercalciuria
and she was treated with diuretics successfully. Conclusion: Urolithiasis, including
idiopathic hypercalciuria, may be common in CF. The etiology of urolithiasis in CF
and its relation to the dysfunction of CFTR or other parameters need elucidation.
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Pseudobartter’s syndrome in cystic fibrosis
T. Bolger (Presenting), Turlough Bolger (Presenting), G. Canny , M. Waldron ,1 2 2 3
A. Awan3
Our Lady’s Hospital for Sick Children, Dublin, Ireland, Pulmonology, Our Lady’s1 2
Hospital for Sick Children, Dublin, Ireland, Renal, Our Lady’s Hospital for Sick3
Children, Dublin, Ireland
Introduction: Pseudobartter’s Syndrome is a rare complication of Cystic Fibrosis
(CF). The characteristics of the syndrome are hypokalaemic, hypochloraemic met-
abolic alkalosis and failure to thrive. The mechanism of the syndrome is related to
large extrarenal losses of chloride in the sweat. It is most commonly seen in young
infants who have a high ratio of surface area to weight. Cases: We present 4 cases
of Pseudobartter’s seen in our CF population over a 6-year period. Three patients
were infants, while the fourth was aged 9 yr. The single common symptom among
all 4 cases was failure to thrive or weight loss. The infants were also vomiting. The
older child presented with a severe pneumonia, having recently returned from the
Netherlands, which had been experiencing a heatwave. All cases exhibited hypo-
kalaemic, hypochloraemic metabolic alkalosis. Two patients were also hyponatraem-
ic. Urinary electrolytes confirmed the diagnosis with low urinary chloride excretion.
The three infants were clinically and biochemically dehydrated on presentation.
They responded to intravenous saline rehydration and KCl supplements. The older
child was not clinically dehydrated and was tentatively diagnosed as SIADH due
to low urinary osmolarity. He was treated for the first 24 h with fluid restriction.
On quantification of his urinary electrolytes, the correct diagnosis was made and
NaCl supplementation was commenced. Following this intervention, his biochem-
ical abnormality corrected slowly and he improved clinically. Discussion: Pseudo-
bartter’s Syndrome should be considered in all cases of infants with CF who fail
to thrive. It should be noted that the metabolic abnormality could appear after a
long period of failure to thrive. The syndrome has rarely been described outside
the infantytoddler age group.
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Influence of antitumoral chemotherapy on cystic fibrosis
N. Kashirskaya (Presenting), A. Voronkova, O. Polushkina, N. Kapranov, P. Kopo-
sov, V. Kovalev
Cystic Fibrosis, Research Centre for Medical Genetics RAMS, Moscow, Russia
There are several reports hypothesising that possible long-term expression of
MultiDrug Resistance Protein (MRP) and MultiDrug Resistance associated Protein
(MDR) induced by chemotherapy may complement unfunctional CFTR protein and
provide an unexpected therapeutic approach in cystic fibrosis (Lallemand et al.,
Jaffe et al.). Case report: A two-and-a-half year old boy with CF developed an
alveolar rhabdomyosarcoma of the right thigh with metastases in the regional lymph
nodes and prostate. Sweat test: chloride 64.3 mmolyl. Genetics: deltaF508y
unknown. Sputum microbiology: P. aeruginosa, S. aureus. Regular treatment: pan-
creatic enzymes, vitamins, DNase, physiotherapy. The child had combined treatment
with surgery 12.01.2000, chemotherapy (protocol CWS-96) and radiation therapy.
He underwent the following chemotherapy protocol over a 9 months period: Taxoter
(docetaxel) before starting IVA2 regime: Vincristine, Goloxan (ifosfamide), Cos-
megene (dactinomycin). He is stable after cancer treatment for 3 yr. Results: We
did not see any clinical improvement of the respiratory system in this boy contrary
to other investigators. He was an infected with P. aeruginosa, has 4–5 chest exac-
erbations a year and decreased nutritional status. Unfortunately, we did not do any
special investigations before and after chemotherapy (sweat test, nasalybronchial
brushings for MDR mRNA and nasal potential difference). Conclusion: We agree
that reports of further cases of patients with CF with cancer are needed because
this results may provide evidence for a novel therapeutic approach to overcoming
defective CFTR through modulation of MDR. We support Jaffe et al. that in all CF
patients with cancer there should be used special investigation regimen prior to and
following chemotherapy.
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Hypoelectrolytemia and sweat test levels in cystic fibrosis patients –
how many concordance or discordance parameters are there?
I. Galeva (Presenting), A. Kufardjieva
Pediatric Clinic, Alexander’s State University Hospital, Sofia, Bulgaria
Aim: Logically in cystic fibrosis (CF) patients the higher the sweat salt losses are,
the higher the risk for hypoelectrolytemia andyor alkalosis is. Is there a positive
correlation between sweat test levels and electrolyte disturbance incidences? Mate-
rial and methods: A number of 129 CF patients (55 boys and 74 girls) were
analyzed for hypochloremia, hyponatremia andyor alkalosis at the time of CF diag-
nosing (median age at diagnosis – 4 m). 52 of them (40.31%) were homozygous
for F508, 51 – compound heterozygous for F508 and 26 – non-delta F. The birth
weights (Z-scores), sex, mean sweat test levels, genotype and the age of intestinal
and lung onset were compared for patients with and without hypoelectrolytemia
andyor alkalosis. Results: Electrolyte and acid-base disturbances were found in 20
(15.50%) patients – 9 boys and 11 girls (10 homozygous, seven compound het-
erozygous and 3 – non-delta F). The incidence difference between homozygous
and compound heterozygous (Ps0.45) and between homozygous and non-delta F
(Ps0.39) did not have statistical value. Nor there was a significant difference in
birth weights (Z-scores) between patients with and without hypoelectrolytemia andy
or alkalosis (Ps0.34). Electrolyte disturbances were established in every 1 in 4
CF patients with high sweat test levels ()90 mmolyl), in every 1 in 7 – with
moderate sweat test levels and in every 1 in 9 with sweat test levels less than 70
mmolyl. Those differences had still no statistical value. Hypoelectrolytemia andyor
alkalosis were found more often among CF patients with earlier intestinal andyor
lung involvement (P-0.01). Conclusions: Sweat salt losses are not the only reason
for hypoelectrolytemia andyor alkalosis in CF patients.
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Diagnosis of cystic fibrosis (CF) over 18 years of age
K. Kelemen (Presenting), J. Mester, Z. Barath, K. Fuzesi, E. Csiszer´ ´¨
Pulmonology, Koranyi National Institute for Tuberculosis and Respiratory Medi-´
cine, Budapest, Hungary
Objective: CF is usually diagnosed in childhood. In Hungary the number of CF
cases diagnosed over 18 yr of age is increasing. Design: The aim of this study was
to identify diagnostic characteristics of these ‘late’ diagnosed CF cases. Since 1986
regular follow up of 78 adult CF patients have been performed in our Institute.
Method: Characteristics of ‘missed’ diagnoses in childhood were analysed by clin-
ical data and results of laboratory tests. Results: Twelve of them (9 males, 3
females) were diagnosed in adulthood. The mean age of late diagnosis was 26.7 yr
(18–37 yr). In childhood 3 patients had respiratory symptoms (1 bilateral bron-
chiectasis, 1 bronchitis asthma, 1 periodic cough), and 3 patients had pancreatic
insufficiency. Symptoms at the time of diagnosis: persistent respiratory symptoms
(11 cases), intestinal symptoms (6 cases), Pseudomonas infection in sputum (3
cases), Staphylococcus infection in sputum (4 cases), radiologic alterations (12
cases), sinus disease (8 cases), abnormal sweat chloride test (12 cases). Two
patients died after 5 and 6 yr follow up. Three of the 6 examined patients have
azoospermia. Genotypes: DF 508 homozygote-3 cases, DF 508 heterozygote-4 cas-
es; 5 patients do not carry the examined most frequent mutations. Conclusions:
Every other patient was suspicious for CF and had symptoms in childhood. The
rest had symptoms after adolescence. The recently increased number of diagnosis
with CF in adulthood is due to the wider knowledge of CF.
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Cholestatic jaundice caused by inspisated bile and Choledocholithiasis
in CF toddler. Role of Endoscopic Retrograde
Cholangiopancreatography (ERCP) in diagnosis and treatment. case
report
V. Skalicka (Presenting), R. Keil , J. Zezulkova , R, Kotalova , Z. Vancikova , K.1 2 3 1 1
Kotrcova , V. Vavrova1 1
Paediatric Department, Charles University and Medical Faculty, University Hos-1
pital Motol, Prague, Czech Republic, Clinic of Internal Medicine, Charles Uni-2
versity and Medical Faculty, University Hospital Motol, Prague, Czech Republic,
Clinic of Radiological Techniques, Charles University and Medical Faculty, Uni-3
versity Hospital Motol, Prague, Czech Republic
Introduction: Cholestatic jaundice due to extrinsic biliary obstruction in CF children
is a rare occurrence, sometimes present in neonates and young infants. The inci-
dence of gallbladder abnormalities, biliary sludge and gallstones increases with
patient age. It has been related to biliary stasis caused by increased bile viscosity
secondary to the underlying defect in fluid and electrolyte transport. Case report:
2 1y4-years old CF boy, F508del homozygous, pancreatic insufficient, with a history
of meconium ileus, meconium peritonitis and recurrent severe sepsis during the first
three months of life. Intensive permanent treatment including efficacious caloric
intake (135 kcalykgyday), appropriate pancreatic enzyme replacement and urso-
deoxycholic acid (UDCA) 20 mgykgyday administration led to a period of a very
good compensation. Sudden jaundice and intermittent hypocholic stools occurred
at the age of 28 months after a 2-week stay in a hot climate, possibly without
adequate fluid intake. Laboratory analysis revealed biochemical signs of cholestasis,
normal pancreatic enzymes, negative inflammatory parameters and negative hepatal
infections serology. Sonography showed a dilatation of hepatocholedochus and a
high density content of gallbladder. ERCP brought out dilatation of common bile
duct up to 6 mm with a tiny choledocholithiasis; for this reason stenting (5-Fr) of
the junction had been performed. Medication was enhanced by elevation of UDCA
to 35 mgykgyday and hymecromon administration. Complete resolving of chole-
stasis was marked within 1 week after ERCP. A stent was removed 1 month later,
UDCA administration reduced back to 20 mgykgyday and hymecromon discontin-
ued. Signs of cholestasis did not appear any more. Conclusion: Biliary sludge and
gallstones in CF may occur even in early childhood. ERCP with a possibility of
temporary implementation of stent provided important diagnostic information and
contemporary high efficacy treatment. VZ: MSMT 111300003.
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Uncommon middle lobe syndrome in a child with cystic fibrosis
J. Barben (Presenting), P. Waibel , W. Weder1 1 2
Radiology, Children’s Hospital, St. Gallen, Switzerland, Thoracic Surgery, Uni-1 2
versity Hospital, Zurich, Switzerland¨
Background: Middle lobe syndrome (MLS) is common in patients with cystic fibro-
sis (CF) with most cases due to viscous mucous with plugs. We report the case of
a child whose MLS was due to a congenitally atelectatic middle lobe (ML) infected
solely with Pseudomonas aeruginosa (PA). Case report: An 8-year-old female with
CF (dF508yG542X) diagnosed at the age of 3 months had asymptomatic mild lung
disease (FVC 1.6 Ls100%, FEV 1.4 Ls100%, MEF25 0.6 Ls48%). Annual1
chest X-ray (CXR) consistently showed a visible atelectatic ML. Because she was
asymptomatic, no intervention took place. Annual throat swabs and sputum culture
consistently revealed staphylococcus aureus (SA): her uncommon respiratory exac-
erbations were treated accordingly. At the age of 8 yr, an aggressive attempt to treat
the MLS with intensive physiotherapy and inhalations failed. Bronchoscopy showed
a scarred ML stenosis. Lavage (BAL) of the ML revealed PA although BAL of the
lingula grew only SA. A CT scan showed a grossly damaged ML and some cylin-
dric bronchiectasis in the antero-basal under lobe right; the remaining segments of
the right and left lung were unaffected. The ML was removed thoracoscopically
and she was treated with 6-months of tobramycin inhalation: sputum culture still
shows SA and her lung function remains unchanged. In retrospect, the ML changes
were identifiable on her first CXR at 3 months of age when diagnosis of CF was
made. Conclusion: A persistent atelectatic ML should always be investigated with
bronchoscopy (including BAL) and CT, especially in a young child, even if asymp-
tomatic. In the case of ML dysplasia, thoracoscopic resection is indicated in order
to remove a possible bacterial reservoir.
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Succesful lobectomy in a child with CF and acute abscess-forming
process in the right lower and middle pulmonary lobe
T. Gonska (Presenting), E, Stoelben , J. Kuehr , M, Brandis1 2 1 1
Department of Peadiatrics and Adolescent Medicine, University hospital, Freiburg,1
Germany, Department of thoracic surgery, University hospital, Freiburg, Germany2
Pulmonary lobectomy in patients with Cystic fibrosis is seldom reported and only
in relation to massive hemoptysis. Here, we present a case where lobectomy was
performed to stop an acute abscess-forming process, which led to a very critical
clinical situation of a 12-year old boy. Diagnosis was made at the age of 3–5 yr
based on pancreatic insufficiency and dystrophy (weight-3.0 percentile). Because
of very early onset of chronic infection with Pseudomonas aeruginosa, regular iv-
antibiotic and inhalative tobramycin courses were performed. From December 2001
until May 2002 the boy was hospitalised repeatedly with recurrent severe pulmonal
exacerbation. In spite of intensive antibiotic treatment, physiotherapy and even
repetitive bronchoscopic lavage with DNAse, pulmonary function decreased (FVC
56%; FEV 37%) and radiological examination showed a constant atelectasis in the1
right lower and middle pulmonary lobe. In May, his general condition was very
critical with global pulmonary insufficiency, oxygen need of 8 lymin, increasing
antibiotic resistance of the Pseudomonas strains, weight loss, electrolyte imbalance
and insulin requirement. We decided for lobectomy of the affected pulmonary lobes.
After successful lobectomy of the right lower and middle lobe the child recovered
within 3 weeks. Under re-uptake of the antibiotic scheme, intensive physio- and
inhalation therapy pulmonary status improved and thoracic X-ray showed an extend-
ed right upper lobe and less signs of pulmonary destruction after 6 months. Fur-
thermore, we noticed no diurnal oxygen need and a considerably gain in weight.
The boy goes regularly to school and can perform physical exercise at low to
moderate intensity. Of course lobectomy might be an exception in CF patients with
acute severe pulmonary infection, but it may be considered as an alternative option
in critical situations.
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Fatal adenoviral infection in a CF patient
Vilka Hresiæ-Krsuloviæ , Irma Golmajer-Vlahovic , Mirjana Percl1 1 2ˇ ˇ
Pulmonology and allergology, Children’s Hospital Zagreb Medical School, Zagreb,1
Croatia (Presenting), Gastroenterology, Children’s Hospital Zagreb Medical2
School, Zagreb, Croatia
Introduction: In CF both the chronical bacteral infection and the exaggerated
immune response result in structural damage of the airways and lung parenchima.
Viral infections usually cause deterioration of chronic lung disease. Case report: A
16-year old girl was diagnosed with CF at 8 months of age (sweat chloride con-
centration 79 mmolyl, DF508yDF508). At the age of 3 she was chronicly infected
with Pseudomonas aeruginosa and intensely treated. At the age of 16, she had
severe lung disease, cor pulmonale, GER, mild liver disease, pancreatic insuffi-
ciency, glucose intolerance and severe osteoporosis. Allergology tests were negative
and in sputum cultures there were no Aspergillus or Mycobacteria, but two strains
of P. aeruginosa with good sensitivity. Modified Shwachman-Kulczycki score was
38y100 (X-ray score was 6y20, FEV 27%). Together with her parents she refused1
PEG and they were still thinking about the possibility of lung transplantation. She
was admitted to the hospital for the third time in the last year because of progressive
respiratory insufficiecy, sputum production, low fever and elevated inflammation
parametres and intensely treated with antibiotic i.v. among other necessary therapy.
After few days her condition improved. Despite all profilactic measures and seg-
regation, she aquired adenoviral infection on the ward (DFAqqq in nasopharyn-
geal aspirate). She got fever up to 40 8C for 4 days with severe deterioration and
respiratory insufficiency. Intubation and bronchial lavage were indicated and fol-
lowed by mechanical ventilation. Fatal outcame happened after 10 days. Conclu-
sion: Adenoviral infection in a severe CF patient may cause deterioration of chronic
lung disease and lethal outcome, unfortunately without possibility of vaccination or
specific treatment.
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What is lost is lost? A case presentation
L. Lannefors(Presenting), L. Eriksson, U. Dennersten, L. Mared
Lund CF-centre, Department of Respiratory Medicine, Lund University Hospital,
Lund, Sweden
TN born 1954. Diagnosed at the age of four. Compound heterozygote, deltaF508y
3659delC. Pancreatic insufficient, using pancreatic enzymes, BMI 22. Intermittently
colonised with Pseudomonas A, which was cultured for the first time 1987. In 1987
he was referred to Lund University Hospital Respiratory Department for transplant
assessment. TN had been nebulising Ventoline and Acetylcystein for many years.
As airway clearance therapy he had been using postural drainage and clapping
followed by huffing and coughing when needed. Once in every two weeks he visited
a physiotherapist for a ‘complete treatment’. Adherence with the daily inhalations
was good, with the airway clearance poor. He was on oxygen supplementation 12
hyday, in frequent contact with an infectionist and recommended to use antibiotics
when needed. Lung function and working capacity (see table), PaO was 6.9 and2
PaCO 7.7 kPa (without oxygen). Early 1988 TN got in contact with the adult CF-2
team at Lund University Hospital. The major change in the treatment was: optimised
inhalation therapy, changed airway clearance to a combination of modern techniques
effective for TN and introduction of daily high-intensive physical exercise with
oxygen supplementation as well as mobility and strengthening exercises. Adherence
with the treatment is good. Since 1988, TN has gradually re-gained lung function
and working capacity (see table), PaO 9.1 and PaCO 5.9 kPa (without oxygen).2 2
TN works 20 hyweek.
PRIVATE VC%p FEV %p1.0 WC%p
1987 40 22 41
2002 65 42 73
What is lost is gradually re-gained with proper treatment. This probably is relevant
for more patients with sub-optimal treatment. Keywords: CF treatment,
physiotherapy and functional data.
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56-year old patient with cystic fibrosis and celiac disease
S. Lampert(Presenting), S. Pour Schahin, F.S. Fuchs , P. Berg, G.H. Wiest, J.H.1
Ficker
Division of Respiratory Medicine, Department of Medicine 1, University Hospital,
Erlangen, Germany
Although it has been recorded that cystic fibrosis and celiac disease can coexist, a
clean relationship between the diseases has never been firmly established (Katz AJ
et al., Pediatrics; 1976). Our case concerns a 56 year-old man who was diagnosed
with cystic fibrosis (delta F508yN1303J), at two years of age. Over the last two
years he has been complaining of diarrhoea and meteorism. On physical exami-
nation a massive abdominal distension was found, which was resonant on percus-
sion. The serum IgA levels, the levels for IgA antiendomysial autoantibodies, IgA
and IgG antireticulin autoantibodies were in the normal range. The serum level of
tissue transglutaminase was elevated with 8,8 Uyml. The duodenoscopy showed a
typical pattern for celiac disease. This was confirmed by the biopsy. A genetic
examination of our patient showed the genotype HLA-DQ2, which is positive in
95% of patients with celiac disease. After three months on a glutenfree diet the
symptoms of our patient had disappeared. In the literature there are some hypotheses
to explain the coexistence of cystic fibrosis and celiac disease (A.J. Katz et al.,
Pediatrics, 1976). Due to pancreatic insufficency in patients with cystic fibrosis the
mucosa of the bowel may have more contact with the complete gluten protein.
Further malnutrition might contribute to some additional mucosal damage. Both
together might induce an inappropriate immune response to dietary wheat gluten.
In the literature all other cystic fibrosis patients with celiac disease were diagnosed
with both disease in childhood with a maximum latency between both diseases of
26 months. It seems unlikely that the celiac disease remained undiagnosed in our
patient since childhood. The long time gap between the diagnosing of cystic fibrosis
and the first symptoms of the celiac disease in our patient could support the above
mentioned pathophysiologic hypotheses.
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Echogenic bowel on antenatal ultrasound and CF
S. Hall(Presenting), I.J.M. Doull
Department of Child Health, Cardiff, United Kingdom
All women attending the University Hospital of Wales, whose foetus display ech-
ogenic bowel on antenatal scan are offered amniocentesis (for karyotype) and CF
mutation analysis of the foetus using the CF 31 kit. All infants with at least one
identified CF mutation are referred to the CF Unit in the antenatal period. Between
January 1999 and 2003, 3 foetuses were referred with 2 identified mutations, and
6 with a single identified mutation. Ordinarily a foetus with the combination of
echogenic bowel and one identified CF mutation will have a 1:15 chance of having
Cystic Fibrosis, and all have a postnatal sweat test. Of the 3 infants identified with
2 CF mutations, 1 presented with meconium ileus (dF508yV520F), but the other
2 have very mild disease and are pancreatic sufficient (dF508y3272A)G and
dF508yR117H). Of those with a single CF mutation identified, all but 1 had a
normal sweat test (R117Hynil) – a sweat test on this male infant was performed
at 9 days of age, weight of sweat 0.244 g, sodium 70 mmolyl, chloride 55 mmoly
l. However, the baby was asymptomatic and repeats sweat test at 2 weeks of age,
weight 0.275 g, sodium 50, chloride 37. Sweat test at 4 weeks of age weight 0.299
g, sodium 36, chloride 22. The infant is now 9 months of age and is thriving
normally with no respiratory symptoms. In this small series, echogenic bowel is
associated with milder CF. Care must be taken in the interpretation of early sweat
tests.
